{
  "filename": "ehac244.pdf",
  "title": "2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)",
  "type": "cardio_oncology",
  "year": 2022,
  "total_pages": 133,
  "extracted_at": "2026-01-15T00:24:17.529133",
  "chapters": [
    {
      "number": "1",
      "title": "2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)",
      "start_page": 1,
      "end_page": 6,
      "content": "2022 ESC Guidelines on cardio-oncology\ndeveloped in collaboration with the European\nHematology Association (EHA), the European\nSociety for Therapeutic Radiology and\nOncology (ESTRO) and the International\nCardio-Oncology Society (IC-OS)\nDeveloped by the task force on cardio-oncology of the European\nSociety of Cardiology (ESC)\nAuthors/Task Force Members: Alexander R. Lyon*† (Chairperson) (United\nKingdom), Teresa López-Fernández*† (Chairperson) (Spain), Liam S. Couch (Task\nForce Coordinator) (United Kingdom), Riccardo Asteggiano (Italy),\nMarianne C. Aznar1 (United Kingdom), Jutta Bergler-Klein (Austria),\nGiuseppe Boriani (Italy), Daniela Cardinale (Italy), Raul Cordoba2 (Spain),\nBernard Cosyns (Belgium), David J. Cutter (United Kingdom),\nEvandro de Azambuja (Belgium), Rudolf A. de Boer (Netherlands), Susan F. Dent3\n(United States of America), Dimitrios Farmakis (Cyprus), Soﬁe A. Gevaert\n(Belgium), Diana A. Gorog (United Kingdom), Joerg Herrmann3 (United States of\nAmerica), Daniel Lenihan3 (United States of America), Javid Moslehi (United\nStates of America), Brenda Moura (Portugal), Sonja S. Salinger (Serbia),\nRichard Stephens (United Kingdom), Thomas M. Suter (Switzerland),\nSebastian Szmit (Poland), Juan Tamargo (Spain), Paaladinesh Thavendiranathan\n(Canada), Carlo G. Tocchetti (Italy), Peter van der Meer (Netherlands),\nHelena J.H. van der Pal (Netherlands), and ESC Scientiﬁc Document Group\n*Corresponding authors: Alexander R. Lyon, National Heart and Lung Institute, Imperial College London and Cardio-Oncology Service, Royal Brompton Hospital, London, United\nKingdom. Tel: +44 207 352 8121, E-mail: a.lyon@imperial.ac.uk.\nTeresa López-Fernández, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain. Tel: +34 619 227 076, E-mail: tlfernandez8@gmail.com.\n† The two chairpersons contributed equally to the document and are joint corresponding authors.\nAuthor/Task Force Member afﬁliations are listed in Author information.\n1Representing the European Society for Therapeutic Radiology and Oncology (ESTRO); 2representing the European Hematology Association (EHA); 3representing the International\nCardio-Oncology Society (IC-OS).\nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.\nESC subspecialty communities having participated in the development of this document:\nAssociations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC),\nEuropean Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).\nCouncils: Council of Cardio-Oncology, Council on Hypertension, Council on Valvular Heart Disease.\nWorking Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, e-Cardiology, Myocardial Function, Pulmonary Circulation and Right Ventricular Function,\nThrombosis.\nPatient Forum\nEuropean Heart Journal (2022) 43, 4229–4361\nhttps://doi.org/10.1093/eurheartj/ehac244\nESC GUIDELINES\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nDocument Reviewers: Patrizio Lancellotti (CPG Review Coordinator) (Belgium), Franck Thuny (CPG Review\nCoordinator) (France), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Berthe Aleman1 (Netherlands),\nJoachim Alexandre (France), Ana Barac3 (United States of America), Michael A. Borger (Germany),\nRuben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta Čelutkienė (Lithuania), Maja Cikes\n(Croatia), Alain Cohen-Solal (France), Kreena Dhiman (United Kingdom), Stéphane Ederhy (France),\nThor Edvardsen (Norway), Laurent Fauchier (France), Michael Fradley3 (United States of America), Julia Grapsa\n(United Kingdom), Sigrun Halvorsen (Norway), Michael Heuser2 (Germany), Marc Humbert (France),\nTiny Jaarsma (Sweden), Thomas Kahan (Sweden), Aleksandra Konradi (Russian Federation),\nKonstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Bonnie Ky3 (United States\nof America), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip\n(United Kingdom), Maja-Lisa Løchen (Norway), Katarzyna Malaczynska-Rajpold (United Kingdom),\nMarco Metra (Italy), Richard Mindham (United Kingdom), Marie Moonen (Belgium), Tomas G. Neilan\n(United States of America), Jens Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva Prescott\n(Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem (France), Gianluigi Savarese (Sweden), Marta Sitges\n(Spain), Jurrien ten Berg (Netherlands), Rhian M. Touyz (Canada/United Kingdom), Agnieszka Tycinska\n(Poland), Matthias Wilhelm (Switzerland), and Jose Luis Zamorano (Spain)\nAll experts involved in the development of these Guidelines have submitted declarations of interest. These have\nbeen compiled in a report and published in a supplementary document simultaneously to the Guidelines. The\nreport is also available on the ESC website www.escardio.org/Guidelines\nSee the European Heart Journal online for supplementary data that includes background information and\ndetailed discussion of the data that have provided the basis of the guidelines.\n- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -\nKeywords\nGuidelines • Androgen deprivation therapy • Anthracycline • Atrial ﬁbrillation • Arrhythmias • Biomarkers •\nCancer • Cancer survivors • Carcinoid syndrome • Amyloid light-chain cardiac amyloidosis • Cardiac magnetic\nresonance • Cardiac tumour • Cardio-oncology • Cardiotoxicity • Coronary artery disease • Chemotherapy •\nEchocardiography • Fluoropyrimidine • Heart failure • Haematopoietic stem cell transplantation • Hormone therapy\n• Hypertension • Immunotherapy • Ischaemic heart disease • Myocarditis • Pericardial disease • Pulmonary\nhypertension • Thrombosis • Risk stratiﬁcation • Trastuzumab • Valvular heart disease • Vascular endothelial\ngrowth factor inhibitors (VEGFi) • Venous thromboembolism • Pericardial disease • Proteasome inhibitors • QTc\nprolongation • Radiotherapy • Strain\nThe content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC\nGuidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University\nPress, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).\nDisclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the\ntime of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations\nor guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the\nESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strat-\negies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consid-\neration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health\nprofessionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to\nmanage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to\nverify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\nThis article has been co-published with permission in the European Heart Journal and the European Heart Journal – Cardiovascular Imaging. © The European Society of Cardiology 2022. All\nrights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For\npermissions please e-mail: journals.permissions@oup.com.\n4230\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nTable of contents\n1. Preamble ........................................................................................................\n4236\n2. Introduction .................................................................................................\n4238\n2.1. Cancer and cardiovascular needs of patients with cancer\n4238\n2.2. Role of cardio-oncology services ............................................... 4238\n2.3. General principles of cardio-oncology ..................................... 4239\n3. Cancer therapy-related cardiovascular toxicity deﬁnitions .....\n4242\n4. Cardiovascular toxicity risk stratiﬁcation before anticancer\ntherapy .................................................................................................................\n4244\n4.1. General approach to cardiovascular toxicity risk in patients\nwith cancer ................................................................................................... 4244\n4.2. History and clinical examination ................................................. 4249\n4.3. Electrocardiogram ............................................................................. 4249\n4.4. Cardiac serum biomarkers ............................................................ 4251\n4.5. Cardiovascular imaging ................................................................... 4252\n4.6. Cardiopulmonary ﬁtness assessment ....................................... 4253\n4.7. Cardiovascular risk evaluation before cancer surgery ...... 4254\n4.8. Genetic testing ................................................................................... 4254\n5. Prevention and monitoring of cardiovascular complications\nduring cancer therapy ...................................................................................\n4254\n5.1. General principles ............................................................................. 4254\n5.2. Primary prevention strategies ...................................................... 4256\n5.2.1. Primary prevention of cancer therapy-related\ncardiovascular toxicity during anthracycline\nchemotherapy ..................................................................................\n4256\n5.2.2. Primary prevention of radiation-induced\ncardiovascular toxicity ..................................................................\n4256\n5.3. Secondary prevention strategies ................................................ 4257\n5.4. Cardiovascular surveillance during cancer therapies ......... 4257\n5.4.1. Cardiac serum biomarkers .............................................\n4257\n5.4.2. Cardiac imaging ....................................................................\n4257\n5.5. Cancer therapy-related cardiovascular toxicity monitoring\nprotocols ....................................................................................................... 4259\n5.5.1. Anthracycline chemotherapy .........................................\n4259\n5.5.2. HER2-targeted therapies .................................................\n4259\n5.5.3. Fluoropyrimidines ...............................................................\n4261\n5.5.4. Vascular endothelial growth factor inhibitors ........\n4261\n5.5.5. Multitargeted kinase inhibitors targeting BCR-ABL\n4264\n5.5.6. Bruton tyrosine kinase inhibitors .................................\n4267\n5.5.7. Multiple myeloma therapies ...........................................\n4268\n5.5.8. Rapidly accelerated ﬁbrosarcoma and mitogen-\nactivated extracellular signal-regulated kinase inhibitor\ntreatment ............................................................................................\n4271\n5.5.9. Immune checkpoint inhibitors ......................................\n4273\n5.5.10. Androgen deprivation therapies for prostate\ncancer ...................................................................................................\n4274\n5.5.11. Endocrine therapies for breast cancer ...................\n4276\n5.5.12. Cyclin-dependent kinase 4/6 inhibitors ..................\n4276\n5.5.13. Anaplastic lymphoma kinase inhibitors ...................\n4277\n5.5.14. Epidermal growth factor receptor inhibitors ......\n4277\n5.5.15. Chimeric antigen receptor\nT cell and tumour-inﬁltrating lymphocytes therapies .....\n4278\n5.5.16. Radiotherapy ......................................................................\n4279\n5.5.17. Haematopoietic stem cell transplantation ............\n4279\n5.5.18. Other cancer treatments .............................................\n4282\n6. Diagnosis and management of acute and subacute\ncardiovascular toxicity in patients receiving anticancer treatment\n4282\n6.1. Cancer therapy-related cardiac dysfunction .......................... 4282\n6.1.1. Anthracycline chemotherapy-related cardiac\ndysfunction .........................................................................................\n4282\n6.1.2. Human epidermal receptor 2-targeted therapy-\nrelated cardiac dysfunction .........................................................\n4284\n6.1.3. Immune checkpoint inhibitor-associated\nmyocarditis and non-inﬂammatory heart failure ...............\n4286\n6.1.4. Chimeric antigen receptor T cell and tumour-\ninﬁltrating lymphocytes therapies and heart dysfunction\n4290\n6.1.5. Heart failure during haematopoietic stem cell\ntransplantation .................................................................................\n4291\n6.1.6. Takotsubo syndrome and cancer ................................\n4291\n6.2. Coronary artery disease ................................................................. 4291\n6.2.1. Acute coronary syndromes ............................................\n4291\n6.2.2. Chronic coronary syndromes .......................................\n4293\n6.3. Valvular heart disease ...................................................................... 4293\n6.4. Cardiac arrhythmias ......................................................................... 4294\n6.4.1. Atrial ﬁbrillation ...................................................................\n4294\n6.4.2. Long corrected QT interval and ventricular\narrhythmias ........................................................................................\n4298\n6.4.3. Bradyarrhythmias ................................................................\n4300\n6.5. Arterial hypertension ....................................................................... 4300\n6.6. Thrombosis and thromboembolic events .............................. 4303\n6.6.1. Venous thromboembolism .............................................\n4303\n6.6.2. Arterial thromboembolism ............................................\n4304\n6.6.3. Intracardiac thrombosis ...................................................\n4304\n6.6.4. Anticoagulation therapy ...................................................\n4305\n6.7. Bleeding complications .................................................................... 4306\n6.7.1. High-risk patients ................................................................\n4306\n6.7.2. Antiplatelet therapy ...........................................................\n4306\n6.7.3. Management of bleeding ..................................................\n4306\n6.8. Peripheral artery disease ................................................................ 4307\n6.9. Pulmonary hypertension ................................................................ 4307\n6.10. Pericardial diseases ......................................................................... 4308\n6.10.1. Pericarditis ...........................................................................\n4308\n6.10.2. Pericardial effusion ...........................................................\n4308\n7. End-of-cancer therapy cardiovascular risk assessment .............\n4309\n7.1. Cardiovascular evaluation during the ﬁrst year after\ncardiotoxic anticancer therapy ............................................................ 4309\n7.2. Which cancer survivors require cardiovascular surveillance\nin the ﬁrst year after cancer treatment? .......................................... 4309\n7.3. Management of cancer therapy-related cardiac dysfunction\nat the end-of-therapy assessment ...................................................... 4310\n7.4. Cardiopulmonary exercise testing and ﬁtness during the\nend-of-therapy assessment .................................................................... 4310\n7.5. The role of cardiac rehabilitation ............................................... 4310\n8. Long-term follow-up and chronic cardiovascular complications\nin cancer survivors ..........................................................................................\n4312\n8.1. Cancer survivors ................................................................................ 4312\n8.1.1. Adult survivors of childhood and adolescent\ncancer ...................................................................................................\n4312\n8.1.2. Adult cancer survivors ......................................................\n4313\n8.2. Myocardial dysfunction and heart failure ................................ 4315\n8.3. Coronary artery disease ................................................................. 4316\n8.4. Valvular heart disease ...................................................................... 4317\n8.5. Peripheral artery disease and stroke ........................................ 4317\n8.6. Pericardial complications ................................................................ 4317\n8.7. Arrhythmias and autonomic disease ......................................... 4318\nESC Guidelines\n4231\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus,\nand hypertension ........................................................................................ 4318\n8.9. Pregnancy in cancer survivors ..................................................... 4318\n8.10. Pulmonary hypertension .............................................................. 4319\n9. Special populations ....................................................................................\n4319\n9.1. Cardiac tumours ................................................................................ 4319\n9.2. Pregnant patients with cancer ..................................................... 4319\n9.2.1. Left ventricular dysfunction and heart failure ........\n4320\n9.2.2. Venous thromboembolism and pulmonary\nembolism ..................................................................................... 4320\n9.3. Carcinoid valvular heart disease ................................................. 4323\n9.4. Amyloid light-chain cardiac amyloidosis .................................. 4324\n9.5. Cardiac implantable electronic devices .................................... 4326\n10. Patient information, communication, and self-management\n4330\n11. The role of scientiﬁc societies in the promotion and\ndevelopment of cardio-oncology in modern medicine ..................\n4331\n12. Key messages ............................................................................................\n4331\n13. Future needs ..............................................................................................\n4332\n14. Gaps in evidence ......................................................................................\n4333\n15. ‘What to do’ and ‘what not to do’ messages from the\nGuidelines ...........................................................................................................\n4333\n16. Quality indicators for cardio-oncology ..........................................\n4342\n17. Supplementary data ................................................................................\n4342\n18. Data availability statement ...................................................................\n4342\n19. Author information ................................................................................\n4342\n20. Appendix .....................................................................................................\n4342\n21. References ..................................................................................................\n4343\nTables of Recommendations\nRecommendation Table 1 — Recommendations for a general\napproach to cardiovascular toxicity risk categorization .................\n4249\nRecommendation Table 2 — Recommendations for\nelectrocardiogram baseline assessment ................................................\n4251\nRecommendation Table 3 — Recommendation for cardiac\nbiomarker assessment prior to potentially cardiotoxic therapies .\n4252\nRecommendation Table 4 — Recommendations for cardiac\nimaging modalities in patients with cancer ..........................................\n4253\nRecommendation Table 5 — Recommendations for\nprimary prevention of cancer therapy-related cardiovascular\ntoxicity ......................................................................................................... 4256\nRecommendation Table 6 — Recommendation for secondary\nprevention of cancer therapy-related cardiovascular toxicity .....\n4257\nRecommendation Table 7 — Recommendations for baseline risk\nassessment and monitoring during anthracycline chemotherapy\nand in the ﬁrst 12 months after therapy ..............................................\n4259\nRecommendation Table 8 — Recommendations for baseline risk\nassessment and monitoring during human epidermal receptor\n2-targeted therapies and in the ﬁrst 12 months after therapy ...\n4260\nRecommendation Table 9 — Recommendations for baseline risk\nassessment and monitoring during ﬂuoropyrimidine therapy .....\n4261\nRecommendation Table 10 — Recommendations for baseline\nrisk assessment and monitoring during vascular endothelial\ngrowth factor inhibitors ...............................................................................\n4264\nRecommendation Table 11 — Recommendations for baseline\nrisk assessment and monitoring during second- and\nthird-generation breakpoint cluster region–Abelson oncogene\nlocus tyrosine kinase inhibitors .................................................................\n4267\nRecommendation Table 12 — Recommendations for baseline\nrisk assessment and monitoring during Bruton tyrosine kinase\ninhibitor therapy ..............................................................................................\n4267\nRecommendation Table 13 — Recommendations for baseline\nrisk assessment and monitoring during multiple myeloma\ntherapies ..................................................................................................... 4271\nRecommendation Table 14 — Recommendations for baseline\nrisk assessment and monitoring during combined rapidly\naccelerated ﬁbrosarcoma and mitogen-activated extracellular\nsignal-regulated kinase inhibitor therapy ...............................................\n4272\nRecommendation Table 15 — Recommendations for baseline\nrisk assessment and monitoring during immunotherapy ...............\n4274\nRecommendation Table 16 — Recommendations for baseline\nrisk assessment and monitoring during androgen deprivation\ntherapy for prostate cancer .......................................................................\n4276\nRecommendation Table 17 — Recommendations for baseline\nrisk assessment and monitoring during endocrine therapy for\nbreast cancer ....................................................................................................\n4276\nRecommendation Table 18 — Recommendations for baseline\nrisk assessment and monitoring during cyclin-dependent kinase\n4/6 inhibitor therapy ......................................................................................\n4277\nRecommendation Table 19 — Recommendations for baseline\nrisk assessment and monitoring during anaplastic lymphoma\nkinase and epidermal growth factor receptor inhibitors ...............\n4277\nRecommendation Table 20 — Recommendations for baseline\nrisk assessment and monitoring in patients receiving chimeric\nantigen receptor T cell and tumour-inﬁltrating lymphocytes\ntherapies .............................................................................................................\n4279\nRecommendation Table 21 — Recommendations for baseline\nrisk assessment of patients before radiotherapy to a volume\nincluding the heart ..........................................................................................\n4279\nRecommendation Table 22 — Recommendations for baseline\nrisk assessment in haematopoietic stem cell transplantation\npatients ................................................................................................................\n4281\nRecommendation Table 23 — Recommendation for the\nmanagement of cardiovascular disease and cancer\ntherapy-related cardiovascular toxicity in patients receiving\nanticancer treatment .....................................................................................\n4282\nRecommendation Table 24 — Recommendations for the\nmanagement of cancer treatment-related cardiac dysfunction\nduring anthracycline chemotherapy ........................................................\n4284\nRecommendation Table 25 — Recommendations for the\nmanagement of cancer treatment-related cardiac dysfunction\nduring human epidermal receptor 2-targeted therapies ...............\n4286\nRecommendation Table 26 — Recommendations for the\ndiagnosis and management of immune checkpoint\ninhibitor-associated myocarditis ...............................................................\n4289\nRecommendation Table 27 — Recommendations for the\ndiagnosis and management of Takotsubo syndrome in patients\nwith cancer ........................................................................................................\n4291\nRecommendation Table 28 — Recommendations for the\nmanagement of acute coronary syndromes in patients receiving\nanticancer treatment .....................................................................................\n4292\nRecommendation Table 29 — Recommendation for the\nmanagement of chronic coronary syndromes in patients receiving\nanticancer treatment .....................................................................................\n4293\nRecommendation Table 30 — Recommendations for the\nmanagement of valvular heart disease in patients receiving\nanticancer treatment .....................................................................................\n4293\n4232\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 31 — Recommendations for the\nmanagement of atrial ﬁbrillation in patients receiving anticancer\ntreatment ............................................................................................................\n4297\nRecommendation Table 32 — Recommendations for the\nmanagement of long corrected QT interval and ventricular\narrhythmias in patients receiving anticancer treatment .................\n4300\nRecommendation Table 33 — Recommendations for the\nmanagement of arterial hypertension in patients receiving\nanticancer treatment .....................................................................................\n4302\nRecommendation Table 34 — Recommendations for the\nmanagement of venous thromboembolism in patients receiving\nanticancer treatment .....................................................................................\n4305\nRecommendation Table 35 — Recommendations for venous\nthromboembolism prophylaxis during anticancer treatment ......\n4306\nRecommendation Table 36 — Recommendation for management\nof peripheral artery disease during anticancer treatment ..................\n4307\nRecommendation Table 37 — Recommendations for the\nmanagement of pulmonary hypertension during anticancer\ntreatment ............................................................................................................\n4308\nRecommendation Table 38 — Recommendations for the\nmanagement of pericardial diseases in patients receiving\nanticancer treatment .....................................................................................\n4309\nRecommendation Table 39 — Recommendations for\nend-of-cancer therapy cardiovascular risk assessment ...................\n4312\nRecommendation Table 40 — Recommendations for\ncardiovascular surveillance in asymptomatic adults who are\nchildhood and adolescent cancer survivors .........................................\n4313\nRecommendation Table 41 — Recommendations for\ncardiovascular surveillance in asymptomatic adult cancer survivors\n4314\nRecommendation Table 42 — Recommendations for adult\ncancer survivors who develop cancer therapy-related cardiac\ndysfunction late after cardiotoxic cancer therapy ............................\n4316\nRecommendation Table 43 — Recommendations for adult\ncancer survivors with coronary artery disease ..................................\n4316\nRecommendation Table 44 — Recommendations for adult\ncancer survivors with valvular heart disease .......................................\n4317\nRecommendation Table 45 — Recommendation for adult cancer\nsurvivors with pericardial complications ...............................................\n4318\nRecommendation Table 46 — Recommendations for\ncardiovascular monitoring in cancer survivors during pregnancy\n4319\nRecommendation Table 47 — Recommendations for cardiovascular\nassessment and monitoring of pregnant women with cancer .............\n4323\nRecommendation Table 48 — Recommendations for carcinoid\nvalvular heart diseases ...................................................................................\n4323\nRecommendation Table 49 — Recommendations for amyloid\nlight-chain cardiac amyloidosis diagnosis and monitoring ..............\n4326\nRecommendation Table 50 — Recommendations for risk\nstratiﬁcation and monitoring for patients with cardiac implantable\nelectronic devices undergoing radiotherapy ....................................................\n4330\nList of tables\nTable 1 Classes of recommendations ....................................................\n4237\nTable 2 Levels of evidence ..........................................................................\n4237\nTable 3 Cancer therapy-related cardiovascular toxicity deﬁnitions\n4243\nTable 4 Heart Failure Association–International Cardio-Oncology\nSociety baseline cardiovascular toxicity risk stratiﬁcation ............... 4246\nTable 5 Anthracycline equivalence dose ...............................................\n4247\nTable 6 Factors that could inﬂuence peri-operative risk during\ncancer surgery and preventive strategies .............................................\n4254\nTable 7 Cancer treatments that predispose to acute coronary\nsyndromes ..........................................................................................................\n4291\nTable 8 Risk factors for drug-induced QT prolongation and\ntorsade de pointes ..........................................................................................\n4298\nTable 9 Classiﬁcation of corrected QT interval prolongation\ninduced by cancer drug therapy ...............................................................\n4298\nTable 10 Risk factors for future cardiovascular disease at the\nend-of-cancer therapy cardiovascular risk assessment ...................\n4310\nTable 11 Risk categories for asymptomatic adults who are\nchildhood and adolescent cancer survivors .........................................\n4313\nTable 12 Risk categories for asymptomatic adult cancer survivors\n4314\nTable 13 Management strategies and surgery indications for\nsymptomatic and asymptomatic patients with benign and\nmalignant cardiac tumours ..........................................................................\n4321\nList of ﬁgures\nFigure 1 Video 1 Central Illustration: Dynamics of\ncardiovascular toxicity risk of patients with cancer over their\ntherapy continuum .................................................................................. 4239\nFigure 2 Cardio-oncology care pathways .............................................\n4240\nFigure 3 Baseline cardiovascular toxicity risk assessment checklist\n4241\nFigure 4 Dimensions of cancer therapy-related cardiovascular\ntoxicity risk and disease severity ..............................................................\n4242\nFigure 5 Baseline cardiovascular toxicity risk assessment before\nanticancer therapy ..........................................................................................\n4245\nFigure 6 General cardio-oncology approach after Heart Failure\nAssociation–International Cardio-Oncology Society\ncardiovascular toxicity risk assessment ................................................ 4248\nFigure 7 Baseline screening recommendations for patients with\ncancer treated with potentially cardiotoxic drugs ............................\n4250\nFigure 8 Recommended transthoracic echocardiography and\ncardiac magnetic resonance imaging parameters in the evaluation of\npatients with cancer ...............................................................................................\n4252\nFigure 9 Primary and secondary cancer therapy-related\ncardiovascular toxicity prevention ..................................................................\n4255\nFigure 10 Cardiovascular toxicity monitoring in patients receiving\nanthracycline chemotherapy ......................................................................\n4258\nFigure 11 Cardiovascular toxicity monitoring in patients receiving\nhuman epidermal receptor 2-targeted therapies ..............................\n4260\nFigure 12 Vascular endothelial growth factor inhibitors-related\ncardiovascular toxicities ...............................................................................\n4262\nFigure 13 Cardiovascular toxicity monitoring in patients receiving\nvascular endothelial growth factor inhibitors .....................................\n4263\nFigure 14 Breakpoint cluster region–Abelson oncogene locus\ntyrosine kinase inhibitor-related cardiovascular toxicities ............\n4265\nFigure 15 Second- and third-generation breakpoint cluster\nregion–Abelson oncogene locus tyrosine kinase inhibitors\nsurveillance protocol .....................................................................................\n4266\nFigure 16 Multiple myeloma drug-related cardiovascular toxicities\n4268\nFigure 17 Cardiovascular monitoring in patients with multiple\nmyeloma receiving proteasome inhibitors ...........................................\n4269\nFigure 18 Risk factors for venous thromboembolic events in\npatients with multiple myeloma ...............................................................\n4270\nFigure 19 Rapidly accelerated ﬁbrosarcoma and mitogen-activated\nextracellular signal-regulated kinase inhibitor-related cardiovascular\ntoxicities ........................................................................................................................\n4272\nESC Guidelines\n4233\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nFigure 20 Cardiovascular surveillance in patients treated with\nimmune checkpoint inhibitors ...................................................................\n4273\nFigure 21 Androgen deprivation therapy-related cardiovascular\ntoxicities ..............................................................................................................\n4275\nFigure 22 Anaplastic lymphoma kinase and epidermal growth\nfactor receptor inhibitor-related cardiovascular toxicities ...........\n4278\nFigure 23 Radiotherapy mean heart dose and associated\ncardiovascular toxicity risk ..........................................................................\n4280\nFigure 24 Risk factors and cardiovascular surveillance in patients\nreferred for haematopoietic stem cell transplantation ..................\n4281\nFigure 25 Management of anthracycline chemotherapy-related\ncardiac dysfunction .........................................................................................\n4283\nFigure 26 Management of human epidermal receptor 2-targeted\ntherapy-related cardiac dysfunction ........................................................\n4285\nFigure 27 Direct and indirect immune checkpoint\ninhibitor-related cardiovascular toxicity ................................................\n4287\nFigure 28 Diagnosis and management of immune checkpoint\ninhibitor-related myocarditis ......................................................................\n4288\nFigure 29 Diagnosis and management workup in cancer-related\nTakotsubo syndrome ....................................................................................\n4290\nFigure 30 Pathophysiology of atrial ﬁbrillation associated with\ncancer ...................................................................................................................\n4295\nFigure 31 Structured approach to anticoagulation for atrial\nﬁbrillation in patients with cancer ............................................................\n4296\nFigure 32 Corrected QT interval monitoring before and during\ntreatment with corrected QT interval-prolonging anticancer drugs\n4299\nFigure 33 Recommended threshold for asymptomatic\nhypertension treatment in different clinical scenarios ....................\n4301\nFigure 34 Treatment of arterial hypertension in patients with\ncancer ...................................................................................................................\n4302\nFigure 35 Risk factors for venous thromboembolism in patients\nwith cancer ........................................................................................................\n4303\nFigure 36 Structured approach to anticoagulation for venous\nthromboembolism in patients with active cancer ............................\n4304\nFigure 37 Management of cancer therapy-related cardiac\ndysfunction after cancer therapy .............................................................\n4311\nFigure 38 Long-term follow-up in cancer survivors .........................\n4315\nFigure 39 Location of primary and secondary cardiac tumours .\n4320\nFigure 40 Diagnostic algorithm for cardiac masses ..........................\n4321\nFigure 41 Cardiac monitoring protocol for pregnant women\nreceiving anthracycline-based chemotherapy .....................................\n4322\nFigure 42 Carcinoid heart disease: clinical features and diagnostic\ntests .......................................................................................................................\n4324\nFigure 43 Non-invasive diagnosis of amyloid light-chain cardiac\namyloidosis .........................................................................................................\n4325\nFigure 44 Risk stratiﬁcation in patients with a cardiac implantable\nelectronic device undergoing radiotherapy .........................................\n4327\nFigure 45 Management of patients with a cardiac implantable\nelectronic device located in the radiotherapy treatment beam .\n4328\nFigure 46 Management of patients with a cardiac implantable\nelectronic device located outside the radiotherapy treatment\nvolume .................................................................................................................\n4329\nFigure 47 Patient information, communication, and\nself-management ..............................................................................................\n4330\nFigure 48 The role of scientiﬁc societies in the promotion and\ndevelopment of cardio-oncology .............................................................\n4331\nAbbreviations and acronyms\n2D\nTwo-dimensional\n3D\nThree-dimensional\n5-FU\n5-ﬂuorouracil\n5HIAA\n5-hydroxyindoleacetic acid\na′\nLate diastolic velocity of mitral annulus\nobtained by tissue Doppler imaging\nABC\nAtrial ﬁbrillation Better Care\nABI\nAnkle–brachial index\nAC\nAnthracycline chemotherapy\nACE-I\nAngiotensin-converting enzyme inhibitors\nACS\nAcute coronary syndromes\nADT\nAndrogen deprivation therapy\nADVANCE\nAction in Diabetes and Vascular Disease:\nPreterax and Diamicron-MR Controlled\nEvaluation\nAF\nAtrial ﬁbrillation\nAI\nAromatase inhibitors\nAL-CA\nAmyloid light-chain cardiac amyloidosis\nALK\nAnaplastic lymphoma kinase\nANS\nAutonomic nervous system\nARB\nAngiotensin receptor blockers\nARISTOTLE\nApixaban for Reduction in Stroke and Other\nThromboembolic Events in Atrial Fibrillation\nASCVD\nAtheroSclerotic Cardiovascular Disease\nASPIRE\nCarﬁlzomib, Lenalidomide, and\nDexamethasone vs. Lenalidomide and\nDexamethasone for the Treatment of\nPatients with Relapsed Multiple Myeloma\nASTCT\nAmerican Society for Transplantation and\nCellular Therapy\nATAC\n‘Arimidex’ and Tamoxifen Alone or in\nCombination\nATE\nArterial thromboembolism\nAV\nAtrioventricular\nBB\nBeta-blockers\nBC\nBreast cancer\nBCR-ABL\nBreakpoint cluster region–Abelson oncogene\nlocus\nBIG\nBreast International Group\nBLEED\nIncreased bleeding risk\nBMI\nBody mass index\nBNP\nB-type natriuretic peptide\nBP\nBlood pressure\nBTK\nBruton tyrosine kinase\nC\nChemotherapy cycle\nCABG\nCoronary artery bypass graft\nCAD\nCoronary artery disease\nCARDIOTOX\nCARDIOvascular TOXicity induced by\ncancer-related therapies\nCAR-T\nChimeric antigen receptor T cell\nCCB\nCalcium channel blockers\nCCS\nChronic coronary syndromes\nCCTA\nCoronary computed tomography\nangiography\n4234\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 2",
          "page": 2,
          "content": " |  | rheartj/article/43/41/4229/6673995 by\n | - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -\nKeywords Guidelines • Androgen deprivation therapy • Anthracycline • Atrial fibrillation • Arrhythmias • Biomarkers •\nCancer • Cancer survivors • Carcinoid syndrome • Amyloid light-chain cardiac amyloidosis • Cardiac magnetic\nresonance • Cardiac tumour • Cardio-oncology • Cardiotoxicity • Coronary artery disease • Chemotherapy •\nEchocardiography • Fluoropyrimidine • Heart failure • Haematopoietic stem cell transplantation • Hormone therapy\n• Hypertension • Immunotherapy • Ischaemic heart disease • Myocarditis • Pericardial disease • Pulmonary\nhypertension • Thrombosis • Risk stratification • Trastuzumab • Valvular heart disease • Vascular endothelial\ngrowth factor inhibitors (VEGFi) • Venous thromboembolism • Pericardial disease • Proteasome inhibitors • QTc\nprolongation • Radiotherapy • Strain | \n |  | ",
          "rows": 3,
          "cols": 3
        }
      ],
      "keywords": [
        "society",
        "ct",
        "intervention",
        "cardio",
        "association",
        "international",
        "developed",
        "heart failure",
        "therapeutic",
        "radiology",
        "estro",
        "european",
        "guidelines",
        "oncology",
        "pci",
        "collaboration",
        "imaging",
        "hematology"
      ]
    },
    {
      "number": "2",
      "title": "Abbreviations and acronyms",
      "start_page": 6,
      "end_page": 8,
      "content": "Figure 20 Cardiovascular surveillance in patients treated with\nimmune checkpoint inhibitors ...................................................................\n4273\nFigure 21 Androgen deprivation therapy-related cardiovascular\ntoxicities ..............................................................................................................\n4275\nFigure 22 Anaplastic lymphoma kinase and epidermal growth\nfactor receptor inhibitor-related cardiovascular toxicities ...........\n4278\nFigure 23 Radiotherapy mean heart dose and associated\ncardiovascular toxicity risk ..........................................................................\n4280\nFigure 24 Risk factors and cardiovascular surveillance in patients\nreferred for haematopoietic stem cell transplantation ..................\n4281\nFigure 25 Management of anthracycline chemotherapy-related\ncardiac dysfunction .........................................................................................\n4283\nFigure 26 Management of human epidermal receptor 2-targeted\ntherapy-related cardiac dysfunction ........................................................\n4285\nFigure 27 Direct and indirect immune checkpoint\ninhibitor-related cardiovascular toxicity ................................................\n4287\nFigure 28 Diagnosis and management of immune checkpoint\ninhibitor-related myocarditis ......................................................................\n4288\nFigure 29 Diagnosis and management workup in cancer-related\nTakotsubo syndrome ....................................................................................\n4290\nFigure 30 Pathophysiology of atrial ﬁbrillation associated with\ncancer ...................................................................................................................\n4295\nFigure 31 Structured approach to anticoagulation for atrial\nﬁbrillation in patients with cancer ............................................................\n4296\nFigure 32 Corrected QT interval monitoring before and during\ntreatment with corrected QT interval-prolonging anticancer drugs\n4299\nFigure 33 Recommended threshold for asymptomatic\nhypertension treatment in different clinical scenarios ....................\n4301\nFigure 34 Treatment of arterial hypertension in patients with\ncancer ...................................................................................................................\n4302\nFigure 35 Risk factors for venous thromboembolism in patients\nwith cancer ........................................................................................................\n4303\nFigure 36 Structured approach to anticoagulation for venous\nthromboembolism in patients with active cancer ............................\n4304\nFigure 37 Management of cancer therapy-related cardiac\ndysfunction after cancer therapy .............................................................\n4311\nFigure 38 Long-term follow-up in cancer survivors .........................\n4315\nFigure 39 Location of primary and secondary cardiac tumours .\n4320\nFigure 40 Diagnostic algorithm for cardiac masses ..........................\n4321\nFigure 41 Cardiac monitoring protocol for pregnant women\nreceiving anthracycline-based chemotherapy .....................................\n4322\nFigure 42 Carcinoid heart disease: clinical features and diagnostic\ntests .......................................................................................................................\n4324\nFigure 43 Non-invasive diagnosis of amyloid light-chain cardiac\namyloidosis .........................................................................................................\n4325\nFigure 44 Risk stratiﬁcation in patients with a cardiac implantable\nelectronic device undergoing radiotherapy .........................................\n4327\nFigure 45 Management of patients with a cardiac implantable\nelectronic device located in the radiotherapy treatment beam .\n4328\nFigure 46 Management of patients with a cardiac implantable\nelectronic device located outside the radiotherapy treatment\nvolume .................................................................................................................\n4329\nFigure 47 Patient information, communication, and\nself-management ..............................................................................................\n4330\nFigure 48 The role of scientiﬁc societies in the promotion and\ndevelopment of cardio-oncology .............................................................\n4331\nAbbreviations and acronyms\n2D\nTwo-dimensional\n3D\nThree-dimensional\n5-FU\n5-ﬂuorouracil\n5HIAA\n5-hydroxyindoleacetic acid\na′\nLate diastolic velocity of mitral annulus\nobtained by tissue Doppler imaging\nABC\nAtrial ﬁbrillation Better Care\nABI\nAnkle–brachial index\nAC\nAnthracycline chemotherapy\nACE-I\nAngiotensin-converting enzyme inhibitors\nACS\nAcute coronary syndromes\nADT\nAndrogen deprivation therapy\nADVANCE\nAction in Diabetes and Vascular Disease:\nPreterax and Diamicron-MR Controlled\nEvaluation\nAF\nAtrial ﬁbrillation\nAI\nAromatase inhibitors\nAL-CA\nAmyloid light-chain cardiac amyloidosis\nALK\nAnaplastic lymphoma kinase\nANS\nAutonomic nervous system\nARB\nAngiotensin receptor blockers\nARISTOTLE\nApixaban for Reduction in Stroke and Other\nThromboembolic Events in Atrial Fibrillation\nASCVD\nAtheroSclerotic Cardiovascular Disease\nASPIRE\nCarﬁlzomib, Lenalidomide, and\nDexamethasone vs. Lenalidomide and\nDexamethasone for the Treatment of\nPatients with Relapsed Multiple Myeloma\nASTCT\nAmerican Society for Transplantation and\nCellular Therapy\nATAC\n‘Arimidex’ and Tamoxifen Alone or in\nCombination\nATE\nArterial thromboembolism\nAV\nAtrioventricular\nBB\nBeta-blockers\nBC\nBreast cancer\nBCR-ABL\nBreakpoint cluster region–Abelson oncogene\nlocus\nBIG\nBreast International Group\nBLEED\nIncreased bleeding risk\nBMI\nBody mass index\nBNP\nB-type natriuretic peptide\nBP\nBlood pressure\nBTK\nBruton tyrosine kinase\nC\nChemotherapy cycle\nCABG\nCoronary artery bypass graft\nCAD\nCoronary artery disease\nCARDIOTOX\nCARDIOvascular TOXicity induced by\ncancer-related therapies\nCAR-T\nChimeric antigen receptor T cell\nCCB\nCalcium channel blockers\nCCS\nChronic coronary syndromes\nCCTA\nCoronary computed tomography\nangiography\n4234\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCCU\nCoronary care unit\nCDK\nCyclin-dependent kinase\nCHA2DS2-VASc\nCongestive heart failure, Hypertension, Age\n≥75 years (2 points), Diabetes mellitus,\nStroke (2 points)—Vascular disease, Age\n65–74 years, Sex category (female)\nCIED\nCardiac implantable electronic device\nCML\nChronic myeloid leukaemia\nCMR\nCardiac magnetic resonance\nCOMPASS-CAT\nProspective COmparison of Methods for\nthromboembolic risk assessment with clinical\nPerceptions and AwareneSS in real-life\npatients—Cancer Associated Thrombosis\nCPET\nCardiopulmonary exercise testing\nCrCl\nCreatinine clearance\nCRF\nCardiorespiratory ﬁtness\nCRS\nCytokine release syndrome\nCS\nCancer survivors\nCT\nComputed tomography\nCTLA-4\nCytotoxic T lymphocyte-associated\nantigen-4\ncTn\nCardiac troponin\nCTRCD\nCancer therapy-related cardiac\ndysfunction\nCTR-CVT\nCancer therapy-related cardiovascular\ntoxicity\nCV\nCardiovascular\nCVD\nCardiovascular disease\nCVRF\nCardiovascular risk factors\nDAPT\nDual antiplatelet therapy\nDASISION\nDASatinib vs. Imatinib Study In\ntreatment-Naïve chronic myeloid\nleukaemia patients\nDL\nDyslipidaemia\nDM\nDiabetes mellitus\nDNR\nDo not resuscitate\nDVT\nDeep vein thrombosis\nE\nMitral inﬂow early diastolic velocity\nobtained by pulsed wave\ne′\nEarly diastolic velocity of the mitral annulus\nobtained by tissue Doppler imaging\nEACTS\nEuropean Association for Cardio-Thoracic\nSurgery\nEBC\nEarly breast cancer\nECG\nElectrocardiogram\nEcho\nEchocardiography\nECV\nExtracellular volume fraction\neGFR\nEstimated glomerular ﬁltration rate\nEGFR\nEpidermal growth factor receptor\nEMA\nEuropean Medicines Agency\nEMB\nEndomyocardial biopsy\nENGAGE AF-TIMI 48\nEffective Anticoagulation with Factor\nXa Next Generation in Atrial Fibrillation-\nThrombolysis in Myocardial Infarction 48\nENOXACAN\nEnoxaparin and Cancer\nEoL\nEnd of life\nERS\nEuropean Respiratory Society\nESC\nEuropean Society of Cardiology\nESC-CCO\nEuropean Society of Cardiology Council of\nCardio-Oncology\nESH\nEuropean Society of Hypertension\nEuroSCORE\nEuropean System for Cardiac Operative\nRisk Evaluation\nFAC\nFractional area change\nFDA\nFood and Drug Administration\nFLT3\nFMS-like tyrosine kinase 3\nFWLS\nFree wall longitudinal strain\nGI\nGastrointestinal\nGLS\nGlobal longitudinal strain\nGnRH\nGonadotropin-releasing hormone\nGU\nGenitourinary\nGVHD\nGraft vs. host disease\nGy\nGray\nHAS-BLED\nHypertension, Abnormal renal and liver\nfunction, Stroke, Bleeding Labile\ninternational normalized ratio, Elderly,\nDrugs or alcohol\nHbA1c\nGlycated haemoglobin\nHDU\nHigh-dependency unit\nHER2\nHuman epidermal receptor 2\nHF\nHeart failure\nHFA\nHeart Failure Association\nHFmrEF\nHeart failure with mildly reduced ejection\nfraction\nHFpEF\nHeart failure with preserved ejection fraction\nHFrEF\nHeart failure with reduced ejection fraction\nHG\nHyperglycaemia\nHIIT\nHigh-intensity interval training\nHSCT\nHaematopoietic stem cell transplantation\nhs-cTn\nHigh-sensitivity cardiac troponin\nHTN\nHypertension\nICD\nImplantable cardioverter deﬁbrillator\nICI\nImmune checkpoint inhibitors\nICOS\nInternational Cardio-Oncology Society\nICU\nIntensive care unit\nIHD\nIschaemic heart disease\nIMiD\nImmunomodulatory drugs\ni.v.\nIntravenous\nIVC\nInferior vena cava\nIVS\nIntraventricular septum\nLA\nLeft atrial\nLAA\nLeft atrial appendage\nLGE\nLate gadolinium enhancement\nLIMA\nLeft internal mammary artery\nLMWH\nLow-molecular-weight heparins\nLQTS\nLong QT syndrome\nLS\nLongitudinal strain\nLV\nLeft ventricular\nLVD\nLeft ventricular dysfunction\nLVEDD\nLeft ventricular end diastolic diameter\nLVEF\nLeft ventricular ejection fraction\nLVV\nLeft ventricular volume\nM\nMonths\nMACE\nMajor adverse cardiovascular events\nMCS\nMechanical circulatory support\nMDT\nMultidisciplinary team\nESC Guidelines\n4235\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nMedDRA\nMedical dictionary for regulatory activities\nMEK\nMitogen-activated extracellular\nsignal-regulated kinase\nMHD\nMean heart dose\nMI\nMyocardial infarction\nMM\nMultiple myeloma\nMUGA\nMultigated acquisition nuclear imaging\nN\nNo\nNOAC\nNon-vitamin K antagonist oral\nanticoagulants\nNP\nNatriuretic peptides\nNSTE-ACS\nNon-ST-segment elevation acute coronary\nsyndromes\nNT-proBNP\nN-terminal pro-B-type natriuretic peptide\nPAD\nPeripheral artery disease\nPAH\nPulmonary arterial hypertension\nPAP\nPulmonary arterial pressure\nPCI\nPercutaneous coronary intervention\nPD-1\nProgrammed death-1\nPD-L1\nProgrammed death-ligand 1\nPE\nPulmonary embolism\nPeric-E\nPericardial effusion\nPET\nPositron emission tomography\nPH\nPulmonary hypertension\nPI\nProteasome inhibitors\nPleu-E\nPleural effusion\nPRECISE-DAPT\nPREdicting bleeding Complications In\npatients undergoing Stent implantation and\nsubsEquent Dual Anti Platelet Therapy\nPRONOUNCE\nA Trial Comparing Cardiovascular Safety\nof Degarelix Versus Leuprolide in Patients\nWith Advanced Prostate Cancer and\nCardiovascular Disease\nPW\nLeft ventricular posterior wall\nQI\nQuality indicator\n↑QTc\nCorrected QT interval prolongation\nQTc\nCorrected QT interval\nQTcF\nCorrected QT interval using Fridericia\ncorrection\nRA\nRight atrial\nRAF\nRapidly accelerated ﬁbrosarcoma\nRCT\nRandomized controlled trial\nRIMA\nRight internal mammary artery\nROCKET AF\nRivaroxaban Once Daily Oral Direct Factor\nXa Inhibition Compared with Vitamin K\nAntagonism for Prevention of Stroke and\nEmbolism Trial in Atrial Fibrillation\nRT\nRadiotherapy\nRV\nRight ventricular\nRVEF\nRight ventricular ejection fraction\nRVV\nRight ventricular volume\ns′\nSystolic velocity of tricuspid annulus\nobtained by doppler tissue imaging\nSBr\nSinus bradycardia\nSCORE2\nSystematic Coronary Risk Estimation 2\nSCORE2-OP\nSystematic Coronary Risk Estimation 2—\nOlder Persons\nSEER\nSurveillance, Epidemiology, and End Results\nSMART\nSecond manifestations of arterial disease\nsPAP\nSystolic pulmonary artery pressure\nSPEP\nSerum protein electrophoresis\nSTEMI\nST-segment elevation myocardial infarction\nSTIR\nShort tau inversion recovery\nSTS PROM\nSociety of Thoracic Surgeons – Predicted\nRisk of Mortality\nSVT\nSupraventricular tachycardia\nSYNTAX\nSYNergy between percutaneous coronary\nintervention with TAXus and cardiac surgery\nTAPSE\nTricuspid annular plane systolic excursion\nTAVI\nTranscatheter aortic valve implantation\nTBIP\nThromboembolic risk, Bleeding risk, drug–\ndrug Interactions, Patient preferences\nTdP\nTorsade de pointes\nTIL\nTumour-inﬁltrating lymphocytes\nTKI\nTyrosine kinase inhibitors\nTRV\nTricuspid regurgitation velocity\nTTE\nTransthoracic echocardiography\nTTS\nTakotsubo syndrome\ntx\nTreatment\nULN\nUpper limit of normal\nUPEP\nUrine protein electrophoresis\nVA\nVentricular arrhythmias\nVascTox\nVascular toxicity\nVEGF\nVascular endothelial growth factor\nVEGFi\nVascular endothelial growth factor inhibitors\nVH\nVery high risk\nVHD\nValvular heart disease\nVKA\nVitamin K antagonists\nVTE\nVenous thromboembolism\nY\nYes\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management strat-\negies for an individual patient with a given condition. Guidelines and\ntheir recommendations should facilitate decision making of health pro-\nfessionals in their daily practice. However, guidelines are not a substi-\ntute for the patient’s relationship with their practitioner. The ﬁnal\ndecisions concerning an individual patient must be made by the re-\nsponsible health professional(s), based on what they consider to be\nthe most appropriate in the circumstances. These decisions are\nmade in consultation with the patient and caregiver as appropriate.\nGuidelines are intended for use by health professionals. To ensure\nthat all users have access to the most recent recommendations, the\nESC makes its Guidelines freely available. The ESC warns readers\nthat the technical language may be misinterpreted and declines any\nresponsibility in this respect.\nA great number of guidelines have been issued in recent years by the\nESC. Because of their impact on clinical practice, quality criteria for the\ndevelopment of guidelines have been established to make all decisions\ntransparent to the user. The recommendations for formulating and is-\nsuing ESC Guidelines can be found on the ESC website (https://www.\nescardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial pos-\nition of the ESC on a given topic and are regularly updated.\n4236\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "anticoagulation",
        "ct",
        "asymptomatic",
        "monitoring",
        "follow-up",
        "acronyms",
        "risk",
        "symptomatic",
        "abbreviations",
        "treatment",
        "diagnosis"
      ]
    },
    {
      "number": "3",
      "title": "1. Preamble",
      "start_page": 8,
      "end_page": 10,
      "content": "MedDRA\nMedical dictionary for regulatory activities\nMEK\nMitogen-activated extracellular\nsignal-regulated kinase\nMHD\nMean heart dose\nMI\nMyocardial infarction\nMM\nMultiple myeloma\nMUGA\nMultigated acquisition nuclear imaging\nN\nNo\nNOAC\nNon-vitamin K antagonist oral\nanticoagulants\nNP\nNatriuretic peptides\nNSTE-ACS\nNon-ST-segment elevation acute coronary\nsyndromes\nNT-proBNP\nN-terminal pro-B-type natriuretic peptide\nPAD\nPeripheral artery disease\nPAH\nPulmonary arterial hypertension\nPAP\nPulmonary arterial pressure\nPCI\nPercutaneous coronary intervention\nPD-1\nProgrammed death-1\nPD-L1\nProgrammed death-ligand 1\nPE\nPulmonary embolism\nPeric-E\nPericardial effusion\nPET\nPositron emission tomography\nPH\nPulmonary hypertension\nPI\nProteasome inhibitors\nPleu-E\nPleural effusion\nPRECISE-DAPT\nPREdicting bleeding Complications In\npatients undergoing Stent implantation and\nsubsEquent Dual Anti Platelet Therapy\nPRONOUNCE\nA Trial Comparing Cardiovascular Safety\nof Degarelix Versus Leuprolide in Patients\nWith Advanced Prostate Cancer and\nCardiovascular Disease\nPW\nLeft ventricular posterior wall\nQI\nQuality indicator\n↑QTc\nCorrected QT interval prolongation\nQTc\nCorrected QT interval\nQTcF\nCorrected QT interval using Fridericia\ncorrection\nRA\nRight atrial\nRAF\nRapidly accelerated ﬁbrosarcoma\nRCT\nRandomized controlled trial\nRIMA\nRight internal mammary artery\nROCKET AF\nRivaroxaban Once Daily Oral Direct Factor\nXa Inhibition Compared with Vitamin K\nAntagonism for Prevention of Stroke and\nEmbolism Trial in Atrial Fibrillation\nRT\nRadiotherapy\nRV\nRight ventricular\nRVEF\nRight ventricular ejection fraction\nRVV\nRight ventricular volume\ns′\nSystolic velocity of tricuspid annulus\nobtained by doppler tissue imaging\nSBr\nSinus bradycardia\nSCORE2\nSystematic Coronary Risk Estimation 2\nSCORE2-OP\nSystematic Coronary Risk Estimation 2—\nOlder Persons\nSEER\nSurveillance, Epidemiology, and End Results\nSMART\nSecond manifestations of arterial disease\nsPAP\nSystolic pulmonary artery pressure\nSPEP\nSerum protein electrophoresis\nSTEMI\nST-segment elevation myocardial infarction\nSTIR\nShort tau inversion recovery\nSTS PROM\nSociety of Thoracic Surgeons – Predicted\nRisk of Mortality\nSVT\nSupraventricular tachycardia\nSYNTAX\nSYNergy between percutaneous coronary\nintervention with TAXus and cardiac surgery\nTAPSE\nTricuspid annular plane systolic excursion\nTAVI\nTranscatheter aortic valve implantation\nTBIP\nThromboembolic risk, Bleeding risk, drug–\ndrug Interactions, Patient preferences\nTdP\nTorsade de pointes\nTIL\nTumour-inﬁltrating lymphocytes\nTKI\nTyrosine kinase inhibitors\nTRV\nTricuspid regurgitation velocity\nTTE\nTransthoracic echocardiography\nTTS\nTakotsubo syndrome\ntx\nTreatment\nULN\nUpper limit of normal\nUPEP\nUrine protein electrophoresis\nVA\nVentricular arrhythmias\nVascTox\nVascular toxicity\nVEGF\nVascular endothelial growth factor\nVEGFi\nVascular endothelial growth factor inhibitors\nVH\nVery high risk\nVHD\nValvular heart disease\nVKA\nVitamin K antagonists\nVTE\nVenous thromboembolism\nY\nYes\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management strat-\negies for an individual patient with a given condition. Guidelines and\ntheir recommendations should facilitate decision making of health pro-\nfessionals in their daily practice. However, guidelines are not a substi-\ntute for the patient’s relationship with their practitioner. The ﬁnal\ndecisions concerning an individual patient must be made by the re-\nsponsible health professional(s), based on what they consider to be\nthe most appropriate in the circumstances. These decisions are\nmade in consultation with the patient and caregiver as appropriate.\nGuidelines are intended for use by health professionals. To ensure\nthat all users have access to the most recent recommendations, the\nESC makes its Guidelines freely available. The ESC warns readers\nthat the technical language may be misinterpreted and declines any\nresponsibility in this respect.\nA great number of guidelines have been issued in recent years by the\nESC. Because of their impact on clinical practice, quality criteria for the\ndevelopment of guidelines have been established to make all decisions\ntransparent to the user. The recommendations for formulating and is-\nsuing ESC Guidelines can be found on the ESC website (https://www.\nescardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial pos-\nition of the ESC on a given topic and are regularly updated.\n4236\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nIn addition to the publication of Clinical Practice Guidelines, the ESC\ncarries out the EURObservational Research Programme of internation-\nal registries of cardiovascular diseases and interventions, which are es-\nsential to assess diagnostic/therapeutic processes, use of resources\nand adherence to guidelines. These registries aim at providing a better\nunderstanding of medical practice in Europe and around the world,\nbased on high-quality data collected during routine clinical practice.\nFurthermore, the ESC develops sets of quality indicators (QIs),\nwhich are tools to evaluate the level of implementation of the guide-\nlines and may be used by the ESC, hospitals, healthcare providers and\nprofessionals to measure clinical practice, and in educational pro-\ngrammes, alongside the key messages from the guidelines, to im-\nprove quality of care and clinical outcomes.\nThe Members of this Task Force were selected by the ESC to re-\npresent professionals involved with the medical care of patients with\nthis pathology. The selection procedure aimed to ensure that there is\na representative mix of members predominantly from across the whole\nof the ESC region and from relevant ESC Subspecialty Communities.\nConsideration was given to diversity and inclusion, notably with respect\nto gender and country of origin. A critical evaluation of diagnostic and\ntherapeutic procedures was performed, including assessment of the\nrisk–beneﬁt ratio. The level of evidence and the strength of the recom-\nmendation of particular management options were weighed and scored\naccording to predeﬁned scales, as outlined below. The Task Force fol-\nlowed the ESC voting procedures. All recommendations subject to a\nvote achieved at least 75% among voting members.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived as\nreal or potential sources of conﬂicts of interest. Their declarations of\ninterest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines) and have been compiled in a report and published in a\nsupplementary document simultaneously to the guidelines.\nThis process ensures transparency and prevents potential biases in\nthe development and review processes. Any changes in declarations\nof interest that arise during the writing period were notiﬁed to the\nTable 1\nClasses of recommendations\n©ESC 2022\nClasses of recommendations\nClass I \nEvidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective.\nefficacy of the given treatment or procedure.\nfavour of usefulness/efficacy.\nUsefulness/efficacy is less well\nuseful/effective, and in some cases\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \n \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven treatment or procedure is not\nmay be harmful. \nIs not recommended\n     Class IIb\nestablished by evidence/opinion.\nMay be considered\n \n   Class IIa\nWeight of evidence/opinion is in\nShould be considered\nClass II \nTable 2\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC 2022\nESC Guidelines\n4237\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nESC and updated. The Task Force received its entire ﬁnancial support\nfrom the ESC without any involvement from the healthcare industry.\nThe ESC CPG supervises and coordinates the preparation of new\nguidelines. The Committee is also responsible for the approval pro-\ncess of these guidelines. The ESC Guidelines undergo extensive re-\nview by the CPG and external experts, including a mix of\nmembers from across the whole of the ESC region and from relevant\nESC Subspecialty Communities and National Cardiac Societies. After\nappropriate revisions, the guidelines are signed off by all the experts\ninvolved in the Task Force. The ﬁnalized document is signed off by\nthe CPG for publication in the European Heart Journal. The guidelines\nwere developed after careful consideration of the scientiﬁc and med-\nical knowledge and the evidence available at the time of their writing.\nThe task of developing ESC Guidelines also includes the creation of\neducational tools and implementation programmes for the recommen-\ndations, including condensed pocket guideline versions, summary slides,\nsummary cards for non-specialists and an electronic version for digital\napplications (smartphones, etc.). These versions are abridged and thus,\nfor more detailed information, the user should always access the full-\ntext version of the guidelines, which is freely available via the ESC web-\nsite and the European Heart Journal. The National Cardiac Societies of\nthe ESC are encouraged to endorse, adopt, translate and implement all\nESC Guidelines. Implementation programmes are needed because it\nhas been shown that the outcome of disease may be favourably inﬂu-\nenced by the thorough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC Guidelines\nfully into account when exercising their clinical judgement, as well\nas in the determination and the implementation of preventive, diag-\nnostic or therapeutic medical strategies. However, the ESC\nGuidelines do not override in any way whatsoever the individual re-\nsponsibility of health professionals to make appropriate and accurate\ndecisions in consideration of each patient’s health condition and in\nconsultation with that patient or the patient’s caregiver where ap-\npropriate and/or necessary. It is also the health professional’s re-\nsponsibility to verify the rules and regulations applicable in each\ncountry to drugs and devices at the time of prescription and to re-\nspect the ethical rules of their profession.\nOff-label use of medication may be presented in this guideline if\nsufﬁcient level of evidence shows that it can be considered medically\nappropriate to a given condition and if patients could beneﬁt from\nthe recommended therapy. However, the ﬁnal decisions concerning\nan individual patient must be made by the responsible health profes-\nsional giving special consideration to:\n(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nlabel use of medication should be limited to situations where it\nis in the patient’s interest to do so, with regard to the quality,\nsafety and efﬁcacy of care, and only after the patient has been in-\nformed and has provided consent;\n(2) country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies and the ethical rules to which health\nprofessionals are subject, where applicable.\n2. Introduction\nThis is the ﬁrst European Society of Cardiology (ESC) guideline on\ncardio-oncology. The aim of this guideline is to help all the healthcare\nprofessionals providing care to oncology patients before, during, and\nafter their cancer treatments with respect to their cardiovascular (CV)\nhealth and wellness. This guideline provides guidance on the deﬁnitions,\ndiagnosis, treatment, and prevention of cancer therapy-related CV\ntoxicity (CTR-CVT), and the management of CV disease (CVD)\ncaused directly or indirectly by cancer. This area of medicine has lim-\nited trials and evidence on which to base decision-making and,\nwhere evidence is limited, this guideline provides the consensus of\nexpert opinion to guide healthcare professionals.\nThis guideline includes the deﬁnitions of CTR-CVT (Section 3),1 and\nprovides a personalized approach to care based upon the baseline\nCV toxicity risk assessment (Section 4) and new protocols for CV sur-\nveillance during cancer treatment (Section 5). The management of acute\nCTR-CVT is addressed in Section 6, where patients with activecancer are\nthose receiving anticancer treatment. Throughout these sections,\ndecision-making depends upon the risk/beneﬁt balance of oncology\ntreatment efﬁcacy and the severity and impact of CTR-CVT. Guidance\nis provided for the ﬁrst 12 months after completion of cardiotoxic treat-\nments (Section 7), when subacute CVD can emerge, and when patients\nwho developed CTR-CVT during cancer treatment are reviewed.\nDiagnosis and management of the long-term CV complications of previ-\nous oncology treatments, beyond 12 months after completing the cardi-\notoxic treatments, and integration into the overall survivorship strategy\nfor cancer survivors (CS) is presented in Section 8 with new long-term\nsurveillance recommendations for high-risk patients.\nIn Section 9, we address special populations where CVDs are dir-\nectly caused by the cancer, or where special considerations are re-\nquired. Section 10 provides information for patients’ involvement in\ntheir own care. The ﬁnal section highlights the role of the ESC and\nthe ESC Council of Cardio-Oncology (ESC-CCO).\nCTR-CVT risk is a dynamic variable, and the risk changes through-\nout the pathway of care (Figure 1, Video 1). Absolute risk of\nCTR-CVT is important to understand and balance against the abso-\nlute beneﬁt of the cancer treatment before and during treatment.\nHowever, CTR-CVT risk can be inﬂuenced by several variables, in-\ncluding implementation of primary prevention treatments, optimiza-\ntion of pre-existing CVD, dose, frequency, and duration of oncology\ntreatment, emergence of CV complications during treatment and\ntheir severity, and in CS, the overall cumulative treatment received,\nthe time since treatment, and the interaction with other CVDs.\n2.1. Cancer and cardiovascular needs of\npatients with cancer\nSince the 1990s, there has been a steady decline in cancer-related\nmortality mirrored by a steady increase in CS.2,3 In this context,\ntreatment-related\nside\neffects\nhave\ngained\nmore\nsigniﬁcance.\nManagement of CTR-CVT has a tremendous impact on the type of\nanticancer therapies that patients can receive as well as the long-term\nmorbidity and mortality outcomes of patients with cancer. Effective\nmanagement of patients with both cancer and CVD requires the un-\nique interest and expertise of healthcare providers, which has led to\nthe formation of a new discipline: cardio-oncology.4,5 A recently pub-\nlished ESC-CCO document describes appropriate criteria for the or-\nganization and implementation of cardio-oncology services.5\n2.2. Role of cardio-oncology services\nThe overarching goal of the cardio-oncology discipline is to allow pa-\ntients with cancer to receive the best possible cancer treatments safely,\n4238\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\nefficacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/efficacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "rows": 5,
          "cols": 5
        }
      ],
      "keywords": [
        "atrial fibrillation",
        "echocardiography",
        "myocardial infarction",
        "intervention",
        "echo",
        "ct",
        "tricuspid regurgitation",
        "preamble",
        "surgery",
        "risk",
        "tavi",
        "pci",
        "treatment",
        "imaging",
        "pulmonary hypertension"
      ]
    },
    {
      "number": "4",
      "title": "2. Introduction",
      "start_page": 10,
      "end_page": 14,
      "content": "ESC and updated. The Task Force received its entire ﬁnancial support\nfrom the ESC without any involvement from the healthcare industry.\nThe ESC CPG supervises and coordinates the preparation of new\nguidelines. The Committee is also responsible for the approval pro-\ncess of these guidelines. The ESC Guidelines undergo extensive re-\nview by the CPG and external experts, including a mix of\nmembers from across the whole of the ESC region and from relevant\nESC Subspecialty Communities and National Cardiac Societies. After\nappropriate revisions, the guidelines are signed off by all the experts\ninvolved in the Task Force. The ﬁnalized document is signed off by\nthe CPG for publication in the European Heart Journal. The guidelines\nwere developed after careful consideration of the scientiﬁc and med-\nical knowledge and the evidence available at the time of their writing.\nThe task of developing ESC Guidelines also includes the creation of\neducational tools and implementation programmes for the recommen-\ndations, including condensed pocket guideline versions, summary slides,\nsummary cards for non-specialists and an electronic version for digital\napplications (smartphones, etc.). These versions are abridged and thus,\nfor more detailed information, the user should always access the full-\ntext version of the guidelines, which is freely available via the ESC web-\nsite and the European Heart Journal. The National Cardiac Societies of\nthe ESC are encouraged to endorse, adopt, translate and implement all\nESC Guidelines. Implementation programmes are needed because it\nhas been shown that the outcome of disease may be favourably inﬂu-\nenced by the thorough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC Guidelines\nfully into account when exercising their clinical judgement, as well\nas in the determination and the implementation of preventive, diag-\nnostic or therapeutic medical strategies. However, the ESC\nGuidelines do not override in any way whatsoever the individual re-\nsponsibility of health professionals to make appropriate and accurate\ndecisions in consideration of each patient’s health condition and in\nconsultation with that patient or the patient’s caregiver where ap-\npropriate and/or necessary. It is also the health professional’s re-\nsponsibility to verify the rules and regulations applicable in each\ncountry to drugs and devices at the time of prescription and to re-\nspect the ethical rules of their profession.\nOff-label use of medication may be presented in this guideline if\nsufﬁcient level of evidence shows that it can be considered medically\nappropriate to a given condition and if patients could beneﬁt from\nthe recommended therapy. However, the ﬁnal decisions concerning\nan individual patient must be made by the responsible health profes-\nsional giving special consideration to:\n(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nlabel use of medication should be limited to situations where it\nis in the patient’s interest to do so, with regard to the quality,\nsafety and efﬁcacy of care, and only after the patient has been in-\nformed and has provided consent;\n(2) country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies and the ethical rules to which health\nprofessionals are subject, where applicable.\n2. Introduction\nThis is the ﬁrst European Society of Cardiology (ESC) guideline on\ncardio-oncology. The aim of this guideline is to help all the healthcare\nprofessionals providing care to oncology patients before, during, and\nafter their cancer treatments with respect to their cardiovascular (CV)\nhealth and wellness. This guideline provides guidance on the deﬁnitions,\ndiagnosis, treatment, and prevention of cancer therapy-related CV\ntoxicity (CTR-CVT), and the management of CV disease (CVD)\ncaused directly or indirectly by cancer. This area of medicine has lim-\nited trials and evidence on which to base decision-making and,\nwhere evidence is limited, this guideline provides the consensus of\nexpert opinion to guide healthcare professionals.\nThis guideline includes the deﬁnitions of CTR-CVT (Section 3),1 and\nprovides a personalized approach to care based upon the baseline\nCV toxicity risk assessment (Section 4) and new protocols for CV sur-\nveillance during cancer treatment (Section 5). The management of acute\nCTR-CVT is addressed in Section 6, where patients with activecancer are\nthose receiving anticancer treatment. Throughout these sections,\ndecision-making depends upon the risk/beneﬁt balance of oncology\ntreatment efﬁcacy and the severity and impact of CTR-CVT. Guidance\nis provided for the ﬁrst 12 months after completion of cardiotoxic treat-\nments (Section 7), when subacute CVD can emerge, and when patients\nwho developed CTR-CVT during cancer treatment are reviewed.\nDiagnosis and management of the long-term CV complications of previ-\nous oncology treatments, beyond 12 months after completing the cardi-\notoxic treatments, and integration into the overall survivorship strategy\nfor cancer survivors (CS) is presented in Section 8 with new long-term\nsurveillance recommendations for high-risk patients.\nIn Section 9, we address special populations where CVDs are dir-\nectly caused by the cancer, or where special considerations are re-\nquired. Section 10 provides information for patients’ involvement in\ntheir own care. The ﬁnal section highlights the role of the ESC and\nthe ESC Council of Cardio-Oncology (ESC-CCO).\nCTR-CVT risk is a dynamic variable, and the risk changes through-\nout the pathway of care (Figure 1, Video 1). Absolute risk of\nCTR-CVT is important to understand and balance against the abso-\nlute beneﬁt of the cancer treatment before and during treatment.\nHowever, CTR-CVT risk can be inﬂuenced by several variables, in-\ncluding implementation of primary prevention treatments, optimiza-\ntion of pre-existing CVD, dose, frequency, and duration of oncology\ntreatment, emergence of CV complications during treatment and\ntheir severity, and in CS, the overall cumulative treatment received,\nthe time since treatment, and the interaction with other CVDs.\n2.1. Cancer and cardiovascular needs of\npatients with cancer\nSince the 1990s, there has been a steady decline in cancer-related\nmortality mirrored by a steady increase in CS.2,3 In this context,\ntreatment-related\nside\neffects\nhave\ngained\nmore\nsigniﬁcance.\nManagement of CTR-CVT has a tremendous impact on the type of\nanticancer therapies that patients can receive as well as the long-term\nmorbidity and mortality outcomes of patients with cancer. Effective\nmanagement of patients with both cancer and CVD requires the un-\nique interest and expertise of healthcare providers, which has led to\nthe formation of a new discipline: cardio-oncology.4,5 A recently pub-\nlished ESC-CCO document describes appropriate criteria for the or-\nganization and implementation of cardio-oncology services.5\n2.2. Role of cardio-oncology services\nThe overarching goal of the cardio-oncology discipline is to allow pa-\ntients with cancer to receive the best possible cancer treatments safely,\n4238\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nminimizing CTR-CVT across the entire continuum of cancer care.5\nBefore initiation of cancer therapies with a known CV toxicity proﬁle,\nthe cardio-oncology team should identify and treat CV risk factors\n(CVRF) and pre-existing CVDs and deﬁne an appropriate prevention\nand surveillance plan for early identiﬁcation and appropriate manage-\nment of potential CV complications (Figure 2). Another important as-\npect is the participation in interdisciplinary discussions regarding the\nbeneﬁts and risks of certain cancer treatments and their continuation\nor interruption should side effects become apparent. After cancer\ntreatment has been completed, the focus shifts to co-ordination of\nlong-term follow-up and treatment. For patients on long-term cancer\ntherapies with CV toxicity risk, surveillance should continue until the\ntreatment is ﬁnished.6–8 There is also the need for re-assessment of\nCV risks in patients requiring treatment for secondary malignancies.\n2.3. General principles of\ncardio-oncology\nA guiding principle of cardio-oncology is the integration of clinical dis-\nciplines. Cardio-oncology providers must have knowledge of the\nbroad scope of cardiology, oncology, and haematology management.5\nRecommendations are formed regarding the most permissible (from a\nTime\nBaseline\nrisk\nDu\nD ring cardiotoxic\ncancer therapy\np\nLong-term foll\nf\now-up after\ncancer treatment\nPrimary and\nsecondary\nprevention\nstrategies\nCancer treatment\nsurveillance\nEarly CTR-CVT\nmanagement\nCancer survivorship programmes\nLow risk\nHigh risk\nCTR-CVT\nCTR-CVT\nrisk\nrisk\nFigure 1 Video 1 Central Illustration: Dynamics of cardiovascular toxicity risk of patients with cancer over their therapy continuum. CS, cancer\nsurvivors; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk fac-\ntors; CTR-CVT risk is a dynamic variable that changes through the pathway of care, and is inﬂuenced by several conditions including age, cancer\nhistory, pre-existing CVRF or CVD, and previous cardiotoxic cancer therapy. The CTR-CVT risk changes during and after treatment according\nto type, dose, frequency, and duration of oncology treatment (blue solid line). Pre-existing CVRF, CVD, or previous cancer treatments may increase\nthe magnitude of acute and long-term CV toxicity risk (purple solid line). CTR-CVT risk remains variable in extent during anticancer treatment and\nmay or may not gradually increase over time (dotted lines). Cardio-oncology strategy may reduce the magnitude of CTR-CVT by: (1) optimizing CVD\nand CVRF management (green arrows); (2) considering cardioprotective strategies in high-risk patients (green arrows); (3) organizing cancer treat-\nment surveillance; and (4) introducing early cardioprotection after the detection of subclinical CTR-CVT (purple arrows). CV risk assessment within\nthe ﬁrst year after completion of cardiotoxic cancer therapy identiﬁes CS who require long-term follow-up. Cancer survivorship programmes that\ninclude annual CV risk assessment and CVRF/CVD management are recommended to minimize long-term CV adverse events (brown arrows).\nESC Guidelines\n4239\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCVD perspective) and the most effective (from an oncological per-\nspective) cancer treatment. Adjudication of CV events occurring in pa-\ntients\non\nactive\ntherapy\nis\nanother\nimportant\naspect\nof\ncardio-oncology practice.1,3 This is in addition to recommendations\non best treatment and management practices. This includes the full\nscope of CV therapies, including healthy lifestyle promotion and\npharmacological, device, and surgical treatments.4,9,10\nThe principle underlying the dynamic course of CTR-CVT develop-\nment in patients with cancer is that the absolute risk depends on their\nbaseline risk and changes with exposure to cardiotoxic therapies over\nNew cancer\ndiagnosis\nDuring cancer\ntreatmenta\nFirst year after\ncancer treatmentb\nLong term\nfollow-up\nCardio-Oncology Care Pathways\nClass 1\nClass 1Ia\nClass 1Ib\nBaseline CV\ntoxicity risk\nassessmentc\nInforming, advising, and supporting patients to promote a healthy lifestyle\nManagement of CVRF and CVD according to ESC Guidelines\nLow risk\npatients\nAnnual CVRF\nassessmente\nReassessment if new CV\nsigns/symptoms \nStandard\nsurveillance\nAssessment at 1 year\nafter completion of\ncancer therapy\nModerate risk\n patients\nAnnual CVRF assessmente\nCV toxicity re-stratification\nat 5 years\nTTE every 5 years\nCardiology referrald\nAssessment at 1 year\nafter completion of\ncancer therapy\nHigh and\nvery high risk\npatients\nAnnual CVRF\nassessmente\nTTE at years 1, 3, 5 and \nevery 5 years\nCardiology referrald\nCVD prevention\nAssessment at 3\nmonths and 1 year\nafter completion of\ncancer therapy\nCardiology referrald if new CV signs/symptoms or CTR-CVT develop\nFigure 2 Cardio-oncology care pathways. BP, blood pressure; CS, cancer survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity;\nCV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; ESC, European Society of\nCardiology; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic pep-\ntides; RT, radiotherapy; TTE, transthoracic echocardiography. aCV surveillance according to baseline CV toxicity risk, type of cancer, cancer\nstage, and cancer therapy. bCTR-CVT risk assessment is recommended during the ﬁrst year after cardiotoxic cancer treatment to establish a\nlong-term follow-up care plan. cThe use of HFA-ICOS risk assessment tools should be considered to assess CTR-CVT risk in patients with can-\ncer scheduled to receive cardiotoxic anticancer therapy. Clinical assessment and ECG are recommended at baseline in all patients with cancer\nand echocardiography, cardiac biomarkers, or other cardiac imaging tests in selected patients according to baseline CV toxicity risk and cancer\ntreatment type (see Figure 7). dCardio-oncology referral is recommended when available, alternatively patients should be referred to a specia-\nlized cardiologist with expertise in managing CVD in patients with cancer. eAnnual CV risk assessment (including clinical review, BP, lipid proﬁle,\nHbA1c, ECG, and NP) and CVRF management is recommended in CS who were treated with a potentially cardiotoxic cancer drug or RT to a\nvolume exposing the heart.\n4240\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\ntime (Figure 3).11 This has been recognized in conceptual models, with\nrisk stratiﬁcation tools designed to grade patients with cancer into\nlow, moderate, high, and very high risk of CV complications prior to\nstarting treatment. These have been published by the Heart Failure\nAssociation (HFA) of the ESC in collaboration with the International\nCardio-Oncology Society (ICOS) (see Section 4).12,13 Severity, dur-\nation, and type of manifestation of CTR-CVT vary by type of malig-\nnancy and cancer treatment. The risk itself can be understood in\ntwo ways: (1) the likelihood of its occurrence and (2) the severity of\nthe complication (Figure 4). For example, a patient could be very likely\nto experience a CTR-CVT, but if this event is mild, oncology treat-\nment should continue. Conversely, a patient at low likelihood could\nstill be at high risk according to the severity of the event, which would\nlead to interruption of cancer treatment, e.g. a signiﬁcant decline in\nleft ventricular (LV) ejection fraction (LVEF) to , 40% with anthracy-\ncline chemotherapy. The timeline of these developments may also be\nrather different. After the cardiotoxic cancer treatment has been\ncompleted, a new risk assessment is recommended to establish differ-\nent long-term trajectories of CV health. These trajectories are im-\npacted by the permanent CV toxic effects and cardiac or vascular\ninjury of some cancer therapies, patient-related CVRF, environmental\nfactors, and stressors (e.g. acute viral infections). The aim should be to\npersonalize approaches to minimize CTR-CVT and improve both\ncancer and CV outcomes.\nBaseline CV toxicity risk assessment checklist\nCancer treatment history\nCV history\nCVRF\nPhysical examination\nVital signs measurementa\nBNP or NT-p\nT roBNPb\ncTnb\nECG\nFasting plasma glucose / HbA1c\nKidney function / eGFR\nLipid profile\nTTEc\nClinical assessment\nComplementary tests\nCTR-CVT\nrisk factors\nMedical\nCVRF\nPrevious\nCVD\nLifestyle\nrisk factors\nECG, TTE, and\ncardiac biomarkers\nabnormalities\nPrevious\ncardiotoxic \ntherapies\nAge, sex,\ngenetics\nFigure 3 Baseline cardiovascular toxicity risk assessment checklist. BNP, B-type natriuretic peptide; cTn, cardiac troponin; CTR-CVT, cancer therapy-related\ncardiovascular toxicity; CV, cardiovascular; CVD, CV disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; eGFR, estimated glomerular ﬁltration\nrate; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-BNP; TTE, transthoracic echocardiography. aIncluding blood pressure, heart rate, height,\nweight, and body mass index. bCardiac biomarkers (troponin and NP) should be measured in patients at risk of CTRCD where available and results should\nbe interpreted according to the patient clinical status, type of cancer treatment, and kidney function. cConsider other CV complementary tests in selected\npatients: cardiac magnetic resonance, coronary computed tomography angiography, CPET (in selected patients for pre-operative [lung, colon, and rectal can-\ncers] risk stratiﬁcation). See Section 4.6.\nESC Guidelines\n4241\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n3. Cancer therapy-related\ncardiovascular toxicity deﬁnitions\nSeveral terminologies and deﬁnitions have previously been proposed\nto describe the spectrum of CTR-CVT, leading to inconsistencies in\ndiagnosis and management. The need to harmonize these deﬁnitions\nhas frequently been stated and recognized, and resulted in the recent\ninternational deﬁnitions of CTR-CVT1 supported by this guideline\n(Table 3; Supplementary data, Table S1). This document will focus\non consensus deﬁnitions for cardiomyopathy and heart failure\n(HF), myocarditis, vascular toxicities, hypertension, cardiac arrhyth-\nmias, and corrected QT interval (QTc) prolongation. The deﬁnitions\nof other CTR-CVT, including pericardial and valvular heart diseases\n(VHDs), are the same as those used for the general cardiology popu-\nlation. For cardiac injury, cardiomyopathy, and HF, the descriptive\nterm cancer therapy-related cardiac dysfunction (CTRCD) is recom-\nmended as it captures the broad spectrum of possible presentations\nand the aetiological link with the broad scope of various cancer ther-\napies, including chemotherapy, targeted agents, immune therapies,\nand radiation therapy.\nHigh\nIntermediate\nLow\nSevere and\nvery severe\nModerate\nMild\nLikelihood of\nCTR-CVT\nClinical severity of CTR-CVT\nFigure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity. CTR-CVT, cancer therapy-related cardiovascular tox-\nicity; CV, cardiovascular. The ultimate risk is the combination of the likelihood (based on reported incidence) and degree (severity or grade) of the adverse\nevent. The most vulnerable patient groups are those at high likelihood of experiencing a severe adverse event. The level of attention that needs to be\ndevoted to these patients varies accordingly. The risk and type of CTR-CVT, as well as the potential for reversibility, depends on different factors, listed in\nFigure 3, that should be considered to deﬁne global CV and oncological prognosis and to individualize CTR-CVT surveillance. Additional factors that add to\nthe complexity of CTR-CVT risk assessment are the cancer type and prognosis, and type, duration, and intensity of cancer treatment.\n4242\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 11",
          "page": 11,
          "content": "Du ring | cardiot\n | er thera",
          "rows": 2,
          "cols": 2
        },
        {
          "title": "Table on page 11",
          "page": 11,
          "content": "Long-term f |  | ollo | w-up after\n | cancer t | reatment | ",
          "rows": 2,
          "cols": 4
        }
      ],
      "keywords": [
        "introduction",
        "ct",
        "recommendation"
      ]
    },
    {
      "number": "5",
      "title": "3. Cancer therapy-related cardiovascular toxicity definitions",
      "start_page": 14,
      "end_page": 16,
      "content": "3. Cancer therapy-related\ncardiovascular toxicity deﬁnitions\nSeveral terminologies and deﬁnitions have previously been proposed\nto describe the spectrum of CTR-CVT, leading to inconsistencies in\ndiagnosis and management. The need to harmonize these deﬁnitions\nhas frequently been stated and recognized, and resulted in the recent\ninternational deﬁnitions of CTR-CVT1 supported by this guideline\n(Table 3; Supplementary data, Table S1). This document will focus\non consensus deﬁnitions for cardiomyopathy and heart failure\n(HF), myocarditis, vascular toxicities, hypertension, cardiac arrhyth-\nmias, and corrected QT interval (QTc) prolongation. The deﬁnitions\nof other CTR-CVT, including pericardial and valvular heart diseases\n(VHDs), are the same as those used for the general cardiology popu-\nlation. For cardiac injury, cardiomyopathy, and HF, the descriptive\nterm cancer therapy-related cardiac dysfunction (CTRCD) is recom-\nmended as it captures the broad spectrum of possible presentations\nand the aetiological link with the broad scope of various cancer ther-\napies, including chemotherapy, targeted agents, immune therapies,\nand radiation therapy.\nHigh\nIntermediate\nLow\nSevere and\nvery severe\nModerate\nMild\nLikelihood of\nCTR-CVT\nClinical severity of CTR-CVT\nFigure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity. CTR-CVT, cancer therapy-related cardiovascular tox-\nicity; CV, cardiovascular. The ultimate risk is the combination of the likelihood (based on reported incidence) and degree (severity or grade) of the adverse\nevent. The most vulnerable patient groups are those at high likelihood of experiencing a severe adverse event. The level of attention that needs to be\ndevoted to these patients varies accordingly. The risk and type of CTR-CVT, as well as the potential for reversibility, depends on different factors, listed in\nFigure 3, that should be considered to deﬁne global CV and oncological prognosis and to individualize CTR-CVT surveillance. Additional factors that add to\nthe complexity of CTR-CVT risk assessment are the cancer type and prognosis, and type, duration, and intensity of cancer treatment.\n4242\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nTable 3\nCancer therapy-related cardiovascular toxicity deﬁnitions\nCTRCD\nSymptomatic CTRCD (HF)a,b\nVery severe\nHF requiring inotropic support, mechanical circulatory support, or\nconsideration of transplantation\nSevere\nHF hospitalization\nModerate\nNeed for outpatient intensiﬁcation of diuretic and HF therapy\nMild\nMild HF symptoms, no intensiﬁcation of therapy required\nAsymptomatic CTRCD\nSevere\nNew LVEF reduction to ,40%\nModerate\nNew LVEF reduction by ≥10 percentage points to an LVEF\nof 40–49%\nOR\nNew LVEF reduction by ,10 percentage points to an LVEF of 40–\n49% AND either new relative decline in GLS by .15% from baseline\nOR new rise in cardiac biomarkersc\nMild\nLVEF ≥50%\nAND new relative decline in GLS by .15% from baseline\nAND/OR new rise in cardiac biomarkersc\nICI myocarditis (either pathohistological diagnosis or clinical diagnosis)\nPathohistological diagnosis (EMB)\nMultifocal inﬂammatory cell inﬁltrates with overt cardiomyocyte loss by light microscopy\nClinical diagnosisd\ncTn elevation (new or signiﬁcant change from baseline)e with 1 major criterion or 2 minor criteria,\nafter exclusion of ACS and acute infectious myocarditis based on clinical suspicionf\nMajor criterion:\n• CMR diagnostic for acute myocarditis (modiﬁed Lake Louise criteria)g\nMinor criteria:\n• Clinical syndrome (including any one of the following: fatigue, myalgias, chest pain, diplopia, ptosis,\nshortness of breath, orthopnoea, lower-extremity oedema, palpitations, light-headedness/dizziness,\nsyncope, muscle weakness, cardiogenic shock)\n• Ventricular arrhythmia (including cardiac arrest) and/or new conduction system disease\n• Decline in LV systolic function, with or without regional wall motion abnormalities in a non-Takotsubo\npattern\n• Other immune-related adverse events, particularly myositis, myopathy, myasthenia gravis\n• Suggestive CMRh\nSeverity of myocarditis\n• Fulminant: Haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or\nhigh-grade heart block, and/or signiﬁcant ventricular arrhythmia\n• Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and\nincidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have\nreduced LVEF but no features of severe disease\n• Steroid refractory: non-resolving or worsening myocarditis (clinical worsening or persistent troponin\nelevation after exclusion of other aetiologies) despite high-dose methylprednisolone\nRecovery from myocarditis\n• Complete recovery: Patients with complete resolution of acute symptoms, normalization of\nbiomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE\nor elevated T1 due to ﬁbrosis, but any suggestion of acute oedema should be absent\n• Recovering: Ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging\nparameters, but not yet normalized, while on tapering doses of immunosuppression\nVascular toxicity (for general cardiology deﬁnitions, see Supplementary data, Table S1)\nAsymptomatic vascular toxicity\nCAD\nSymptomatic vascular\ntoxicity\nStroke\nPAD\nTransient ischaemic attack\nCarotid artery disease\nMI\nVenous thrombosis\nACS\nArterial thrombosis\nCCS\nPeripheral vasoreactivity\nPAD\nContinued\nESC Guidelines\n4243\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n4. Cardiovascular toxicity risk\nstratiﬁcation before anticancer\ntherapy\nThe optimal time to consider CVD prevention strategies in patients\nwith cancer is at the time of cancer diagnosis and prior to the initi-\nation of cancer treatment.4,5 This enables the oncology team to con-\nsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, personalizing CV surveillance and\nfollow-up strategies, and making appropriate referrals of high-risk pa-\ntients to cardio-oncology services. These strategies are needed to\nmitigate CVD risk, and improve the adherence to effective cancer\ntreatments and the overall survival.\nCVD prevention strategies require a personalized approach. Risk\nassessment is a challenging task and it is vital that clinicians adopt a\nsystematic approach without delaying oncological treatment.12,21,22\nFigure 5 provides a comprehensive approach to risk assessment.\nThe choice of the cardiac tests (electrocardiogram [ECG], biomar-\nkers, and imaging) should be individualized based on CV risk and\nthe planned cancer treatments.\n4.1. General approach to cardiovascular\ntoxicity risk in patients with cancer\nPre-treatment CTR-CVT risk assessment should ideally be per-\nformed using a recognized risk stratiﬁcation method where multiple\nrisk factors are incorporated to determine patient-speciﬁc risk.23\nCoronary epicardial\nvasoreactivity\nVasospastic angina\nCoronary microvascular\nvasoreactivity\nMicrovascular angina\nRaynaud’s phenomenon\nArterial hypertension\nTreatment threshold for\nhypertension before, during, and\nafter therapy\nIn patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic\nOtherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic\nCancer therapy holding threshold\n≥180 mmHg systolic and/or ≥110 mmHg diastolic\nHypertensive emergency\n(Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage\nCardiac arrhythmias\nQT prolongation\nProlonged: QTcF . 500 msj\nBradycardia\nFor general cardiology deﬁnitions, see Supplementary data, Table S1\nSupraventricular tachycardia\nVentricular arrhythmias\nAF\n© ESC 2022\nACS, acute coronary syndromes; AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CMR,\ncardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular volume fraction; EMB,\nendomyocardial biopsy; ESC, European Society of Cardiology; GLS, global longitudinal strain; HF, heart failure; HFmrEF, HF with mildly reduced ejection fraction; HFpEF, heart\nfailure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LV, left\nventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; QTcF,\ncorrected QT interval using Fridericia correction; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—Older Persons.\nSee Supplementary data, Table S1 for expanded deﬁnitions.\naWith LVEF and supportive diagnostic biomarkers based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14\nbSymptomatic CTRCD represents HF, which is a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g.\nelevated jugular venous pressure, pulmonary crackles, and peripheral oedema) and has traditionally been divided into distinct phenotypes based on the measurement of LVEF: ≤40% =\nHFrEF; 41–49% = HFmrEF; ≥50% = HFpEF.\nccTnI/cTnT . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL or new signiﬁcant rise from baseline beyond the biological and analytical variation of the assay used.\ndClinical diagnoses should be conﬁrmed with magnetic resonance imaging or EMB if possible and without causing treatment delays. Treatment with immunosuppression should be\npromptly initiated while awaiting further conﬁrmatory testing in symptomatic patients.\neBoth troponin I and troponin T can be used; however, clinical observations suggest that troponin T may be falsely elevated in patients with concomitant myositis and without myocarditis.15–17\nfAccording to local protocols.\ngDiagnostic CMR: Based on updated Lake Louise criteria18: T2-based criterion + T1-based criterion + supportive criteria (T2-based criteria: regional or global increase of native T2, or T2signal\nintensity; T1-based criteria: regional or global increase of native T1, or regional or global increase in the ECV, or presence of LGE; supportive criteria: pericarditis and/or regional or global LV\nsystolic dysfunction).\nhSuggestive CMR: meeting some but not all of the modiﬁed Lake Louise criteria. The presence of T2- or T1-based criteria may support a diagnosis of acute myocardial inﬂammation in the\nappropriate clinical scenario.\niSCORE2 (,70 years), SCORE2-OP (≥70 years) or equivalent.19 CV risk stratiﬁcation: ,50 years: low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%;\nmoderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%, moderate risk 7.5% to ,15%, high risk ≥15%.\njQTcF 480–500 ms: correct reversible causes, minimize other QT prolonging medications, close QTcF monitoring. Fridericia correction is recommended (QTcF = QT/3√RR).20\n4244\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "CTRCD |  |  |  |  | \nSymptomatic CTRCD (HF)a,b |  | Very severe | HF requiring inotropic support, mechanical circulatory support, or\nconsideration of transplantation |  | \n |  | Severe | HF hospitalization |  | \n |  | Moderate | Need for outpatient intensification of diuretic and HF therapy |  | \n |  | Mild | Mild HF symptoms, no intensification of therapy required |  | \nAsymptomatic CTRCD |  | Severe | New LVEF reduction to ,40% |  | \n |  | Moderate | New LVEF reduction by ≥10 percentage points to an LVEF\nof 40–49%\nOR\nNew LVEF reduction by ,10 percentage points to an LVEF of 40–\n49% AND either new relative decline in GLS by .15% from baseline\nOR new rise in cardiac biomarkersc |  | \n |  | Mild | LVEF ≥50%\nAND new relative decline in GLS by .15% from baseline\nAND/OR new rise in cardiac biomarkersc |  | \n | ICI myocarditis (either pathohistological diagnosis or clinical diagnosis) |  |  |  | \nPathohistological diagnosis (EMB) |  | Multifocal inflammatory cell infiltrates with overt cardiomyocyte loss by light microscopy |  |  | \nClinical diagnosisd |  | cTn elevation (new or significant change from baseline)e with 1 major criterion or 2 minor criteria,\nafter exclusion of ACS and acute infectious myocarditis based on clinical suspicionf |  |  | \n |  | Major criterion:\n• CMR diagnostic for acute myocarditis (modified Lake Louise criteria)g |  |  | \n |  | Minor criteria:\n• Clinical syndrome (including any one of the following: fatigue, myalgias, chest pain, diplopia, ptosis,\nshortness of breath, orthopnoea, lower-extremity oedema, palpitations, light-headedness/dizziness,\nsyncope, muscle weakness, cardiogenic shock)\n• Ventricular arrhythmia (including cardiac arrest) and/or new conduction system disease\n• Decline in LV systolic function, with or without regional wall motion abnormalities in a non-Takotsubo\npattern\n• Other immune-related adverse events, particularly myositis, myopathy, myasthenia gravis\n• Suggestive CMRh |  |  | \nSeverity of myocarditis |  | • Fulminant: Haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or\nhigh-grade heart block, and/or significant ventricular arrhythmia\n• Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and\nincidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have\nreduced LVEF but no features of severe disease\n• Steroid refractory: non-resolving or worsening myocarditis (clinical worsening or persistent troponin\nelevation after exclusion of other aetiologies) despite high-dose methylprednisolone |  |  | \nRecovery from myocarditis |  | • Complete recovery: Patients with complete resolution of acute symptoms, normalization of\nbiomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE\nor elevated T1 due to fibrosis, but any suggestion of acute oedema should be absent\n• Recovering: Ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging\nparameters, but not yet normalized, while on tapering doses of immunosuppression |  |  | \n | Vascular toxicity (for general cardiology definitions, see Supplementary data, Table S1) |  |  |  | \nAsymptomatic vascular toxicity |  | CAD | Symptomatic vascular\ntoxicity | Stroke | \n |  | PAD |  | Transient ischaemic attack | \n |  | Carotid artery disease |  | MI | \n |  | Venous thrombosis |  | ACS | \n |  | Arterial thrombosis |  | CCS | \n |  | Peripheral vasoreactivity |  | PAD | ",
          "rows": 22,
          "cols": 6
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": " |  | Coronary epicardial\nvasoreactivity |  | Vasospastic angina | \n |  | Coronary microvascular\nvasoreactivity |  | Microvascular angina | \n |  |  |  | Raynaud’s phenomenon | \n | Arterial hypertension |  |  |  | \nTreatment threshold for\nhypertension before, during, and\nafter therapy |  | In patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic |  |  | \n |  | Otherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic |  |  | \nCancer therapy holding threshold |  | ≥180 mmHg systolic and/or ≥110 mmHg diastolic |  |  | \nHypertensive emergency |  | (Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage |  |  | \n | Cardiac arrhythmias |  |  |  | \nQT prolongation |  | Prolonged: QTcF . 500 msj |  |  | \nBradycardia |  | For general cardiology definitions, see Supplementary data, Table S1 |  |  | \nSupraventricular tachycardia |  |  |  |  | \nVentricular arrhythmias |  |  |  |  | \nAF |  |  |  |  | ",
          "rows": 14,
          "cols": 6
        }
      ],
      "keywords": [
        "prognosis",
        "asymptomatic",
        "definitions",
        "toxicity",
        "cardiomyopathy",
        "cardiovascular",
        "therapy",
        "diagnosis",
        "cancer",
        "treatment",
        "moderate",
        "ct",
        "heart failure",
        "related",
        "mild",
        "diuretic",
        "risk",
        "severe",
        "symptomatic"
      ]
    },
    {
      "number": "6",
      "title": "4. Cardiovascular toxicity risk stratification before anticancer therapy",
      "start_page": 16,
      "end_page": 26,
      "content": "4. Cardiovascular toxicity risk\nstratiﬁcation before anticancer\ntherapy\nThe optimal time to consider CVD prevention strategies in patients\nwith cancer is at the time of cancer diagnosis and prior to the initi-\nation of cancer treatment.4,5 This enables the oncology team to con-\nsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, personalizing CV surveillance and\nfollow-up strategies, and making appropriate referrals of high-risk pa-\ntients to cardio-oncology services. These strategies are needed to\nmitigate CVD risk, and improve the adherence to effective cancer\ntreatments and the overall survival.\nCVD prevention strategies require a personalized approach. Risk\nassessment is a challenging task and it is vital that clinicians adopt a\nsystematic approach without delaying oncological treatment.12,21,22\nFigure 5 provides a comprehensive approach to risk assessment.\nThe choice of the cardiac tests (electrocardiogram [ECG], biomar-\nkers, and imaging) should be individualized based on CV risk and\nthe planned cancer treatments.\n4.1. General approach to cardiovascular\ntoxicity risk in patients with cancer\nPre-treatment CTR-CVT risk assessment should ideally be per-\nformed using a recognized risk stratiﬁcation method where multiple\nrisk factors are incorporated to determine patient-speciﬁc risk.23\nCoronary epicardial\nvasoreactivity\nVasospastic angina\nCoronary microvascular\nvasoreactivity\nMicrovascular angina\nRaynaud’s phenomenon\nArterial hypertension\nTreatment threshold for\nhypertension before, during, and\nafter therapy\nIn patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic\nOtherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic\nCancer therapy holding threshold\n≥180 mmHg systolic and/or ≥110 mmHg diastolic\nHypertensive emergency\n(Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage\nCardiac arrhythmias\nQT prolongation\nProlonged: QTcF . 500 msj\nBradycardia\nFor general cardiology deﬁnitions, see Supplementary data, Table S1\nSupraventricular tachycardia\nVentricular arrhythmias\nAF\n© ESC 2022\nACS, acute coronary syndromes; AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CMR,\ncardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular volume fraction; EMB,\nendomyocardial biopsy; ESC, European Society of Cardiology; GLS, global longitudinal strain; HF, heart failure; HFmrEF, HF with mildly reduced ejection fraction; HFpEF, heart\nfailure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LV, left\nventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; QTcF,\ncorrected QT interval using Fridericia correction; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—Older Persons.\nSee Supplementary data, Table S1 for expanded deﬁnitions.\naWith LVEF and supportive diagnostic biomarkers based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14\nbSymptomatic CTRCD represents HF, which is a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g.\nelevated jugular venous pressure, pulmonary crackles, and peripheral oedema) and has traditionally been divided into distinct phenotypes based on the measurement of LVEF: ≤40% =\nHFrEF; 41–49% = HFmrEF; ≥50% = HFpEF.\nccTnI/cTnT . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL or new signiﬁcant rise from baseline beyond the biological and analytical variation of the assay used.\ndClinical diagnoses should be conﬁrmed with magnetic resonance imaging or EMB if possible and without causing treatment delays. Treatment with immunosuppression should be\npromptly initiated while awaiting further conﬁrmatory testing in symptomatic patients.\neBoth troponin I and troponin T can be used; however, clinical observations suggest that troponin T may be falsely elevated in patients with concomitant myositis and without myocarditis.15–17\nfAccording to local protocols.\ngDiagnostic CMR: Based on updated Lake Louise criteria18: T2-based criterion + T1-based criterion + supportive criteria (T2-based criteria: regional or global increase of native T2, or T2signal\nintensity; T1-based criteria: regional or global increase of native T1, or regional or global increase in the ECV, or presence of LGE; supportive criteria: pericarditis and/or regional or global LV\nsystolic dysfunction).\nhSuggestive CMR: meeting some but not all of the modiﬁed Lake Louise criteria. The presence of T2- or T1-based criteria may support a diagnosis of acute myocardial inﬂammation in the\nappropriate clinical scenario.\niSCORE2 (,70 years), SCORE2-OP (≥70 years) or equivalent.19 CV risk stratiﬁcation: ,50 years: low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%;\nmoderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%, moderate risk 7.5% to ,15%, high risk ≥15%.\njQTcF 480–500 ms: correct reversible causes, minimize other QT prolonging medications, close QTcF monitoring. Fridericia correction is recommended (QTcF = QT/3√RR).20\n4244\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nOnly a limited number of retrospective risk scores have been pub-\nlished in patients with cancer. Most of these scores have been devel-\noped for speciﬁc cancer-patient groups and cannot be readily applied\nor extrapolated to other type of malignancies.24–29 While further\nvalidation is needed, HFA-ICOS risk assessment tools should be con-\nsidered to determine pre-treatment risk of CTR-CVT as they are\neasy to use and implement in oncology and haematology services\n(Table 4; Supplementary data, Tables S2–S7).12,13 Other CV risk\nPhysical and metabolic\nassessmentb\nECG\n(Class I)\nPre-existing CVD or\nat risk of CTRCDc\nNew, untreated or\nuncontrolled medical, and\nlifestyle CVRF\nArrhythmias\nProlonged QTcF\nCheck and correct\nprecipitant factorsf\n(Class I)\nRef\ncardiologistg\n(Class I)\nRef\nrdiologist g\n(Class I)\nSuspected\nCVD\ncTn and NP\nincreasedd\nTTE\n(LVEF and GLS)\nreducede\nAggressive management of\nCVRF and pre-existing CVD\naccording to ESC Guidelines\nHealthy lifestyle promotion\n(Class I)\nBaseline cardiovascular toxicity risk assessment\nConsider primary vs secondary preventive strategies according to CV toxicity risk,\npre-existing CVD, and cancer treatment type\nHFA-ICOS risk\nassessment:\nCVRFa\nCVD history\nCancer history\nCancer treatment history\nFigure 5 Baseline cardiovascular toxicity risk assessment before anticancer therapy. BNP, B-type natriuretic peptide; cTn, cardiac troponin; CTRCD,\ncancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ECG, electrocardiogram; ESC, European\nSociety of Cardiology; GLS, global longitudinal strain; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; LVEF, left ven-\ntricular ejection fraction; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-BNP peptide; QTc, corrected QT\ninterval; QTcF, corrected QT interval using Fridericia correction; TTE, transthoracic echocardiography. aWhen assessing CVRF, include information\nabout unhealthy lifestyle including sedentary behaviour, smoking, and alcohol intake. bSee Figure 3. cAccording to cancer treatment and HFA-ICOS\nrisk assessment. dcTnI/T . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL. ePatients with baseline LVEF , 50% or in the low normal\nrange (LVEF 50–54%) should be referred to a specialized cardiologist or cardio-oncologist. When TTE is used, ideally three-dimensional-LVEF and GLS\nshould be measured. If GLS assessment is not available, other markers of longitudinal function (e.g. annular Doppler velocity) should be considered.\nCardiac magnetic resonance should be considered if echocardiography is of non-diagnostic quality. fAnaemia, infections, electrolyte abnormalities, meta-\nbolic problems, other QTc-prolonging drugs. gCardio-oncology referral is recommended when available; alternatively, patients should be referred to a\nspecialized cardiologist with expertise in managing CVD in patients with cancer.\nESC Guidelines\n4245\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nTable 4\nHeart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk\nstratiﬁcation\nBaseline CV toxicity\nrisk factors\nAnthracycline\nchemotherapy\nHER2-targeted\ntherapies\nVEGF\ninhibitors\nBCR-ABL\ninhibitors\nMultiple\nmyeloma\ntherapies\nRAF and\nMEK\ninhibitors\nPrevious CVD\nHF/cardiomyopathy/\nCTRCD\nVH\nVH\nVH\nH\nVH\nVH\nSevere VHD\nH\nH\n–\n–\n–\nH\nMI or PCI or CABG\nH\nH\nVH\n–\n–\nH\nStable angina\nH\nH\nVH\n–\n–\nH\nArterial vascular disease\n–\n–\nVH\nVH\nVH\n–\nAbnormal ankle-brachial\npressure index\n–\n–\n–\nH\n–\n–\nPH\n–\n–\n–\nH\n–\n–\nArterial thrombosis with TKI\n–\n–\n–\nVH\n–\n–\nVenous thrombosis\n(DVT/PE)\n–\n–\nH\nM2\nVH\n–\nArrhythmiaa\n–\nM2\nM2\nM2\nM2\nM1\nQTc ≥480 ms\n–\n–\nH\nH\n–\n–\n450 ≤QTc , 480 ms (men);\n460 ≤QTc , 480 ms\n(women)\n–\n–\nM2\nM2\n–\n–\nPrior PI CV toxicity\n–\n–\n–\n–\nVH\n–\nPrior IMiD CV toxicity\n–\n–\n–\n–\nH\n–\nCardiac imaging\nLVEF , 50%\nH\nH\nH\nH\nH\nH\nLVEF 50–54%\nM2\nM2\nM2\n–\nM2\nM2\nLV hypertrophy\n–\n–\n–\n–\nM1\n–\nCardiac amyloidosis\n–\n–\n–\n–\nVH\n–\nCardiac biomarkers\nElevated baseline cTnb\nM1\nM2\nM1\n–\nM2\nM2\nElevated baseline NPb\nM1\nM2\nM1\n–\nH\nM2\nAge and CVRF\nAge ≥80 years\nH\nH\n–\n–\n–\nM1\nAge 65–79 years\nM2\nM2\n–\n–\n–\nM1\nAge ≥75 years\n–\n–\nH\nH\nH\nM1\nAge 65–74 years\n–\n–\nM1\nM2\nM1\nM1\nAge ≥60 years\n–\n–\n–\nM1\n–\n–\nCVD 10-year risk score\n. 20%\n–\n–\n–\nH\n–\n–\nHypertensionc\nM1\nM1\nH\nM2\nM1\nM2\nChronic kidney diseased\nM1\nM1\nM1\nM1\nM1\nM1\nProteinuria\n–\n–\nM1\n–\n–\n–\nDMe\nM1\nM1\nM1\nM1\nM1\nM1\nHyperlipidaemiaf\n–\n–\nM1\nM1\nM1\n–\nFamily history of\nthrombophilia\n–\n–\n–\nM1\nM1\n–\nContinued\n4246\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\ncalculators (e.g. SMART [Second manifestations of arterial disease]\nrisk score, ADVANCE [Action in Diabetes and Vascular Disease:\nPreterax and Diamicron-MR Controlled Evaluation] risk score,\nSCORE2 [Systematic Coronary Risk Estimation 2], SCORE2-OP\n[Systematic Coronary Risk Estimation 2—Older Persons], ASCVD\n[AtheroSclerotic Cardiovascular Disease] risk score, U-Prevent,\nand lifetime risk calculators) may be considered at baseline for the\nassessment of CV risk, considering that cancer itself may increase\nthe likelihood of CVD.19,23,30,31\nBaseline risk assessment should be considered by the treating on-\ncology or haematology team for all patients diagnosed with cancer\nwho are scheduled to receive a cancer treatment identiﬁed to\nhave a clinically signiﬁcant level of CRT-CVT, or by a cardiologist if\nappropriate.\nIn\nthe\ncase\nof\npatients\nscheduled\nto\nreceive\nCurrent cancer treatment\nDexamethasone . 160 mg/\nmonth\n–\n–\n–\n–\nM1\n–\nIncludes anthracycline\nbefore HER2-targeted\ntherapy\n–\nM1g\n–\n–\n–\n–\nPrevious exposure to\nAnthracycline\nH\nM2h\nH\n–\nH\nH\nTrastuzumab\n–\nVH\n–\n–\n–\n–\nRT to left chest or\nmediastinum\nH\nM2\nM1\n–\nM1\nM2\nNon-anthracycline\nchemotherapy\nM1\n–\n–\n–\n–\n–\nLifestyle risk factors\nCurrent smoker or\nsigniﬁcant smoking history\nM1\nM1\nM1\nH\nM1\nM1\nObesity (BMI . 30 kg/m2)\nM1\nM1\nM1\nM1\nM1\nM1\n© ESC 2022\nAF, atrial ﬁbrillation; BCR-ABL, breakpoint cluster region–Abelson oncogene locus; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery\nbypass graft; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DM, diabetes\nmellitus; DVT, deep vein thrombosis; eGFR, estimated glomerular ﬁltration rate; H, high risk; HbA1c, glycated haemoglobin; HER2, human epidermal receptor 2; HF, heart failure; IMiD,\nimmunomodulatory drugs; LV, left ventricular; LVEF, left ventricular ejection fraction; M, moderate risk; MEK, mitogen-activated extracellular signal-regulated kinase; MI, myocardial\ninfarction; MM, multiple myeloma; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary\nintervention; PE, pulmonary embolism; PH, pulmonary hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; RAF, rapidly accelerated ﬁbrosarcoma; RT,\nradiotherapy; TKI, tyrosine kinase inhibitors; ULN, upper limit of normal; VEGFi, vascular endothelial growth factor inhibitors; VH, very high risk; VHD, valvular heart disease.\nAn expanded version of this table is provided in Supplementary data, Tables S2–S7.\nRisk level: Low risk = no risk factors OR one moderate1 risk factor; moderate risk (M) = moderate risk factors with a total of 2–4 points (Moderate 1 [M1] = 1 point; Moderate\n[M2] = 2 points); high risk (H) = moderate risk factors with a total of ≥5 points OR any high-risk factor; very-high risk (VH) = any very-high risk factor.\naAF, atrial ﬂutter, ventricular tachycardia, or ventricular ﬁbrillation.\nbElevated above the ULN of the local laboratory reference range.\ncSystolic BP . 140 mmHg or diastolic BP . 90 mmHg, or on treatment.\ndeGFR , 60 mL/min/1.73 m2.\neHbA1c . 7.0% or .53 mmol/mol, or on treatment.\nfNon-high density lipoprotein cholesterol .3.8 mmol/L (.145 mg/dL) or on treatment.\ngHigh risk if anthracycline chemotherapy and trastuzumab delivered concurrently.\nhPrevious malignancy (not current treatment protocol).\nTable 5\nAnthracycline equivalence dose\nDoxorubicin\nEpirubicin\nDaunorubicin\nMitoxantrone\nIdarubicina\nCV toxicity dose ratio\n1\n0.8\n0.6\n10.5\n5\nIsoequivalent dose\n100 mg/m2\n125 mg/m2\n167 mg/m2\n9.5 mg/m2\n20 mg/m2\n© ESC 2022\nThis table refers to anthracycline equivalence dose using doxorubicin as a reference. Note that these isoequivalent doses are derived from paediatric CS.\nCS, cancer survivors; CV, cardiovascular.\naData for idarubicin are based upon an estimated anticancer efﬁcacy ratio, not derived from cardiotoxicity data. The CV toxicity dose ratio provides the value that should be used to\nmultiply the dose of the anthracycline of interest to convert to isoequivalent doses of doxorubicin; e.g. to convert 125 mg/m2 of epirubicin to doxorubicin isoequivalent, multiply the dose\nby 0.8 (125 mg/m2 × 0.8 = 100 mg/m2 of doxorubicin).\nESC Guidelines\n4247\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nanthracycline chemotherapy, the total planned cumulative anthracy-\ncline dose is also relevant, and ≥250 mg/m2 of doxorubicin or\nequivalent should be considered higher risk (Table 5).32\nCV risk stratiﬁcation results should be discussed with the patient\nand documented in clinical notes. This process will also enable future\nvalidation of these tools.\nCardiology referral (cardio-oncology programme or cardiolo-\ngist with expertise in managing CVD in patients with cancer) is\nrecommended for patients identiﬁed to be at high or very high\nrisk for CTR-CVT at baseline (Table 4) to institute strategies to miti-\ngate risk.33 Patients at moderate risk can beneﬁt from closer cardiac\nmonitoring, strict management of traditional CVRF, and selected\nmoderate-risk patients may also beneﬁt from a cardio-oncology re-\nferral (Figure 6). Low-risk patients can be followed within the oncol-\nogy programme with appropriate referral to cardio-oncology if a\nCTR-CVT emerges or new or uncontrolled CVRF appear.\nAND\nAND\nAND\nAND\nAND\nCV risk stratification befof re anticancer therapy\np\n(Class I)\nCommunicate the CV toxicity risk assessment results (Class I)\nEducate patients regarding risks and protective healthy lifestyle (Class I)\nf\nManagement of CVRF and CVD according to ESC Guidelines (Class I)\nHFA-ICOS baseline risk assessment\nF\n(Class IIa)\nLow risk\nRoutine oncology foll\nf\now-up\nModerate risk\nCardiologya refef rral if\nCV toxicity develops\n(Class I)\nCloser oncology foll\nf\now-up\nCardiologya refef rral if\nCV toxicity develops\n(Class I)\nCardiology refef rrala\n(Class IIb)\nCardiologya refef rral\n(Class I)\nCardioprotective strategies\n(Class IIa)\nDiscussion of the risk/benefit\nbalance of cardiotoxic\nanticancer treatment\n(Class I)\nHFA-ICOS\nF\nresults\nHigh/very high risk\nPatient with cancer\nFigure 6 General cardio-oncology approach after Heart Failure Association–International Cardio-Oncology Society cardiovascular toxicity risk assess-\nment. CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Society of Cardiology; HFA, Heart Failure Association; ICOS,\nInternational Cardio-Oncology Society. aCardio-oncology referral is recommended when available; alternatively, patients should be referred to a spe-\ncialized cardiologist with expertise in managing CVD in patients with cancer.\n4248\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n4.2. History and clinical examination\nA careful clinical history and physical examination is recommended as\npart of the baseline risk assessment. Oncology patients can be di-\nvided into two cohorts with respect to the presence or absence of\npre-existing CVD. A primary prevention strategy can be considered\nin patients without previous CVD or CTR-CVT while secondary\nprevention includes interventions in patients with prior or active\nCVD or previous CTR-CVT.12\nReviewing traditional risk factors for CVD is recommended.\nWhere present, the efﬁcacy of treatment and control of these modi-\nﬁable risk factors should be determined to ensure optimal control\nduring\ncancer\ntherapy.4,34\nAlthough\nrecent\nSCORE2\nand\nSCORE2-OP19 tables are not focused on patients with cancer, risk\ncalculation is recommended for patients with cancer .40 years of\nage (unless they are automatically categorized as being at high risk\nor very high risk based on documented CVD, diabetes mellitus\n[DM], kidney disease, or a highly elevated single risk factor) as a ref-\nerence to optimize CVRF treatment goals.19,31,35 A family history of\npremature CVD should be considered because genetic abnormalities\nassociated with CVD may predispose patients with cancer to a high-\ner risk of CTR-CVT.36–38 Lifestyle factors such as smoking, alcohol\nconsumption, sedentary lifestyle, exposure to pollution, and frailty\nare important shared risk factors for both cancer and CVD.\nInformation on prior history of cancer, cardiotoxic cancer therapies,\nand their respective doses should be collected. Patients should be\nasked about typical cardiac symptoms (e.g. chest pain with activity,\ndyspnoea on exertion, orthopnoea, palpitations, and peripheral oe-\ndema), which can guide clinical examination and investigations.\nPhysical examination should document vital signs and look for poten-\ntial indicators of undiagnosed CVD such as HF, pericardial disease,\nVHD, and arrhythmias.39–42\nThe second scenario is secondary prevention in patients with a\nprior history of CVD. These patients with cancer are potentially at\nhigh or very high risk of future CV events,12 and require a more\ncomprehensive clinical evaluation of their CVD, its severity, and\nprior and current treatments. Depending on the type and severity\nof CVD, additional investigations—including resting or stress echo-\ncardiography, cardiac magnetic resonance (CMR), nuclear perfusion\nimaging, and coronary computed tomography angiography (CCTA)\n—may be indicated to determine risk status. Identifying prior CVD\nshould not automatically be a reason to withhold cancer therapy\nbut considered an opportunity to optimize CV risk prior to and dur-\ning treatment. Risk/beneﬁt discussions should include the patient,\noncologist or haematologist, and—where available—a specialized\ncardio-oncology service.\nAdditional factors that add to the complexity of baseline CV risk\nassessment are the cancer type and prognosis, and type, duration,\nand intensity of cancer treatment (Figure 1).4,12,43 Clinical history,\nphysical examination features, and treatment-related risk factors\nthat contribute to CTR-CVT for various cancer therapies are sum-\nmarized in Supplementary data, Table S8. These risk factors should\nbe collected and considered along with baseline ECG, cardiac serum\nbiomarkers, and cardiac imaging tests (summarized in Figure 7) to\ncomplete baseline CTR-CVT evaluation.\n4.3. Electrocardiogram\nA baseline 12-lead ECG is a readily available test that can provide im-\nportant clues to underlying CVD. ECG evidence of chamber enlarge-\nment, conduction abnormalities, arrhythmias, ischaemia, or prior\nmyocardial infarction (MI), and low voltages should be interpreted\nin the clinical context. A baseline ECG is recommended prior to\nstarting a cancer treatment known to cause QTc prolongation.44–49\nMeasurement of QTc using the Fridericia correction (QTcF) is\nRecommendation Table 1 — Recommendations for a\ngeneral\napproach\nto\ncardiovascular\ntoxicity\nrisk\ncategorization\nRecommendations\nClassa\nLevelb\nCV toxicity risk stratiﬁcationc before starting\npotentially cardiotoxic anticancer therapy is\nrecommended in all patients with\ncancer.12,14,19,21,25,28,31\nI\nB\nCommunicating the results of the CV toxicity risk\nassessment to the patient and other appropriate\nhealthcare professionals is recommended.\nI\nC\nThe use of HFA-ICOS risk assessment should be\nconsidered to stratify CV toxicity risk in patients\nwith cancer scheduled to receive cardiotoxic\nanticancer therapy.12\nIIa\nC\nIt is recommended that patients categorized to be\nat low CV toxicity risk should proceed to\nanticancer therapy without delay.\nI\nC\nIn patients categorized at moderate CV toxicity\nrisk, cardiology referrald may be considered.e\nIIb\nC\nCardiology referrald is recommended in high-risk\nand very high-risk patients before anticancer\ntherapy.f\nI\nC\nDiscussion of the risk/beneﬁt balance of\ncardiotoxic anticancer treatment in high- and very\nhigh-risk patients in a multidisciplinary approach\nprior to starting treatment is recommended.\nI\nC\nCardiology referrald is recommended for patients\nwith cancer and pre-existing CVD or abnormal\nﬁndings at baseline CV toxicity risk assessmentg\nwho require potentially cardiotoxic anticancer\ntherapy.\nI\nC\n© ESC 2022\nCV, cardiovascular; CVD, CV disease; ECG, electrocardiogram; GLS, global longitudinal\nstrain; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS,\nInternational Cardio-Oncology Society; LVEF, left ventricular ejection fraction; TTE,\ntransthoracic echocardiography; ULN, upper limit of normal; VHD, valvular heart\ndisease.\naClass of recommendation.\nbLevel of evidence.\ncIncluding clinical history and physical examination, ECG, general blood test, HbA1c,\nlipid proﬁle, and cardiac serum biomarkers and/or TTE (according to cancer drug\ntype and CV toxicity risk).\ndCardio-oncology referral is recommended when available; alternatively, the patients\nshould be referred to a specialized cardiologist with expertise in managing CVD in\npatients with cancer.\neWithout delaying cancer treatments.\nfUnless there is an oncology emergency requiring immediate cancer treatment.\ngModerate-to-severe pre-existing CVDs or new abnormal ﬁndings (baseline cardiac\nserum biomarkers . ULN, LVEF ≤50%, GLS under normal local values, previously\nundiagnosed moderate-to-severe myocardial, pericardial, or VHDs, abnormal baseline\nECG).\nESC Guidelines\n4249\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nHER2-targeted therapiesc\nBaseline clinical CV assessment, p\n, hysical exam and ECG are recommended\nin all cancer patients scheduled for ca\nf\nrdiotoxic therapiesa\nPrevious\nCVD\nPrevious\nCVD\nAll other\npatients\nAll\npatients\nAll\npatients\nAll other\npatients\nPrevious\nCVD\nAll\npatients\nHigh and\nvery high risk\nModerate\nrisk\nLow\nrisk\nOther\nconditions\nClass IIb\nClass IIa\nClass I\nAnthracyclines\nFluoropyrymidines\nVEGFi\nSecond- and third-generation BCR-ABL TKId\nBTK inhibitors\nPIe\nRAF and MEK inhibitors\nICI\nOsimertinib\nCAR-T and TIL\nRT to a\nR\nvolume including the heart\nHSCT\nTTEb\nPatient risk level\nNP\ncTn\nFigure 7 Baseline screening recommendations for patients with cancer treated with potentially cardiotoxic drugs. 3D, three-dimensional; ADT, andro-\ngen deprivation therapy; AL-CA, amyloid light-chain cardiac amyloidosis; BC, breast cancer; BCR-ABL, breakpoint cluster region-Abelson oncogene locus;\nBNP, B-type natriuretic peptide; BTK, Bruton tyrosine kinase; CAR-T, chimeric antigen receptor T cell; CDK, cyclin-dependent kinase; CMR, cardiac mag-\nnetic resonance; cTn, cardiac troponin; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GLS, global longitudinal strain; HER2,\nhuman epidermal receptor 2; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; LVEF, left ventricular ejection fraction;\nMEK, mitogen-activated extracellular signal-regulated kinase; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal\npro-B-type natriuretic peptide; PI, proteasome inhibitors; RAF, rapidly accelerated ﬁbrosarcoma; RT, radiotherapy; TIL, tumour-inﬁltrating lymphocytes;\nTKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitors. aIncluding patients scheduled to\nreceive ADT for prostate cancer, CDK 4/6 inhibitors, endocrine hormone therapy for BC and anaplastic lymphoma kinase inhibitors. bTTE is recom-\nmended as the ﬁrst-line modality for the assessment of cardiac function. 3D echocardiography is recommended to measure LVEF. GLS is recommended\nin all patients with cancer having echocardiography, if available. CMR should be considered when echocardiography is unavailable or not diagnostic.\ncBaseline cTn measurement should be considered (Class IIa, Level A) in low- and moderate-risk patients post-anthracycline chemotherapy but prior\nto starting HER2-targeted therapies. Baseline NP and cTn measurement may be considered (Class IIb, Level C) in low- and moderate-risk patients.\ndBaseline echocardiography is recommended in patients scheduled to receive dasatinib (Class I, Level C). eNP and cTn measurements are recommended\nat baseline in patients with AL-CA (Class I, Level B).\n4250\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nrecommended.44–48 When baseline QTcF prolongation is recog-\nnized, the correction of reversible causes and the identiﬁcation of\ngenetic conditions that prolong QT is recommended (see Section\n6.4.2).45\nLeft atrial enlargement on baseline ECG before ibrutinib has\nbeen shown to be a predictor for the development of atrial ﬁbril-\nlation (AF) during chemotherapy.50,51 The presence of atrioven-\ntricular (AV) conduction delays and premature atrial complexes\nare associated with the development of atrial arrhythmias in pa-\ntients undergoing autologous haematopoietic stem cell transplant-\nation (HSCT).52\n4.4. Cardiac serum biomarkers\nThe literature on the use of biomarkers for CTR-CVT risk strati-\nﬁcation before cancer therapy is limited, and recommendations\nare mostly based on expert opinion.12,43,53–55 Four recent position\npapers based on collaboration among the Cardio-Oncology Study\nGroup of the HFA of the ESC, the ESC-CCO, and ICOS have sug-\ngested that measurement of cardiac serum biomarkers—cardiac\ntroponin (cTn) I or T and natriuretic peptides (NP) (e.g. B-type\nnatriuretic\npeptide\n[BNP]\nor\nN-terminal\npro-BNP\n[NT-proBNP])—help in baseline CV risk stratiﬁcation of patients\nscheduled for cancer therapies including anthracyclines, human\nepidermal receptor 2 (HER2)-targeted therapies, vascular endo-\nthelial growth factor (VEGF) inhibitors (VEGFi), proteasome inhi-\nbitors (PI), immune checkpoint inhibitors (ICI), chimeric antigen\nreceptor T cell (CAR-T) and tumour-inﬁltrating lymphocytes\n(TIL) therapies, allowing identiﬁcation of those who may beneﬁt\nfrom cardioprotective therapy.12,43,53,54 Baseline cardiac serum\nbiomarker measurements are required if the degree of change in\nthe biomarkers is to be used to identify subclinical cardiac injury\nduring cancer treatment.\nA few studies of paediatric and adult patients requiring an-\nthracycline chemotherapy have reported that patients with can-\ncer with an increased cTn before treatment were more likely to\ndevelop CTRCD.56–58 However, most published studies have\nnot reported on the prognostic value of baseline cTn measure-\nments, possibly due to the low prevalence of patients with pre-\nvious CVD or CVRF in these studies.55,59,60 A study of 251\nwomen receiving trastuzumab for early HER2-positive breast\ncancer (BC) reported that 19% of the patients who developed\ncardiac dysfunction during trastuzumab therapy had positive ul-\ntrasensitive troponin I at baseline (.80 ng/L).61 Furthermore,\nbaseline high cTnI level was a predictor of lack of recovery des-\npite optimal HF therapy.61 These ﬁndings have been conﬁrmed\nin a subsequent study of 533 patients with BC who had serial\nhigh-sensitivity cTn (hs-cTn) I and T measurements during tras-\ntuzumab\ntherapy.62\nIncreased\nbaseline\ncTn\n(.40 ng/L\nand\n.14 ng/L for hs-cTnI and hs-cTnT, respectively) was associated\nwith a four-fold risk of developing LV dysfunction (LVD).62\nHowever, given the high proportion of patients with previous\nanthracycline exposure in both studies, these elevated cTn levels\nare not a true baseline as they reﬂect pre-trastuzumab but post-\nanthracycline\nchemotherapy.\nIt\nis\nunclear\nwhether\npre-\ntreatment cTn levels will be predictive of LVD in patients before\nany treatment, or for those BC patients treated with trastuzu-\nmab without prior anthracyclines.\nNP are another potential biomarker for CV risk stratiﬁcation.\nSeveral studies have shown the role of NP measurement at baseline\nor NP changes to predict future CTR-CVT.63–65 In patients with mul-\ntiple myeloma (MM), pre-treatment NP may be a predictive marker\nfor subsequent CV adverse events. In 109 patients with relapsed MM,\nBNP . 100 pg/mL or NT-proBNP . 125 pg/mL levels before initi-\nation of carﬁlzomib were associated with an odds ratio of 10.8 for\nsubsequent CV adverse events.66 Therefore, baseline NP measure-\nment is recommended in high- and very high-risk patients and should\nbe considered in low- and moderate-risk patients before PI\ntreatment.\nBaseline elevated values of CV functional peptides (including\nNT-proBNP) and hs-cTnT were strongly related to all-cause mortal-\nity in 555 patients with different types of tumours, suggesting that\nthe presence of a subclinical myocardial injury might be directly\nlinked to disease progression.67 However, in the CARDIOTOX\n(CARDIOvascular TOXicity induced by cancer-related therapies)\nregistry, in 855 patients treated with a range of oncological treat-\nments, including radiotherapy (RT), both NT-proBNP and cTn eleva-\ntion at baseline were not associated with the development of severe\nCTRCD (LVEF , 40% or clinical HF).68\nThere has also been interest in other novel biomarkers for\nCTR-CVT risk stratiﬁcation before cancer treatment; however,\nthe literature is limited. Candidates include myeloperoxidase,\nC-reactive protein, galectin-3, arginine–nitric oxide metabolites,\ngrowth\ndifferentiation\nfactor-15,\nplacental\ngrowth\nfactor,\nfms-like tyrosine kinase-1, micro-ribonucleic acids, and immuno-\nglobulin E.60,69–71 Currently, there is no evidence to support\nroutine measurement of these novel biomarkers and more re-\nsearch is required.\nRecommendation Table 2 — Recommendations for\nelectrocardiogram baseline assessment\nRecommendations\nClassa\nLevelb\nAn ECG is recommended in all patients starting\ncancer therapy as part of their baseline CV risk\nassessment.\nI\nC\nIn patients with an abnormal baseline ECG,c\nreferral to a cardiologistd is recommended.\nI\nC\n© ESC 2022\nAF, atrial ﬁbrillation; CV, cardiovascular; ECG, electrocardiogram; LV, left ventricular;\nQTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction.\naClass of recommendation.\nbLevel of evidence.\ncAdvanced conduction disease (left bundle branch block, right bundle branch block,\nsecond degree heart block, severe ﬁrst degree heart block with a PR interval\n.300 ms); Q waves in two or more contiguous leads; LV hypertrophy; AF/atrial\nﬂutter if previously undiagnosed; QTc prolongation using Fridericia correction\nformula (QTcF = QT/3√RR) .450 ms for men and .460 ms for women or other\nECG abnormality raising concern.\ndCardio-oncology referral is recommended when available; alternatively, the patients\nshould be referred to a specialized cardiologist with expertise in managing CVD in\npatients with cancer.\nESC Guidelines\n4251\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n4.5. Cardiovascular imaging\nCV imaging has an important role in identifying patients with subclin-\nical CVD, determining the degree of pre-existing cardiac comorbidity\nprior to decisions regarding cancer therapy, and serves as a reference\nfor identiﬁcation of changes during treatment and long-term follow-\nup.12,54,72–74 Transthoracic echocardiography (TTE) is the preferred\nimaging technique for baseline risk stratiﬁcation as it provides quan-\ntitative assessment of LV and right ventricular (RV) function, cham-\nber dilation, LV hypertrophy, regional wall motion abnormalities,\ndiastolic function, VHD, pulmonary arterial pressure (PAP), and peri-\ncardial disease, which may inﬂuence the therapeutic decision.22,72\nSuggestions for the components of a baseline echocardiography\nstudy are provided in Figure 8.\nCurrent deﬁnitions of CTRCD are based on a reduction of LVEF\nand/or relative changes in global longitudinal strain (GLS) (Table 3).\nThree-dimensional (3D) echocardiography is the preferred echocar-\ndiography modality for the assessment of LVEF and cardiac\nRecommendation Table 3 — Recommendation for\ncardiac biomarker assessment prior to potentially car-\ndiotoxic therapies\nRecommendation\nClassa\nLevelb\nBaseline measurement of NPc and/or cTnd is\nrecommended in all patients with cancer at risk of\nCTRCD if these biomarkers are going to be\nmeasured during treatment to detect\nCTRCD.e,53,55\nI\nC\n© ESC 2022\ncTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; NP,\nnatriuretic peptides.\naClass of recommendation.\nbLevel of evidence.\ncNPs including B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide.\ndcTn includes any of troponin I, troponin T, or hs-cTnT.\neSpeciﬁc recommendations for baseline cardiac biomarkers in patients with cancer at\nlow, moderate, high, and very high risk of cancer therapy-related cardiovascular\ntoxicity are included in Section 5.\nTTE\nLeft ventricle-left atriuma\nTTE\nLVV and LV mass\n3D-LVEF (2D-LVEF if \n3D not available)\nContrast echo if inadequate \nTTE image quality\nGLS \nE/e´, LAV\nRVV\nRVEF\nCMR\nRight ventricle-right atriuma\nRV dimensions\nS´\nTAPSE\nFAC\nRV-FWLS\nRA area\nPeak TRV\nLVV and LV mass\nLVEF \nLS and circumferential strain\nif available\nMyocardial Characterization \nT2w (STIR), T1, T2 maps, LGE\nCMR\nValvular and pericardial\ndiseases\nIVC diameter, and respiratory\nchanges\nValvular and pericardial\ndiseases\nOther parameters\nTTE\nCMR\nFigure 8 Recommended transthoracic echocardiography and cardiac magnetic resonance imaging parameters in the evaluation of patients with cancer.\n2D, two-dimensional; 3D, three-dimensional; BP, blood pressure; CMR, cardiac magnetic resonance; E, mitral inﬂow early diastolic velocity obtained by pulsed\nwave; e′, early diastolic velocity of the mitral annulus obtained by tissue doppler imaging; echo, echocardiography; FAC, fractional area change; FWLS, free wall\nlongitudinal strain; GLS, global longitudinal strain; IVC, inferior vena cava; LAV, left atrial volume; LGE, late gadolinium enhancement; LS, longitudinal strain; LV,\nleft ventricular; LVEF, left ventricular ejection fraction; LVV, left ventricular volume; RA, right atrial; RV, right ventricular; RVEF, right ventricular ejection fraction;\nRVV, right ventricular volume; s′, systolic velocity of tricuspid annulus obtained by doppler tissue imaging; STIR, short tau inversion recovery; TAPSE, tricuspid\nannular plane systolic excursion; TTE, transthoracic echocardiography; TRV, tricuspid regurgitation velocity. aChanges in systemic arterial BP and loading con-\nditions may inﬂuence cardiac function measurements.\n4252\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nvolumes.54,75–79 If 3D echocardiography is not feasible (e.g. unavail-\nable or poor tracking), the modiﬁed two-dimensional (2D)\nSimpson’s biplane method is recommended.80,81 In patients with in-\nadequate TTE image quality, ultrasound-enhancing contrast agents\nshould be added to improve evaluation of LV function and volumes\nif two or more LV segments are not well visualized.82 Alternatively, in\nsubjects with poor-quality echocardiography windows, when avail-\nable, CMR should be considered (Figure 8).14,72,83,84 If TTE and\nCMR are both unavailable for the assessment of LVEF, multigated ac-\nquisition nuclear imaging (MUGA) can be considered as a third-line\nmodality. MUGA scans should be avoided whenever possible due\nto radiation exposure and the inability to obtain other important in-\nformation (e.g. VHD, PAP, or GLS).\nBaseline LVEF and GLS are recommended in all patients evaluated\nwith TTE before cardiotoxic cancer treatment initiation to stratify\nCTR-CVT risk and to identify signiﬁcant changes during treat-\nment.8,64 Changes in loading conditions occur frequently during\nchemotherapy (e.g. volume increase due to intravenous [i.v.] ﬂuids,\nvolume loss due to vomiting or diarrhoea, blood pressure [BP] and\nheart rate changes with pain or stress) and may affect cardiac vo-\nlumes, LVEF, and GLS quantiﬁcation. Systemic arterial BP measure-\nment is recommended with all resting TTE as it can inﬂuence\ncardiac function measurements and should be recorded on the\nTTE report. A baseline borderline (50–54%) or reduced (,50%)\nLVEF is a risk factor for future CTR-CVT from most cardiotoxic can-\ncer therapies, in particular with anthracyclines or trastuzumab.12,24,74\nIncreased baseline indexed LV end-diastolic volume can be a predict-\nor of major CV events (symptomatic HF or cardiac death) during an-\nthracycline chemotherapy in patients with preserved LVEF.85\nA normal LVEF does not exclude CTRCD and deformation para-\nmeters can detect early systolic impairment with sufﬁcient test reli-\nability.86–89 Determination of GLS using speckle tracking is\nrecommended at baseline, using three apical views,90 particularly\nin moderate- and high-risk patients. Baseline GLS can predict\nLVD89–94 in patients receiving anthracyclines and/or trastuzumab.\nStrain measurements may be subject to inter-vendor variability95\nand serial GLS measurement for each patient is recommended to\nbe performed using the same machine/software. A median GLS\nchange of 13.6% predicted a future fall in LVEF with a 95% upper limit\nof GLS reduction of 15%.93 Using the 15% cut-off improves speciﬁ-\ncity and is therefore the threshold recommended when monitoring\nGLS during cancer therapy. Global circumferential strain96 has been\nreported to identify patients at risk of CTRCD, but data are currently\ninsufﬁcient to recommend its use routinely. Baseline LV diastolic\nfunction may be associated with a small risk of subsequent systolic\ndysfunction, especially with anthracyclines and trastuzumab, al-\nthough the evidence is not consistent.97,98 Chest computed tomog-\nraphy (CT) or CMR may be helpful for identifying subclinical CVD\nsuch as coronary calcium or intracardiac masses on readily available\nroutine imaging performed for cancer staging.99\nIn the secondary prevention setting or patients with symptoms or\nsigns of pre-existing CVD, a careful evaluation should begin with a\ncomprehensive TTE.73 This is both to obtain baseline assessment\nas in the primary prevention setting and to determine the severity\nof the underlying CVD. In case of poor-quality or uninterpretable\nTTE images, or if a speciﬁc CVD is identiﬁed (e.g. hypertrophic\ncardiomyopathy), CMR should be considered for further risk\nassessment.\nFunctional imaging tests for myocardial ischaemia—including\nstress echocardiography, perfusion CMR, or nuclear myocardial per-\nfusion imaging—should be performed to assess for ischaemia in\nsymptomatic patients (stable angina, limiting dyspnoea) if clinical sus-\npicion of coronary artery disease (CAD) exists, especially prior to\nuse of cancer therapies associated with vascular toxicity (e.g. ﬂuoro-\npyrimidines, VEGFi, breakpoint cluster region–Abelson oncogene lo-\ncus [BCR-ABL], tyrosine kinase inhibitors [TKI]). Alternatively, in\npatients with low to intermediate pre-test probability of CAD,\nCCTA is a robust alternate modality with high sensitivity to rule\nout obstructive CAD.100,101\n4.6. Cardiopulmonary ﬁtness assessment\nMaximal cardiopulmonary exercise testing (CPET) assesses the inte-\ngrative capacity of the CV system to transport oxygen and energy\nsubstrate to skeletal muscle during exercise,109 described as cardio-\nrespiratory ﬁtness (CRF). CPET can therefore provide a more global\nassessment of CV health than organ-speciﬁc tools. CPET-derived\nRecommendation Table 4 — Recommendations for\ncardiac imaging modalities in patients with cancer\nGeneral\nClassa\nLevelb\nEchocardiography is recommended as the\nﬁrst-line modality for the assessment of cardiac\nfunction in patients with cancer.4,12,54,94\nI\nC\n3D echocardiography is recommended as the\npreferred echocardiographic modality to measure\nLVEF.77–79,89\nI\nB\nGLS is recommended in all patients with cancer\nhaving echocardiography, if\navailable.75,80,81,89,90,92,93,102,103\nI\nC\nCMR should be considered for the assessment of\ncardiac function when echocardiography is\nunavailable or non-diagnostic.83,104,105\nIIa\nC\nMUGA may be considered when TTE is not\ndiagnostic and CMR is not available.106–108\nIIb\nC\nBaseline cardiac imaging prior to potentially cardiotoxic\ntherapiesc\nBaseline comprehensive TTE is recommended in\nall patients with cancer at high risk and very high\nrisk of CV toxicity before starting anticancer\ntherapy.d,54\nI\nC\n© ESC 2022\n3D, three-dimensional;\nCMR,\ncardiac magnetic\nresonance;\nCTR-CVT, cancer\ntherapy-related CV toxicity; CV, cardiovascular; GLS, global longitudinal strain; LVEF,\nleft ventricular ejection fraction; MUGA, multigated acquisition nuclear imaging; TTE,\ntransthoracic echocardiography.\naClass of recommendation.\nbLevel of evidence.\ncSpeciﬁc recommendations for baseline CV imaging in patients with cancer at low or\nmoderate risk of CTR-CVT are included in Section 5.\ndExcept asymptomatic patients referred to breakpoint cluster region-Abelson oncogene\nlocus therapy (BCR-ABL) where baseline TTE should be considered (see Figure 7\nand Section 5.5.5).\nESC Guidelines\n4253\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCRF—typically measured as the peak rate of oxygen consump-\ntion110,111 or metabolic equivalents111,112 during exercise—is one\nof the most robust predictors of CV health and longevity,113,114\nand improves risk classiﬁcation.115–121 Evidence for CPET pre-\ntreatment is limited to pre-operative risk stratiﬁcation particularly\nfor patients with lung,122 colon,123 and rectal124 cancers. Whether\nCPET performed prior to cardiotoxic cancer therapies is prognostic\nof future CV events is unknown.\n4.7. Cardiovascular risk evaluation\nbefore cancer surgery\nCancer surgery remains the primary treatment modality for many\ncancers. Cardio-oncology teams should be involved in pre-operative\nCV risk stratiﬁcation to identify and provide appropriate manage-\nment and surveillance of the potential risk factors.5\nIn patients undergoing oncological surgery, peri-operative car-\ndiac complications are determined by patient-related risk factors,\nthe tumour type, concomitant cancer therapies, and the expected\nsurgical risk. To ensure safe cancer surgery, consultations should\nbe directed at: (1) patients with previous signiﬁcant or symptom-\natic CVD; (2) patients at high and very high CV toxicity risk, ac-\ncording to baseline HFA-ICOS risk assessment tools,12 when\nadjuvant (post-surgery) cancer treatment is planned; and (3) pa-\ntients who have received neoadjuvant (prior to surgery) cancer\ntherapy that is potentially cardiotoxic. Pre-operative clinical evalu-\nation should not delay surgery. Complementary tests required for\nthe patients included in groups 1 and 2 should be guided by general\nESC Guidelines.125 However, in group 3 patients, the pre-\noperative evaluation should be aimed at conﬁrming that no rele-\nvant events have occurred during CV monitoring (Section 5).\nTable 6 summarizes factors that could inﬂuence peri-operative\nrisk during cancer surgery.\n4.8. Genetic testing\nCandidate gene and genome-wide association studies have re-\nsulted in the identiﬁcation of 40 candidate genes and single nucleo-\ntide polymorphisms associated with anthracycline-related cardiac\ndysfunction.37,126–128 It should be noted that with the advent of\nimmunotherapies, germline genes may not be the only genetic pre-\ndispositions to CTR-CVT. A study of patients with ICI-associated\nmyocarditis identiﬁed that the selective clonal T-cell populations\ninﬁltrating the myocardium were identical to those present in tu-\nmours and skeletal muscle, with ribonucleic acid sequencing stud-\nies revealing expression of cardiac-speciﬁc genes in the tumour,129\nraising the intriguing possibility that somatic mutations in the tu-\nmour itself could contribute to CTR-CVT. A list of genetic variants\nassociated\nwith\nCVD\nduring\ncancer\ntherapy\nis\nprovided\n(Supplementary data, Table S9) and has recently been reviewed.38\nRoutine use of genetic testing for the assessment of CTR-CVT risk\nprior to initiation of cancer therapy is not currently recommended.\nIn the future, a personalized genetic approach may help deﬁne indi-\nvidual susceptibility to CVD in patients with cancer and more re-\nsearch is required.\n5. Prevention and monitoring of\ncardiovascular complications\nduring cancer therapy\n5.1. General principles\nCTR-CVT risk may vary according to cancer type and stage, antic-\nancer drugs, doses, and underlying comorbidities. Certain therapy\ncombinations (drug–drug or drug–radiation) may have a synergis-\ntically toxic effect on the heart, possibly depending on the timing\nof these therapies (sequential or concomitant) and previous co-\nmorbidities. The pathophysiology of CTR-CVT is out of the scope\nof this guideline and is extensively reviewed in the\nESC\nCardioMed textbook.130\nCVD and cancer share common modiﬁable and non-modiﬁable\nrisk factors (Figure 3).4,131,132 The ﬁrst step is to optimize lifestyle\nCVRF, smoking cessation, restricting alcohol consumption to a max-\nimum of 100 g per week, and maintaining adequate physical activ-\nity.30 Exercise prescription seems to be a promising treatment to\nTable 6\nFactors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies\nFactors that could inﬂuence peri-operative risk during cancer surgery\nPreventive strategies\nPatient-related\nfactors\n• Lifestyle risk factors: smoking, obesity, sedentary lifestyle\n• Poorly controlled CVRF: hypertension, DM\n• Pre-existing CVD including CTR-CVT\n• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and\nanticoagulants)\n• Historical primary malignancy\n• Current cancer type, stage and location\n• Optimal management of CVRF and\nCVD (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\nNeoadjuvant cancer\ntherapy\n• Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline\nchemotherapy and/or trastuzumab, ICI, VEGFi, ﬂuoropyrimidine, and thoracic RT)\n• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK\ninhibitors)\n• Thrombocytopaenia caused by cancer treatment\n• Ensure optimal CV monitoring of\nneoadjuvant therapy (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\n© ESC 2022\nATE, arterial thromboembolism; BTK, Bruton tyrosine kinase; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,\ncardiovascular risk factors; DM, diabetes mellitus; ICI, immune checkpoint inhibitors; RT, radiotherapy; VEGFi, vascular endothelial growth factor inhibitors; VTE, venous\nthromboembolism.\n4254\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 16",
          "page": 16,
          "content": " |  | Coronary epicardial\nvasoreactivity |  | Vasospastic angina | \n |  | Coronary microvascular\nvasoreactivity |  | Microvascular angina | \n |  |  |  | Raynaud’s phenomenon | \n | Arterial hypertension |  |  |  | \nTreatment threshold for\nhypertension before, during, and\nafter therapy |  | In patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic |  |  | \n |  | Otherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic |  |  | \nCancer therapy holding threshold |  | ≥180 mmHg systolic and/or ≥110 mmHg diastolic |  |  | \nHypertensive emergency |  | (Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage |  |  | \n | Cardiac arrhythmias |  |  |  | \nQT prolongation |  | Prolonged: QTcF . 500 msj |  |  | \nBradycardia |  | For general cardiology definitions, see Supplementary data, Table S1 |  |  | \nSupraventricular tachycardia |  |  |  |  | \nVentricular arrhythmias |  |  |  |  | \nAF |  |  |  |  | ",
          "rows": 14,
          "cols": 6
        },
        {
          "title": "Table on page 18",
          "page": 18,
          "content": "Baseline CV toxicity\nrisk factors |  | Anthracycline\nchemotherapy | HER2-targeted\ntherapies | VEGF\ninhibitors | BCR-ABL\ninhibitors | Multiple\nmyeloma\ntherapies | RAF and\nMEK\ninhibitors | \n | Previous CVD |  |  |  |  |  |  | \nHF/cardiomyopathy/\nCTRCD |  | VH | VH | VH | H | VH | VH | \nSevere VHD |  | H | H | – | – | – | H | \nMI or PCI or CABG |  | H | H | VH | – | – | H | \nStable angina |  | H | H | VH | – | – | H | \nArterial vascular disease |  | – | – | VH | VH | VH | – | \nAbnormal ankle-brachial\npressure index |  | – | – | – | H | – | – | \nPH |  | – | – | – | H | – | – | \nArterial thrombosis with TKI |  | – | – | – | VH | – | – | \nVenous thrombosis\n(DVT/PE) |  | – | – | H | M2 | VH | – | \nArrhythmiaa |  | – | M2 | M2 | M2 | M2 | M1 | \nQTc ≥480 ms |  | – | – | H | H | – | – | \n450 ≤QTc , 480 ms (men);\n460 ≤QTc , 480 ms\n(women) |  | – | – | M2 | M2 | – | – | \nPrior PI CV toxicity |  | – | – | – | – | VH | – | \nPrior IMiD CV toxicity |  | – | – | – | – | H | – | \n | Cardiac imaging |  |  |  |  |  |  | \nLVEF , 50% |  | H | H | H | H | H | H | \nLVEF 50–54% |  | M2 | M2 | M2 | – | M2 | M2 | \nLV hypertrophy |  | – | – | – | – | M1 | – | \nCardiac amyloidosis |  | – | – | – | – | VH | – | \n | Cardiac biomarkers |  |  |  |  |  |  | \nElevated baseline cTnb |  | M1 | M2 | M1 | – | M2 | M2 | \nElevated baseline NPb |  | M1 | M2 | M1 | – | H | M2 | \n | Age and CVRF |  |  |  |  |  |  | \nAge ≥80 years |  | H | H | – | – | – | M1 | \nAge 65–79 years |  | M2 | M2 | – | – | – | M1 | \nAge ≥75 years |  | – | – | H | H | H | M1 | \nAge 65–74 years |  | – | – | M1 | M2 | M1 | M1 | \nAge ≥60 years |  | – | – | – | M1 | – | – | \nCVD 10-year risk score\n. 20% |  | – | – | – | H | – | – | \nHypertensionc |  | M1 | M1 | H | M2 | M1 | M2 | \nChronic kidney diseased |  | M1 | M1 | M1 | M1 | M1 | M1 | \nProteinuria |  | – | – | M1 | – | – | – | \nDMe |  | M1 | M1 | M1 | M1 | M1 | M1 | \nHyperlipidaemiaf |  | – | – | M1 | M1 | M1 | – | \nFamily history of\nthrombophilia |  | – | – | – | M1 | M1 | – | ",
          "rows": 37,
          "cols": 9
        },
        {
          "title": "Table on page 19",
          "page": 19,
          "content": " | Current cancer treatment |  |  |  |  |  |  | \nDexamethasone . 160 mg/\nmonth |  | – | – | – | – | M1 | – | \nIncludes anthracycline\nbefore HER2-targeted\ntherapy |  | – | M1g | – | – | – | – | \n | Previous exposure to |  |  |  |  |  |  | \nAnthracycline |  | H | M2h | H | – | H | H | \nTrastuzumab |  | – | VH | – | – | – | – | \nRT to left chest or\nmediastinum |  | H | M2 | M1 | – | M1 | M2 | \nNon-anthracycline\nchemotherapy |  | M1 | – | – | – | – | – | \n | Lifestyle risk factors |  |  |  |  |  |  | \nCurrent smoker or\nsignificant smoking history |  | M1 | M1 | M1 | H | M1 | M1 | \nObesity (BMI . 30 kg/m2) |  | M1 | M1 | M1 | M1 | M1 | M1 | ",
          "rows": 11,
          "cols": 9
        },
        {
          "title": "Table on page 19",
          "page": 19,
          "content": " | Doxorubicin | Epirubicin | Daunorubicin | Mitoxantrone | Idarubicina\nCV toxicity dose ratio | 1 | 0.8 | 0.6 | 10.5 | 5\nIsoequivalent dose | 100 mg/m2 | 125 mg/m2 | 167 mg/m2 | 9.5 mg/m2 | 20 mg/m2",
          "rows": 3,
          "cols": 6
        },
        {
          "title": "Table on page 21",
          "page": 21,
          "content": "Recommendations | Classa | Levelb\nCV toxicity risk stratificationc before starting\npotentially cardiotoxic anticancer therapy is\nrecommended in all patients with\ncancer.12,14,19,21,25,28,31 | I | B\nCommunicating the results of the CV toxicity risk\nassessment to the patient and other appropriate\nhealthcare professionals is recommended. | I | C\nThe use of HFA-ICOS risk assessment should be\nconsidered to stratify CV toxicity risk in patients\nwith cancer scheduled to receive cardiotoxic\nanticancer therapy.12 | IIa | C\nIt is recommended that patients categorized to be\nat low CV toxicity risk should proceed to\nanticancer therapy without delay. | I | C\nIn patients categorized at moderate CV toxicity\nrisk, cardiology referrald may be considered.e | IIb | C\nCardiology referrald is recommended in high-risk\nand very high-risk patients before anticancer\ntherapy.f | I | C\nDiscussion of the risk/benefit balance of\ncardiotoxic anticancer treatment in high- and very\nhigh-risk patients in a multidisciplinary approach\nprior to starting treatment is recommended. | I | C\nCardiology referrald is recommended for patients\nwith cancer and pre-existing CVD or abnormal\nfindings at baseline CV toxicity risk assessmentg\nwho require potentially cardiotoxic anticancer\ntherapy. | I | C",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 22",
          "page": 22,
          "content": "Baseline clinical CV assessment, physical exam and ECG are recommended\nin all cancer patients scheduled for cardiotoxic therapiesa\nPatient risk level TTEb NP cTn\nAnthracyclines\nHER2-targeted therapiesc\nFluoropyrymidines Previous\nCVD\nVEGFi\nSecond- and third-generation BCR-ABL TKId All\npatients\nBTK inhibitors\nPIe\nRAF and MEK inhibitors\nICI\nAll other\npatients\nOsimertinib All\npatients\nCAR-T and TIL Previous\nCVD\nAll other\npatients\nRT to avolume including the heart Previous\nCVD\nHSCT All\npatients\nHigh and Moderate Low Other\nClass I Class IIa Class IIb\nvery high risk risk risk conditions |  | \n |  | ",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 23",
          "page": 23,
          "content": "Recommendations | Classa | Levelb\nAn ECG is recommended in all patients starting\ncancer therapy as part of their baseline CV risk\nassessment. | I | C\nIn patients with an abnormal baseline ECG,c\nreferral to a cardiologistd is recommended. | I | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 24",
          "page": 24,
          "content": "Recommendation | Classa | Levelb\nBaseline measurement of NPc and/or cTnd is\nrecommended in all patients with cancer at risk of\nCTRCD if these biomarkers are going to be\nmeasured during treatment to detect\nCTRCD.e,53,55 | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 25",
          "page": 25,
          "content": "General |  | Classa | Levelb | \nEchocardiography is recommended as the\nfirst-line modality for the assessment of cardiac\nfunction in patients with cancer.4,12,54,94 |  | I | C | \n3D echocardiography is recommended as the\npreferred echocardiographic modality to measure\nLVEF.77–79,89 |  | I | B | \nGLS is recommended in all patients with cancer\nhaving echocardiography, if\navailable.75,80,81,89,90,92,93,102,103 |  | I | C | \nCMR should be considered for the assessment of\ncardiac function when echocardiography is\nunavailable or non-diagnostic.83,104,105 |  | IIa | C | \nMUGA may be considered when TTE is not\ndiagnostic and CMR is not available.106–108 |  | IIb | C | \n | Baseline cardiac imaging prior to potentially cardiotoxic\ntherapiesc |  |  | \nBaseline comprehensive TTE is recommended in\nall patients with cancer at high risk and very high\nrisk of CV toxicity before starting anticancer\ntherapy.d,54 |  | I | C | ",
          "rows": 8,
          "cols": 5
        },
        {
          "title": "Table on page 26",
          "page": 26,
          "content": " | Factors that could influence peri-operative risk during cancer surgery | Preventive strategies\nPatient-related\nfactors | • Lifestyle risk factors: smoking, obesity, sedentary lifestyle\n• Poorly controlled CVRF: hypertension, DM\n• Pre-existing CVD including CTR-CVT\n• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and\nanticoagulants)\n• Historical primary malignancy\n• Current cancer type, stage and location | • Optimal management of CVRF and\nCVD (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\nNeoadjuvant cancer\ntherapy | • Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline\nchemotherapy and/or trastuzumab, ICI, VEGFi, fluoropyrimidine, and thoracic RT)\n• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK\ninhibitors)\n• Thrombocytopaenia caused by cancer treatment | • Ensure optimal CV monitoring of\nneoadjuvant therapy (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)",
          "rows": 3,
          "cols": 3
        }
      ],
      "keywords": [
        "cardiovascular",
        "ct",
        "follow-up",
        "heart failure",
        "mild",
        "stratification",
        "risk",
        "before",
        "anticancer",
        "toxicity",
        "treatment",
        "imaging",
        "therapy",
        "diagnosis"
      ]
    },
    {
      "number": "7",
      "title": "5. Prevention and monitoring of cardiovascular complications during cancer therapy",
      "start_page": 26,
      "end_page": 40,
      "content": "CRF—typically measured as the peak rate of oxygen consump-\ntion110,111 or metabolic equivalents111,112 during exercise—is one\nof the most robust predictors of CV health and longevity,113,114\nand improves risk classiﬁcation.115–121 Evidence for CPET pre-\ntreatment is limited to pre-operative risk stratiﬁcation particularly\nfor patients with lung,122 colon,123 and rectal124 cancers. Whether\nCPET performed prior to cardiotoxic cancer therapies is prognostic\nof future CV events is unknown.\n4.7. Cardiovascular risk evaluation\nbefore cancer surgery\nCancer surgery remains the primary treatment modality for many\ncancers. Cardio-oncology teams should be involved in pre-operative\nCV risk stratiﬁcation to identify and provide appropriate manage-\nment and surveillance of the potential risk factors.5\nIn patients undergoing oncological surgery, peri-operative car-\ndiac complications are determined by patient-related risk factors,\nthe tumour type, concomitant cancer therapies, and the expected\nsurgical risk. To ensure safe cancer surgery, consultations should\nbe directed at: (1) patients with previous signiﬁcant or symptom-\natic CVD; (2) patients at high and very high CV toxicity risk, ac-\ncording to baseline HFA-ICOS risk assessment tools,12 when\nadjuvant (post-surgery) cancer treatment is planned; and (3) pa-\ntients who have received neoadjuvant (prior to surgery) cancer\ntherapy that is potentially cardiotoxic. Pre-operative clinical evalu-\nation should not delay surgery. Complementary tests required for\nthe patients included in groups 1 and 2 should be guided by general\nESC Guidelines.125 However, in group 3 patients, the pre-\noperative evaluation should be aimed at conﬁrming that no rele-\nvant events have occurred during CV monitoring (Section 5).\nTable 6 summarizes factors that could inﬂuence peri-operative\nrisk during cancer surgery.\n4.8. Genetic testing\nCandidate gene and genome-wide association studies have re-\nsulted in the identiﬁcation of 40 candidate genes and single nucleo-\ntide polymorphisms associated with anthracycline-related cardiac\ndysfunction.37,126–128 It should be noted that with the advent of\nimmunotherapies, germline genes may not be the only genetic pre-\ndispositions to CTR-CVT. A study of patients with ICI-associated\nmyocarditis identiﬁed that the selective clonal T-cell populations\ninﬁltrating the myocardium were identical to those present in tu-\nmours and skeletal muscle, with ribonucleic acid sequencing stud-\nies revealing expression of cardiac-speciﬁc genes in the tumour,129\nraising the intriguing possibility that somatic mutations in the tu-\nmour itself could contribute to CTR-CVT. A list of genetic variants\nassociated\nwith\nCVD\nduring\ncancer\ntherapy\nis\nprovided\n(Supplementary data, Table S9) and has recently been reviewed.38\nRoutine use of genetic testing for the assessment of CTR-CVT risk\nprior to initiation of cancer therapy is not currently recommended.\nIn the future, a personalized genetic approach may help deﬁne indi-\nvidual susceptibility to CVD in patients with cancer and more re-\nsearch is required.\n5. Prevention and monitoring of\ncardiovascular complications\nduring cancer therapy\n5.1. General principles\nCTR-CVT risk may vary according to cancer type and stage, antic-\nancer drugs, doses, and underlying comorbidities. Certain therapy\ncombinations (drug–drug or drug–radiation) may have a synergis-\ntically toxic effect on the heart, possibly depending on the timing\nof these therapies (sequential or concomitant) and previous co-\nmorbidities. The pathophysiology of CTR-CVT is out of the scope\nof this guideline and is extensively reviewed in the\nESC\nCardioMed textbook.130\nCVD and cancer share common modiﬁable and non-modiﬁable\nrisk factors (Figure 3).4,131,132 The ﬁrst step is to optimize lifestyle\nCVRF, smoking cessation, restricting alcohol consumption to a max-\nimum of 100 g per week, and maintaining adequate physical activ-\nity.30 Exercise prescription seems to be a promising treatment to\nTable 6\nFactors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies\nFactors that could inﬂuence peri-operative risk during cancer surgery\nPreventive strategies\nPatient-related\nfactors\n• Lifestyle risk factors: smoking, obesity, sedentary lifestyle\n• Poorly controlled CVRF: hypertension, DM\n• Pre-existing CVD including CTR-CVT\n• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and\nanticoagulants)\n• Historical primary malignancy\n• Current cancer type, stage and location\n• Optimal management of CVRF and\nCVD (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\nNeoadjuvant cancer\ntherapy\n• Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline\nchemotherapy and/or trastuzumab, ICI, VEGFi, ﬂuoropyrimidine, and thoracic RT)\n• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK\ninhibitors)\n• Thrombocytopaenia caused by cancer treatment\n• Ensure optimal CV monitoring of\nneoadjuvant therapy (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\n© ESC 2022\nATE, arterial thromboembolism; BTK, Bruton tyrosine kinase; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,\ncardiovascular risk factors; DM, diabetes mellitus; ICI, immune checkpoint inhibitors; RT, radiotherapy; VEGFi, vascular endothelial growth factor inhibitors; VTE, venous\nthromboembolism.\n4254\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\ncounteract anticancer treatment side effects and different types of\ntraining can be prescribed during cancer therapy according to a pa-\ntient’s individual characteristics.133 A healthy lifestyle decreases the\nrisks of cancer, CVD, and transition from diagnosed cancer to subse-\nquent CVD.134,135\nPoor CRF is associated with a higher prevalence of acute and\nchronic CTR-CVT and exercise positively impacts CRF during\nchemotherapy, although in a recent meta-analysis, the ability of exer-\ncise to prevent CTRCD is unclear.136,137 CVRF must be corrected\nwith intensive treatment of arterial hypertension,138 DM,139 and\nManagement of CVD and CVRF \n according to ESC Guidelines\nPrimary vs secondary prevention\nMinimize the use of cardiotoxic drugs\nACE-I/ARB and beta-blockers\nDexrazoxane/liposomal anthracyclines\n(patients treated with anthracyclines)\nStatins\nPrimary and secondary cancer-therapy related CV toxicity prevention strategies\nIn patients at high and very high\nrisk of CTRCD\n1°prevention\nBaseline CV risk\nassessment\n2°prevention\n1st cancer requiring cardiotoxic cancer therapy\n2nd cancer requiring cardiotoxic cancer therapy\nCVD\nCTR-CVT\nClass IIa\nClass I\nFigure 9 Primary and secondary cancer therapy-related cardiovascular toxicity prevention. ACE-I, angiotensin-converting enzyme inhibitors; ARB, angio-\ntensin receptor blockers; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; CTR-CVT, cancer therapy-related cardiovascular\ntoxicity; CTRCD, cancer therapy-related cardiac dysfunction; ESC, European Society of Cardiology.12 Left panel represents examples of ﬁve different primary\nor secondary prevention strategies deﬁnition based on the history of pre-existing CVD and/or prior CTR-CVT. Right panel describes general strategies to\nmitigate CTR-CVT risk in patients at high and very high risk of CTRCD.\nESC Guidelines\n4255\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\ndyslipidaemia,140 and underlying CVD and modiﬁable comorbidities\nshould be managed according to appropriate 2021 ESC Guidelines\non CVD prevention in clinical practice (Figure 9).19\nSpecial attention should also be paid to the polypharmacy fre-\nquently seen in patients with cancer, reducing the use of drugs\nthat may interfere with cancer therapies to the essential and ac-\ntively monitoring their CV side effects and drug–drug interac-\ntions.141\nElectrolyte\nimbalances\nsuch\nas\nhypokalaemia\nand\nhypomagnesaemia should be corrected. The CV risk management\nplan should be shared with the cancer specialist team, the pri-\nmary care physician, and the patient to coordinate treatment\nstrategies.\n5.2. Primary prevention strategies\nPrimary prevention of CTR-CVT aims to avoid or minimize the de-\nvelopment of CV damage due to therapy in patients without\nCVD12,142 and requires a multidisciplinary team (MDT) discussion\nbetween oncologists and cardiologists for complex patients with\ncancer with multiple comorbidities.4,21,22,43,143,144\n5.2.1. Primary prevention of cancer\ntherapy-related cardiovascular toxicity during\nanthracycline chemotherapy\nNeurohormonal therapies during anthracycline chemotherapy (with\nor without subsequent trastuzumab treatment) reduced the risk of\nsigniﬁcant LVEF decline during follow-up in several small randomized\ncontrolled trials (RCTs) (Supplementary data, Table S10).145–154\nRecent meta-analyses including patients with cancer treated with an-\nthracycline chemotherapy and HER2-targeted therapies reported\nthat renin–angiotensin–aldosterone system blockers, beta-blockers,\nand mineralocorticoid receptor antagonists have a signiﬁcant beneﬁt\nin preventing LVEF reduction, but no statistical differences in the in-\ncidence of overt HF or other clinical outcomes were demonstrated\n(Supplementary data, Table S11).155–160 This may be due, in part, to\nthe fact that most trials included patients with a low baseline CTRCD\nrisk and therefore larger RCTs are needed in high-risk populations.\nFrom the oncological perspective, some strategies that have been\ninvestigated include managing anthracycline-related toxicity by ad-\njusting the infusion time and dose intensity.161 Dexrazoxane and lipo-\nsomal anthracyclines are currently approved in patients with high and\nvery high CTRCD risk or who have already received high cumulative\nanthracyclines doses.158,162–167 Dexrazoxane is protective against\nanthracycline-induced CTRCD. Currently, dexrazoxane is formally\napproved in adult patients with advanced or metastatic BC who\nhave already received a minimum cumulative anthracycline dose of\n300 mg/m2 of doxorubicin or equivalent (Table 5; Supplementary\ndata, Table S12).163 In clinical practice, dexrazoxane infusion (dosage\nratio dexrazoxane/doxorubicin is 10/1; e.g. 500 mg/m2 dexrazoxane\nper 50 mg/m2 doxorubicin) should be considered (at least 30 min\nprior to each anthracycline cycle) in adult patients with cancer sched-\nuled to receive a high total cumulative anthracycline dose for curative\ntreatment, and in patients with high and very high CTRCD risk (in-\ncluding those with pre-existing HF or low-normal or reduced\nLVEF) where anthracycline chemotherapy is deemed essential.163\nPegylated and non-pegylated liposomal doxorubicin164,165,168\nmodify pharmacokinetics and tissue distribution without com-\npromising antitumour efﬁcacy. Pegylated and non-pegylated liposo-\nmal doxorubicin are approved for metastatic BC and pegylated\nliposomal doxorubicin is also approved for advanced ovarian can-\ncer, acquired immune deﬁciency syndrome-related Kaposi sar-\ncoma, and MM. In a recent meta-analysis of 19 trials, in both the\nadjuvant and metastatic context, liposomal doxorubicin was re-\nported to be less cardiotoxic than conventional doxorubicin.165\nLiposomal daunorubicin is also available for acute leukaemia pa-\ntients\nin\nplace\nof\ndaunorubicin\nwhen\npre-existing\nLVD\nis\npresent.164,165\n5.2.2. Primary prevention of radiation-induced\ncardiovascular toxicity\nPrimary prevention of RT-induced damage to the CV system de-\npends on technological advances that allow improved targeting of\nRT delivery, thereby maintaining or increasing oncological efﬁcacy\nwhile reducing CTR-CVT.169,170 Modern techniques strive to\nminimize the mean heart dose (MHD), either by shaping the\ndose distribution (intensity-modulated RT) or by using respira-\ntory management (gating or breath-hold).171,172 Proton therapy\noffers the potential to further decrease exposure to surrounding\nhealthy organs.173 However, complete cardiac avoidance is not\nalways possible due to the proximity of the tumour (e.g. central\nlung tumours, mediastinal lymphomas, irradiation of the internal\nmammary chain in BC). In patients where RT only has a consoli-\ndating role and the risk of RT-induced CV injury is very high (e.g.\ndue to baseline risk factors), a MDT is needed to consider the\nrisk/beneﬁt of RT.171,174\nThere are no proven medical therapies to prevent RT-induced CV\ntoxicity. One component of RT-induced CV toxicity is accelerating\npre-existing CAD, and therefore tight control of CVRFs is\nrecommended.\nRecommendation Table 5 — Recommendations for\nprimary prevention of cancer therapy-related car-\ndiovascular toxicity\nRecommendations\nClassa\nLevelb\nManagement of CVRF according to the 2021 ESC\nGuidelines on CVD prevention in clinical practice\nis recommended before,c during, and after cancer\ntherapy.19\nI\nC\nDexrazoxane should be considered in adult\npatients with cancer at high and very high CV\ntoxicity risk when anthracycline chemotherapy is\nindicated.d,158\nIIa\nB\nLiposomal anthracyclines should be considered in\nadult patients with cancer at high and very high CV\ntoxicity risk when anthracycline chemotherapy is\nindicated.e,164,165,168\nIIa\nB\nContinued\n4256\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n5.3. Secondary prevention strategies\nSecondary prevention refers to interventions in patients with pre-\nexisting CVD, including prior CTR-CVT, and new emerging\nCTR-CVT during cancer therapy. CVD and comorbidities should re-\nceive the optimal therapy before and during cancer therapy as dis-\ncussed in previous sections. Regular clinical assessments, physical\nexaminations, and CV investigations (including 12-lead ECG, TTE,\nand cardiac biomarkers) are recommended in patients receiving spe-\nciﬁc cardiotoxic cancer therapies, with the frequency of surveillance\nguided\nby\nbaseline\nrisk\nand\nthe\nemergence\nof\nnew\nCTR-CVT.5,12,33,53,54,187–190\n5.4. Cardiovascular surveillance during\ncancer therapies\nA careful clinical evaluation and physical examination is recom-\nmended during cancer treatment to detect early signs and symptoms\nof CTR-CVT. ECG monitoring is required in patients at risk of car-\ndiac arrhythmias according to speciﬁc drug protocols.\n5.4.1. Cardiac serum biomarkers\nDuring therapy, NP and cTn should be used for CTRCD screening\nand diagnosis and they may also serve to guide therapy.55,63,191–194\nThe release of cTn and NP differ for different cancer treatments.\nTherefore, an increase in biomarker level should be interpreted in\nthe\npatient\nclinical\ncontext\n(cancer\ntreatment\ntiming\nand\ncomorbidities).\nIt is important to consider that generally accepted cut-offs and ref-\nerence values of CV biomarkers have not been established for pa-\ntients with cancer or for those who receive cancer therapies. In\naddition, levels of NP and cTn may differ according to local labora-\ntories and may be altered by many factors, including age, sex, renal\nfunction, obesity, infections, and comorbidities such as AF and\npulmonary embolism (PE).53,63,195–197\n5.4.2. Cardiac imaging\nCardiac imaging plays a critical role in clinical decision-making during\nthe cancer process.72,198 Imaging techniques—particularly advanced\nechocardiography and CMR—facilitate early diagnosis and manage-\nment of CTR-CVT.22,54,94 The frequency of cardiac imaging monitor-\ning during therapy should be adapted according to the estimated\nbaseline risk12 and the expected CTR-CVT manifestation.54 The car-\ndiac imaging technique used should be based on local expertise and\navailability, and the same imaging modality (i.e. 3D-TTE, 2D-TTE,\nCMR) is recommended throughout the entire treatment to decrease\ninter-technique variability.94,199,200 Cardiac imaging should be per-\nformed at any time if patients receiving cardiotoxic therapies present\nwith new cardiac symptoms.\nNew deﬁnitions of CTRCD are presented in Section 3.1 Early\nrecognition of asymptomatic CTRCD allows clinicians to incorp-\norate cardioprotective therapy before there is a signiﬁcant decline\nin LVEF, which may or may not be reversible, and also decreases\nthe risk of interruptions in cancer therapy, which could otherwise\naffect patients’ survival.22,43,72,94 For the diagnosis and manage-\nment of asymptomatic CTRCD during cancer treatment, TTE—in-\ncluding 3D-LVEF and GLS assessment—is the preferred technique\nto detect and conﬁrm cardiac dysfunction.72,83,93,102 GLS evalu-\nation is particularly important in patients with low-normal LVEF\nto conﬁrm or not asymptomatic myocardial damage.201 It is re-\ncommended to use the same vendor to analyse GLS during cancer\ntreatment to accurately compare values over time.73 Therefore, a\nrelative change in GLS has been suggested as the ideal tool to iden-\ntify asymptomatic mild CTRCD.1,4,94 Different thresholds have\nbeen considered in the literature in recent years.93,202,203\nCurrently, a relative GLS decrease of .15% compared with base-\nline is the recommended threshold as it reﬂects the 95% upper\nRecommendation Table 6 — Recommendation for\nsecondary prevention of cancer therapy-related car-\ndiovascular toxicity\nRecommendation\nClassa\nLevelb\nManagement of CVD according to applicable ESC\nGuidelines is recommended before,c during, and\nafter cancer therapy.\nI\nC\n© ESC 2022\nCVD, cardiovascular disease; ESC, European Society of Cardiology.\naClass of recommendation.\nbLevel of evidence.\ncWithout delaying cancer treatments.\nACE-I or ARB and beta-blockers recommended\nfor HFf should be considered for primary\nprevention in high- and very high-risk patients\nreceiving anthracyclines and/or anti-HER2\ntherapies.145,150,155–157,159,160,175\nIIa\nB\nACE-I or ARB and beta-blockers recommended\nfor HFf should be considered for primary\nprevention in high- and very high-risk patients\nreceiving targeted cancer therapies that may cause\nHF.g\nIIa\nC\nStatins should be considered for primary\nprevention in adult patients with cancer at high\nand very high CV toxicity risk.h,149,176–185\nIIa\nB\n© ESC 2022\nACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;\nCV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Society\nof Cardiology; HER2, human epidermal receptor 2; HF, heart failure; HFA, Heart\nFailure\nAssociation;\nICOS,\nInternational\nCardio-Oncology\nSociety;\nMEK,\nmitogen-activated extracellular signal-regulated kinase; PI, proteasome inhibitors;\nRAF, rapidly accelerated ﬁbrosarcoma; VEGFi, vascular endothelial growth factor\ninhibitors.\naClass of recommendation.\nbLevel of evidence.\ncWithout delaying cancer treatments.\ndAs per the European Medicine Agency: ≥350 mg/m2 doxorubicin or equivalent; as per the\nUnited States Food and Drug Administration: ≥300 mg/m2 doxorubicin or equivalent.\neSee Section 5.2.1 for speciﬁc liposomal doxorubicin type and malignancies.\nfCarvedilol (preferred beta-blocker for CV protection if there is no contraindication),186\nbisoprolol, controlled/extended-release metoprolol succinate and nebivolol.\ngVEGFi and bevacizumab, RAF inhibitor, MEK inhibitor, PI, dasatinib, ponatinib, and\nosimertinib.\nhAccording to HFA-ICOS risk assessment tools (Section 4.1; Table 4).\nESC Guidelines\n4257\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nlimit in the meta-analysis of GLS to predict future signiﬁcant LVEF\nreduction.93 Using the 15% threshold will maximize speciﬁcity and\nminimize overdiagnosis of CTRCD and guide cardioprotective\ntherapy.1,4,93\nIn patients with poor TTE image quality or when TTE is not diag-\nnostic, CMR should be considered, including fast strain-encoded\nCMR when available.105,204–206 MUGA can be considered as a third-\nline modality.\nBaseline\nC4\nC5\nC6\n3 M\npost tx\n12 M\npost tx\nC1\nC2\nC3\nAnthracycline chemotherapy surveillance protocol\nClass 1\nClass 1Ia\nClass 1Ib\nECG\ncTnb / NPb\nTTEa\nECG\ncTnb / NPb\nTTEa\nECG\ncTn / NP\nTTEa\nHigh and \nvery high \nrisk\nModerate\nrisk\nLow\nrisk\nFigure 10 Cardiovascular toxicity monitoring in patients receiving anthracycline chemotherapy. cTn, cardiac troponin; C, chemotherapy cycle;\nECG, electrocardiogram; M, months; NP, natriuretic peptides; TTE, transthoracic echocardiography; tx, treatment. Biomarker and TTE assessment\nshould ideally be performed before the corresponding anthracycline cycle (C1–C6). aCardiac magnetic resonance should be considered for the assess-\nment of cardiac function when TTE is unavailable or not diagnostic. In moderate-risk patients, TTE should be considered after a cumulative dose of\n≥250 mg/m2 of doxorubicin or equivalent. In low-risk patients, TTE may be considered after a cumulative dose of ≥250 mg/m2 of doxorubicin or equiva-\nlent. bMeasurement of NP and/or cTn is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring.\ncTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion may be considered in low-risk\npatients (Class IIb, Level C). cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion\nshould be considered in moderate-risk patients and in low-risk patients receiving a cumulative dose of ≥250 mg/m2 of doxorubicin or equivalent (Class IIa,\nLevel C).\n4258\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n5.5. Cancer therapy-related\ncardiovascular toxicity monitoring\nprotocols\n5.5.1. Anthracycline chemotherapy\nAnthracycline-induced CTRCD is a dose-dependent and cumulative\nprocess of variable onset that may present with symptomatic or\nasymptomatic CTRCD.4\nFigure 10 summarizes the recommended monitoring protocol\nduring anthracycline therapy according to baseline CTRCD risk\n(Table 4). Clinical assessment combined with cardiac biomarkers\n(cTn and NP) and TTE (including 3D-LVEF and GLS when avail-\nable) can identify both symptomatic and asymptomatic CTRCD\nwith a reasonably high negative predictive value. This topic has\nbeen\nextensively\nreviewed\nin\ntwo\nrecent\nHFA\nposition\nstatements.53,54 Classifying patients based on their risk of\nanthracycline-induced CV toxicity has allowed the early implemen-\ntation of personalized preventive strategies (Section 5.2.1).14\nPatients with pre-existing CVD should be treated with guideline-\nbased medical therapy.14,19,207\n5.5.2. HER2-targeted therapies\nHER2-targeted therapies are a crucial part of the treatment of\npatients with HER2-positive invasive BC in both early and meta-\nstatic settings. In the neoadjuvant and/or adjuvant settings, drugs\ncurrently approved are trastuzumab, pertuzumab, trastuzumab\nemtansine, and neratinib. In the metastatic setting, trastuzumab,\npertuzumab, trastuzumab emtansine, tucatinib, and trastuzumab\nderuxtecan are currently approved.214–216 Trastuzumab can\nalso be used in patients with HER2-overexpressing metastatic\ngastric adenocarcinomas in combination with platinum-based\nchemotherapy and either capecitabine or 5-ﬂuorouracil (5-FU).\nIt is recognized that anti-HER2 therapies may lead to LVD in\nup to 15–20% of patients and to overt HF if surveillance is\nmissed, or in high- and very high-risk patients.217–220 LV function\nsurveillance based on LVEF and GLS is recommended prior to\nand every 3 months during HER2-targeted therapies treatment\nsurveillance (Figure 11).22 However, this single algorithm has\nnot been tested in low- or high-risk patients and increased fre-\nquency of assessment (according to local availability) is recom-\nmended in high-risk patients.\nThe use of cardiac serum biomarkers to identify CTRCD is\nless well-deﬁned during anti-HER2 treatments.217 Measurement\nof cTn in BC patients after anthracycline-based chemotherapy\nbut prior to trastuzumab should be considered, as an elevated\ncTn identiﬁes patients at higher risk of trastuzumab-induced\nCTRCD. Serial NP measurement was more sensitive than cTn\nat predicting subsequent declines in LVEF during trastuzumab\ntreatment.74\nRecommendation Table 7 — Recommendations for\nbaseline risk assessment and monitoring during an-\nthracycline chemotherapy and in the ﬁrst 12 months\nafter therapy\nRecommendations\nClassa\nLevelb\nTTE\nBaseline echocardiographyc is recommended in all\npatients with cancer before anthracycline\nchemotherapy.12,24,208–210\nI\nB\nIn all adults receiving anthracycline chemotherapy,\nan echocardiogram is recommended within 12\nmonths after completing treatment.208\nI\nB\nIn high- and very high-risk patients,\nechocardiography is recommended every two\ncycles and within 3 months after completing\ntreatment.24,208–210\nI\nC\nIn moderate-risk patients, additional\nechocardiography should be considered after a\ncumulative dose of ≥250 mg/m2 of doxorubicin\nor equivalent.7\nIIa\nC\nIn low-risk patients, additional echocardiography\nmay be considered after a cumulative\ndose of ≥250 mg/m2 of doxorubicin or\nequivalent.7\nIIb\nC\nCardiac serum biomarkers\nBaseline measurement of NP and cTn is\nrecommended in high- and very high-risk patients\nprior to anthracycline chemotherapy.55,65,211\nI\nB\nContinued\nBaseline measurement of NP and cTn should be\nconsidered in low- and moderate-risk patients\nprior to anthracycline chemotherapy.211\nIIa\nC\ncTn and NP monitoring before every cycle during\nanthracycline chemotherapy and 3 and 12 months\nafter therapy completion is recommended in high-\nand very high-risk patients.55,175,211\nI\nB\ncTn and NP monitoring every two cycles during\nanthracycline chemotherapy and within 3 months\nafter therapy completion should be considered in\nmoderate-risk patients and in low-risk patients\nreceiving a cumulative dose of ≥250 mg/m2 of\ndoxorubicin or equivalent.55,59,212,213\nIIa\nC\ncTn and NP monitoring every two cycles during\nanthracycline chemotherapy and within 3 months\nafter therapy completion may be considered in\nlow-risk patients.55,59,212,213\nIIb\nC\n© ESC 2022\ncTn, cardiac troponin; NP, natriuretic peptides; TTE, transthoracic echocardiography.\naClass of recommendation.\nbLevel of evidence.\ncIf echocardiography is unavailable or non-diagnostic, follow general cardiac imaging\nmodalities recommendations (see Section 4.5).\nESC Guidelines\n4259\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nFor\npatients\nrequiring\nadjuvant\nchemotherapy\nand\nanti-HER2-targeted therapy, the use of non-anthracycline chemo-\ntherapy should be considered by the MDT according to\nrisk of relapse, cardiac risks, and in discussion with the\ntreating oncologist.217 When anthracycline chemotherapy in the\n(neo)-adjuvant setting is necessary, sequential use (anthracyclines\nfollowed by taxanes and anti-HER2 agents) has been shown\nto signiﬁcantly decrease the incidence of CTRCD in several\nadjuvant trials, compared with concomitant use in earlier\ntrials.220–224\nRecommendation Table 8 — Recommendations for\nbaseline risk assessment and monitoring during hu-\nman epidermal receptor 2-targeted therapies and in\nthe ﬁrst 12 months after therapy\nRecommendations\nClassa\nLevelb\nTTE\nBaseline echocardiographyc is recommended\nbefore HER2-targeted therapies in all patients.225\nI\nB\nContinued\n9 M\n12 M\n3 M\n6 M\nHER2-targeted therapy surveillance protocol\nHigh and \nvery high \nriskb\nLow and\nmoderate\nriska\nBaseline\ne\nECG\ncTnd / NPd\nTTEc\nECG\ncTn / NP\nTTEc\nClass 1\nClass 1Ia\nClass 1Ib\n3 M\npost tx\n12 M\npost tx\nFigure 11 Cardiovascular toxicity monitoring in patients receiving human epidermal receptor 2-targeted therapies. cTn, cardiac troponin; CV,\ncardiovascular; EBC, early breast cancer; ECG, electrocardiogram; HER2, human epidermal receptor 2; M, months; NP, natriuretic peptides; TTE, trans-\nthoracic echocardiography; tx, treatment. This protocol refers to CV toxicity monitoring in patients receiving neoadjuvant or adjuvant anti-HER2 tar-\ngeted therapies for non-metastatic disease or ﬁrst year in metastatic disease. Biomarker assessment should ideally be performed before the\ncorresponding trastuzumab cycle. TTE should be performed in week 2 or 3 of a 3-weekly trastuzumab cycle. aIn low-risk HER2+ EBC patients who\nare asymptomatic and with a normal assessment after 3 months, reducing TTE monitoring to every 4 months may be considered (Class IIb, Level C).\nIn low- and moderate-risk metastatic HER2+ disease, TTE surveillance can be reduced to every 6 months after the ﬁrst year in asymptomatic patients\nwith normal TTE assessment (Class I, Level C). bIn high- and very high-risk metastatic HER2+ disease, TTE monitoring every 2–3 cycles may be considered\ndepending on the absolute risk and local availability. cCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE\nis unavailable or not diagnostic. dMeasurement of NP and/or cTn is recommended in all patients with cancer if these biomarkers are going to be used\nduring treatment monitoring. eBaseline cTn measurement should be considered in low- and moderate-risk patients after anthracycline chemotherapy\nbut prior to starting anti-HER2 targeted therapies for CV toxicity risk prediction.\n4260\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n5.5.3. Fluoropyrimidines\nFluoropyrimidines such as 5-FU and its oral prodrug capecitabine\nare mainly used for gastrointestinal (GI) malignancies and advanced\nBC.\nThe\nmost\ncommon\nCTR-CVTs\nare\nangina\npectoris,\nischaemia-related ECG abnormalities, hypertension, Takotsubo syn-\ndrome (TTS), and MI (even in patients with normal coronary arter-\nies),1,4,10,43,229,230 with rarer CTR-CVT including myocarditis,\narrhythmias, and peripheral arterial toxicity (Raynaud’s phenomenon\nand ischaemic stroke).231 The incidence of myocardial ischaemia var-\nies according to the dose, scheduling, and route of administration and\nis up to 10%.232 Among the several mechanisms responsible for\n5-FU-induced myocardial ischaemia are coronary vasospasm and\nendothelial injury.233 Chest pain and ischaemic ECG changes usually\noccur at rest (less typically during exercise) within days of drug ad-\nministration and sometimes persist even after treatment cessation.\nCTR-CVT risk markedly increases in patients with cancer with pre-\nexisting CAD. Aggressive control of modiﬁable CVRFs, according to\nthe 2021 ESC Guidelines on CVD prevention in clinical practice,19 is\nrecommended during and after treatment. A baseline TTE is\nrecommended in patients with a history of symptomatic CV to\nconﬁrm\nthe\npresence\nof\npre-existing\nregional\nwall\nmotion\nabnormalities or LVD. Screening for CAD may be considered in\nselected high- and very high-risk patients before the administration\nof these drugs and according to local protocols and current\nrecommendations.12,234,235\n5.5.4. Vascular endothelial growth factor inhibitors\nAberrant activation of kinases plays a critical role in both the devel-\nopment of numerous cancer types and in CV and metabolic homeo-\nstasis. Inhibition of the VEGF signalling pathway is achieved with\neither monoclonal antibodies (administered i.v.) against circulating\nVEGF or with small-molecule TKI (taken orally) targeting VEGF re-\nceptors.236 VEGFi are used for the treatment of numerous cancer\ntypes, including renal, thyroid, and hepatocellular carcinomas.\nHowever, their use is associated with a wide array of CV complica-\ntions including hypertension, HF, QTc prolongation, and acute vascu-\nlar events (Figure 12).131,237–240 It can be challenging to assess the\nprognosis of patients experiencing severe CV side effects because\nIn patients receiving neoadjuvant or adjuvant\nHER2-targeted therapies, echocardiography is\nrecommended every 3 months and within 12\nmonths after completing treatment.225,226\nI\nB\nIn low-risk HER2+ EBC patientsd who are\nasymptomatic and with a normal assessment after\n3 months, reducing monitoring to every 4 months\nmay be considered.\nIIb\nC\nIn high- and very high-risk HER2+ EBC patients,d\nmore frequent echocardiography monitoringe\nshould be considered during treatment.\nIIa\nC\nIn metastatic HER2+ disease, echocardiography is\nrecommended every 3 months during the ﬁrst\nyear; if the patient remains asymptomatic without\nCV toxicity, then surveillance can be reduced to\nevery 6 months during future treatment.f\nI\nC\nIn metastatic HER2+ disease patients at high- and\nvery high-risk, more frequent echocardiography\nmonitoringe may be considered.\nIIb\nC\nCardiac biomarkers\nBaseline NP and cTn measurement are\nrecommended in high- and very high-risk patients\nprior to anti-HER2-targeted therapies.227,228\nI\nC\nNP and cTn monitoring every 2–3 cycles during\ntherapy and 3 and 12 months after the end of\ntherapy should be considered in high- and very\nhigh-risk HER2+ EBC patients.d,55\nIIa\nC\nBaseline cTn measurement should be considered\nin low- and moderate-risk patients\npost-anthracycline chemotherapy but prior to\nstarting anti-HER2-targeted therapies.55,62\nIIa\nA\nNP and cTn monitoring at baseline, every 3\nmonths, and 12 months after therapy may be\nconsidered in low- and moderate-risk HER2+\nEBC patients.d,55\nIIb\nC\n© ESC 2022\nBC, breast cancer; cTn, cardiac troponin; CV, cardiovascular; EBC, early breast cancer;\nHER2, human epidermal receptor 2; NP, natriuretic peptides; TTE, transthoracic\nechocardiography.\naClass of recommendation.\nbLevel of evidence.\ncIf echocardiography is unavailable or non-diagnostic, follow general cardiac imaging\nmodalities recommendations (see Section 4.5).\ndThese recommendations are also applicable for HER2+ non-BC patients.\neEvery 2–3 cycles depending on the absolute risk and local availability.\nfPatients at low and moderate risk.\nRecommendation Table 9 — Recommendations for\nbaseline risk assessment and monitoring during ﬂuor-\nopyrimidine therapy\nRecommendations\nClassa\nLevelb\nBaseline CV risk assessment and evaluation\nincluding BP measurement, ECG, lipid proﬁle,\nHbA1c measurement, and SCORE2/\nSCORE2-OPc or equivalent is recommended19\nbefore starting ﬂuoropyrimidines.\nI\nC\nA baseline echocardiogram is recommended in\npatients with a history of symptomatic CVD\nbefore starting ﬂuoropyrimidines.\nI\nC\nScreening for CADd may be considered in patients\nat high and very high risk of CADc before\nﬂuoropyrimidines.\nIIb\nC\n© ESC 2022\nBP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; CVD,\ncardiovascular disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin;\nSCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary\nRisk Estimation 2—Older Persons.\naClass of recommendation.\nbLevel of evidence.\ncSCORE2 (,70 years) or SCORE2-OP (≥70 years) CV risk stratiﬁcation: ,50 years:\nlow risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk\n,5%; moderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%,\nmoderate risk 7.5% to ,15%, high risk ≥15%.\ndAccording to pre-existing CVD and local protocols.234\nESC Guidelines\n4261\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nthese drugs are often used in patients with advanced cancer. The goal\nmust be to continue VEGFi treatment for as long as possible with ini-\ntiation or optimization of CV treatment if indicated.\nHypertension is a class effect and is the most reported adverse\nevent under VEGFi treatment. It occurs within hours or days, is dose-\ndependent,\nand\nis\nusually\nreversed\nby\nVEGFi\ndiscontinu-\nation.131,239,241–243 The risk is higher in patients with pre-existing\nhypertension or CVD, previous anthracycline treatment, advanced\nage, history of smoking, hyperlipidaemia, and/or obesity (Table 4).4,244\nLVD and HF occur in a minority of patients in RCTs,245 but are re-\nported more frequently in routine practice246 and are often revers-\nible.247 Acute arterial events (aortic dissection, stroke, arterial\nthrombosis,\nacute\ncoronary events, vasospasm)\nand venous\nthromboembolism (VTE) can also complicate treatment with\nVEGFi.248 QTc prolongation has been described with sunitinib, sor-\nafenib, and vandetanib,249 but it is rarely related to severe arrhythmic\nevents, except with vandetanib.250 Some small-molecule TKI (e.g.\nsorafenib and sunitinib) can cause AF251 and HF.43,129,247\nAflibercept\nMonoclonal antibodies\nVEGF TKI\nBevacizumaba\nRamucirumaba\nAxitinib\nCabozantinib\nLenvatinib\nPazopanib\nRegorafenib\nSorafenib\nSunitinib\nVandetanib\nHTN\nHF\nVTE\nATE\nMI\nVEGFi-related cardiovascular toxicities\nVery common: ≥10% incidence\nCommon: 1% to <10% incidence\nUncommon: 0.1% to < 1% incidence\nRare: <0.1% incidence\nQTc\nFigure 12 Vascular endothelial growth factor inhibitors-related cardiovascular toxicities. ATE, arterial thromboembolism; EMA, European Medicines\nAgency; FDA, Food and Drug Administration; HF, heart failure; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial\ninfarction; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor; VEGFi, vascular endothe-\nlial growth factor inhibitors; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed\nby system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.\naBevacizumab: hypertension frequency 5–42% (EMA); 60–77% of the patients who received bevacizumab in combination with erlotinib. Pre-existing\nhypertension should be adequately controlled before starting treatment. Ramucirumab: hypertension frequency 16–26% (EMA/FDA); in combination\nwith erlotinib, the incidence of hypertension was 24–45%. Patients with uncontrolled hypertension were excluded from the trials. Figure developed\nfrom EMA prescribing information,252 FDA prescribing information.253\n4262\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nA baseline CV risk assessment includes clinical examination, BP\nmeasurement, and an ECG with baseline QTcF measurement (see\nSection 4).20 Especially in patients with known hypertension, BP\nshould be controlled before VEGFi therapy. A baseline TTE is\nrecommended for high- and very high-risk patients.14 Patients with\nimpaired LV function and/or patients at high or very high risk of de-\nveloping HF should be referred to the cardiologist before starting\nVEGFi therapy.14\nECGa\nECGa\nTTEb\n6 M\n8 M\n9 M\n12 M\nEvery\n6–12 M\n3 M\n4 M\nNPc,d\nECGa\nNPc\nTTEb\nVEGFi surveillance protocol\nHigh and \nvery high \nrisk\nModerate\nrisk\nLow\nrisk\nTTEb,d\nBaseline\nClass 1\nClass 1Ia\nClass 1Ib\nFigure 13 Cardiovascular toxicity monitoring in patients receiving vascular endothelial growth factor inhibitors. ECG, electrocardiogram; M, months;\nNP, natriuretic peptides; QTc, corrected QT interval; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitors. aIn pa-\ntients treated with VEGFi at moderate or high risk of QTc prolongation, ECG is recommended (Class I, Level C) monthly during the ﬁrst 3 months and\nevery 3–6 months thereafter (Section 6.4). Consider an ECG 2 weeks after starting treatment in high-risk patients and new monitoring in the case of any\ndose increase (see Section 6.4.2). bCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE is unavailable or not\ndiagnostic. cMeasurement of NP is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring. dTTE\nand NP should be considered at 4 weeks after starting treatment in very high-risk patients.\nESC Guidelines\n4263\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nMonitoring during and after treatment is indicated for all patients\ntreated with a VEGFi and is based on close clinical follow-up using\nserial ECGs, biomarkers, and echocardiography. Early recognition\nand treatment of hypertension are essential to prevent other CV\ncomplications, especially HF. Home BP monitoring is recommended\ndaily during the ﬁrst cycle, after each increase of anticancer therapy\ndose, and every 2–3 weeks thereafter.138,254,255 When treatment\nwith a VEGFi is stopped, a drop in BP must be anticipated and\nBP-lowering therapy must be reduced and/or interrupted according-\nly (Section 6).\nIn patients at risk of QTc prolongation, regular monitoring of the\nQTc interval is recommended after a dose increase, whenever other\nQT-prolonging agents are added, or if electrolyte imbalances occur\n(Section 6).\nPatients treated with a VEGFi must also be screened regu-\nlarly for symptoms and clinical signs of HF. Regular NP meas-\nurement\nand\nechocardiography\ncan\nbe\nuseful\nfor\nthe\ndetection\nof\nCTRCD,\nalthough\nevidence\nis\nweak\n(Figure 13).138,254,255\n5.5.5. Multitargeted kinase inhibitors targeting\nBCR-ABL\nChronic myeloid leukaemia (CML) results from aberrant acti-\nvation of ABL1 kinase due to a chromosomal translocation.\nSmall-molecule TKIs targeting BCR-ABL—including imatinib,\nbosutinib, dasatinib, nilotinib, and ponatinib—have proven ef-\nfective in the treatment of CML. The toxicities associated\nwith these TKIs are unique and due to ‘off-target’ effects of\neach drug. Dasatinib is associated with group 1 pulmonary\nhypertension (PH), HF, and pleural and pericardial effusion,\nwhereas\nnilotinib\nand\nponatinib\nare\ngenerally\nassociated\nwith\nvascular\nevents\n(Figure\n14).131,256–259\nSecond-\ngeneration BCR-ABL TKI may induce a QTc prolongation\n(see Section 6.4.2). CV toxicity risk is higher in patients\naged .65 years (relative risk 1.8) and in those with under-\nlying DM (relative risk 2.5), hypertension (relative risk 3.2) or\npre-existing\nCAD\n(relative\nrisk\n2.6).256–258,260\nBefore\nBCR-ABL TKI therapy, it is critical to deﬁne baseline CV tox-\nicity risk with special attention to BP, glucose, and lipids.\nRecommendation Table 10 — Recommendations for\nbaseline risk assessment and monitoring during vascu-\nlar endothelial growth factor inhibitors\nRecommendations\nClassa\nLevelb\nBP monitoring\nBP measurement is recommended for patients\ntreated with VEGFi, bevacizumab, or\nramucirumab at every clinical visit.\nI\nC\nDaily home monitoring of BP for patients treated\nwith VEGFi during the ﬁrst cycle, after each\nincrease of VEGFi dose, and every 2–3 weeks\nthereafter is recommended.\nI\nC\nECG monitoring\nIn patients treated with VEGFi at moderate or\nhigh risk of QTc prolongation, QTcc monitoring is\nrecommended monthly during the ﬁrst 3 months\nand every 3–6 months thereafter.d\nI\nC\nEchocardiography\nBaseline echocardiography is recommended in\nhigh- and very high-risk patients treated with\nVEGFi or bevacizumab.\nI\nC\nBaseline echocardiography should be considered\nin low- and moderate-risk patients treated with a\nVEGFi or bevacizumab.\nIIa\nC\nContinued\nEchocardiography may be considered every 4\nmonths during the ﬁrst year in moderate-risk\npatients receiving VEGFi or bevacizumab.\nIIb\nC\nEchocardiography should be considered every 3\nmonths during the ﬁrst year in high- and very\nhigh-risk patients receiving a VEGFi or\nbevacizumab.e\nIIa\nC\nEchocardiography every 6–12 months should be\nconsidered in moderate- and high-risk patients\nwith cancer who require long-term treatment\nwith a VEGFi.\nIIa\nC\nCardiac biomarker\nNP may be considered at baseline and then every\n4 months during the ﬁrst year in moderate-risk\npatients receiving a VEGFi.\nIIb\nC\nNP should be considered at baseline, 4 weeks\nafter starting treatment, and them every 3 months\nduring the ﬁrst year in high- and very high-risk\npatients receiving a VEGFi.\nIIa\nC\n© ESC 2022\nBP, blood pressure; ECG, electrocardiogram; NP, natriuretic peptides; QTc, corrected\nQT interval; QTcF, corrected QT interval using Fridericia correction; VEGFi, vascular\nendothelial growth factor inhibitors.\naClass of recommendation.\nbLevel of evidence.\ncQTc interval using Fridericia correction (QTcF = QT/3√RR) is the preferred method.\ndConsider an ECG 2 weeks after starting treatment in high-risk patients and new\nmonitoring in the case of any dose increase (see Section 6.4.2).\neAn additional echocardiography 4 weeks after starting treatment should be considered\nin selected high- and very high-risk patients according to local availability, especially if\ncardiac biomarker surveillance is not available.\n4264\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nImatinib\n1st generation\nBCR-ABL TKI\n2nd generation\nBCR-ABL TKI\n3rd generation\nBCR-ABL TKI\nNilotinib\nDasatinib\nBosutinib\nPonatinib\nHTN\nHF\nHG\nAF\nDL\nPeric-E\nPleu-E\nPH\nVascTox\nBCR-ABL TKI-related cardiovascular toxicities\nVery common: ≥10% incidence\nCommon: 1% to <10% incidence\nUncommon: 0.1% to < 1% incidence\nRare: <0.1% incidence\nQTc\nFigure 14 Breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitor-related cardiovascular toxicities. AF, atrial ﬁbrillation; BCR-ABL,\nbreakpoint cluster region–Abelson oncogene locus; DL, dyslipidaemia; EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart\nfailure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; PAD, peripheral artery\ndisease; Peric-E, pericardial effusion; PH, pulmonary hypertension; Pleu-E, pleural effusion; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase\ninhibitors; VascTox, vascular toxicity (stroke, MI, PAD). Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by\nsystem organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.261\nFigure developed from EMA prescribing information,252 FDA prescribing information.253\nESC Guidelines\n4265\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nBaseline\n3 M\n6 M\n9 M\n12 M\nEvery\n6–12 M\nBP\nHbA1c\nECG\nABI\nTTE\nPhysical \nexaminationa\nBosutinib\nDasatinib\nNilotinib\nPonatinib\nNilotinib\nPonatinib\nNilotinib\nPonatinib\nDasatinib\nNilotinib\nPonatinib\nHigh and very high risk patients\ntreated with dasatinib or ponatinib\nSecond and third generation\u0002BCR-ABL TKI surveillance protocol\nClass 1\nClass 1Ia\nClass 1Ib\nBosutinib\nDasatinib\nNilotinib\nPonatinib\nNilotinib\nPonatinib\nDasatinib\nPonatinib\nBosutinib\nNilotinib\nPonatinib\nLipid profile/\nFigure 15 Second- and third-generation breakpoint cluster region–Abelson oncogene locus tyrosine kinase inhibitors surveillance protocol. ABI, ankle–\nbrachial index; BCR-ABL, breakpoint cluster region-Abelson oncogene locus; BP, blood pressure; CV, cardiovascular; ECG, electrocardiogram; HbA1c,\nglycated haemoglobin; M, months; TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography. aCoronary artery calcium scoring can reclassify\nCV risk upwards and downwards in addition to conventional risk factors, and may be considered in men and women with calculated CV risk around\ndecision thresholds.19\n4266\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nBaseline ECG is recommended in all patients and QTc mon-\nitoring in patients treated with second-generation BCR-ABL\nTKI. Depending on the type of therapy used, speciﬁc CV as-\nsessments\nshould\nbe\nperformed\nafter\ndrug\ninitiation\n(Figure 15).256\n5.5.6. Bruton tyrosine kinase inhibitors\nBruton tyrosine kinase (BTK) inhibitors are increasingly used to\ntreat lymphoid malignancies. Ibrutinib, a ﬁrst-in-class irreversible\noral inhibitor of BTK, has proven highly effective in chronic\nlymphocytic leukaemia and related B-cell malignancies including\nmantle cell lymphoma, Waldenström macroglobulinemia, and mar-\nginal zone lymphomas.262 These disorders are usually diagnosed in\nelderly patients in whom frequent comorbidities coexist at diagno-\nsis that increase the risk of CTR-CVT.263,264 Ibrutinib has been as-\nsociated with bleeding diathesis, infections, and an increased risk of\nhypertension, AF, and HF.265–267 Ibrutinib may also cause ventricular\narrhythmias without prolonging QT.267,268 Acalabrutinib is a second-\ngeneration BTK inhibitor with greater BTK selectivity. In a recent\nphase III, randomized, multicentre, open-label, non-inferiority study,\nacalabrutinib demonstrated a non-inferior progression-free survival\ncompared to ibrutinib in patients with previously treated chronic\nlymphocytic leukaemia with a lower incidence of symptomatic CV\nevents.269 However, grade ≥3 AF (symptomatic AF where urgent\nintervention is indicated)270 and AF in patients ≥75 years old or with\nprevious AF history were comparable between groups, as was the\nrisk of CV events in patients with pre-existing CVRFs or CVD.271\nTherefore, we currently do not have enough data to establish different\nmonitoring strategies in patients treated with these drugs.\nDue to the lack of evidence-based recommendations, the manage-\nment of these CV events is challenging.264 Antihypertensive initiation\nhas been associated with a lower risk of a major adverse CV events\n(MACE).264 Opportunistic screening for AF by pulse-taking or ECG\nrhythm strip is recommended at every clinical visit during BTK inhibi-\ntor therapy.272\nDue to a higher bleeding risk, ibrutinib should be temporarily\ninterrupted in patients requiring dual antiplatelet therapy (DAPT)\nand 3–7 days before invasive procedures. In case of emergency inter-\nventions, platelet transfusion should be considered to minimize\nbleeding risks.262\nRecommendation Table 11 — Recommendations for\nbaseline\nrisk\nassessment\nand\nmonitoring\nduring\nsecond- and third-generation breakpoint cluster re-\ngion–Abelson\noncogene\nlocus\ntyrosine\nkinase\ninhibitors\nRecommendations\nClassa\nLevelb\nBaseline CV risk assessmentc is recommended in\npatients who require second- or third-generation\nBCR-ABL TKI.256,261\nI\nC\nIn patients treated with nilotinib or ponatinib, CV\nrisk assessmentc is recommended every 3 months\nduring the ﬁrst year and every 6–12 months\nthereafter.256,261\nI\nC\nQTcd measurement should be considered at\nbaseline, at 2 and 4 weeks after starting nilotinib,\nand 2 weeks after any dose increase.259\nIIa\nC\nBaseline echocardiography should be considered\nin all patients before starting second- and\nthird-generation BCR-ABL TKI.\nIIa\nC\nBaseline echocardiography is recommended in\npatients scheduled to receive dasatinib.\nI\nC\nEchocardiography should be considered every 3\nmonths during the ﬁrst year in high- and very\nhigh-risk patients receiving dasatinib or ponatinib.\nIIa\nC\nEchocardiography may be considered every 6–12\nmonths in patients who require long-term (.12\nmonths) ponatinib or dasatinib.\nIIb\nC\nSerial assessment of ankle brachial index may be\nconsidered to detect subclinical peripheral\nvascular disease.\nIIb\nC\n© ESC 2022\nBCR-ABL, breakpoint cluster region–Abelson oncogene locus; BP, blood pressure; CV,\ncardiovascular; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HFA, Heart\nFailure Association; ICOS, International Cardio-Oncology Society; QTc, corrected\nQT interval; QTcF, corrected QT interval using Fridericia correction; TKI, tyrosine\nkinase inhibitors.\naClass of recommendation.\nbLevel of evidence.\ncPhysical examination, BP measurement, ECG, lipid proﬁle, and HbA1c measurement.\nCoronary artery calcium scoring can reclassify CV disease risk upwards and downwards\nin addition to conventional risk factors, and may be considered at baseline in low- and\nmoderate-risk patients as per HFA-ICOS risk assessment tools.19\ndQTc interval using Fridericia correction (QTcF = QT/3√RR) is the preferred\nmethod.\nRecommendation Table 12 — Recommendations for\nbaseline\nrisk\nassessment\nand\nmonitoring\nduring\nBruton tyrosine kinase inhibitor therapy\nRecommendations\nClassa\nLevelb\nBP monitoring and management\nBP measurement is recommended for patients\ntreated with BTK inhibitors at every clinical\nvisit.264\nI\nB\nWeekly home monitoring of BP during the ﬁrst 3\nmonths and every month thereafter should be\nconsidered for patients treated with BTK\ninhibitors.\nIIa\nC\nEchocardiography\nBaseline echocardiography is recommended in\nhigh-risk patientsc scheduled to receive BTK\ninhibitors.267,268\nI\nC\nTTE is recommended in all patients who develop\nAF during BTK inhibitor therapy.\nI\nC\nContinued\nESC Guidelines\n4267\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n5.5.7. Multiple myeloma therapies\nThere are many classes of pharmacotherapy that are approved for\nthe treatment of MM using a range of combinations. These include\nimmunomodulatory drugs (IMiD), dexamethasone, PI, and monoclo-\nnal antibodies (e.g. daratumumab). PI—including bortezomib, carﬁl-\nzomib, and ixazomib—have become a mainstay of therapy for\nnewly diagnosed MM as well as relapsed disease.276,277 Several large\nstudies using combination therapy for MM have demonstrated an in-\ncreased risk of serious CV adverse events.278–281 MM patients being\ntreated with PI have a high incidence of coexistent CV comorbidities\nAF\nOpportunistic screening for AF by pulse-taking or\nECG rhythm strip is recommended at every\nclinical visit during BTK inhibitor therapy.273\nI\nC\n© ESC 2022\nAF, atrial ﬁbrillation; BP, blood pressure; BTK, Bruton tyrosine kinase; DM, diabetes\nmellitus; ECG, electrocardiogram; HF, heart failure; QTc, corrected QT interval; TTE,\ntransthoracic echocardiography; VHD, valvular heart disease.\naClass of recommendation.\nbLevel of evidence.\ncMale, age ≥65 years, previous history of hypertension, DM, QTc ≥480 ms, AF, HF,\ncardiomyopathy, or severe VHD.263,274,275\nCyclophosphamide\nMelphalan\nLenalidomide\nPomalidomide\nAlkylating agents\nBortezomib\nCarfilzomib\nProteasome inhibitorsa\nImmunomodulatory drugs\nThalidomide\nDaratumumab\nElotuzumab\nMonoclonal antibodies\nIsatuximab\nHTN\nHF\nAF\nHG/DM\nMI\nVTE\nPH\nATE\nMultiple myeloma drugs-related cardiovascular toxicities\nVery common: ≥10% incidence\nCommon: 1% to <10% incidence\nUncommon: 0.1% to < 1% incidence\nRare: <0.1% incidence\nFigure 16 Multiple myeloma drug-related cardiovascular toxicities. AF, atrial ﬁbrillation; ATE, arterial thromboembolism; DM, diabetes mellitus; EMA,\nEuropean Medicines Agency; FDA, Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary\nfor regulatory activities; MI, myocardial infarction; PH, pulmonary hypertension; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical\ntrials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the\navailable data, a blank space has been left. aIxazomib produces peripheral oedema in up to 18% of patients and hyperglycaemia in combination with lenalidomide\nor pomalidomide and dexamethasone. Figure developed from EMA prescribing information,252 FDA prescribing information.253\n4268\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 26",
          "page": 26,
          "content": " | Factors that could influence peri-operative risk during cancer surgery | Preventive strategies\nPatient-related\nfactors | • Lifestyle risk factors: smoking, obesity, sedentary lifestyle\n• Poorly controlled CVRF: hypertension, DM\n• Pre-existing CVD including CTR-CVT\n• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and\nanticoagulants)\n• Historical primary malignancy\n• Current cancer type, stage and location | • Optimal management of CVRF and\nCVD (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\nNeoadjuvant cancer\ntherapy | • Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline\nchemotherapy and/or trastuzumab, ICI, VEGFi, fluoropyrimidine, and thoracic RT)\n• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK\ninhibitors)\n• Thrombocytopaenia caused by cancer treatment | • Ensure optimal CV monitoring of\nneoadjuvant therapy (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 28",
          "page": 28,
          "content": "Recommendations | Classa | Levelb\nManagement of CVRF according to the 2021 ESC\nGuidelines on CVD prevention in clinical practice\nis recommended before,c during, and after cancer\ntherapy.19 | I | C\nDexrazoxane should be considered in adult\npatients with cancer at high and very high CV\ntoxicity risk when anthracycline chemotherapy is\nindicated.d,158 | IIa | B\nLiposomal anthracyclines should be considered in\nadult patients with cancer at high and very high CV\ntoxicity risk when anthracycline chemotherapy is\nindicated.e,164,165,168 | IIa | B",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 29",
          "page": 29,
          "content": "ACE-I or ARB and beta-blockers recommended\nfor HFf should be considered for primary\nprevention in high- and very high-risk patients\nreceiving anthracyclines and/or anti-HER2\ntherapies.145,150,155–157,159,160,175 | IIa | B\nACE-I or ARB and beta-blockers recommended\nfor HFf should be considered for primary\nprevention in high- and very high-risk patients\nreceiving targeted cancer therapies that may cause\nHF.g | IIa | C\nStatins should be considered for primary\nprevention in adult patients with cancer at high\nand very high CV toxicity risk.h,149,176–185 | IIa | B",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 29",
          "page": 29,
          "content": "Recommendation | Classa | Levelb\nManagement of CVD according to applicable ESC\nGuidelines is recommended before,c during, and\nafter cancer therapy. | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Baseline measurement of NP and cTn should be\nconsidered in low- and moderate-risk patients\nprior to anthracycline chemotherapy.211 | IIa | C\ncTn and NP monitoring before every cycle during\nanthracycline chemotherapy and 3 and 12 months\nafter therapy completion is recommended in high-\nand very high-risk patients.55,175,211 | I | B\ncTn and NP monitoring every two cycles during\nanthracycline chemotherapy and within 3 months\nafter therapy completion should be considered in\nmoderate-risk patients and in low-risk patients\nreceiving a cumulative dose of ≥250 mg/m2 of\ndoxorubicin or equivalent.55,59,212,213 | IIa | C\ncTn and NP monitoring every two cycles during\nanthracycline chemotherapy and within 3 months\nafter therapy completion may be considered in\nlow-risk patients.55,59,212,213 | IIb | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Recommendations |  | Classa | Levelb | \n | TTE |  |  | \nBaseline echocardiographyc is recommended in all\npatients with cancer before anthracycline\nchemotherapy.12,24,208–210 |  | I | B | \nIn all adults receiving anthracycline chemotherapy,\nan echocardiogram is recommended within 12\nmonths after completing treatment.208 |  | I | B | \nIn high- and very high-risk patients,\nechocardiography is recommended every two\ncycles and within 3 months after completing\ntreatment.24,208–210 |  | I | C | \nIn moderate-risk patients, additional\nechocardiography should be considered after a\ncumulative dose of ≥250 mg/m2 of doxorubicin\nor equivalent.7 |  | IIa | C | \nIn low-risk patients, additional echocardiography\nmay be considered after a cumulative\ndose of ≥250 mg/m2 of doxorubicin or\nequivalent.7 |  | IIb | C | \n | Cardiac serum biomarkers |  |  | \nBaseline measurement of NP and cTn is\nrecommended in high- and very high-risk patients\nprior to anthracycline chemotherapy.55,65,211 |  | I | B | ",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 32",
          "page": 32,
          "content": "Recommendations |  | Classa | Levelb | \n | TTE |  |  | \nBaseline echocardiographyc is recommended\nbefore HER2-targeted therapies in all patients.225 |  | I | B | ",
          "rows": 3,
          "cols": 5
        },
        {
          "title": "Table on page 33",
          "page": 33,
          "content": "In patients receiving neoadjuvant or adjuvant\nHER2-targeted therapies, echocardiography is\nrecommended every 3 months and within 12\nmonths after completing treatment.225,226 |  | I | B | \nIn low-risk HER2+ EBC patientsd who are\nasymptomatic and with a normal assessment after\n3 months, reducing monitoring to every 4 months\nmay be considered. |  | IIb | C | \nIn high- and very high-risk HER2+ EBC patients,d\nmore frequent echocardiography monitoringe\nshould be considered during treatment. |  | IIa | C | \nIn metastatic HER2+ disease, echocardiography is\nrecommended every 3 months during the first\nyear; if the patient remains asymptomatic without\nCV toxicity, then surveillance can be reduced to\nevery 6 months during future treatment.f |  | I | C | \nIn metastatic HER2+ disease patients at high- and\nvery high-risk, more frequent echocardiography\nmonitoringe may be considered. |  | IIb | C | \n | Cardiac biomarkers |  |  | \nBaseline NP and cTn measurement are\nrecommended in high- and very high-risk patients\nprior to anti-HER2-targeted therapies.227,228 |  | I | C | \nNP and cTn monitoring every 2–3 cycles during\ntherapy and 3 and 12 months after the end of\ntherapy should be considered in high- and very\nhigh-risk HER2+ EBC patients.d,55 |  | IIa | C | \nBaseline cTn measurement should be considered\nin low- and moderate-risk patients\npost-anthracycline chemotherapy but prior to\nstarting anti-HER2-targeted therapies.55,62 |  | IIa | A | \nNP and cTn monitoring at baseline, every 3\nmonths, and 12 months after therapy may be\nconsidered in low- and moderate-risk HER2+\nEBC patients.d,55 |  | IIb | C | ",
          "rows": 10,
          "cols": 5
        },
        {
          "title": "Table on page 33",
          "page": 33,
          "content": "Recommendations | Classa | Levelb\nBaseline CV risk assessment and evaluation\nincluding BP measurement, ECG, lipid profile,\nHbA1c measurement, and SCORE2/\nSCORE2-OPc or equivalent is recommended19\nbefore starting fluoropyrimidines. | I | C\nA baseline echocardiogram is recommended in\npatients with a history of symptomatic CVD\nbefore starting fluoropyrimidines. | I | C\nScreening for CADd may be considered in patients\nat high and very high risk of CADc before\nfluoropyrimidines. | IIb | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 36",
          "page": 36,
          "content": "Echocardiography may be considered every 4\nmonths during the first year in moderate-risk\npatients receiving VEGFi or bevacizumab. |  | IIb | C | \nEchocardiography should be considered every 3\nmonths during the first year in high- and very\nhigh-risk patients receiving a VEGFi or\nbevacizumab.e |  | IIa | C | \nEchocardiography every 6–12 months should be\nconsidered in moderate- and high-risk patients\nwith cancer who require long-term treatment\nwith a VEGFi. |  | IIa | C | \n | Cardiac biomarker |  |  | \nNP may be considered at baseline and then every\n4 months during the first year in moderate-risk\npatients receiving a VEGFi. |  | IIb | C | \nNP should be considered at baseline, 4 weeks\nafter starting treatment, and them every 3 months\nduring the first year in high- and very high-risk\npatients receiving a VEGFi. |  | IIa | C | ",
          "rows": 6,
          "cols": 5
        },
        {
          "title": "Table on page 36",
          "page": 36,
          "content": "Recommendations |  | Classa | Levelb | \nBP monitoring |  |  |  | \nBP measurement is recommended for patients\ntreated with VEGFi, bevacizumab, or\nramucirumab at every clinical visit. |  | I | C | \nDaily home monitoring of BP for patients treated\nwith VEGFi during the first cycle, after each\nincrease of VEGFi dose, and every 2–3 weeks\nthereafter is recommended. |  | I | C | \n | ECG monitoring |  |  | \nIn patients treated with VEGFi at moderate or\nhigh risk of QTc prolongation, QTcc monitoring is\nrecommended monthly during the first 3 months\nand every 3–6 months thereafter.d |  | I | C | \n | Echocardiography |  |  | \nBaseline echocardiography is recommended in\nhigh- and very high-risk patients treated with\nVEGFi or bevacizumab. |  | I | C | \nBaseline echocardiography should be considered\nin low- and moderate-risk patients treated with a\nVEGFi or bevacizumab. |  | IIa | C | ",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 39",
          "page": 39,
          "content": "Recommendations | Classa | Levelb\nBaseline CV risk assessmentc is recommended in\npatients who require second- or third-generation\nBCR-ABL TKI.256,261 | I | C\nIn patients treated with nilotinib or ponatinib, CV\nrisk assessmentc is recommended every 3 months\nduring the first year and every 6–12 months\nthereafter.256,261 | I | C\nQTcd measurement should be considered at\nbaseline, at 2 and 4 weeks after starting nilotinib,\nand 2 weeks after any dose increase.259 | IIa | C\nBaseline echocardiography should be considered\nin all patients before starting second- and\nthird-generation BCR-ABL TKI. | IIa | C\nBaseline echocardiography is recommended in\npatients scheduled to receive dasatinib. | I | C\nEchocardiography should be considered every 3\nmonths during the first year in high- and very\nhigh-risk patients receiving dasatinib or ponatinib. | IIa | C\nEchocardiography may be considered every 6–12\nmonths in patients who require long-term (.12\nmonths) ponatinib or dasatinib. | IIb | C\nSerial assessment of ankle brachial index may be\nconsidered to detect subclinical peripheral\nvascular disease. | IIb | C",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 39",
          "page": 39,
          "content": "Recommendations |  | Classa | Levelb | \n | BP monitoring and management |  |  | \nBP measurement is recommended for patients\ntreated with BTK inhibitors at every clinical\nvisit.264 |  | I | B | \nWeekly home monitoring of BP during the first 3\nmonths and every month thereafter should be\nconsidered for patients treated with BTK\ninhibitors. |  | IIa | C | \n | Echocardiography |  |  | \nBaseline echocardiography is recommended in\nhigh-risk patientsc scheduled to receive BTK\ninhibitors.267,268 |  | I | C | \nTTE is recommended in all patients who develop\nAF during BTK inhibitor therapy. |  | I | C | ",
          "rows": 7,
          "cols": 5
        },
        {
          "title": "Table on page 40",
          "page": 40,
          "content": " | AF |  |  | \nOpportunistic screening for AF by pulse-taking or\nECG rhythm strip is recommended at every\nclinical visit during BTK inhibitor therapy.273 |  | I | C | ",
          "rows": 2,
          "cols": 5
        }
      ],
      "keywords": [
        "cardiovascular",
        "ct",
        "cancer",
        "complications",
        "monitoring",
        "during",
        "surgery",
        "risk",
        "prevention",
        "treatment",
        "therapy"
      ]
    },
    {
      "number": "8",
      "title": "6. Diagnosis and management of acute and subacute cardiovascular toxicity in patients receiving anticancer treatment",
      "start_page": 54,
      "end_page": 68,
      "content": "5.5.18. Other cancer treatments\nSeveral other cancer therapies may also induce clinically relevant CV\nevents. Cyclophosphamide, cisplatin, ifosfamide, and taxanes (pacli-\ntaxel and docetaxel) can induce myocardial dysfunction and HF.4\nCyclophosphamide CV toxicity is primarily seen in patients receiving\nhigh doses (.140 mg/kg) before HSCT and typically occurs within\ndays of drug administration.410\nPlatinum-containing chemotherapy (cisplatin, carboplatin, oxali-\nplatin) may cause vascular disease (vasospasm, MI, and venous and\narterial thrombosis). These may occur during treatment and also\ncontribute to increased long-term risk of CAD in survivors.\nPatients with testicular cancer treated with cisplatin have a higher\nrisk for vascular disease at long-term follow-up.421 The risk of the in-\ndividual patient is still hard to predict, but lifestyle interventions, a\nhigh degree of clinical suspicion in patients who experience chest\npain, and close CVRF monitoring is recommended during and after\ntherapy.422 Cisplatin422 infrequently causes HF; however, because\nit requires the administration of a high i.v. volume to avoid renal tox-\nicity, patients with pre-existing CVD may develop symptomatic HF.\nArsenic trioxide is used to treat some leukaemias and myelomas.\nArsenic trioxide frequently prolongs the QT interval (26–93% of pa-\ntients), and life-threatening ventricular tachyarrhythmias have been\nreported.45,259 QTc prolongation was observed 1–5 weeks after ar-\nsenic trioxide infusion and then returned towards baseline by the end\nof 8 weeks. Patients receiving treatment with arsenic trioxide should\nbe monitored weekly with ECG during the ﬁrst 8 weeks of therapy.\nElectrolyte monitoring is also required as arsenic trioxide may induce\nhypokalaemia, hypomagnesaemia, and renal dysfunction. Risk factors\nfor QT prolongation should be controlled before, during, and after\ncancer treatment (Section 6.4.2).\nSeveral FMS-like tyrosine kinase 3 (FLT3) inhibitors (ﬁrst-generation:\nmidostaurin; second-generation: gilteritinib) have been tested for the\ntreatment of acute myeloid leukaemias. Gilterinib-induced differenti-\nation syndrome (fever, dyspnoea, pleuropericardial effusion, pulmon-\nary oedema, peripheral oedema, hypotension, renal dysfunction, and\nrash) requires early corticosteroid therapy and haemodynamic moni-\ntoring until resolution of symptoms. Midostaurin and gilterinib may\nprolong QTc interval and close electrolyte surveillance and minimizing\ndrug–drug interactions are required (see Section 6.4.2; Table 9;\nSupplementary data, Tables S15 and S16).423\n6. Diagnosis and management of\nacute and subacute cardiovascular\ntoxicity in patients receiving\nanticancer treatment\nA coordinated MDT is recommended to discuss patients with cancer\nwho develop acute CV complications of their cancer treatment.5\nReferral to a specialized cardio-oncology service is recommended\nfor patients with cancer who present with new CTR-CVT during\nand after cancer treatment.12 The prevention and management of\nCVD in patients with cancer should generally follow published ESC\nGuidelines for speciﬁc CVD. This chapter provides guidance on\nthe management of CTR-CVT that occur during cancer treatment,\nand highlights where management differs for patients with cancer\ncompared with those without. The decision to initiate CV treatment\n(medication, devices) needs to include consideration of a range of\nfactors including both cancer and CV symptom burden, cancer prog-\nnosis, ongoing cancer treatment requirements including alternative\noptions, possible adverse drug reactions, drug–drug interactions,\nand patient preferences. An extensive list of drug–drug interactions\nis provided in Supplementary data, Tables S15–S17.\n6.1. Cancer therapy-related cardiac\ndysfunction\n6.1.1. Anthracycline chemotherapy-related cardiac\ndysfunction\nCTRCD during anthracycline chemotherapy may present clinically or\nbe detected in asymptomatic patients during surveillance (Figure 10;\nTable 3).4 The diagnosis of anthracycline chemotherapy-related car-\ndiac dysfunction includes new CV symptoms, new abnormalities in\ncardiac function on CV imaging, and/or new increases in cardiac bio-\nmarkers (Table 3). A MDT discussion is recommended to consider\nthe risk/beneﬁt ratio of continuing anthracycline chemotherapy in\npatients who develop new CTRCD.\nDiscontinuation of anthracycline chemotherapy is recommended\nin patients with cancer who develop severe symptomatic CTRCD.22\nThere are rare exceptions where rechallenge with further anthracy-\ncline chemotherapy may be considered after a MDT discussion, using\nprevention strategies described below and under close monitoring\nwith each cycle of anthracycline chemotherapy. Temporary interrup-\ntion of anthracycline chemotherapy is recommended in patients who\ndevelop moderate symptomatic CTRCD, and in patients who de-\nvelop moderate or severe asymptomatic CTRCD. A MDT approach\nregarding interruption vs. continuation of anthracycline chemother-\napy is recommended in patients who develop mild symptomatic\nCTRCD.\nGuideline-based HF therapy is recommended in patients who de-\nvelop symptomatic CTRCD or asymptomatic moderate or severe\nCTRCD during anthracycline chemotherapy. The use of an ACE-I/\nARB or angiotensin receptor–neprilysin inhibitor, a beta-blocker, a\nsodium–glucose co-transporter 2 inhibitor, and a mineralocorticoid re-\nceptor antagonist is recommended unless the drugs are contraindi-\ncated or not tolerated. Up-titration to target doses as described in\nthe 2021 ESC Guidelines for the diagnosis and treatment of acute\nand chronic HF is recommended.14 ACE-I, ARB, and/or beta-blockers\nRecommendation Table 23 — Recommendation for\nthe management of cardiovascular disease and cancer\ntherapy-related cardiovascular toxicity in patients re-\nceiving anticancer treatment\nRecommendation\nClassa\nLevelb\nA specialist CV assessmentc is recommended for\noptimal diagnostic workup and management of\npatients with cancer who present with new CV\ntoxicity during and after cancer treatment.5\nI\nC\n© ESC 2022\nCV, cardiovascular; CVD, cardiovascular disease.\naClass of recommendation.\nbLevel of evidence.\ncCardio-oncology referral is recommended when available; alternatively, patients should\nbe referred to a specialized cardiologist with expertise in managing CVD in patients with\ncancer.\n4282\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nshould be considered in mild asymptomatic CTRCD while anthracy-\ncline chemotherapy continues uninterrupted (Figure 25).1,14,102,424\nThe beneﬁcial effects of aerobic exercise before and during anthracy-\ncline chemotherapy have been demonstrated and is recommended\nfor patients with cancer who develop CTRCD.11\nA MDT is recommended to discuss restarting anthracycline\nchemotherapy in patients who developed mild or moderate\nsymptomatic CTRCD, or moderate or severe asymptomatic\nCTRCD, after recovery of LV function under HF treatment. If there\nis a compelling reason to continue anthracycline chemotherapy,\nthree other strategies exist in addition to continuing ACE-I/ARB\nand beta-blockers at target doses for HF.14 First, minimizing the\ndose of anthracycline chemotherapy administered. Second, switch-\ning to liposomal anthracycline preparations. Third, pre-treatment\nDiscontinue\nAC\n(Class I)\nInterrupt\nAC\n(Class I)\nMDT approach\nregarding interruption\nvs. conti\n.\nnuation\nof AC\n(Class I)\nInterrupt\nAC\n(Class I)\nContinue\nAC\nwith CV monitoring\n(Class I)\nSymptomatic CTRCDa\nVe\nV ry severe/severe\nOncological\nstrategy\nCV\nstrategy\nModerate\nMDTb\nMild\nSevere/moderate\nMild\nGLS decrease >15%\nor cTn increase\nACE-I/ARB\nand/or BB\n(Class IIb)\nACE-I/ARB\nand/or BB\n(Class IIa)\nHF therapy\np\n(Class I)\nNP increase\nAsymptomatic CTRCDa\nManagement of patients with AC-related cardiac dysfunction\nAND\nMDTc\nAND\nMDTc\nAND\nFigure 25 Management of anthracycline chemotherapy-related cardiac dysfunction. AC, anthracycline chemotherapy; ACE-I, angiotensin-converting\nenzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta-blockers; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction;\nCV, cardiovascular; GLS, global longitudinal strain; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary\nteam; NP, natriuretic peptides. aSee Table 3 (Section 3) for complete deﬁnition (symptomatic CTRCD: symptomatic conﬁrmed HF syndrome; asymptom-\natic severe CTRCD: LVEF , 40%; asymptomatic moderate CTRCD: LVEF 40–49%; asymptomatic mild CTRCD: LVEF . 50%). bIn rare exceptions, an-\nthracycline chemotherapy may be restarted after recovery of LV function with optimal HF therapy. cA MDT discussion is recommended before restarting\nanthracycline chemotherapy after recovery of LV function.\nESC Guidelines\n4283\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nwith dexrazoxane before each further cycle of anthracycline chemo-\ntherapy (Section 5.2.1).\nClose cardiac monitoring every 1–2 cycles is recommended in pa-\ntients who restart anthracycline chemotherapy following an episode\nof CTRCD and in patients with mild asymptomatic CTRCD while\nthey continue anthracycline chemotherapy.\n6.1.2. Human epidermal receptor 2-targeted\ntherapy-related cardiac dysfunction\nThe diagnosis of HER2-targeted therapy-related CTRCD can be\nmade using the combination of new CV symptoms, imaging, and\nbiomarkers. Patients may present with symptomatic CTRCD or\nmay be asymptomatic.426 Early treatment of symptomatic and\nasymptomatic severe CTRCD (LVEF , 40%), according to the\n2021 ESC Guidelines for the diagnosis and treatment of acute\nand chronic HF,14 is recommended to prevent worsening HF,425\nparticularly when targeted cancer therapy is continued.427 In pa-\ntients who develop CTRCD, a MDT is recommended to guide\nclinical\ndecisions.\nTemporary\ninterruption\nis\nrecommended\nin patients who develop moderate or severe symptomatic\nCTRCD or severe asymptomatic CTRCD (LVEF , 40%) during\nHER2-targeted therapy. In patients with mild symptomatic\nCTRCD, a MDT approach is recommended to continue vs. inter-\nrupt HER2-targeted therapy. In patients with asymptomatic mod-\nerate CTRCD (LVEF 40–49%), HER2-targeted treatment should\nbe continued, and cardioprotective therapy (ACE-I/ARB and beta-\nblockers) is recommended with frequent cardiac monitor-\ning.22,33,189 In patients with asymptomatic mild CTRCD (LVEF ≥\n50% with a signiﬁcant new GLS reduction and/or cardiac biomark-\ner increase), continuing HER2-targeted treatment is recom-\nmended\nand\ncardioprotective\ntherapy\n(ACE-I/ARB\nand/or\nbeta-blockers) should be considered.22,211,428,429\nFrequent cardiac surveillance with cardiac imaging and cardiac\nserum biomarkers is recommended in all patients with CTRCD\nRecommendation Table 24 — Recommendations for\nthe management of cancer treatment-related cardiac\ndysfunction during anthracycline chemotherapy\nRecommendations\nClassa\nLevelb\nAnthracycline chemotherapy-induced symptomatic CTRCD\nHF therapy is recommended for patients who\ndevelop symptomatic CTRCD during\nanthracycline chemotherapy.c,208,425\nI\nB\nDiscontinuation of anthracycline chemotherapy is\nrecommended in patients who develop\nsymptomatic severe CTRCD.c\nI\nC\nTemporary interruption of anthracycline\nchemotherapy is recommended in patients who\ndevelop symptomatic moderate CTRCDc and a\nmultidisciplinary approach regarding the decision\nto restart is recommended.\nI\nC\nA multidisciplinary approach regarding\ninterruption vs. continuation of anthracycline\nchemotherapy is recommended in patients who\ndevelop mild symptomatic CTRCD.c\nI\nC\nAnthracycline chemotherapy-induced asymptomatic\nCTRCD\nTemporary interruption of anthracycline\nchemotherapy and initiation of HF therapy is\nrecommended in patients who develop\nasymptomatic moderate or severe CTRCD.c,22\nI\nC\nA multidisciplinary approach regarding the\ndecision when to restart is recommended in all\npatients with moderate or severe asymptomatic\nCTRCD.c,22\nI\nC\nContinuation of anthracycline chemotherapy is\nrecommended in asymptomatic patients who\nhave LVEF ≥50% and who have developed a\nsigniﬁcant fall in GLSc or a troponin or a NP\nelevation . ULN.\nI\nC\nAsymptomatic patients who have LVEF ≥50%\nand who have developed a signiﬁcant fall in GLSc\nshould be considered for ACE-I/ARB and/or\nbeta-blockers.d,75,93,102\nIIa\nB\nAsymptomatic patients who have LVEF ≥50%\nand who have developed a troponin elevation\n.ULN should be considered for ACE-I/ARB and/\nor beta-blockers.d,147,211\nIIa\nB\nContinued\nAsymptomatic patients who have LVEF ≥50%\nand who have developed NP .ULN may be\nconsidered for ACE-I/ARB and/or\nbeta-blockers.d,211\nIIb\nC\nStrategies for restarting anthracycline chemotherapy in\npatients with CTRCD\nLiposomal anthracyclinee may be considered in\npatients with moderate or severe symptomatic or\nasymptomatic CTRCDc who require further\nanthracycline chemotherapy to reduce the risk of\nfurther CV toxicity.\nIIb\nC\nDexrazoxanef may be considered in patients with\nmoderate or severe symptomatic or\nasymptomatic CTRCDc who require further\nanthracycline chemotherapy to reduce the risk of\nfurther CV toxicity.\nIIb\nC\n© ESC 2022\nACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;\nCTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; GLS, global\nlongitudinal strain; HF, heart failure; LVEF, left ventricular ejection fraction; NP,\nnatriuretic peptides; ULN, upper limit of normal.\naClass of recommendation.\nbLevel of evidence.\ncSee Table 3. Signiﬁcant fall in GLS = relative reduction .15%.\ndAvoid hypotension.\neSee text for speciﬁc liposomal doxorubicin type and malignancies (Section 5.2).\nfAs per the European Medicines Agency: ≥350 mg/m2 doxorubicin or equivalent; as\nper the United States Food and Drug Administration: ≥300 mg/m2 doxorubicin or\nequivalent.\n4284\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nwho continue HER2-targeted cancer therapies and in those who\nrestart after an interruption following resolution of HF signs and\nsymptoms and recovery of LVEF ≥40% (and ideally recovery to\nLVEF ≥50%) (Figure 26).22,33,189 Echocardiography and cardiac\nserum biomarker measurement every two cycles for the ﬁrst\nfour cycles after restarting HER2-targeted therapy is recom-\nmended, and then the frequency can be reduced if cardiac function\nand biomarker levels remain stable.\nAnti-HER2\ninterruption\n(Class I)\nAnti-HER2\ninterruption\n(Class I)\nMDT approach\nregarding\ninterruption\nvs. conti\n.\nnuation of\nanti-HER2\n(Class I)c\nContinue anti-HER2\nunder CV monitoring\n(Class I)\nContinue anti-HER2\nunder CV monitoring\n(Class IIa)\nSymptomatic CTRCDa\nModerata e to very severe\nOncological\nstrategy\nCV\nstrategy\nMild\nMDTb,c\nSevere\nModerate\nMild\nACE-I/ARB\nand/or BB\n(Class IIa)\nHF therapy\np\n(Class I)\nAsymptomatic CTRCDa\nManagement of patients with HER2-targeted therapies related cardiac dysfunction\nAND\nMDTb,c\nAND\nGLS decrease >15%\ncTn and NP increase\nFigure 26 Management of human epidermal receptor 2-targeted therapy-related cardiac dysfunction. ACE-I, angiotensin-converting enzyme inhibitors;\nARB, angiotensin receptor blockers; BB, beta-blockers; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular;\nGLS, global longitudinal strain; HER2, human epidermal receptor 2; HF, heart failure; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team;\nNP, natriuretic peptides. aSee Table 3 (Section 3) (symptomatic CTRCD: symptomatic conﬁrmed HF syndrome; asymptomatic severe CTRCD: LVEF ,\n40%; asymptomatic moderate CTRCD: LVEF 40–49%; asymptomatic mild CTRCD: LVEF . 50%). bFor patients in whom HER2-targeted therapy has\nbeen interrupted, whose signs and symptoms of HF do not resolve and/or LVEF remains ,40%, resumption of HER2-targeted therapy may be considered\nif no alternative therapeutic option exists. In advanced cancer that only responds well to trastuzumab, the risk/beneﬁt ratio may warrant continued ther-\napy if other options remain limited.22 cFor patients where HER2-targeted therapy has been interrupted and who have recovered LVEF ≥40% and are\nnow asymptomatic, resumption of HER2-targeted therapy should be considered, supported by HF therapy, and echocardiography and cardiac biomarker\nassessment every two cycles for the ﬁrst four cycles after restarting and then the frequency can be reduced.22\nESC Guidelines\n4285\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n6.1.3. Immune checkpoint inhibitor-associated\nmyocarditis and non-inﬂammatory heart failure\nMyocarditis is a severe complication of ICI with a high fatality\nrate that most frequently develops during the ﬁrst 12 weeks of\ntreatment, although late cases (after week 20) may occur.386\nOther ICI-related CV toxicities include dyslipidaemia, ACS, vascu-\nlitis, AV block, supraventricular and ventricular arrhythmias, sud-\nden death, TTS, non-inﬂammatory LVD, pericarditis, pericardial\neffusion, and ischaemic stroke, with higher risks for myocarditis\n(odds\nratio\n4.42)\nand\ndyslipidaemia\n(odds\nratio\n3.68)\n(Figure 27).323,325\nThe diagnosis of ICI-associated myocarditis is initially based on the\npresence of symptoms, a new increase in troponin (associated with\neither CV symptoms or non-CV immuno-related adverse events),\nand new ECG abnormalities (AV or intraventricular conduction dis-\norders,\nbradycardia,\ntachyarrhythmias)\n(see\nSection\n3;\nTable 3).17,434,435 Any abnormal ﬁnding should prompt urgent CV im-\naging and other causes of myocardial injury (e.g. ACS, acute infec-\ntious myocarditis) should be excluded. Treatment with high-dose\nmethylprednisolone should be promptly initiated in haemodynamic-\nally unstable patients (including those with ventricular arrhythmias\n[VA] or complete AV block) while awaiting further conﬁrmatory\ntesting.436 TTE and CMR are recommended in all patients with sus-\npected ICI-associated myocarditis. Currently, speciﬁc CMR features\nfor ICI-induced myocarditis are not well described and modiﬁed Lake\nLouise criteria are recommended (Table 3).18 Cardiac ﬂuorodeoxy-\nglucose positron emission tomography (PET) may be consid-\nered437,438 if CMR is not available or contraindicated, although PET\nsensitivity is low and requires a strict 18-h carbohydrate-free\nfast.439 Endomyocardial biopsy (EMB) should be considered in cases\nwhere the diagnosis is suspected but not conﬁrmed non-invasively\n(e.g. conﬂicting results of cardiac imaging and biomarkers or clinically\nunstable patients).440 All cases of ICI-associated myocarditis should\nbe classiﬁed according to the severity of the myocarditis (fulminant\nRecommendation Table 25 — Recommendations for\nthe management of cancer treatment-related cardiac\ndysfunction during human epidermal receptor 2-tar-\ngeted therapies\nRecommendations\nClassa\nLevelb\nHER2-targeted therapy-induced symptomatic CTRCD\nHF therapy is recommended for patients who\ndevelop symptomatic moderate-to-severe\nCTRCD with LVEF , 50%c during HER2-targeted\ntreatment.14,61,430,431\nI\nB\nTemporary interruption of HER2-targeted\ntreatment is recommended in patients who\ndevelop moderate or severe symptomatic\nCTRCDc and the decision to restart should be\nbased on a multidisciplinary approach after\nimprovement of LV function and symptoms\nresolved.d\nI\nC\nIn patients who develop mild symptomatic\nCTRCD,c HF therapy and a multidisciplinary\napproach regarding the decision to continue vs.\ninterrupt HER2-targeted therapy are\nrecommended.d,431,432\nI\nC\nHER2-targeted therapy-induced asymptomatic CTRCD\nTemporary interruption of HER2-targeted\ntherapy and initiation of HF therapy is\nrecommended in patients who develop\nasymptomatic severe CTRCD.c\nI\nC\nA multidisciplinary approach regarding the\ndecision to restart HER2-targeted treatment is\nrecommended in patients with severe\nasymptomatic CTRCD.c\nI\nC\nContinuation of HER2-targeted therapy should be\nconsidered in patients who develop asymptomatic\nmoderate (LVEF 40–49%) CTRCDc with more\nfrequent cardiac monitoring.33,189,428,433\nIIa\nB\nContinuation of HER2-targeted therapy is\nrecommended in patients who develop\nasymptomatic mild (LVEF ≥50%) CTRCDc with\nmore frequent cardiac monitoring.428\nI\nC\nACE-I/ARB and beta-blockers are recommended\nin patients who develop asymptomatic moderate\n(LVEF 40–49%) CTRCDc during HER2-targeted\ntreatment.e,189\nI\nC\nACE-I/ARB and/or beta-blockers should be\nconsidered in asymptomatic patients receiving\nHER2-targeted therapies who have LVEF ≥50%\nbut develop a signiﬁcant fall in GLSc while\ncontinuing HER2-targeted therapy.e,22,428\nIIa\nB\nContinued\nACE-I/ARB and/or beta-blockers should be\nconsidered in asymptomatic patients receiving\nHER2-targeted therapies who have LVEF ≥50%\nbut develop a new troponin or NP rise while\ncontinuing HER2-targeted therapy.e,22,211,428\nIIa\nB\n© ESC 2022\nACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;\nCTRCD, cancer therapy-related cardiac dysfunction; GLS, global longitudinal strain;\nHER2, human epidermal receptor 2; HF, heart failure; LV, left ventricular; LVEF, LV\nejection fraction; NP, natriuretic peptides.\naClass of recommendation.\nbLevel of evidence.\ncSee Table 3.\ndFor patients where HER2-targeted therapy has been interrupted and who have\nrecovered LVEF ≥40% and are now asymptomatic, resumption of HER2-targeted\ntherapy should be considered supported by HF therapy and echocardiography and\ncardiac biomarkers assessment every two cycles for the ﬁrst four cycles after\nrestarting and then frequency can be reduced.\neAvoid hypotension.\n4286\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nor non-fulminant, including symptomatic but haemodynamically and\nelectrically stable patients and incidental cases diagnosed at the same\ntime as other immune-related adverse events) to guide the manage-\nment pathway (Figure 28).331\nInterruption of ICI treatment is recommended in all cases of\nsuspected ICI-associated myocarditis (any patient developing\nnew cardiac symptoms, new cardiac arrhythmias, new heart\nblocks, or new troponin increase who has received an ICI therapy\nin the past 12 weeks) while investigations are performed. Once\nthe abnormal ﬁndings have resolved, a MDT discussion is recom-\nmended to determine the risk/beneﬁt to permanent stopping vs.\nresuming ICI treatment in patients with suspected but not con-\nﬁrmed myocarditis.\nCessation of ICI treatment is recommended in patients with can-\ncer with fulminant or non-fulminant ICI-associated myocarditis and\nthe patient should be admitted to hospital and a level 2 or 3 bed\nwith continuous ECG monitoring is required. CV complications\nshould be treated as per speciﬁc ESC Guidelines (HF,14 tachyarrhyth-\nmias,441,442 AV block,443 or pericardial effusion444).\nTreatment of both non-fulminant and fulminant ICI-associated\nmyocarditis with methylprednisolone 500–1000 mg i.v. bolus once\ndaily for the ﬁrst 3–5 days should be started as soon as possible,\nonce the diagnosis is considered likely, to reduce MACE including\nmortality.386,436 If clinical improvement is observed (cTn reduced\nby .50% from peak level within 24–72 h and any LVD, AV block,\nand arrhythmias resolved), switching to oral prednisolone is\nDirect CV Toxicity\nArrhythmias\nArrhythmias\nMyocarditis\nNon-inflammatory HF\nTakotsubo syndrome\nPericarditis\nVascular\nIndirect CV Toxicity\nThyroid\nAdrenal\nPituitary\nPancreas\nEmbolism\nFigure 27 Direct and indirect immune checkpoint inhibitor-related cardiovascular toxicity. CV, cardiovascular; HF, heart failure.\nESC Guidelines\n4287\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nrecommended starting at 1 mg/kg up to 80 mg/day. Although the\nmost appropriate weaning off protocol is not conﬁrmed, a weekly\nreduction of oral prednisolone (most commonly by 10 mg per\nweek) under clinical, ECG, and cTn surveillance should be consid-\nered (Figure 28). A reassessment of LV function and cTn should be\nconsidered when the prednisolone dose is reduced to 20 mg/day\nand then continue weaning the prednisolone by 5 mg per week to\n5 mg/day, and a ﬁnal reduction from 5 mg/day in 1-mg per week\nsteps.\nIf the troponin does not reduce signiﬁcantly (.50% reduction\nfrom peak) and/or AV block, ventricular arrhythmias, or LVD persist\ndespite 3 days of i.v. methylprednisolone plus cardiac treatments,\nthen steroid-resistant ICI-associated myocarditis is conﬁrmed and\nsecond-line immunosuppression should be considered.22,445,446\nComplete recovery\nRecoveringb\nSteroid refractory\nHaemodynamically unstable\nfulminant myocarditis\nSwitching to\noral prednisolone (1 mg/kg/day)\na\n(Class IIa)\nSecond-line immunosuppression\n(Class IIa)\nMethylprednisolone 500–1000 mg i.v.v bolus once dai\n.\nly (minimum 3 days)\na\n(Class I)\nDiscontinue ICI; hospital admission\n;\n; ECG monitoring\n;\n(Class I)\nSeverity (fulminant vs. non-fulminant)\n.\na\nAdmission to ICU (level 3)\n(Class I)\nOptimal CV treatment\nincluding MCS\n(Class I)\nWeaning p\nW\nrotocol by 10 mg/week\nwith troponin monitoring\n(Class IIa)\nManagement of patients with a definitive diagnosis of ICI-related myocarditis\nAND\nAND\nSecond-line immunosuppression\n(Class I)\nAND\nFigure 28 Diagnosis and management of immune checkpoint inhibitor-related myocarditis. CMR, cardiac magnetic resonance; CV, cardiovascular;\nECG, electrocardiogram; HF, heart failure; ICI, immune checkpoint inhibitor; ICU, intensive care unit; i.v., intravenous; LGE, late gadolinium enhancement;\nLVEF, left ventricular ejection fraction; MCS, mechanical circulatory support. aFulminant: haemodynamic instability, HF requiring non-invasive or inva-\nsive ventilation, complete or high-grade heart block, and/or signiﬁcant ventricular arrhythmia. Non-fulminant: including symptomatic but haemo-\ndynamically and electrically stable patients and incidental cases diagnosed at the same time as other immuno-related adverse events. Patients may\nhave reduced LVEF but no features of severe disease. bRecovering: ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging\nparameters, but not yet normalized, while on tapering doses of immunosuppression. Complete recovery: patients with complete resolution of acute\nsymptoms, normalization of biomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE or elevated T1 due\nto ﬁbrosis, but any suggestion of acute oedema should be absent.\n4288\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nThere is a lack of data to recommend a speciﬁc second-line immunosup-\npression regimen and MDT discussion is recommended. Several agents\nare currently being investigated with promising results from case series\nincluding i.v. mycophenolate mofetil, anti-thymocyte globulin (anti-CD3\nantibody), i.v. immunoglobulin, plasma exchange, tocilizumab, abatacept\n(CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and tofacitinib.\nCaution is advised against the use of inﬂiximab for steroid-refractory\nmyocarditis and HF.447,448 Patients with fulminant ICI-associated myo-\ncarditis, complicated by haemodynamic and/or electrical instability, re-\nquire admission to the intensive care unit (ICU) and cardiogenic\nshock should be managed according to the 2021 ESC Guidelines for\nthe diagnosis and treatment of acute and chronic HF.14 A single dose\nof i.v. methylprednisolone should be considered in clinically unstable pa-\ntients with cancer where ICI-induced myocarditis is suspected at pres-\nentation but before deﬁnitive diagnosis can be conﬁrmed.\nFollowing recovery from ICI-associated myocarditis and weaning\nof oral steroid therapy, MDT discussion is recommended to review\nthe decision on whether to restart ICI treatment. This depends on\nvarious factors including the severity of the ICI-associated myocardi-\ntis (fulminant vs. non-fulminant vs. asymptomatic), alternative oncol-\nogy\ntreatment\noptions,\nmetastatic\nvs.\nadjuvant/neoadjuvant\nindication, and reducing from dual ICI to single ICI treatment if trig-\ngered by combination ICI treatment.449\nNon-inﬂammatory HF syndromes have also been observed in pa-\ntients treated with ICI. These include TTS, non-inﬂammatory HF or\nLVD,450 and post-MI HF.451,452 Non-inﬂammatory HF is generally a\nlate event and the diagnostic workﬂow should be based on deﬁning\nthe HF phenotype and excluding myocarditis, TTS, and ACS.14 There\nis also evidence that vasculitis and CAD can occur after ICI treat-\nment.335 HF treatment as per the 2021 ESC Guidelines for the diagno-\nsis and treatment of acute and chronic HF is indicated,14 but there is no\nindication for immunosuppression if myocarditis has been excluded.\nInterruption vs. continuing ICI therapy depends on the severity of\nthe HF syndrome and each case should be reviewed by a MDT.\nArrhythmias, such as AF, can be seen in patients with ICI therapy with-\nout myocarditis (e.g. ICI-associated thyroiditis with thyrotoxicosis,\nICI-associated pericarditis, or ICI-associated severe systemic inﬂamma-\ntory syndromes). ICI treatment can be continued after excluding\nmyocarditis.\nRecommendation Table 26 — Recommendations for\nthe diagnosis and management of immune checkpoint\ninhibitor-associated myocarditis\nRecommendations\nClassa\nLevelb\ncTn, ECG, and CV imaging (echocardiography and\nCMR) are recommended to diagnose\nICI-associated myocarditis.320,434,435,453\nI\nB\nIn patients with suspected ICI-associated\nmyocarditis, temporary interruption of ICI\ntreatment is recommended until the diagnosis is\nconﬁrmed or refuted.\nI\nC\nContinued\nEMB should be considered to conﬁrm the\ndiagnosis of ICI-associated myocarditis if the\ndiagnosis is suspected but not conﬁrmed after\ncardiac imaging and biomarkers.c\nIIa\nC\nInterruption of ICI treatment is recommended in\npatients with conﬁrmed ICI-associated\nmyocarditis.\nI\nC\nContinuous ECG monitoring to assess for new\nAV block and tachyarrhythmias during the acute\nphase is recommended for all patients with\nsymptomatic ICI-associated myocarditis.\nI\nC\nEarly high-dose corticosteroidsd are\nrecommended in patients with cancer and\nconﬁrmed ICI-associated myocarditis.22,436,454\nI\nC\nContinuation of high-dose corticosteroids is\nrecommended for the treatment of ICI-associated\nmyocarditis until resolution of symptoms, LV\nsystolic dysfunction, conduction abnormalities,\nand signiﬁcant cTn reduction.e\nI\nC\nSwitching from i.v. to oral prednisolone should be\nconsidered after clinical improvement (resolution\nof: symptoms, LV systolic dysfunction, conduction\nabnormalities, and signiﬁcant cTn reductione).f\nIIa\nC\nSecond-line immunosuppression treatment\nshould be considered in patients with\nsteroid-refractory ICI-associated myocarditis.g\nIIa\nC\nAdmission to ICU (level 3), treatment with i.v.\nmethylprednisolone, and optimal CV treatment\nincluding mechanical support (when indicated) is\nrecommended for patients with ICI-associated\nfulminant myocarditis.14\nI\nC\nA single dose of i.v. methylprednisoloned should\nbe considered in unstableh patients with cancer\nwhere ICI-induced myocarditis is suspected.\nIIa\nC\nA multidisciplinary discussion is recommended\nbefore restarting ICI treatment in selected\npatients with previous uncomplicated\nICI-associated myocarditis.\nI\nC\n© ESC 2022\nAV, atrioventricular; CMR, cardiac magnetic resonance; cTn, cardiac troponin;\nCV, cardiovascular; ECG, electrocardiogram; EMB, endomyocardial biopsy; HF, heart\nfailure; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous;\nLGE, late gadolinium enhancement; LV, left ventricular; LVD, LV dysfunction; LVEF,\nLV ejection fraction.\naClass of recommendation.\nbLevel of evidence.\ncSee Table 3 for ICI-related myocarditis deﬁnition. EMB should be considered in unstable\npatients or when CMR is contraindicated.\ndEarly: ≤24 h; high-dose corticosteroids (methylprednisolone 500–1000 mg/day).\neReduction of cTn by .50% from peak level.\nfComplete recovery: Patients with complete resolution of acute symptoms,\nnormalization of biomarkers, or reduction of cTn by .50% from peak level and\nrecovery of LVEF after discontinuation of immunosuppression are considered to\nhave achieved complete recovery. CMR may still show LGE or elevated T1 due to\nﬁbrosis but any suggestion of acute oedema should be absent. Incomplete\nrecovery: (1) an increase in symptoms or biomarkers of myocarditis or an inability\nto taper immunosuppression without a clinical or biomarker ﬂare; (2) patients with\npersistent LVD despite resolution of acute symptoms with immunosuppression.\ngSteroid refractory: non-resolving or worsening myocarditis (clinical worsening or\npersistent troponin elevation after exclusion of other aetiologies) despite high-dose\nmethylprednisolone (Table 3; Supplementary data, Table S1).\nhUnstable: patients with symptomatic HF, ventricular arrhythmias, new complete\nheart block.\nESC Guidelines\n4289\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n6.1.4. Chimeric antigen receptor T cell and\ntumour-inﬁltrating lymphocytes therapies and\nheart dysfunction\nAlthough no large-scale studies on the multiple CV complications\namong adults treated with CAR-T therapies exist, small studies\nand case reports have shown that CV complications represent\naround 20% of adverse events.378 CV complications are associated\nwith high mortality rates, and are secondary to CRS and immune ef-\nfector cell-associated neurotoxicity syndrome. The most common\nCV complications in patients receiving CAR-T therapies are arrhyth-\nmias (77.6%), including QTc prolongation, ventricular arrhythmias,\nand AF; HF (14.3%); and MI and VTE (0.5%).455 When suspected, a\nresting 12-lead ECG, continuous ECG monitoring, TTE, and cTn\nand NP are recommended. Admission to ICU (level 3) is recom-\nmended in severe cases due to the risk of malignant cardiac arrhyth-\nmias, circulatory collapse, and multiorgan system failure. In general,\nthe degree of elevation of cytokines correlates with the severity of\nCRS. C-reactive protein is not speciﬁc for CRS and changes in\nC-reactive protein may lag behind clinical changes by ≥12 h. A dra-\nmatic elevation of interleukin-6 is a supportive ﬁnding for the diagno-\nsis of CRS. Management of the speciﬁc CV complication should\nfollow ESC Guidelines, with additional management of the CRS\n(e.g. the anti-interleukin-6 receptor antibody, tocilizumab, and\ndexamethasone).381\nRecovery of function\nMDT\n(Class I)\nN\nDiagnosis and management workup in patients with cancer-r related Ta\nT kotsubo synd\nk\nrome\nAND\nCoronary angiography\n(invasive or CCTA)\nT\nto exclude ACS\n(Class I)\nCMR\nto exclude myocarditis and\nmyocardial infarction\n(Class I)\nAND\nY\nClinical evaluation\nECG\nTTE\nCardiac serum biomarkers\nk\nAND\nInterruption of the\nculprit cancer drug\n(Class I)\nAv\nA oid QT-p\nT rolonging\ndrugs\n(Class III)\nConsider resuming cancer\ntreatment under close\nmonitoring\n(Class I)\nMDT approach regarding\ninterruption vs resuming\nthe culprit cancer drug\nFor ICI-related TTS:\nmethylprednisolone \n(1000 mg i.v.)\nv\nAND\nCCU/HDU/ICU admission\nECG monitoring\nFigure 29 Diagnosis and management workup in cancer-related Takotsubo syndrome. ACS, acute coronary syndromes; CCTA, coronary computed\ntomography angiography; CCU, coronary care unit; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HDU, high-dependency unit; ICI, im-\nmune checkpoint inhibitor; ICU, intensive care unit; i.v., intravenous; MDT, multidisciplinary team; N, no TTE, transthoracic echocardiography; TTS,\nTakotsubo syndrome; Y, yes.\n4290\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nAlthough CV complications are common with TIL therapies, sur-\nvival does not appear to be signiﬁcantly affected. The most frequent\nCV events are hypotension that may require treatment with i.v. ﬂuids\nand pressors, AF, and to a lesser extent, cTn elevation suggestive of\nmyocardial damage.380 Further research is needed to deﬁne mechan-\nisms and potential prevention strategies to help clinicians with the\nmanagement of these CV events.\n6.1.5. Heart failure during haematopoietic stem cell\ntransplantation\nCV complications during HSCT, including congestive HF,456 arterial\nevents, tamponade, and rhythm disturbances (AF, atrial ﬂutter, and\nsupraventricular tachycardia),457 are uncommon but clinically rele-\nvant, and should be treated as per speciﬁc ESC Guidelines (HF,14 ta-\nchyarrhythmias,273,441 pericardial effusion,444 or acute coronary\nsyndrome458). Studies of treatments during HSCT to prevent both\nacute and late CV toxicity are limited.145 ACE-I and beta-blockers\nmay\nbe\neffective,\nbut\nthis\nrequires\nfurther\nconﬁrmation.\nOutpatient and home-based exercise and education programmes in-\nstituted after HSCT can improve exercise capacity and quality of\nlife,459 and the role of exercise pre-habilitation prior to HSCT is\nbeing investigated.460,461\n6.1.6. Takotsubo syndrome and cancer\nThe prevalence of malignant diseases is high in patients with TTS\nand is a risk factor for worse outcomes. Malignancy itself, some\ncancer treatments (5-FU, ICI, VEGFi), and the stress associated\nwith the diagnosis, investigations, and treatment are recognized\ntriggers or predisposing factors for TTS.462–466 Diagnosis using\ngeneral TTS criteria is recommended.467,468 Investigations in a pa-\ntient with cancer with suspected TTS should include clinical exam-\nination, ECG, TTE, cardiac biomarkers (cTn and NP), and CMR\n(Figure 29).468,469 Most patients require invasive coronary angiog-\nraphy to exclude acute MI. In patients with advanced malignancy or\nsigniﬁcant thrombocytopaenia where invasive coronary angiog-\nraphy is contraindicated, a CCTA is recommended. Cardiac im-\naging studies should be performed as early as possible when the\ndiagnosis is suspected as LVD can be transient, and if signiﬁcant\nLVD is detected then repeat imaging to conﬁrm recovery is\nrecommended.\nInterruption of the culprit cancer drug in patients with TTS is re-\ncommended. QT-prolonging drugs should be avoided.467 In cases of\nICI-associated TTS, the role of immunosuppression is unknown and\nif myocardial inﬂammation is present in a TTS pattern on CMR then\ni.v. methylprednisolone is recommended given the overlap between\nICI-induced TTS and ICI-induced myocarditis. Limited information\nexists regarding the feasibility of ICI rechallenge following TTS and\nafter recovery of LV function.\nA MDT discussion is recommended after recovery from the\nacute phase of TTS and, if restarting the culprit cancer drug is re-\nquired from an oncology perspective, regular cardiac biomarker\nmonitoring is recommended (e.g. cTn and NP measured before\nevery ICI cycle, and TTE if a new rise in cardiac biomarkers occurs)\n(Figure 29).\n6.2. Coronary artery disease\n6.2.1. Acute coronary syndromes\nPatients with cancer are at increased risk of CAD because of shared\nCVRFs34 and CV toxicity of cancer therapy12 compounded by a\ncancer-induced\npro-inﬂammatory\nand\nprothrombotic\nstate\n(Table 7).467,468,470–473\nCurrent knowledge on ACS in patients with cancer is based on\nobservational data and registries demonstrating that, especially\nwhen diagnosed within 1 year, they are at increased risk for major\nCV events, bleeding, and cardiac and non-cardiac mortality.474–480\nThe proportion of ACS patients with a diagnosis of cancer is rising\nand constitutes about 3% of large series.475\nDiagnosis of ACS is based on the same principles as in patients\nwithout cancer, including symptoms, an early 12-lead ECG, and serial\nmeasurements of hs-cTn for patients presenting with possible\nnon-ST-segment elevation ACS (NSTE-ACS).458 Clinical presenta-\ntion can be atypical481 or masked by cancer or therapy-related\nside effects; therefore, diagnostic suspicion should be increased in pa-\ntients at high CV risk or treated with vascular cardiotoxic therapies\nRecommendation Table 27 — Recommendations for\nthe diagnosis and management of Takotsubo syn-\ndrome in patients with cancer\nRecommendations\nClassa\nLevelb\nCoronary angiography (invasive or CCTA) is\nrecommended to exclude ACS.\nI\nC\nCMR is recommended to exclude myocarditis and\nMI.458\nI\nB\nQT-prolonging drugs are not recommended\nduring the acute TTS phase.c\nIII\nC\n© ESC 2022\nACS, acute coronary syndromes; CMR, cardiac magnetic resonance; CCTA, coronary\ncomputed tomography angiography; LV, left ventricular; MI, myocardial infarction;\nQTc, corrected QT interval; TTS, Takotsubo syndrome.\naClass of recommendation.\nbLevel of evidence.\ncUntil full recovery and normalization of LV function and QTc.\nTable 7\nCancer treatments that predispose to acute\ncoronary syndromes\nAccelerated atherosclerosis\nand plaque rupture\nADT (GnRH agonists), ICI, nilotinib,\nponatinib, radiation therapy, VEGFi\nVasospasm\nBleomycin, ﬂuoropyrimidines, taxanes,\nVEGFi, vinca alkaloids\nCoronary thrombosis\nAlkylating agents (cisplatin,\ncyclophosphamide), erlotinib, ICI, IMiD\n(lenalidomide, thalidomide), monoclonal\nantibodies (VEGFi, anti-CD20), nilotinib,\nplatinum chemotherapy, PI, ponatinib,\nVEGFi.\n© ESC 2022\nADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; ICI,\nimmune checkpoint inhibitors; IMiD, immunomodulatory drugs; PI, proteasome\ninhibitors; VEGFi, vascular endothelial growth factor inhibitors.\nESC Guidelines\n4291\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n(Table 7). Echocardiography improves the diagnostic precision in pa-\ntients with atypical symptoms and assesses for other cardiac causes\nof chest pain.\nManagement of ACS in patients with cancer can be challenging be-\ncause of frailty, increased bleeding risk, thrombocytopaenia, increased\nthrombotic risk, and the possible need for future surgery/interven-\ntions.482 Cancer treatment should be temporarily interrupted, and\nan urgent multidisciplinary approach5 is indicated to plan an individua-\nlized guideline-based management, taking into account cancer status,\nprognosis, and the patient’s preferences regarding invasive manage-\nment. As in patients without cancer, admission to a monitored unit\nand initiation of appropriate anti-ischaemic and antithrombotic treat-\nment are indicated, in the absence of contraindications.\nA large retrospective propensity score-matching analysis\nfound that percutaneous coronary intervention (PCI), despite\nits lower use, was strongly associated with lower adjusted\nMACE\nand\nall-cause\nmortality\nin\npatients\nwith\ncancer\n(Hodgkin and non-Hodgkin lymphomas and breast, lung, colon,\nand prostate cancers).483 Therefore, immediate coronary angi-\nography and PCI are recommended in patients with cancer\nand ACS if cancer prognosis is ≥6 months or if they have acute\ncomplications of ACS (cardiogenic shock, pulmonary oedema,\nventricular tachyarrhythmias), where PCI offers palliation of\nsymptoms.483\nWhen\nstenting\nis\nindicated,\nthird-generation\ndrug-eluting stents are preferred because of the lower risk of\nin-stent thrombosis. Balloon angioplasty is associated with\nworse outcome474 and should only be used in case of severe\nthrombocytopaenia or need for urgent surgery. Fractional\nﬂow reserve or instantaneous free wave ratio are advised by\nexperts484 to avoid unnecessary interventions while intravascu-\nlar ultrasound and optical coherence tomography can be used\nto ensure optimal stent apposition and expansion, to avoid\nthrombotic complications.485\nRetrospective data have demonstrated a lower use of invasive\nmanagement in patients with cancer with ST-segment elevation MI\n(STEMI), with a better outcome for invasively treated pa-\ntients.475,480,483 PCI has not demonstrated a mortality beneﬁt in pa-\ntients with advanced cancer and NSTE-ACS compared with optimal\nmedical therapy.479 Therefore, a non-invasive approach can be at-\ntempted in low-risk (without signs or symptoms of ongoing ischae-\nmia or haemodynamic instability) NSTE-ACS patients with poor\ncancer prognosis (,6 months).\nDue to a potentially higher bleeding risk (especially in patients with\nactive GI cancer),477 the preferred antithrombotic strategy after\ndrug-eluting stent consists of DAPT with aspirin and clopidogrel in-\nstead of newer P2Y12 antagonists. The duration of DAPT should be\nkept as short as possible (1–3 months).458 In patients with need for\ntherapeutic anticoagulation and antiplatelet therapy, a NOAC and\nsingle oral antiplatelet (preferably clopidogrel) is the default strategy\nafter a short period of triple antithrombotic therapy (up to 1 week in\nhospital).458 Coronary artery bypass graft (CABG) surgery can be\nconsidered in patients with extensive CAD who are not amenable\nwith PCI, after MDT discussion and where cancer prognosis is\n.12 months.\nThrombocytopaenia (platelet count , 100 000/µL) is present in\nabout 10% of patients with cancer and may complicate ACS manage-\nment. Based on a small series, coronary angiography can be safely per-\nformed in these patients when preventative measures to avoid\nbleeding are taken: platelet transfusion before catheterization (for\nplatelets ,20 000/µL), radial access, careful haemostasis, and\nthe use of a lower heparin dose (30–50 U/kg).486 Antiplatelets should\nnot be withheld unless platelet count is ,10 000/µL for aspirin or\n,30 000/µL for clopidogrel. For PCI and CABG, experts advise min-\nimum platelet counts of 30 000/µL and 50 000/µL, respectively.484\nIn case of MI with non-obstructive coronary arteries, CMR may be\nconsidered to detect other causes of myocardial injury, especially\nmyocarditis and TTS.\nWhen acute ischaemia is provoked by cancer therapy, alternative\ncancer therapies should be considered after a MDT discussion. In the\ncase of coronary vasospasm secondary to ﬂuoropyrimidines, and in\nthe absence of an alternative therapy, a rechallenge, although contro-\nversial, can be considered in a monitored unit after exclusion of se-\nvere CAD (CT or coronary angiography) and after initiation of\nprophylactic therapy with long-acting nitrates and calcium channel\nblockers (CCB).487–489\nFollowing ACS, a review of the cancer medications is recom-\nmended, and any cancer drug associated with thrombosis and MI\nshould be stopped. Restarting cancer drugs associated with acute\nthrombosis and MI after ACS (Table 7) should occur only after a\nMDT to explore other cancer therapies, with appropriate patient\neducation and consent. Cancer therapies not associated with MI\ncan be restarted once revascularization, where indicated, has been\ncompleted and the patient is stabilized on ACS medical therapy with-\nout complications.\nRecommendation Table 28 — Recommendations for\nthe management of acute coronary syndromes in pa-\ntients receiving anticancer treatment\nRecommendations\nClassa\nLevelb\nAn invasive strategy is recommended in patients\nwith cancer presenting with STEMI or high-risk\nNSTE-ACS with life expectancy ≥6\nmonths.475,479,483\nI\nB\nA conservative non-invasive strategy should be\nconsidered in patients with poor cancer\nprognosisc (with life expectancy ,6 months) and/\nor very high bleeding risk presenting with STEMI\nor NSTE-ACS.479\nIIa\nC\nA temporary interruption of cancer therapy is\nrecommended in patients where the cancer\ntherapy is suspected as a contributing\ncause.d,10,490\nI\nC\nA short DAPT strategy should be considered in\npatients with cancer with very high bleeding risk\ntreated with PCI for an ACS.e\nIIa\nC\nContinued\n4292\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n6.2.2. Chronic coronary syndromes\nSeveral cancer treatments are associated with an increased risk of\nstable angina and chronic coronary syndromes (CCS).491 5-FU and\ncapecitabine can precipitate effort angina in some cases.4,482,492\nPlatinum-containing chemotherapy-induced ischaemia usually occurs\nafter one of the ﬁrst three cycles and in patients with underlying\nCAD.493 The incidence of cardiac ischaemia is 1–5% with antimicro-\ntubule agents, 2–3% with small-molecule VEGF-TKI, and 0.6–1.5%\nwith VEGFi monoclonal antibody therapies.492 Nilotinib, ponati-\nnib,494 and ICI335 also accelerate atherosclerosis, which can lead to\nstable angina.\nPatients receiving cancer therapy who present with new stable an-\ngina should have careful clinical evaluation, with aggressive CVRF\nmodiﬁcation and an initial medical management of their symp-\ntoms.484 The diagnosis and management of CAD should follow the\n2019 ESC Guidelines for the diagnosis and management of chronic\ncoronary syndromes.100\nThe management of CCS is similar in patients with and with-\nout cancer, in accordance with guideline recommendations.100\nHowever, in the setting of CCS, decisions regarding coronary\nrevascularization should be undertaken by a MDT that includes\ncardio-oncology, intervention, and oncology specialists.5 PCI in\npatients with cancer is associated with an increased risk of\nbleeding, 90-day readmissions for acute MI, in-hospital and long-\nterm mortality, and the need for repeat revascularization, with\nthe magnitude of risk depending on both cancer type and\nstage.495,496 The excess bleeding risk should be mitigated by\nkeeping the duration of DAPT as short as possible.497,498 The\nrisk is higher in patients with a cancer diagnosis within the pre-\nceding year.477\n6.3. Valvular heart disease\nNew or worsening VHD in patients with cancer may be related\nto coexisting conditions, including CTRCD, ACS, PH, endocarditis,\ncardiac tumours, and mechanical prosthetic valve thrombosis.499,500\nPre-existing severe VHD is associated with an increased risk of\nCTRCD,12,501–503 and may also pose a risk for cancer surgery out-\ncomes. In patients with mechanical prosthetic valves, the risk of\nthrombosis vs. bleeding should be carefully balanced during chemo-\ntherapy treatment. In patients with severe VHD diagnosed at base-\nline assessment, a MDT is required before cancer therapy to\ndecide the best treatment option. Cardiac surgery is frequently chal-\nlenging in patients with cancer because of comorbidities, frailty, me-\ndiastinal ﬁbrosis due to prior RT, impaired wound healing, and the\nneed for urgent oncology treatment (surgery, chemotherapy, tar-\ngeted cancer therapies that effect wound healing). Transcatheter\naortic valve implantation (TAVI) may be a viable option for patients\nwith cancer with severe aortic stenosis to limit recovery time and de-\nlays in starting cancer treatment.504–506\nPatients with cancer suspected of new or worsening VHD, such as\ndyspnoea or a new cardiac murmur, or those with fever and positive\nblood cultures, should be screened for endocarditis and managed ac-\ncording to the recommendations from the 2021 ESC/European\nAssociation for Cardio-Thoracic Surgery (EACTS) Guidelines for\nthe management of VHD,507 while considering the cancer-related\nprognosis. If valve surgery or percutaneous valve treatment is indi-\ncated in a patient receiving cancer treatment, then a MDT is recom-\nmended regarding type of valve treatment and periprocedural\nmanagement of cancer treatments.\nIn patients with cancer, thrombocytopaenia,\nand ACS, aspirin is not recommended if platelets\n,10 000/µL.\nIII\nC\nIn patients with cancer, thrombocytopaenia, and\nACS, clopidogrel is not recommended if platelets\n,30 000/µL and prasugrel or ticagrelor are not\nrecommended if platelets ,50 000/µL.\nIII\nC\nTicagrelor or prasugrel may be considered in\npatients with cancer with low bleeding risk and\nexcessive thrombotic risk who are treated with\nPCI for ACS.\nIIb\nC\n© ESC 2022\nACS, acute coronary syndromes; CrCl, creatinine clearance; CV, cardiovascular; DAPT,\ndual\nantiplatelet\ntherapy;\nGI,\ngastrointestinal;\nGU,\ngenitourinary;\nNSTE-ACS,\nnon-ST-segment elevation acute coronary syndromes; PCI, percutaneous coronary\nintervention; STEMI, ST-segment elevation myocardial infarction; ULN, upper limit of\nnormal.\naClass of recommendation.\nbLevel of evidence.\ncRelated to advanced cancer stage and/or severe irreversible non-CV comorbidities.\ndAnticancer therapies associated with high risk of ACS (very common [.10%]):\ncapecitabine, paclitaxel, cisplatin, carﬁlzomib, bevacizumab, ramucirumab, aﬂibercept,\naxitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, ponatinib, erlotinib.\neHigh risk of GI or GU bleeding, signiﬁcant drug–drug interactions, severe renal\ndysfunction (CrCl , 30 mL/min), signiﬁcant liver disease (alanine aminotransferase/\naspartate aminotransferase .2 × ULN), or signiﬁcant thrombocytopaenia (platelet\ncount , 50 000/µL).\nRecommendation Table 29 — Recommendation for\nthe management of chronic coronary syndromes in\npatients receiving anticancer treatment\nRecommendation\nClassa\nLevelb\nIndividualized duration of DAPT is recommended\nin patients with cancer with CCS, following\nrevascularization, based upon thrombotic/\nischaemic and bleeding risk, type and stage of\ncancer, and current cancer treatment.100,498\nI\nC\n© ESC 2022\nCCS, chronic coronary syndromes; DAPT, dual antiplatelet therapy.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 30 — Recommendations for\nthe management of valvular heart disease in patients\nreceiving anticancer treatment\nRecommendations\nClassa\nLevelb\nIn patients with cancer and pre-existing severe\nVHD, management according to the 2021 ESC/\nEACTS Guidelines for the management of VHD is\nrecommended, taking into consideration cancer\nprognosis and patient preferences.507\nI\nC\nContinued\nESC Guidelines\n4293\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n6.4. Cardiac arrhythmias\n6.4.1. Atrial ﬁbrillation\nAF may occur in patients with cancer in different settings: it may be a\nmarker of cancer type or occult cancer, or it may develop in patients\nundergoing surgery, chemotherapy, or RT.508,509 All types of cancer\nshow an increased risk of AF compared with the control group, but\nthe risk of AF depends on the cancer type and stage.510,511 AF during\na cancer treatment may be caused by a speciﬁc therapy or interaction\nwith a pre-existing substrate in older patients with cancer.\nDuring cancer therapy AF may occur with a frequency ranging\nfrom 2% to 16%, according to a variety of factors,4,490,508,512–514\nand may present either as ﬁrst-diagnosed AF or as recurrence of par-\noxysmal AF. The risk of developing AF is greater in patients older\nthan 65 years and/or with pre-existing CVD.4,509,512,515 Cancer sur-\ngery is associated with a variable rate of AF occurrence, with the\nhighest incidence reported for lung surgery, ranging from 6% to\n32%, but with occurrence also in cases of non-thoracic surgery\n(e.g. 4–5% after colectomy).509\nMany anticancer drugs have been associated with an increased risk\nof AF both in terms of incident and recurrent AF (Supplementary\ndata, Table S18).251 AF may occur shortly after treatment516 or\nweeks or months after starting treatment.517,518 The pathophysi-\nology of AF associated with cancer is complex and has been exten-\nsively reviewed elsewhere (Figure 30).509\nIn patients with cancer, the occurrence of AF is associated with a\ntwo-fold higher risk of systemic thromboembolism/stroke and a six-\nfold increase in the risk of HF.4,509,512 The coexistence of cancer in-\ncreases the risk of all-cause mortality, major bleeding, and intracranial\nhaemorrhage in patients with AF. The association between cancer\nand ischaemic stroke differs between cancer types, and in some\ntypes, the risk of bleeding seems to exceed the thromboembolic\nrisk.519 The management of AF in patients with cancer should follow\nthe 2020 ESC Guidelines for the diagnosis and management of atrial\nﬁbrillation273 and the ‘ABC pathway’ (Atrial ﬁbrillation Better Care)\napproach should be applied (A: Anticoagulation to avoid stroke/sys-\ntemic embolism, B: Better symptom control with rate- and/or\nrhythm-control drugs and interventions, and C: Comorbidities and\nCVRF management, including lifestyle changes).273,520\nThe acute management of AF in patients with cancer should con-\nsider electrical cardioversion in cases of haemodynamic instability,521\nwhile in others, the alternative between rate and rhythm control has\nseveral important considerations speciﬁc to patients with cancer.\nDrugs for rhythm control may lead to QT-interval prolongation,369\nfrequently have drug–drug interactions with cancer therapies, or\nmay have a limited efﬁcacy if a cancer therapy is the speciﬁc cause\nof the AF.508 Among rate-control drugs, beta-blockers are preferred,\nespecially if the cancer therapies have potential CTRCD risk, where-\nas diltiazem and verapamil should be avoided where possible due to\ntheir drug–drug interactions and negative inotropic effects.508 The\npossibility of AF ablation should be discussed in selected patients\nwith HF/LVD and/or uncontrolled symptoms, taking into consider-\nation cancer status and prognosis in the context of a MDT\napproach.522\nA complex issue in patients with cancer with new AF is risk strati-\nﬁcation for stroke/systemic embolism, which according to guidelines,\nshould be based on the CHA2DS2-VASc score (Congestive heart fail-\nure, Hypertension, Age ≥75 years [2 points], Diabetes mellitus,\nStroke [2 points]—Vascular disease, Age 65–74 years, Sex category\n[female]).273,523,524 The CHA2DS2-VASc score has not been exten-\nsively validated in patients with cancer.525 In a large cohort of patients\nwith AF, the predictive value of the CHA2DS2-VASc score was lower\nin patients with cancer than in those without, but a progressive in-\ncrease\nin\nthe\nrisk\nof\nischaemic\nstroke\naccording\nto\nthe\nCHA2DS2-VASc score was also found in AF patients with cancer\n(from 0.9% per year to 8.9% per year).519 However, the scope of\nthis score is not to identify high-risk patients, but rather to identify\nlow-risk individuals in whom anticoagulation can be avoided. A study\nbased on the Danish healthcare system data set found that\nCHA2DS2-VASc scores of 0 and 1 in patients with recent cancer\nwere linked with higher risk of stroke/thromboembolism at 2 years\nthan in patients without recent cancer.526 This concept should be\nconsidered in deﬁning the risk/beneﬁt ratio of anticoagulation in indi-\nvidual patients with cancer. Therefore, the decision for anticoagula-\ntion in patients with an active malignancy should take into account\nthe enhanced thrombotic and/or bleeding risk and other risk predic-\ntion scores used for general AF populations.509 For bleeding risk as-\nsessment, the HAS-BLED (Hypertension, Abnormal renal and liver\nfunction, Stroke, Bleeding Labile international normalized ratio,\nElderly, Drugs or alcohol) score may be considered. A proposed ap-\nproach to anticoagulation therapy in cancer, based on the acronym T\n(thrombotic risk), B (bleeding risk), I (interactions among drugs), P\n(patient access and preferences), is outlined in Figure 31.519,527\nLong-term anticoagulation is recommended in adult patients with\nCHA2DS2-VASc score ≥2 in men or ≥3 in women and must be con-\nsidered also when the score is 1 in men and 2 in women.273 The clin-\nical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent,\nlong-standing persistent, permanent, post-operative) should not in-\nﬂuence the indication of thromboprophylaxis.273 The same approach\ncan be proposed for patients with cancer and AF, also considering\nthat the CHA2DS2-VASc score likely underestimates their thrombo-\nembolic risk.530 In the speciﬁc setting of cancer, decision-making on\nlong-term oral anticoagulation should also consider the cancer-\nrelated type, stage, prognosis and the potentially changing thrombo-\nembolic or bleeding risk.508,509 The use of vitamin K antagonists\n(VKA) in cancer is limited by their drawbacks in this setting; however,\nthey remain the only indicated anticoagulants in patients with mod-\nerate to severe mitral stenosis or a mechanical prosthetic valve.\nLMWH constitute a viable short-term anticoagulation option, par-\nticularly in hospitalized patients with a recent cancer diagnosis, ad-\nvanced cancer disease, or during some cancer treatments (e.g.\nIn patients with cancer developing new VHD\nduring cancer therapy, management according to\nthe 2021 ESC/EACTS Guidelines for the\nmanagement of VHD507 is recommended, taking\ninto consideration cancer prognosis and patient\ncomorbidities.\nI\nC\n© ESC 2022\nEACTS, European Association for Cardio-Thoracic Surgery; ESC, European Society of\nCardiology; VHD, valvular heart disease.\naClass of recommendation.\nbLevel of evidence.\n4294\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\npatients receiving myelosuppressive chemotherapy or with recent\nactive bleeding). However, LMWH efﬁcacy for stroke or systemic\nembolism prevention in AF has not been established and their\nuse is only based on their proven efﬁcacy and safety in VTE. The\nuse of a NOAC for AF has not been evaluated in a dedicated\nRCT in patients with cancer. However, secondary analyses of sem-\ninal NOAC trials using direct factor Xa inhibitors (ROCKET AF\n[Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition\nCompared\nwith\nVitamin\nK\nAntagonism\nfor\nPrevention\nof\nStroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE\n[Apixaban for Reduction in Stroke and Other Thromboembolic\nEvents in Atrial Fibrillation], ENGAGE AF-TIMI 48 [Effective\nAnticoagulation with Factor Xa Next Generation in Atrial\nFibrillation–Thrombolysis in Myocardial Infarction 48]) and obser-\nvational data suggest better safety and at least similar effectiveness\nof the NOAC when compared with VKA in patients with AF and\nactive cancer.531–538 NOAC use in cancer is limited by drug–drug\ninteractions,508 severe renal dysfunction, increased risk of bleeding\nin patients with unoperated or residual GI or genitourinary (GU)\nmalignancies, or impaired GI absorption.\nLeft atrial appendage (LAA) occluder devices are used in very se-\nlected patients with cancer in clinical practice. The potential\nPathophysiology of AF associated with cancer\nAF\nin cancer\nAgeing\nCV and metabolic\ncomorbiditiesb\nAnticancer\ntreatmentsa\nCancer\ninvasion\nCancer\nsurgery\nInflammation\nHypoxia\nANS imbalance\nParaneoplastic\nmanifestations\nFigure 30 Pathophysiology of atrial ﬁbrillation associated with cancer. AF, atrial ﬁbrillation; ANS, autonomic nervous system; CV, cardiovascular; DM,\ndiabetes mellitus; HF, heart failure; IHD, ischaemic heart disease; VHD, valvular heart disease. aSupplementary data, Table S18. bObesity, hypertension,\nDM, CVDs (HF, VHD, IHD, cardiomyopathies, cardiac amyloidosis), thyroid diseases, obstructive sleep apnoea, chronic obstructive pulmonary disease,\nchronic kidney disease, autonomic dysfunction, alcohol consumption, genetic predisposition.\nESC Guidelines\n4295\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nThrombocytopaenia\nGI/GU cancer, GI comorbidities, or GI toxicity\nRecent or evolving intracranial lesions\nActive bleeding or recent major bleeding\nSevere renal dysfunction (eGFR <30 mL/min/1.73 m 2)\nBleeding risk scores (e.g., HAS-BLED)\nAssess Bleeding risk:\nCancer-related risk (cancer type and stage, cancer treatment)\nCHA2DS2-VASc score for risk stratiﬁcation (Class IIa)\na\nAssess Thromboembolic risk:\nAnticancer agents\nSupportive therapies\nAssess drug-drug Interactions (P-glycoprotein, CYP3A4):\nAssess Patient preferences and drug availability\nT\nB\nI\nP\nThromboembolic and\nbleeding risk reassessment\n(Class I)\nVery high bleeding riskb\nType of anticoagulant\ntreatment\nLAA oclusionc\n(Class IIb)\nLMWH\n(Class IIa)\nModerate/severe mitral stenosis\nor mechanical prosthetic valve\nPatients suitable\nfor NOACd\nN\nN\nStructured approach to anticoagulation for AF in patients with cancer\nNo anticoagulation\nY\nVKA\n(Class IIa)\nY\nNOAC\n(Class IIa)\nY\nLong-term anticoagulation\naccording to CHA2DS2-VASc score\n≥2 (men) or ≥3 (women) (Class I)\n1 (men) or 2 (women) (Class IIa)\n 0 (men) or 1 (women) (Class IIb)\nN\nFigure 31 Structured approach to anticoagulation for atrial ﬁbrillation in patients with cancer. AF, atrial ﬁbrillation; CHA2DS2-VASc, Congestive heart\nfailure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female); CrCl,\ncreatinine clearance; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal; GU, genitourinary; HAS-BLED, Hypertension, Abnormal renal and\nliver function, Stroke, Bleeding Labile international normalized ratio, Elderly, Drugs or alcohol; LA, left atrial; LAA, left atrial appendage; LMWH,\nlow-molecular-weight heparins; N, no; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonists; Y, yes. aIn selected patients, car-\ndiac imaging parameters related to increased thromboembolic risk should be considered (LAA thrombus, severely dilated left atrium, severely impaired\nLA strain528). bVery high bleeding risk: active or recent major bleeding (,1 month previously); recent/evolving intracranial lesions; platelet count ,25\n000/µL. According to the International Society on Thrombosis and Haemostasis,529 major bleeding is deﬁned as a fall in haemoglobin level ≥2 g/dL and/or\ntransfusion of ≥2 units of red blood cells and/or fatal bleeding and/or bleeding in a critical area (intracranial, intraspinal, intraocular, pericardial,\nintra-articular, intramuscular with compartment syndrome, or retroperitoneal). cPercutaneous left appendage closure may be considered in pa-\ntients with a life expectancy of .1 year who are at high thromboembolic and bleeding risk and in whom anticoagulation is contraindicated. dConditions\nfavouring LMWH: unoperated GI/GU cancer; GI comorbidities or toxicity; severe renal dysfunction (CrCl , 15 mL/min); NOAC major drug–drug\ninteractions, platelet count ,50 000/µL.\n4296\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 54",
          "page": 54,
          "content": "Recommendation | Classa | Levelb\nA specialist CV assessmentc is recommended for\noptimal diagnostic workup and management of\npatients with cancer who present with new CV\ntoxicity during and after cancer treatment.5 | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Asymptomatic patients who have LVEF ≥50%\nand who have developed NP .ULN may be\nconsidered for ACE-I/ARB and/or\nbeta-blockers.d,211 |  | IIb | C | \n | Strategies for restarting anthracycline chemotherapy in\npatients with CTRCD |  |  | \nLiposomal anthracyclinee may be considered in\npatients with moderate or severe symptomatic or\nasymptomatic CTRCDc who require further\nanthracycline chemotherapy to reduce the risk of\nfurther CV toxicity. |  | IIb | C | \nDexrazoxanef may be considered in patients with\nmoderate or severe symptomatic or\nasymptomatic CTRCDc who require further\nanthracycline chemotherapy to reduce the risk of\nfurther CV toxicity. |  | IIb | C | ",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Recommendations |  | Classa | Levelb | \n | Anthracycline chemotherapy-induced symptomatic CTRCD |  |  | \nHF therapy is recommended for patients who\ndevelop symptomatic CTRCD during\nanthracycline chemotherapy.c,208,425 |  | I | B | \nDiscontinuation of anthracycline chemotherapy is\nrecommended in patients who develop\nsymptomatic severe CTRCD.c |  | I | C | \nTemporary interruption of anthracycline\nchemotherapy is recommended in patients who\ndevelop symptomatic moderate CTRCDc and a\nmultidisciplinary approach regarding the decision\nto restart is recommended. |  | I | C | \nA multidisciplinary approach regarding\ninterruption vs. continuation of anthracycline\nchemotherapy is recommended in patients who\ndevelop mild symptomatic CTRCD.c |  | I | C | \n | Anthracycline chemotherapy-induced asymptomatic\nCTRCD |  |  | \nTemporary interruption of anthracycline\nchemotherapy and initiation of HF therapy is\nrecommended in patients who develop\nasymptomatic moderate or severe CTRCD.c,22 |  | I | C | \nA multidisciplinary approach regarding the\ndecision when to restart is recommended in all\npatients with moderate or severe asymptomatic\nCTRCD.c,22 |  | I | C | \nContinuation of anthracycline chemotherapy is\nrecommended in asymptomatic patients who\nhave LVEF ≥50% and who have developed a\nsignificant fall in GLSc or a troponin or a NP\nelevation . ULN. |  | I | C | \nAsymptomatic patients who have LVEF ≥50%\nand who have developed a significant fall in GLSc\nshould be considered for ACE-I/ARB and/or\nbeta-blockers.d,75,93,102 |  | IIa | B | \nAsymptomatic patients who have LVEF ≥50%\nand who have developed a troponin elevation\n.ULN should be considered for ACE-I/ARB and/\nor beta-blockers.d,147,211 |  | IIa | B | ",
          "rows": 12,
          "cols": 5
        },
        {
          "title": "Table on page 58",
          "page": 58,
          "content": "Recommendations |  | Classa | Levelb | \n | HER2-targeted therapy-induced symptomatic CTRCD |  |  | \nHF therapy is recommended for patients who\ndevelop symptomatic moderate-to-severe\nCTRCD with LVEF , 50%c during HER2-targeted\ntreatment.14,61,430,431 |  | I | B | \nTemporary interruption of HER2-targeted\ntreatment is recommended in patients who\ndevelop moderate or severe symptomatic\nCTRCDc and the decision to restart should be\nbased on a multidisciplinary approach after\nimprovement of LV function and symptoms\nresolved.d |  | I | C | \nIn patients who develop mild symptomatic\nCTRCD,c HF therapy and a multidisciplinary\napproach regarding the decision to continue vs.\ninterrupt HER2-targeted therapy are\nrecommended.d,431,432 |  | I | C | \n | HER2-targeted therapy-induced asymptomatic CTRCD |  |  | \nTemporary interruption of HER2-targeted\ntherapy and initiation of HF therapy is\nrecommended in patients who develop\nasymptomatic severe CTRCD.c |  | I | C | \nA multidisciplinary approach regarding the\ndecision to restart HER2-targeted treatment is\nrecommended in patients with severe\nasymptomatic CTRCD.c |  | I | C | \nContinuation of HER2-targeted therapy should be\nconsidered in patients who develop asymptomatic\nmoderate (LVEF 40–49%) CTRCDc with more\nfrequent cardiac monitoring.33,189,428,433 |  | IIa | B | \nContinuation of HER2-targeted therapy is\nrecommended in patients who develop\nasymptomatic mild (LVEF ≥50%) CTRCDc with\nmore frequent cardiac monitoring.428 |  | I | C | \nACE-I/ARB and beta-blockers are recommended\nin patients who develop asymptomatic moderate\n(LVEF 40–49%) CTRCDc during HER2-targeted\ntreatment.e,189 |  | I | C | \nACE-I/ARB and/or beta-blockers should be\nconsidered in asymptomatic patients receiving\nHER2-targeted therapies who have LVEF ≥50%\nbut develop a significant fall in GLSc while\ncontinuing HER2-targeted therapy.e,22,428 |  | IIa | B | ",
          "rows": 12,
          "cols": 5
        },
        {
          "title": "Table on page 61",
          "page": 61,
          "content": "EMB should be considered to confirm the\ndiagnosis of ICI-associated myocarditis if the\ndiagnosis is suspected but not confirmed after\ncardiac imaging and biomarkers.c | IIa | C\nInterruption of ICI treatment is recommended in\npatients with confirmed ICI-associated\nmyocarditis. | I | C\nContinuous ECG monitoring to assess for new\nAV block and tachyarrhythmias during the acute\nphase is recommended for all patients with\nsymptomatic ICI-associated myocarditis. | I | C\nEarly high-dose corticosteroidsd are\nrecommended in patients with cancer and\nconfirmed ICI-associated myocarditis.22,436,454 | I | C\nContinuation of high-dose corticosteroids is\nrecommended for the treatment of ICI-associated\nmyocarditis until resolution of symptoms, LV\nsystolic dysfunction, conduction abnormalities,\nand significant cTn reduction.e | I | C\nSwitching from i.v. to oral prednisolone should be\nconsidered after clinical improvement (resolution\nof: symptoms, LV systolic dysfunction, conduction\nabnormalities, and significant cTn reductione).f | IIa | C\nSecond-line immunosuppression treatment\nshould be considered in patients with\nsteroid-refractory ICI-associated myocarditis.g | IIa | C\nAdmission to ICU (level 3), treatment with i.v.\nmethylprednisolone, and optimal CV treatment\nincluding mechanical support (when indicated) is\nrecommended for patients with ICI-associated\nfulminant myocarditis.14 | I | C\nA single dose of i.v. methylprednisoloned should\nbe considered in unstableh patients with cancer\nwhere ICI-induced myocarditis is suspected. | IIa | C\nA multidisciplinary discussion is recommended\nbefore restarting ICI treatment in selected\npatients with previous uncomplicated\nICI-associated myocarditis. | I | C",
          "rows": 10,
          "cols": 3
        },
        {
          "title": "Table on page 61",
          "page": 61,
          "content": "Recommendations | Classa | Levelb\ncTn, ECG, and CV imaging (echocardiography and\nCMR) are recommended to diagnose\nICI-associated myocarditis.320,434,435,453 | I | B\nIn patients with suspected ICI-associated\nmyocarditis, temporary interruption of ICI\ntreatment is recommended until the diagnosis is\nconfirmed or refuted. | I | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": "Recommendations | Classa | Levelb\nCoronary angiography (invasive or CCTA) is\nrecommended to exclude ACS. | I | C\nCMR is recommended to exclude myocarditis and\nMI.458 | I | B\nQT-prolonging drugs are not recommended\nduring the acute TTS phase.c | III | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": "Accelerated atherosclerosis\nand plaque rupture | ADT (GnRH agonists), ICI, nilotinib,\nponatinib, radiation therapy, VEGFi\nVasospasm | Bleomycin, fluoropyrimidines, taxanes,\nVEGFi, vinca alkaloids\nCoronary thrombosis | Alkylating agents (cisplatin,\ncyclophosphamide), erlotinib, ICI, IMiD\n(lenalidomide, thalidomide), monoclonal\nantibodies (VEGFi, anti-CD20), nilotinib,\nplatinum chemotherapy, PI, ponatinib,\nVEGFi.",
          "rows": 3,
          "cols": 2
        },
        {
          "title": "Table on page 64",
          "page": 64,
          "content": "Recommendations | Classa | Levelb\nAn invasive strategy is recommended in patients\nwith cancer presenting with STEMI or high-risk\nNSTE-ACS with life expectancy ≥6\nmonths.475,479,483 | I | B\nA conservative non-invasive strategy should be\nconsidered in patients with poor cancer\nprognosisc (with life expectancy ,6 months) and/\nor very high bleeding risk presenting with STEMI\nor NSTE-ACS.479 | IIa | C\nA temporary interruption of cancer therapy is\nrecommended in patients where the cancer\ntherapy is suspected as a contributing\ncause.d,10,490 | I | C\nA short DAPT strategy should be considered in\npatients with cancer with very high bleeding risk\ntreated with PCI for an ACS.e | IIa | C",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 65",
          "page": 65,
          "content": "In patients with cancer, thrombocytopaenia,\nand ACS, aspirin is not recommended if platelets\n,10 000/µL. | III | C\nIn patients with cancer, thrombocytopaenia, and\nACS, clopidogrel is not recommended if platelets\n,30 000/µL and prasugrel or ticagrelor are not\nrecommended if platelets ,50 000/µL. | III | C\nTicagrelor or prasugrel may be considered in\npatients with cancer with low bleeding risk and\nexcessive thrombotic risk who are treated with\nPCI for ACS. | IIb | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 65",
          "page": 65,
          "content": "Recommendation | Classa | Levelb\nIndividualized duration of DAPT is recommended\nin patients with cancer with CCS, following\nrevascularization, based upon thrombotic/\nischaemic and bleeding risk, type and stage of\ncancer, and current cancer treatment.100,498 | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 65",
          "page": 65,
          "content": "Recommendations | Classa | Levelb\nIn patients with cancer and pre-existing severe\nVHD, management according to the 2021 ESC/\nEACTS Guidelines for the management of VHD is\nrecommended, taking into consideration cancer\nprognosis and patient preferences.507 | I | C",
          "rows": 2,
          "cols": 3
        }
      ],
      "keywords": [
        "cardiovascular",
        "intervention",
        "ct",
        "acute",
        "monitoring",
        "follow-up",
        "arb",
        "receiving",
        "subacute",
        "management",
        "risk",
        "symptomatic",
        "patients",
        "anticancer",
        "toxicity",
        "treatment",
        "diagnosis"
      ]
    },
    {
      "number": "9",
      "title": "7. End-of-cancer therapy cardiovascular risk assessment",
      "start_page": 81,
      "end_page": 84,
      "content": "7. End-of-cancer therapy\ncardiovascular risk assessment\n7.1. Cardiovascular evaluation during the\nﬁrst year after cardiotoxic anticancer\ntherapy\nEnd-of-cancer therapy CV risk assessment covers the ﬁrst 12\nmonths after the last cardiotoxic cancer treatment. These recom-\nmendations are where cardiotoxic cancer therapy has been success-\nfully\ncompleted\nwith\ngood\nlong-term\nprognosis.\nThese\nrecommendations are not indicated when cancer therapies are dis-\ncontinued due to cancer progression and prognosis is poor, or\nwhere end-of-life care is indicated. Selected patients with cancer\ncontinue on long-term oncology therapies, e.g. women with oestro-\ngen receptor-positive early invasive BC. In this example, the\nend-of-therapy risk assessment refers to the timepoint from the\nlast anthracycline or trastuzumab dose.\nHigh-risk patients can be identiﬁed at completion of their cardio-\ntoxic cancer therapies by their clinical characteristics, history of\nCTR-CVT during treatment, and by elevated cardiac biomarkers\nand/or abnormal CV imaging at follow up.53,54,92 Cardiac serum bio-\nmarkers (NP and cTn) are useful given their high negative predictive\nvalue for future CV events.197,631 In a prospective study of 2625 adult\npatients with cancer that assessed LVEF after anthracycline-based\nchemotherapy, the overall incidence of CTRCD was 9%; 98% of\ncases could be detected within 12 months after chemotherapy and\nthe median time from chemotherapy to CTRCD detection was\n3.5 months (interquartile range 3–6 months).208 The response to\nACE-I treatment declined when the interval between the end of\nchemotherapy and CTRCD detection lengthened; complete LVEF\nrecovery was not observed in patients where treatment was delayed\nby .6 months.425\nMeasurement of cTn after completion of anthracycline chemo-\ntherapy during the end-of-treatment assessment should be consid-\nered. Rises in cTnI after anthracycline chemotherapy identify\npatients at risk of future cardiac dysfunction who then beneﬁt\nfrom CV protection.4 Educating patients with cancer of their poten-\ntial increased CVD risk and supporting them to make appropriate\nhealthy lifestyle choices is recommended. CS should also be advised\nto promptly report early signs and symptoms of possible CVD and\ninform medical teams of their previous cardiotoxic cancer therapies.\nCVRF including hypertension, DM, and dyslipidaemia correlate with\nthe probability of future CV events in CS and should be well con-\ntrolled after completion of cancer therapy.31,632,633\n7.2. Which cancer survivors require\ncardiovascular surveillance in the ﬁrst\nyear after cancer treatment?\nThe end-of-treatment risk assessment ideally identiﬁes those high-risk\nCS, who require long-term CV surveillance, based on the following\ncriteria (Table 10):\n(1) Baseline high or very high risk based on HFA-ICOS risk assess-\nment tools12 (Section 4).\n(2) Cardiotoxic cancer therapy with a high risk of long-term CV\ncomplications7,21 (Section 8).\n(3) Moderate or severe CTR-CVT diagnosed during cancer treat-\nment (Table 3).68\n(4) New abnormalities in cardiac function detected by echocardiog-\nraphy, new elevated cardiac serum biomarkers, or newly CV\nsymptoms detected at the end-of-therapy assessment (3 or 12\nmonths after treatment).68,208\nThe timing of the ﬁrst CV assessment after cardiotoxic cancer\ntreatment depends on the risk deﬁned by baseline CV assessment,\nthe type of cancer therapy, and whether CTR-CVT was diagnosed\nduring treatment.\nIn asymptomatic high-risk patients (Table 10), echocardiography\nand cardiac serum biomarkers are recommended at 3 and 12 months\nafter\ncompletion\nof\ncancer\ntherapy.53,54,59,61,68,148,208,425\nIn\nRecommendation Table 38 — Recommendations for\nthe management of pericardial diseases in patients re-\nceiving anticancer treatment\nRecommendations\nClassa\nLevelb\nGeneral\nDiagnosis and management of acute pericarditis in\npatients with cancer based on the 2015 ESC\nGuidelines for the diagnosis and management of\npericardial diseases is recommended and a\nmultidisciplinary discussion is needed before\ninterrupting cancer therapy.444\nI\nC\nA surgical pericardial window should be\nconsidered if the percutaneous approach is not\nfeasible or in cases of recurrent malignant\npericardial effusions.\nIIa\nC\nIntrapericardial instillation of cytostatic or\nsclerosing agents may be considered for\nprevention of recurrence.\nIIb\nC\nDiagnosis and management of ICI-associated pericarditis\nMultimodality CV imaging (echocardiography,\nCMR + CT), ECG and measurement of cardiac\nbiomarkers are recommended to conﬁrm the\ndiagnosis, assess the haemodynamic\nconsequences of pericardial disease, and rule out\nassociated myocarditis.\nI\nC\nPrednisolone and colchicine are recommended\nfor patients with ICI-associated\npericarditis.326,624,625,630\nI\nC\nInterruption of ICI treatment in patients with\nconﬁrmed ICI-associated pericarditis with\nmoderate-to-severe pericardial effusion is\nrecommended.\nI\nC\nA multidisciplinary discussion is recommended\nbefore restarting ICI treatment.\nI\nC\n© ESC 2022\nCMR, cardiac magnetic resonance; CT, computed tomography; CV, cardiovascular;\nECG, electrocardiogram; ESC, European Society of Cardiology; ICI, immune\ncheckpoint inhibitors.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4309\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nasymptomatic moderate-risk patients (according to CV toxicity\nbaseline risk stratiﬁcation), echocardiography and cardiac serum bio-\nmarkers should be considered within 12 months after completion of\ncancer therapy.53,54,59,61,68,148,208 In asymptomatic low-risk patients\n(according to CV toxicity baseline risk stratiﬁcation), echocardiog-\nraphy and cardiac serum biomarkers may be considered within 12\nmonths after completion of cancer therapy.634\nAll patients started on CV therapies (ACE-I/ARB/angiotensin\nreceptor-neprilysin inhibitors, beta-blockers, mineralocorticoid re-\nceptor antagonists, sodium-glucose co-transporter 2 inhibitors, anti-\nhypertensive medications, antiarrhythmic medications, antiplatelet\ntherapies, statins) for any CTR-CVT (especially CTRCD) should\nhave a clinical assessment, ECG, echocardiography, and cardiac ser-\num biomarkers (if LV systolic dysfunction/HF is a potential risk) at 3,\n6, and 12 months after completing cancer treatment. A MDT-based\napproach to palliative and end-of-life care for patients with cancer\nwith HF or other CTR-CVT should be focused on symptom relief\naccording to general ESC Guidelines.\n7.3. Management of cancer\ntherapy-related cardiac dysfunction at\nthe end-of-therapy assessment\nDuring this end-of-treatment assessment, a review of cardioprotec-\ntive medications initiated during cancer therapy to treat CTRCD is\nrecommended (Figure 37). In selected patients with asymptomatic\nmild or moderate CTRCD who have fully recovered with normal\nTTE and cardiac serum biomarkers, a trial of weaning off CV\nmedication should be considered after MDT discussion. This is\nmost common after asymptomatic mild or moderate CTRCD sec-\nondary to trastuzumab, particularly in younger otherwise healthy\nHER2+ BC survivors with no exposure to anthracycline chemother-\napy. Further assessment of cardiac function with TTE and cardiac\nserum biomarkers is recommended following withdrawal of CV\nmedication in patients with previous CTRCD to ensure cardiac func-\ntion remains normal.\nContinuing long-term CV medication is generally recommended\nin patients with moderate and severe symptomatic or severe asymp-\ntomatic CTRCD due to the high rate of recurrent HF. Long-term\ntreatment is also recommended in CS with mild or moderate\nCTRCD who fail to recover normal LV function at their\nend-of-therapy assessment (Figure 37).\n7.4. Cardiopulmonary exercise testing\nand ﬁtness during the end-of-therapy\nassessment\nCRF impairment is a strong predictor of patient outcome following\ncancer treatment and an intervention target in CS. Low CRF is asso-\nciated with poor quality of life, increased morbidity, reduced exercise\ncardiac function and worse CVD risk proﬁle, and is a robust inde-\npendent predictor of all-cause, cancer-related, and CVD-related\nmortality in CS.119,120 Recent evidence suggests the risk of\nCVD-related mortality in CS decreases by 14% per 1 metabolic\nequivalent (3.5 mL O2/kg/min) increase in CRF.120\nCPET may be considered for CS with exertional limitation, who\nmay have substantial beneﬁt from cardiac rehabilitation. Eligible pa-\ntients include those treated with higher doses of anthracycline\nchemotherapy and/or RT to a volume including the heart, high CV\ntoxicity risk at baseline, patients who developed CTRCD during can-\ncer therapy, and those identiﬁed with new abnormalities in LV func-\ntion at their end-of-therapy assessment.11 CPET can be an objective\ntool in the diagnosis of decreased physical capacity and identify CV vs.\nnon-CV causes.635\n7.5. The role of cardiac rehabilitation\nExercise is a potent multitargeted therapy that prevents and\ntreats multiple competing mechanisms of CTR-CVT in CS, includ-\ning CRF impairment,636 CV injury, and pre-existing and new\nCVRF.137 Prescribing exercise facilitates the delivery of therapeut-\nic exercise that is individualized to a person’s ﬁtness level and sys-\ntematically progressed to optimize physiological adaptation.637\nCurrent evidence demonstrates that supervised exercise therapy\n(including high-intensity interval training [HIIT]) is safe and well\ntolerated,638 attenuates CTR-CVT risk, and improves CRF.\nFurthermore, HIIT reduces CVRF460 and CV risk639 in patients\nTable 10\nRisk factors for future cardiovascular dis-\nease at the end-of-cancer therapy cardiovascular risk\nassessment\nHigh-risk conditions\nHigh- and very-high baseline CV toxicity risk based on HFA-ICOS\nassessment\nSpeciﬁc anticancer treatment proven to have a high risk of long-term CV\ncomplicationsa\nDoxorubicinb ≥250 mg/m2\nRT . 15 Gy MHDc\nBoth doxorubicinb ≥100 mg/m2 and RT 5–15 Gy MHDd\nHigh-risk HSCT patientse\nModerate or severe CTR-CVT during cancer treatment (especially\nCTRCD), ICI-related myocarditis, cardiac arrhythmias, or severe vascular\ntoxicities (ACS, stroke, PVD)\nNew CV symptoms or new asymptomatic abnormalities in\nechocardiography and/or cardiac serum biomarkers at the end of therapy\nassessment\n© ESC 2022\nACS, acute coronary syndromes; CTRCD, cancer therapy-related cardiac dysfunction;\nCTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD,\ncardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host\ndisease; Gy, Gray; HFA, Heart Failure Association; HSCT, haematopoietic stem cell\ntransplantation;\nICI,\nimmune\ncheckpoint\ninhibitors;\nICOS,\nInternational\nCardio-Oncology Society; MHD, mean heart dose; PVD, peripheral vascular disease;\nRT, radiotherapy.\naRT risk categorization based on MHD is recommended over categorization based on\nprescribed dose, which may not accurately reﬂect cardiac radiation exposure.\nDepending on dose distribution and exposure of speciﬁc cardiac substructures (as\nwell as clinical risk factors), the treatment team may judge the patient to belong to a\nhigher risk category. In addition, a patient may be judged to belong to a lower risk\ncategory if only a small part of the heart is exposed to a relatively high prescribed\ndose (i.e. RT to left breast or left chest wall only).\nbOr doxorubicin equivalent.\ncOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available.\ndOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available.\neHigh-risk HSCT patients: allogenic HSCT; pre-existing CVD or multiple uncontrolled\nCVRF; cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating\nagents, .250 mg/m2 doxorubicin or equivalent); conditioning schemes (total body\nirradiation, alkylating agents); development of GVHD.\n4310\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nwith cancer in the pre-, active-, and post-treatment settings.\nHIIT-related beneﬁts on CRF, physical activity behaviour, fatigue,\nand quality of life persist months post-intervention.640,641 HIIT\nmay not be feasible in elderly and frail patients.642 Dedicated\ncardio-oncology rehabilitation programmes are currently under\ndevelopment.11\nCTRCD\nMild or moderate\nPartial or nonea\nFullb\nHigh riskdk\nLow riskek\nMDT to consider\nweaning HF therapy\np c\nRecovery\nPatient risk\nSevere and very severe\nN\nPatients who develop CTRCD during cancer treatment and are being started on HF therapy\np\nY\nContinue HF therapy\np\n(Class I)\nContinue\nHF therapy\np\n(Class I)\nConsider weaning\nHF therapy\np\n(Class IIa)\nFigure 37 Management of cancer therapy-related cardiac dysfunction after cancer therapy. CTRCD, cancer therapy-related cardiac dysfunction; CV,\ncardiovascular; GLS, global longitudinal strain; HF, heart failure; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; LV, left\nventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; N, no; Y, yes. aPartial or no recovery: patients who do not\nmeet all of the criteria for full recovery. bFull recovery: no signs or symptoms of HF + LVEF . 50% + GLS within normal range or similar to baseline\nmeasurements + cardiac serum biomarkers within the normal range or similar to baseline measurements cThe CTRCD trajectory of each patient is\nunique and dynamic and withdrawal of HF therapy requires a MDT to consider several key points that help to stratify patients into low- or high-risk\ncategories. Key points to consider during a MDT discussion are: HFA-ICOS baseline CV toxicity risk assessment, pre-existing indications for\nCV medication, class of cancer treatment causing CTRCD (generally reversible vs. generally irreversible), magnitude and duration of CTRCD before re-\ncovery, intensity of HF therapy needed to recover LV function, family history of cardiomyopathy or known cardiomyopathy gene carrier (see Section 4.8).\ndSee Table 10. eLow-risk patient characteristics: low to moderate baseline CV toxicity risk (HFA-ICOS risk assessment), no pre-existing indications\nfor CV medication, cancer treatment generally associated with reversible myocardial damage, asymptomatic mild CTRCD, early cardiac function recovery\n(3–6 months) under HF therapy, no family history of cardiomyopathy.\nESC Guidelines\n4311\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n8. Long-term follow-up and\nchronic cardiovascular\ncomplications in cancer survivors\n8.1. Cancer survivors\n8.1.1. Adult survivors of childhood and adolescent\ncancer\nThe survival of children and adolescents with cancer has increased\nconsiderably in recent decades, with 5-year survival rates currently\nexceeding 80%.647 However, the long-term health effects in the\ngrowing population of childhood and adolescent CS are a major con-\ncern.648 CTR-CVT, as a consequence of treatment with anthracy-\nclines, mitoxantrone, and/or chest-directed RT can manifest as\nCTRCD but also as VHD, CAD, arrhythmias, autonomic dysfunc-\ntion, pericardial disease, and premature CV mortality, depending\non the type of cardiotoxic treatment.643,649\nCTRCD is one of the most frequent late effects in childhood CS\nwho received cardiotoxic cancer treatment and contributes to sig-\nniﬁcant morbidity and non-cancer-related mortality later in life.650\nThe cumulative incidence of CTRCD varies depending on the diag-\nnostic criteria applied and the population studied and ranges from\n4.8% to 10.6% at 40–45 years of age.651 RT to a ﬁeld involving the\nheart increases the risk of CTRCD and valvular and vascular\ncomplications.652\nFollow-up of paediatric CS according to the International Late\nEffects of Childhood Cancer Guideline Harmonization Group is re-\ncommended.653 This includes risk stratiﬁcation based upon the total\ncumulative dose of anthracycline chemotherapy and MHD delivered\n(Table 11). Annual review of CVRF and education to promote a\nhealthy lifestyle is recommended. The frequency of CV review\nwith TTE depends upon risk. A CV review should be considered\nevery 5 years for moderate-risk childhood and adolescent adult CS\nand every 2 years for high-risk childhood and adolescent adult CS.\nA recent retrospective analysis has shown that quantiﬁcation of\nLVEF .5 years after cancer diagnosis improves long-term childhood\nRecommendation Table 39 — Recommendations for\nend-of-cancer therapy cardiovascular risk assessment\nRecommendations\nClassa\nLevelb\nEducating and supporting patients with cancer to\nmake appropriate healthy lifestyle choices is\nrecommended.c\nI\nC\nEducation is recommended for patients with\ncancer regarding recognition for early signs and\nsymptoms of CVD.\nI\nC\nCVRF assessment is recommended during the\nﬁrst year after cancer therapyc,12,22,31,632,643 and\nthereafter according to the 2021 ESC Guidelines\non CVD prevention in clinical practice.19\nI\nB\nIn asymptomatic high-risk patients,d\nechocardiography and cardiac serum biomarkers\nare recommended at 3 and 12 months after\ncompletion of cancer\ntherapy.53,54,59,61,68,148,208,425\nI\nB\nIn asymptomatic moderate-risk patients,e\nechocardiography and cardiac serum biomarkers\nshould be considered within 12 months after\ncompletion of cancer therapy.53,54,59,61,68,148,208\nIIa\nB\nIn asymptomatic low-risk patients,e\nechocardiography and cardiac serum biomarkers\nmay be considered within 12 months after\ncompletion of cancer therapy.634\nIIb\nC\nCardiology referralf is recommended in patients\nwith cancer with new cardiac symptoms or new\nasymptomatic abnormalities in echocardiography\nand/or cardiac serum biomarkers at the end of\ntherapy assessment.11\nI\nC\nIn selected patients with exercise intolerance\npersisting at 12 months after cancer treatment\nand with normal resting echocardiogram and\ncardiac biomarkers, exercise stress\nechocardiography and/or CPET may be\nconsidered.\nIIb\nC\nTargeted cardiac rehabilitation should be\nconsidered in CS with high CV risk.638–640\nIIa\nB\nLong-term continuation of cardiac medication is\nrecommended in patients who develop severe\nCTRCD during cancer therapy.\nI\nC\nCV follow-up and treatment optimization is\nrecommended in patients who developed\nTKI-mediated hypertension during cancer\ntherapy.644,645\nI\nC\nCV follow-up and treatment optimization is\nrecommended in patients who developed vascular\ntoxicities during cancer therapy.10,237\nI\nC\nContinued\nECG follow-up is recommended in patients who\ndeveloped QT lengthening or LQTS during cancer\ntherapy.646\nI\nC\n© ESC 2022\nCPET, cardiopulmonary exercise testing; CS, cancer survivors; CTRCD, cancer\ntherapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease;\nCVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram;\nESC, European Society of Cardiology; LQTS, long QT syndrome; TKI, tyrosine kinase\ninhibitors.\naClass of recommendation.\nbLevel of evidence.\ncIncluding regulation of hypertension, DM, dyslipidaemia, smoking cessation, weight loss\nin case of obesity, and an adequate amount of exercise.\ndHigh-risk patients: see Table 10.\neModerate- or low-risk patients: according to CV toxicity baseline risk stratiﬁcation.\nfCardio-oncology referral is recommended when available; alternatively, the patient\nshould be referred to a cardiologist with expertise in managing CVD in patients with\ncancer.\n4312\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 81",
          "page": 81,
          "content": "Recommendations |  | Classa | Levelb | \n | General |  |  | \nDiagnosis and management of acute pericarditis in\npatients with cancer based on the 2015 ESC\nGuidelines for the diagnosis and management of\npericardial diseases is recommended and a\nmultidisciplinary discussion is needed before\ninterrupting cancer therapy.444 |  | I | C | \nA surgical pericardial window should be\nconsidered if the percutaneous approach is not\nfeasible or in cases of recurrent malignant\npericardial effusions. |  | IIa | C | \nIntrapericardial instillation of cytostatic or\nsclerosing agents may be considered for\nprevention of recurrence. |  | IIb | C | \n | Diagnosis and management of ICI-associated pericarditis |  |  | \nMultimodality CV imaging (echocardiography,\nCMR + CT), ECG and measurement of cardiac\nbiomarkers are recommended to confirm the\ndiagnosis, assess the haemodynamic\nconsequences of pericardial disease, and rule out\nassociated myocarditis. |  | I | C | \nPrednisolone and colchicine are recommended\nfor patients with ICI-associated\npericarditis.326,624,625,630 |  | I | C | \nInterruption of ICI treatment in patients with\nconfirmed ICI-associated pericarditis with\nmoderate-to-severe pericardial effusion is\nrecommended. |  | I | C | \nA multidisciplinary discussion is recommended\nbefore restarting ICI treatment. |  | I | C | ",
          "rows": 10,
          "cols": 5
        },
        {
          "title": "Table on page 84",
          "page": 84,
          "content": "Recommendations | Classa | Levelb\nEducating and supporting patients with cancer to\nmake appropriate healthy lifestyle choices is\nrecommended.c | I | C\nEducation is recommended for patients with\ncancer regarding recognition for early signs and\nsymptoms of CVD. | I | C\nCVRF assessment is recommended during the\nfirst year after cancer therapyc,12,22,31,632,643 and\nthereafter according to the 2021 ESC Guidelines\non CVD prevention in clinical practice.19 | I | B\nIn asymptomatic high-risk patients,d\nechocardiography and cardiac serum biomarkers\nare recommended at 3 and 12 months after\ncompletion of cancer\ntherapy.53,54,59,61,68,148,208,425 | I | B\nIn asymptomatic moderate-risk patients,e\nechocardiography and cardiac serum biomarkers\nshould be considered within 12 months after\ncompletion of cancer therapy.53,54,59,61,68,148,208 | IIa | B\nIn asymptomatic low-risk patients,e\nechocardiography and cardiac serum biomarkers\nmay be considered within 12 months after\ncompletion of cancer therapy.634 | IIb | C\nCardiology referralf is recommended in patients\nwith cancer with new cardiac symptoms or new\nasymptomatic abnormalities in echocardiography\nand/or cardiac serum biomarkers at the end of\ntherapy assessment.11 | I | C\nIn selected patients with exercise intolerance\npersisting at 12 months after cancer treatment\nand with normal resting echocardiogram and\ncardiac biomarkers, exercise stress\nechocardiography and/or CPET may be\nconsidered. | IIb | C\nTargeted cardiac rehabilitation should be\nconsidered in CS with high CV risk.638–640 | IIa | B\nLong-term continuation of cardiac medication is\nrecommended in patients who develop severe\nCTRCD during cancer therapy. | I | C\nCV follow-up and treatment optimization is\nrecommended in patients who developed\nTKI-mediated hypertension during cancer\ntherapy.644,645 | I | C\nCV follow-up and treatment optimization is\nrecommended in patients who developed vascular\ntoxicities during cancer therapy.10,237 | I | C",
          "rows": 13,
          "cols": 3
        }
      ],
      "keywords": [
        "cardiovascular",
        "moderate",
        "ct",
        "prognosis",
        "cancer",
        "assessment",
        "risk",
        "severe",
        "treatment",
        "imaging",
        "therapy",
        "recommendation"
      ]
    },
    {
      "number": "10",
      "title": "8. Long-term follow-up and chronic cardiovascular complications in cancer survivors",
      "start_page": 84,
      "end_page": 91,
      "content": "8. Long-term follow-up and\nchronic cardiovascular\ncomplications in cancer survivors\n8.1. Cancer survivors\n8.1.1. Adult survivors of childhood and adolescent\ncancer\nThe survival of children and adolescents with cancer has increased\nconsiderably in recent decades, with 5-year survival rates currently\nexceeding 80%.647 However, the long-term health effects in the\ngrowing population of childhood and adolescent CS are a major con-\ncern.648 CTR-CVT, as a consequence of treatment with anthracy-\nclines, mitoxantrone, and/or chest-directed RT can manifest as\nCTRCD but also as VHD, CAD, arrhythmias, autonomic dysfunc-\ntion, pericardial disease, and premature CV mortality, depending\non the type of cardiotoxic treatment.643,649\nCTRCD is one of the most frequent late effects in childhood CS\nwho received cardiotoxic cancer treatment and contributes to sig-\nniﬁcant morbidity and non-cancer-related mortality later in life.650\nThe cumulative incidence of CTRCD varies depending on the diag-\nnostic criteria applied and the population studied and ranges from\n4.8% to 10.6% at 40–45 years of age.651 RT to a ﬁeld involving the\nheart increases the risk of CTRCD and valvular and vascular\ncomplications.652\nFollow-up of paediatric CS according to the International Late\nEffects of Childhood Cancer Guideline Harmonization Group is re-\ncommended.653 This includes risk stratiﬁcation based upon the total\ncumulative dose of anthracycline chemotherapy and MHD delivered\n(Table 11). Annual review of CVRF and education to promote a\nhealthy lifestyle is recommended. The frequency of CV review\nwith TTE depends upon risk. A CV review should be considered\nevery 5 years for moderate-risk childhood and adolescent adult CS\nand every 2 years for high-risk childhood and adolescent adult CS.\nA recent retrospective analysis has shown that quantiﬁcation of\nLVEF .5 years after cancer diagnosis improves long-term childhood\nRecommendation Table 39 — Recommendations for\nend-of-cancer therapy cardiovascular risk assessment\nRecommendations\nClassa\nLevelb\nEducating and supporting patients with cancer to\nmake appropriate healthy lifestyle choices is\nrecommended.c\nI\nC\nEducation is recommended for patients with\ncancer regarding recognition for early signs and\nsymptoms of CVD.\nI\nC\nCVRF assessment is recommended during the\nﬁrst year after cancer therapyc,12,22,31,632,643 and\nthereafter according to the 2021 ESC Guidelines\non CVD prevention in clinical practice.19\nI\nB\nIn asymptomatic high-risk patients,d\nechocardiography and cardiac serum biomarkers\nare recommended at 3 and 12 months after\ncompletion of cancer\ntherapy.53,54,59,61,68,148,208,425\nI\nB\nIn asymptomatic moderate-risk patients,e\nechocardiography and cardiac serum biomarkers\nshould be considered within 12 months after\ncompletion of cancer therapy.53,54,59,61,68,148,208\nIIa\nB\nIn asymptomatic low-risk patients,e\nechocardiography and cardiac serum biomarkers\nmay be considered within 12 months after\ncompletion of cancer therapy.634\nIIb\nC\nCardiology referralf is recommended in patients\nwith cancer with new cardiac symptoms or new\nasymptomatic abnormalities in echocardiography\nand/or cardiac serum biomarkers at the end of\ntherapy assessment.11\nI\nC\nIn selected patients with exercise intolerance\npersisting at 12 months after cancer treatment\nand with normal resting echocardiogram and\ncardiac biomarkers, exercise stress\nechocardiography and/or CPET may be\nconsidered.\nIIb\nC\nTargeted cardiac rehabilitation should be\nconsidered in CS with high CV risk.638–640\nIIa\nB\nLong-term continuation of cardiac medication is\nrecommended in patients who develop severe\nCTRCD during cancer therapy.\nI\nC\nCV follow-up and treatment optimization is\nrecommended in patients who developed\nTKI-mediated hypertension during cancer\ntherapy.644,645\nI\nC\nCV follow-up and treatment optimization is\nrecommended in patients who developed vascular\ntoxicities during cancer therapy.10,237\nI\nC\nContinued\nECG follow-up is recommended in patients who\ndeveloped QT lengthening or LQTS during cancer\ntherapy.646\nI\nC\n© ESC 2022\nCPET, cardiopulmonary exercise testing; CS, cancer survivors; CTRCD, cancer\ntherapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease;\nCVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram;\nESC, European Society of Cardiology; LQTS, long QT syndrome; TKI, tyrosine kinase\ninhibitors.\naClass of recommendation.\nbLevel of evidence.\ncIncluding regulation of hypertension, DM, dyslipidaemia, smoking cessation, weight loss\nin case of obesity, and an adequate amount of exercise.\ndHigh-risk patients: see Table 10.\neModerate- or low-risk patients: according to CV toxicity baseline risk stratiﬁcation.\nfCardio-oncology referral is recommended when available; alternatively, the patient\nshould be referred to a cardiologist with expertise in managing CVD in patients with\ncancer.\n4312\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCS risk stratiﬁcation. A LVEF of 40–49% is associated with an almost\neight-fold increased risk for LVEF ,40% at 10-year follow-up com-\npared with patients with a preserved LVEF (≥50%).654 Lifelong sur-\nveillance for high-risk survivors is recommended.7\n8.1.2. Adult cancer survivors\nLong-term cancer survivorship care is an advancing ﬁeld of research.\nMany survivors will experience several cancer- and treatment-related\nlate effects throughout their lives, including CTR-CVT. Besides affect-\ning their physical and psychosocial health status, these might reduce\nlife expectancy and quality of life. This is relevant in some cancer types,\nwhen CVD risk—especially CTRCD risk—exceeds cancer mortal-\nity.658,659 The risk of fatal heart disease is increased more than two-\nfold in survivors of several solid cancers and lymphoma compared\nwith the general population.660–662\nCV risk assessment at the end of therapy (Section 7) identiﬁes CS\nwho require long-term cardiology follow-up beyond the ﬁrst 12\nmonths after completing their cancer treatment. Asymptomatic\nCS with new or persisting abnormalities at their end-of-therapy as-\nsessment will be identiﬁed as at high risk for future CV events and\nrequire long-term surveillance.\nSpeciﬁc cancer treatments carry the highest risk of long-term CV\ntoxicity including anthracycline chemotherapy and RT where the\nheart is within the RT treatment volume. Progressive RT-related\nCV toxicity typically develops 5–10 years after the initial treatment,\nand may cause CAD and HF at an incidence up to six-fold higher than\nin the general population. An increased CV mortality compared with\nthe general population has been attributed to radiation-associated\nheart disease in Hodgkin lymphoma, non-Hodgkin lymphoma, BC,\nand patients with lung cancer.663–665 The incidence and progression\nof the radiation-related CV complications depends on the dose to\nthe CV tissue and on concomitant cancer therapies and patient char-\nacteristics, such as pre-existing CVD, CVRF, and age.389,400\nLate CV complications are also observed in CS who required HSCT.\nThe incidence of HF increases up to 14.5% in women 15 years after\nHSCT. Risk factors for CVD following HSCT include age, anthracycline\ndose, chest radiation exposure, hypertension, DM, and smoking.666\nLong-term follow-up surveillance, based on CV toxicity risks\n(Table 12), includes patient education and CVRF optimization. An an-\nnual clinical CV risk assessment is recommended for all adult CS to\noptimize CVRF control, promote a healthy lifestyle, and symptom re-\nview. This can be done in collaboration with primary care or a\nTable 11\nRisk categories for asymptomatic adults who are childhood and adolescent cancer survivors\nRisk category\nRT dosea (Gy MHD)\nTotal cumulative doxorubicinb\ndose (mg/m2)\nCombination therapy\nRT dosea (Gy MHD)\nTotal cumulative doxorubicinb\ndose (mg/m2)\nVery high risk\n.25c\n≥400\n.15c\n≥100\nHigh risk\n.15 to 25c\n250–399\n5–15d\n≥100\nModerate risk\n5–15d\n100–249\n,5e\n≥100\nLow risk\n,5e\n,100\n–\n© ESC 2022\nGy, Gray; MHD, mean heart dose; RT, radiotherapy.\naRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately reﬂect cardiac radiation exposure. Depending on dose\ndistribution and exposure of speciﬁc cardiac substructures (as well as clinical risk factors), the treatment team may judge the patient to belong to a higher risk category. In addition, a\npatient may be judged to belong to a lower risk category if only a small part of the heart is exposed to a relatively high prescribed dose.\nbOr doxorubicin equivalent.\ncOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available. Note that in this case, the limited information about cardiac exposure does not allow one to distinguish\nbetween high- and very high-risk categories.\ndOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available.\neOr prescribed RT , 15 Gy to a volume exposing the heart if MHD is not available.\nRecommendation Table 40 — Recommendations for\ncardiovascular surveillance in asymptomatic adults\nwho are childhood and adolescent cancer survivors\nRecommendations\nClassa\nLevelb\nEducation of adults who are childhood and\nadolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding\ntheir increased CV risk is recommended.655–657\nI\nB\nAnnual screening for modiﬁable CVRFc is\nrecommended in adults who are childhood and\nadolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including\nthe heart.\nI\nC\nCV assessmentd is recommended in female\nchildhood and adolescent CS prior to pregnancy\nor in the ﬁrst trimester.\nI\nC\nEchocardiography surveillance should be\nconsidered every 2 years in adults who are\nhigh-risk childhood and adolescente CS.7\nIIa\nB\nEchocardiography surveillance should be\nconsidered every 5 years in adults who are\nmoderate-risk childhood and adolescente CS.7,654\nIIa\nB\n© ESC 2022\nBP, blood pressure; CS, cancer survivors; CV, cardiovascular; CVRF, cardiovascular risk\nfactors; DM, diabetes mellitus; ECG, electrocardiogram; HbA1c, glycated haemoglobin;\nRT, radiotherapy; TTE, transthoracic echocardiography.\naClass of recommendation.\nbLevel of evidence.\ncObesity, sedentary lifestyle, cigarette smoking, alcohol intake, unhealthy diet,\ndyslipidaemia, hypertension, DM.\ndBP, lipids, fasting glucose, HbA1c, ECG, and TTE.\neSee Table 11.\nESC Guidelines\n4313\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nspecialist in CV medicine with expertise in CVRF management. CS at\nhigh or very high risk of future CVD can be divided into those at high\nearly risk (within 5 years of completing cancer therapy) and those at\nhigh late risk (.30 years from completing treatment). The timing and\nfrequency of other complementary tests depends upon the risk for\nCTR-CVT (Figure 38).\nCS with a high or very high baseline risk and patients with abnormal\nLV function at the end-of-therapy assessment have a high or very high\nearly risk, particularly in the ﬁrst 2 years.61,667,668 Annual CV assess-\nment with clinical examination, ECG, and NP measurement is recom-\nmended in CS. TTE should be considered at years 1, 3, and 5 after\ncompletion of cardiotoxic cancer therapy and every 5 years thereafter\nin asymptomatic very high- and early high-risk adult CS.\nIn adult CS with late high CTR-CVT risk (e.g. young adults with\nHodgkin lymphoma or sarcomas who received a high total cumula-\ntive anthracycline dose or patients treated with high-dose radiation\nto a ﬁeld involving the heart, e.g. Mantle RT) there is a progressive\nrisk of CTRCD.661,669 Annual CV assessment with clinical examin-\nation, ECG, and NP measurement is recommended, starting 5 years\nafter the end of treatment, provided the end-of-therapy assessment\nat 12 months is normal. TTE should also be considered every 5 years,\nas well as non-invasive screening for CAD (Section 8.3) and carotid\ndisease (Section 8.5) according to local protocols.670\nThe long-term effects of CTRCD caused by trastuzumab and\nother targeted cancer therapies (e.g. TKI) beyond 10 years are un-\nknown. Currently, there is no recommendation for lifelong surveil-\nlance in these CS unless they have another indication.\nCV assessment with clinical examination, ECG, echocardiography,\nand NP measurement every 5 years should be considered in asymp-\ntomatic adult CS at moderate risk of future CTR-CVT and a normal\nend-of-therapy CV assessment.\nTable 12\nRisk categories for asymptomatic adult can-\ncer survivors\nRisk categorya\nPatient characteristics\nVery high risk\n• Very high baseline CV toxicity risk\npre-treatment\n• Doxorubicinb ≥400 mg/m2\n• RT . 25 Gy MHDc\n• RT . 15–25 Gy MHDc + doxorubicinb\n≥100 mg/m2\nEarly high risk\n(,5 years after\ntherapy)\n• High baseline CV toxicity risk\n• Symptomatic or asymptomatic\nmoderate-to-severe CTRCD during\ntreatment\n• Doxorubicinb 250–399 mg/m2\n• High-risk HSCTd\nLate high risk\n• RT . 15–25 Gy MHDc\n• RT 5–15 Gy MHDe + doxorubicinb\n≥100 mg/m2\n• Poorly controlled CVRF\nModerate risk\n• Moderate baseline CV toxicity risk\n• Doxorubicinb 100–249 mg/m2\n• RT 5–15 Gy MHDe\n• RT , 5 Gy MHDf + doxorubicinb ≥100 mg/\nm2\nLow risk\n• Low baseline CV toxicity risk and normal\nend-of-therapy cardiac assessment\n• Mild CTRCD during therapy but recovered by\nthe end of cancer therapy\n• RT , 5 Gy MHDf\n• Doxorubicinb , 100 mg/m2\n© ESC 2022\nCTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD,\ncardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host\ndisease; Gy, Gray; HSCT, haematopoietic stell cell transplantation; MHD, mean heart\ndose; RT, radiotherapy. References:397,399,400,673,674\naRT risk categorization based on MHD is recommended over categorization based on\nprescribed dose, which may not accurately reﬂect cardiac radiation exposure.\nDepending on dose distribution and exposure of speciﬁc cardiac substructures (as well\nas clinical risk factors), the treatment team may judge the patient to belong to a higher\nrisk category. In addition, a patient may be judged to belong to a lower risk category in\ncase only a small part of the heart is exposed to a relatively high prescribed dose.\nbOr equivalent.\ncOr prescribed RT≥35 Gy to a volume exposing the heart if MHD is not available. Note\nthat in this case, the limited information about cardiac exposure does not allow one to\ndistinguish between high- and very high-risk categories.\ndHigh-risk HSCT patients: allogenic HSCT; pre-existing CVD or multiple uncontrolled\nCVRF; cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating agents,\n.250 mg/m2 doxorubicin or equivalent); conditioning schemes (total body irradiation,\nalkylating agents); development of GVHD.\neOr prescribed RT 15–34 Gy to a volume exposing the heart if MHD is not available.\nfOr prescribed RT , 15 Gy to a volume exposing the heart if MHD is not available.\nRecommendation Table 41 — Recommendations for\ncardiovascular surveillance in asymptomatic adult can-\ncer survivors\nRecommendations\nClassa\nLevelb\nAnnual CV risk assessment,c including ECG and\nNP, and CVRF management is recommended in\nCS who were treated with a potentially\ncardiotoxic cancer drug or RT.d,631–633,671,672\nI\nB\nCV toxicity risk restratiﬁcatione is recommended\n5 years after therapy to organize long-term\nfollow-up.\nI\nC\nEchocardiography at years 1, 3, and 5 after\ncompletion of cardiotoxic cancer therapy and\nevery 5 years thereafter should be considered in\nasymptomatic very high- and early high-risk adult\nCS.f\nIIa\nC\nEchocardiography should be considered in\nasymptomatic late high-risk adult CSf starting at 5\nyears after radiation to a volume including the\nheart and then every 5 years.\nIIa\nC\nEchocardiography may be considered every 5\nyears in asymptomatic moderate-risk adult CS.f\nIIb\nC\nNon-invasive screening for CADg should be\nconsidered every 5–10 years in asymptomatic\npatients who received .15 Gy MHD,d starting at\n5 years after radiation.\nIIa\nC\nCarotid ultrasound imaging should be considered\nevery 5 years in asymptomatic patients with a\nhistory of head/neck RT, starting at 5 years after\nradiation and every 5–10 years thereafter.\nIIa\nC\nContinued\n4314\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n8.2. Myocardial dysfunction and heart\nfailure\nHF treatment in CS should follow the current 2021 ESC Guidelines\nfor the diagnosis and treatment of acute and chronic HF.14\nTreatment with ACE-I/ARB and/or beta-blockers is recommended\nfor both symptomatic and asymptomatic CS who have LVEF ,\n50% detected on CV assessment.14,61,208,675 In CS with mild asymp-\ntomatic CTRCD detected on CV assessment (LVEF . 50% but new\nfall in GLS and/or cardiac serum biomarker increase), treatment with\nACE-I/ARB and/or beta-blockers may be considered.\nRenal artery ultrasound should be considered in\npatients with a history of abdominal and pelvic\nradiation who present with worsening renal\nfunction and/or systemic hypertension.\nIIa\nC\n© ESC 2022\nBP, blood pressure; CAD, coronary artery disease; CMR, cardiac magnetic resonance;\nCS, cancer survivors; CT, computed tomography; CTR-CVT, cancer therapy-related\ncardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,\ncardiovascular risk factors; ECG, electrocardiogram; HbA1c, glycated haemoglobin;\nMHD, mean heart dose; NP, natriuretic peptides; RT, radiotherapy.\naClass of recommendation.\nbLevel of evidence.\ncClinical review, BP, lipid proﬁle, HbA1c.\ndRT risk categorization based on MHD is recommended over categorization based on\nprescribed dose (≥35 Gy to a volume exposing the heart if MHD is not available).\neRestratiﬁcation includes evaluation of new or pre-existing CVRF and CVD (including\nCTR-CVT).\nfSee Table 12.\ngStress echocardiography, cardiac CT, stress CMR, single-photon emission CT stress\ntest, according to local protocol.234\nLong-term surveillance in asymptomatic CS\nHigh and \nvery high \nrisk\nModerate\nrisk\nLow\nrisk\nClass 1\nClass 1Ia\nClass 1Ib\nTTE every 2 years in\nadults who are childhood\nand adolescent CS\nTTE at years 1, 3, and 5 after\ncardiotoxic cancer therapy and\nevery 5 years thereafter in adult CS\nAnnual CV risk \nassessmenta\nCV toxicity risk \nre-stratificationc\nat 5 years \nPatient education and\nCVRF optimization\nCardiology referralb\nif new CV\nsymptoms develop\nTTE every 5 years in\nadults who are childhood\nand adolescent CS\nTTE every 5 years in\nadult CS\nFigure 38 Long-term follow-up in cancer survivors. BP, blood pressure; CAD, coronary artery disease; CS, cancer survivors; CTR-CVT, cancer\ntherapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram;\nHbA1c, glycated haemoglobin; NP, natriuretic peptides; TTE, transthoracic echocardiography. aClinical review, BP, lipid proﬁle, HbA1c, ECG, NP. In\nselected patients, non-invasive screening for CAD and carotid or renal diseases every 5–10 years, starting at 5 years after radiation may be considered.\nbCardio-oncology referral is recommended when available; alternatively, the patient should be referred to a specialized cardiologist with expertise in\nmanaging CVD in patients with cancer. cRestratiﬁcation includes evaluation of new or pre-existing CVRF and CVD (including CTR-CVT).\nESC Guidelines\n4315\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n8.3. Coronary artery disease\nAny vascular location within the RT treatment volume is at increased\nrisk for both accelerated atherosclerosis and RT-related vasculopa-\nthy.173,392 RT to the chest (e.g. treatment of Hodgkin lymphoma,\nearly-stage BC, lung and oesophageal cancer, and for some patients\nreceiving infradiaphragmatic irradiation if the apex of the heart is\nwithin the treatment volume) increases the risk of CAD. The latency\nbetween RT and the appearance of CAD varies from a few years to\nseveral decades, depending upon the presence or absence of pre-\nexisting atherosclerosis and the age of the patient at the time of\nRT. This is a serious complication for young CS with a good progno-\nsis and long-life expectancy (e.g. BC and Hodgkin lymphoma).389,390\nPatients treated for mediastinal Hodgkin lymphoma have shown an\nincreased risk of CAD as a ﬁrst cardiac event.400 RT-induced CAD\ndepends on the location of the RT treatment volume and most com-\nmonly affects either the proximal left anterior descending or the\nright coronary arteries. RT-related vasculopathy is progressive and\ntypically manifests in severe, diffuse, long, smooth and concentric\nangiographic lesions.679,680\nThe risk and severity of CAD increases with radiation dose, larger\nvolume exposed, younger age at time of treatment (,25 years),390\ntime from treatment, smoking,400 the presence of other typical\nCVRF, type of radiation source, and concurrent metabolic risk\nfactors.493 RT accelerates pre-existing atherosclerosis leading to in-\ncreased ACS risk within 10 years of treatment.681\nPatients with RT-induced CAD undergoing PCI with bare-metal\nstent or balloon angioplasty have an increased risk of all-cause and\nCV mortality.682 Conversely, after PCI with a drug-eluting stent,\nthere is no difference in target lesion revascularization or cardiac\nmortality between patients with and without prior chest RT.683\nSurgical revascularization in patients with prior RT may be compli-\ncated by poor tissue healing (skin and sternum), RT-induced injury to\nthe left and right internal mammary arteries (LIMA and RIMA, re-\nspectively), inadequate target coronary vessels, and increased\nsternotomy-related pain.684 Pre-operative assessment of internal\nmammary artery viability, venous access, and sternal wound healing\nis recommended in CS with RT-induced CAD where CABG is con-\nsidered. PCI with drug-eluting stents may be considered over CABG\nin CS with RT-induced severe left main or three-vessel disease, with a\nhigh SYNTAX (SYNergy between percutaneous coronary interven-\ntion with TAXus and cardiac surgery) score (.22), in whom the\nplanned PCI is technically feasible given the increased complications\nassociated with CABG after mediastinal RT.\nScreening for CAD should be considered in high-risk patients who\nhave received chest RT to a treatment volume including the heart.\nScreening should take the form of functional imaging and/or CCTA be-\nginning at 5 years post-RT.234,484 The natural history of RT-related vas-\nculopathy is different to atherosclerosis and may accelerate rapidly.173\nFunctional cardiac imaging should be considered in asymptomatic CS\nwith pre-existing CAD or when new signiﬁcant CAD is detected on\nanatomical imaging. In asymptomatic patients with inducible ischaemia\nsecondary to RT-induced CAD, a MDT is recommended to discuss re-\nvascularization needs according to the location of the RT-induced CAD,\nthe ischaemia burden, LV function, arrhythmia burden, time since treat-\nment, time since previous normal review (if available), concomitant\nvalvular disease, risks of surgical or percutaneous revascularization,\nmedical options, and patient preference.173\nPlatinum-based chemotherapies are now recognized to cause\nCAD in CS. Cisplatin-based chemotherapy for testicular cancer is\nassociated\nwith\na\n1.5–7-fold\nincreased\nrisk\nof\ndeveloping\nCAD.421,493,685 Testicular CS who received platinum-based chemo-\ntherapy should have their CVRF tightly controlled and be educated\nto report any new chest pain or cardiac symptoms to their doctor\npromptly. The role of screening for CAD in patients who received\nplatinum-based chemotherapy is unknown.\nAggressive risk-factor modiﬁcation and CV diagnostic work-up\nstrongly enhance survival.5,672 Medical therapy with aspirin and sta-\ntins for primary/secondary prevention, and beta-blockers and ni-\ntrates for symptom control, are recommended in CS.686,687\nRecommendation Table 42 — Recommendations for\nadult\ncancer\nsurvivors\nwho\ndevelop\ncancer\ntherapy-related cardiac dysfunction late after cardio-\ntoxic cancer therapy\nRecommendations\nClassa\nLevelb\nACE-I/ARB and/or beta-blockers are\nrecommended in adult CS with moderate\nasymptomatic CTRCD.c,208,425,675–678\nI\nC\nACE-I/ARB and/or beta-blockers may be\nconsidered in adult CS with mild asymptomatic\nCTRCD.d\nIIb\nC\n© ESC 2022\nACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;\nCS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; GLS,\nglobal longitudinal strain; LVEF, left ventricular ejection fraction.\naClass of recommendation.\nbLevel of evidence.\ncNew LVEF reduction by ≥10 percentage points to an LVEF of 40–49% OR new LVEF\nreduction by ,10 percentage points to an LVEF of 40–49% AND either new relative\ndecline in GLS by .15% from baseline OR new rise in cardiac biomarkers.\ndLVEF ≥50% and new relative decline in GLS by .15% from baseline AND/OR new\nrise in cardiac biomarkers.\nRecommendation Table 43 — Recommendations for\nadult cancer survivors with coronary artery disease\nRecommendations\nClassa\nLevelb\nAsymptomatic radiation-induced CAD detected during\nsurveillance\nNon-invasive stress testingc is recommended in\nasymptomatic CS with new moderate or severe\nradiation-induced CAD detected on CCTA to\nguide ischaemia-directed management.635,688\nI\nC\nA MDT discussion is recommended for clinical\ndecision-making in patients with radiation-induced\nCAD and inducible ischaemia or severe left main\nCAD.\nI\nC\nSymptomatic CAD\nPre-operative assessment of LIMA and RIMA\nviability, venous access, and sternal wound healing\nis recommended in CS with radiation-induced\nCAD where CABG is considered.\nI\nC\nContinued\n4316\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n8.4. Valvular heart disease\nVHD can appear in CS at any point in time but typically occurs\n10 or more years after cancer treatment.691 Chest RT is the\nmain risk factor in CS, in particular at higher dose ranges, which\ncan\ncause\neither\nstenosis\nor\nregurgitation,\nor\nboth.391\nThe reported incidences of valvular regurgitation are up to\n40% of CS survivors who received high-dose chest RT to a vol-\nume involving the heart, with ,10% presenting with clinically\nsigniﬁcant VHD.670\nPrognosis and management depend on the extent and severity of\nVHD, as it does in patients without cancer.692 TAVI should be con-\nsidered for patients with symptomatic RT-induced severe aortic\nstenosis at intermediate surgical risk.504,506,693,694 Similar strategies\nwith percutaneous mitral valve repair or replacement can be consid-\nered.695 Importantly, commonly used calculators such STS PROM\n(Society of Thoracic Surgeons–Predicted Risk of Mortality) or\nEuroSCORE\n(European\nSystem\nfor\nCardiac\nOperative\nRisk\nEvaluation) II507 may underestimate the surgery-related risk in CS,\nand especially those who develop RT-induced VHD, due to addition-\nal RT-related risk factors such as pericardial calciﬁcation, aortic calci-\nﬁcation, increased bleeding risk, impaired skin healing, and RT-related\npulmonary ﬁbrosis. A Heart Team with cardiac surgeons, interven-\ntional cardiologists, and cardio-oncology specialists should review\neach case to guide appropriate treatment. The Heart Team recom-\nmendation should be discussed with the patient, who can then make\nan informed treatment choice.\n8.5. Peripheral artery disease and stroke\nPeripheral arterial and cerebrovascular disease in CS can be due to\nthe continuum of vascular disease pre-existing before, or developing\nduring or after cancer therapy. Cancer therapies such as cisplatin,\nBCR-ABL inhibitors, and RT can have a direct long-lasting effect on\nthe vasculature. Approximately 30% of CML patients on nilotinib\nmay develop PAD, which is clinically recognized 2–4 years after\nthe start of therapy.698 The disease process may progress even after\ndiscontinuation of nilotinib. Long-term vascular effects, generally as-\nsociated with vascular reactivity, can also be seen in patients treated\nwith ponatinib, cisplatin, and bleomycin.699,700 Accelerated vascular\naging, inﬂammation, ﬁbrosis, and atherosclerosis are characteristic\nconsequences of RT.701 Up to 30% of patients may develop signiﬁ-\ncant carotid artery stenoses (.70%) after head/neck radiation.702,703\nVascular disease can also be an indirect consequence of cancer and\nits therapy, e.g. via reduction in physical activity, hyperlipidaemia, DM,\nobesity, hypothyroidism, and/or kidney disease. These CVRF-related\neffects are mostly additive to the direct treatment-related effects.\nPromoting vascular health and preventing vascular disease in CS is re-\ncommended.672 This should be in line with the 2021 ESC Guidelines\non CVD prevention in clinical practice.19\n8.6. Pericardial complications\nThe risk of long-term pericardial complications after cancer\ndrug-induced acute pericarditis, caused by anthracyclines, cyclophos-\nphamide, cytarabine, and bleomycin, is unknown but generally con-\nsidered low. Long-term dasatinib treatment may lead to pericardial\neffusion and pericarditis. The incidence of long-term ICI-associated\npericardial complications is low.10\nRT-induced chronic pericardial diseases can appear months to\ndecades after the initial RT and constrictive pericarditis is the most\nserious.173,392 Incidence is difﬁcult to determine, and many cases\nare initially asymptomatic.704 Five-yearly echocardiographic surveil-\nlance for pericardial constriction in CS following RT-induced acute\npericarditis may be considered. The absolute risk is considerably re-\nduced with modern radiation protocols,704 but a high rate of pericar-\ndial effusion has still been reported in patients with lung (grade ≥2,\n.40%705) and oesophageal cancer (.25%706) treated with RT.\nPericardial\ndisease has\nbeen\nless\ninvestigated than\nother\nRT-induced CVD, and clear protocols for post-therapy surveillance\nare lacking.707,708 In CS with chronic pericardial effusions following\nRT, cardiac imaging can assess for evidence of inﬂammation,\nPCI may be considered in CS with\nradiation-induced CAD with severe left main or\nthree-vessel disease with a high SYNTAX score\n(.22) in whom the procedure is technically\nfeasible.682,689,690\nIIb\nB\n© ESC 2022\nCABG, coronary artery bypass graft; CAD, coronary artery disease; CCTA, coronary\ncomputed tomography angiography; CS, cancer survivors; LIMA, left internal\nmammary\nartery;\nMDT,\nmultidisciplinary\nteam;\nPCI,\npercutaneous\ncoronary\nintervention; RIMA, right internal mammary artery; SYNTAX, SYNergy between\npercutaneous coronary intervention with TAXus and cardiac surgery.\naClass of recommendation.\nbLevel of evidence.\ncAccording to local protocols and Non-invasive imaging in coronary syndromes:\nrecommendations of the European Association of Cardiovascular Imaging and the\nAmerican Society of Echocardiography, in collaboration with the American Society of\nNuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society\nfor Cardiovascular Magnetic Resonance recommendations.234\nRecommendation Table 44 — Recommendations for\nadult cancer survivors with valvular heart disease\nRecommendations\nClassa\nLevelb\nA MDT approach is recommended to discuss and\ndeﬁne the surgical riskc in CS with severe VHD.\nI\nC\nContinued\nTAVI should be considered for patients with\nsymptomatic severe aortic stenosis caused by\nradiation at intermediate surgical\nrisk.504,506,693,694,696,697\nIIa\nB\n© ESC 2022\nCS, cancer survivors; EuroSCORE, European System for Cardiac Operative Risk\nEvaluation; MDT, multidisciplinary team; STS PROM, Society of Thoracic Surgeons–\nPredicted Risk of Mortality; TAVI, transcatheter aortic valve implantation; VHD,\nvalvular heart disease.\naClass of recommendation.\nbLevel of evidence.\ncSurgical risks include: vascular access, sternal and skin wound healing, concomitant\ncardiac\ndisease,\nradiation-induced\nlung\nand\nthoracic\nvessels\ndisease,\naortic\ncalciﬁcation, STS PROM/EuroSCORE II.\nESC Guidelines\n4317\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nconstriction, or tamponade.709 Percutaneous balloon pericardiot-\nomy or pericardial window creation should be used in selected cases\nfor large or growing chronic effusions if haemodynamic compromise\ndevelops. Management of these conditions should follow general\nguideline recommendations.14,444\n8.7. Arrhythmias and autonomic disease\nArrhythmias, conduction disease, and autonomic disease are com-\nmon complications in CS. Conduction disease after thoracic RT is\ntypically associated with other CTR-CVT.710 It may include AV\nblock, bundle branch block, and sick sinus syndrome that should\nbe monitored and treated according to the 2021 ESC Guidelines\non cardiac pacing and cardiac resynchronization therapy.443\nPatients who require valve replacement after thoracic RT have a\nhigh risk of post-operative AV block requiring permanent pace-\nmaker therapy.711 Supraventricular and ventricular arrhythmias\nare more common in patients after thoracic RT,712 possibly due\nto RT-induced myocardial ﬁbrosis. A common long-term complica-\ntion after HSCT is supraventricular arrhythmia including AF and at-\nrial ﬂutter,457 particularly in CS treated with anthracyclines or with\nnew CVRF or CV toxicity.\nAutonomic dysfunction is an emerging but poorly understood\ncomplication observed in CS, and is most frequently observed as a\nlate complication after thoracic RT. Orthostatic hypotension, pos-\ntural orthostatic tachycardia syndrome, inappropriate sinus tachy-\ncardia, and loss of circadian heart rate variability can occur.713,714\nPhysicians caring for these patients should consider referral for auto-\nnomic evaluation. In addition, the perception of angina pain may be\nimpaired,714 making the diagnosis of post-radiation CAD challenging.\nEvidence-based pharmacological treatment strategies are based on\nstudies of patients with other autonomic dysfunction aetiologies\n(e.g. DM or inﬁltrative diseases) and the reported effectiveness is\ngenerally poor.714\n8.8. Metabolic syndrome, lipid\nabnormalities, diabetes mellitus, and\nhypertension\nThere is a growing understanding about shared CVRF that may be\nresponsible for cancer development or progression and premature\nCV morbi-mortality.34 Modiﬁable CVRF continue to be underdiag-\nnosed and undertreated in CS, especially hypertension,715 obesity,\nDM, metabolic syndrome,716 and dyslipidaemia. Early diagnosis via\nstandardized risk-based screening and management of these condi-\ntions according to general ESC Guidelines is recommended19 to im-\nprove long-term outcomes in CS.672\nIncreasing numbers of patients with cancer are already overweight\nor obese at cancer diagnosis,717 and additional weight gain is a fre-\nquent complication of anticancer treatments.718 Obesity is asso-\nciated with metabolic syndrome, worsening CVRF, and cancer.\nIncreasing evidence indicates that being overweight increases the\nrisk of cancer recurrence and reduces the likelihood of disease-free\nsurvival and overall survival among those diagnosed with cancer.719–\n724 There is also growing evidence to support intentional weight loss\npost-treatment in CS, which may result in improved prognosis and\nsurvival.719 Dietary patterns characterized by a high intake of vegeta-\nbles/fruits and whole grains has been shown to be associated with re-\nduced mortality and cancer recurrence when compared with a high\nintake of reﬁned grains, processed and red meats, and high-fat dairy\nproducts.725–727\nThe identiﬁcation and treatment of hyperlipidaemia in CS is asso-\nciated with a profound impact on outcomes.182,183 There is a beneﬁt\nfor CS from an all-cause mortality perspective as well as for decreas-\ning cancer recurrence.728–730\nSeveral studies have demonstrated the therapeutic beneﬁts of ex-\nercise during primary anticancer treatment,731,732 and exercise is re-\ncommended during and after anticancer treatment.11,733 For CS,734\naerobic exercise results in improved survival.735 Based on current\nguidelines, patients undergoing anticancer therapy and long-term\nCS should be encouraged to exercise for at least 150 min per\nweek.736\n8.9. Pregnancy in cancer survivors\nImprovements in the treatment of cancer have led to an increasing\nnumber of female paediatric and adolescent CS who experience\npregnancy\nmany\nyears\nafter\ntheir\noncological\ntreatments.\nApproximately 60% of them will have been previously exposed to\nanthracycline chemotherapy or chest RT and they have a 15-fold in-\ncrease in their lifetime risk of developing HF.737 As young CS enter\ntheir reproductive years and contemplate pregnancy, it is important\nto understand the impact of cancer and its treatment on fertility,\npregnancy outcomes, and CV health. There are limited data available\nregarding CV risk in pregnancy following cancer treatments. The\noverall incidence of LVD or HF associated with pregnancy in female\nadult CS varies according to the studied population. In a single insti-\ntution report including 337 female CS treated with cardiotoxic ther-\napies, 58 (17%) had a subsequent pregnancy.738 Cardiac events,\ndeﬁned as LVEF , 50% on two TTE or new CAD, were identiﬁed\nin 17 patients.738 Patients with cardiac events were likely to be\nyounger at cancer diagnosis, received a higher cumulative dose of an-\nthracycline, and had a longer delay (in years) from cancer treatment\nto ﬁrst pregnancy compared with pregnant women with no cardiac\nevent.738 In a recent meta-analysis of six studies, the weighted risk of\npregnancy-associated LVD or HF in CS treated with anthracyclines\nwas 1.7% with no reported maternal cardiac deaths.739 Major risk\nfactors for CV events during pregnancy in CS include CTRCD (inci-\ndence 28%; 47.4-fold higher odds),739 younger age at cancer diagno-\nsis,738,740 longer time from cancer treatment to ﬁrst pregnancy, and\ncumulative anthracycline dose.738\nRecommendation Table 45 — Recommendation for\nadult cancer survivors with pericardial complications\nRecommendation\nClassa\nLevelb\nPatients with acute pericarditis during RT to a\nvolume including the heart are at higher risk of\ndeveloping chronic constrictive pericarditis, hence\nechocardiography surveillance every 5 years may\nbe considered.\nIIb\nC\n© ESC 2022\nRT, radiotherapy.\naClass of recommendation.\nbLevel of evidence.\n4318\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nManagement by an expert MDT (the pregnancy heart team) is re-\ncommended for all CS with CTRCD who are considering preg-\nnancy.739,741,742 The risk of HF in CS without CTRCD is low,\nalthough vigilance remains important for potential maternal cardiac\ncomplications.\n8.10. Pulmonary hypertension\nLong-term clinical evaluation may be considered in patients who de-\nvelop PH during therapy (Section 6). In patients with new exertional\ndyspnoea, fatigue, or angina, a TTE is recommended to assess the\nprobability of PH. As TTE alone is not enough to conﬁrm the diagnosis\nof PH, CS diagnosed with high PH probability require a right-heart\ncatheterization to conﬁrm the diagnosis. PH should be treated accord-\ning to general guidelines with referral to a specialist PH service.620\n9. Special populations\n9.1. Cardiac tumours\nCardiac tumours are classiﬁed as either benign or malignant.743 Over\n90% of primary cardiac tumours are benign (myxomas are\npredominant in adults, rhabdomyomas in children).744 Malignant pri-\nmary tumours most commonly consist of sarcomas (approximately\n65%) or lymphomas (approximately 25%).745 Cardiac metastases\n(from melanoma, lymphoma, leukaemia, breast, lung, and oesopha-\ngeal cancers) are much more common than primary cardiac tumours\n(Figure 39).746 Presenting symptoms are paraneoplastic (fever, weak-\nness, fatigue), thromboembolic, haemodynamic (due to compression\nor obstruction from the tumour) or arrhythmic.747,748\nThe diagnostic pathway should be based on knowledge about\ntumour type epidemiology, imaging features, and usually the\nrequirement for a histopathological diagnosis. This topic has been\nextensively reviewed in\nESC CardioMed,749 and here we\nsummarize the main recommendations for differential diagnosis\nand management. Differential diagnosis should exclude cardiac\nthrombi or the presence of chemotherapy catheters. Imaging must\nassess the possibilities of cardiac surgery, and may include: (1) echo-\ncardiography (initial approach using TTE or transoesophageal\nechocardiography)748,750; (2) CMR (for cardiac tumour tissue char-\nacterization)751,752; and (3) CT and PET (to distinguish malignant\nfrom benign lesions and assess for non-cardiac metastatic disease\nor primary cancers) (Figure 40).753,754\nMyxomas are primarily treated with surgery with a good progno-\nsis. Malignant tumours are associated with a poor prognosis and evi-\ndence of the best treatment is lacking. Complete surgical resection is\noften impossible and adjuvant RT, systemic chemotherapy, and/or\ndebulking palliative surgery are needed.755 Cardiac aggressive B-cell\nlymphomas require histopathological diagnosis (often obtained via\nanalysis of pericardial effusion, EMB, or direct surgical biopsy) and\nare\ntreated\nwith\nchemotherapy,\npossibly\nfollowed\nby\nRT\n(Table 13).756\n9.2. Pregnant patients with cancer\nThe diagnosis of cancer during pregnancy is uncommon (1 in every\n1000 pregnant women is diagnosed with cancer), with BC, melan-\noma, and cervical cancer being the most frequent diagnoses.757\nChemotherapy is generally not applied during the ﬁrst trimester\ndue to the high risk of foetal congenital abnormalities (up to 20%)\nand cytotoxic chemotherapies have different risk proﬁles during\nthe second or third trimesters.758,759 Furthermore, chemotherapy\nadministration is usually not given beyond week 34 of gestation to\nprovide a 3-week window between the last cycle and delivery.757\nSupplementary data, Table S19 summarizes the chemotherapies\nfor pregnant patients with cancer.760,761\nCardiac assessment prior to chemotherapy in pregnant women\nwith cancer should consist of clinical history, physical examination,\nECG, cardiac biomarker assessment and TTE (Figure 41).741\nBaseline and follow-up TTE should be interpreted in the context\nof physiological haemodynamic alterations during pregnancy. In nor-\nmal pregnancy, increase in stroke volume, heart rate, and pre-load\nblood volume, and decrease in systemic vascular resistance, lead to\nan increase in cardiac output from the ﬁrst trimester to 80–85%\nabove baseline by the third trimester.762–764 An increase in LV\nmass and LV and RV volumes is observed in the third trimester.\nDuring normal pregnancy, LVEF is usually unchanged and can be\nused for CTRCD monitoring. Although NP and cTn may be slightly\nelevated during normal pregnancy (NT-proBNP , 300 ng/L, BNP ,\n100 pg/mL,14 and hs-cTnT765,766), serial evaluation may be useful for\nRecommendation Table 46 — Recommendations for\ncardiovascular monitoring in cancer survivors during\npregnancy\nRecommendations\nClassa\nLevelb\nIn high-risk female CS, pre-pregnancy counselling\nand management during pregnancy and around\ndelivery by a multidisciplinary pregnancy heart\nteam is recommended.\nI\nC\nA baseline CV evaluation including history,\nphysical examination, ECG, NP, and\nechocardiography is recommended in female CS\nwith a history of CTRCD who are considering\npregnancy.\nI\nC\nA baseline CV evaluation including history,\nphysical examination, ECG, and echocardiography\nshould be considered in all female CS who\nreceived potentially cardiotoxic cancer therapy\nand are considering pregnancy.\nIIa\nC\nA CV evaluation including echocardiography is\nrecommended at 12 weeks of pregnancy in female\nCS who are either high-risk or who received\npotentially cardiotoxic cancer therapy and did not\nhave a baseline CV assessment.\nI\nC\nA second CV evaluation including\nechocardiography should be considered at 20\nweeks of pregnancy in high-risk female CSc who\nreceived potentially cardiotoxic cancer therapy.\nIIa\nC\n© ESC 2022\nCS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV,\ncardiovascular; ECG, electrocardiogram, NP, natriuretic peptides.\naClass of recommendation.\nbLevel of evidence.\ncSee Tables 11 and 12.\nESC Guidelines\n4319\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 84",
          "page": 84,
          "content": "Recommendations | Classa | Levelb\nEducating and supporting patients with cancer to\nmake appropriate healthy lifestyle choices is\nrecommended.c | I | C\nEducation is recommended for patients with\ncancer regarding recognition for early signs and\nsymptoms of CVD. | I | C\nCVRF assessment is recommended during the\nfirst year after cancer therapyc,12,22,31,632,643 and\nthereafter according to the 2021 ESC Guidelines\non CVD prevention in clinical practice.19 | I | B\nIn asymptomatic high-risk patients,d\nechocardiography and cardiac serum biomarkers\nare recommended at 3 and 12 months after\ncompletion of cancer\ntherapy.53,54,59,61,68,148,208,425 | I | B\nIn asymptomatic moderate-risk patients,e\nechocardiography and cardiac serum biomarkers\nshould be considered within 12 months after\ncompletion of cancer therapy.53,54,59,61,68,148,208 | IIa | B\nIn asymptomatic low-risk patients,e\nechocardiography and cardiac serum biomarkers\nmay be considered within 12 months after\ncompletion of cancer therapy.634 | IIb | C\nCardiology referralf is recommended in patients\nwith cancer with new cardiac symptoms or new\nasymptomatic abnormalities in echocardiography\nand/or cardiac serum biomarkers at the end of\ntherapy assessment.11 | I | C\nIn selected patients with exercise intolerance\npersisting at 12 months after cancer treatment\nand with normal resting echocardiogram and\ncardiac biomarkers, exercise stress\nechocardiography and/or CPET may be\nconsidered. | IIb | C\nTargeted cardiac rehabilitation should be\nconsidered in CS with high CV risk.638–640 | IIa | B\nLong-term continuation of cardiac medication is\nrecommended in patients who develop severe\nCTRCD during cancer therapy. | I | C\nCV follow-up and treatment optimization is\nrecommended in patients who developed\nTKI-mediated hypertension during cancer\ntherapy.644,645 | I | C\nCV follow-up and treatment optimization is\nrecommended in patients who developed vascular\ntoxicities during cancer therapy.10,237 | I | C",
          "rows": 13,
          "cols": 3
        },
        {
          "title": "Table on page 85",
          "page": 85,
          "content": "Risk category | RT dosea (Gy MHD) | Total cumulative doxorubicinb\ndose (mg/m2) | Combination therapy | \n |  |  | RT dosea (Gy MHD) | Total cumulative doxorubicinb\ndose (mg/m2)\nVery high risk | .25c | ≥400 | .15c | ≥100\nHigh risk | .15 to 25c | 250–399 | 5–15d | ≥100\nModerate risk | 5–15d | 100–249 | ,5e | ≥100\nLow risk | ,5e | ,100 | – | ",
          "rows": 6,
          "cols": 5
        },
        {
          "title": "Table on page 85",
          "page": 85,
          "content": "Recommendations | Classa | Levelb\nEducation of adults who are childhood and\nadolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding\ntheir increased CV risk is recommended.655–657 | I | B\nAnnual screening for modifiable CVRFc is\nrecommended in adults who are childhood and\nadolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including\nthe heart. | I | C\nCV assessmentd is recommended in female\nchildhood and adolescent CS prior to pregnancy\nor in the first trimester. | I | C\nEchocardiography surveillance should be\nconsidered every 2 years in adults who are\nhigh-risk childhood and adolescente CS.7 | IIa | B\nEchocardiography surveillance should be\nconsidered every 5 years in adults who are\nmoderate-risk childhood and adolescente CS.7,654 | IIa | B",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 86",
          "page": 86,
          "content": "Risk categorya | Patient characteristics\nVery high risk | • Very high baseline CV toxicity risk\npre-treatment\n• Doxorubicinb ≥400 mg/m2\n• RT . 25 Gy MHDc\n• RT . 15–25 Gy MHDc + doxorubicinb\n≥100 mg/m2\nEarly high risk\n(,5 years after\ntherapy) | • High baseline CV toxicity risk\n• Symptomatic or asymptomatic\nmoderate-to-severe CTRCD during\ntreatment\n• Doxorubicinb 250–399 mg/m2\n• High-risk HSCTd\nLate high risk | • RT . 15–25 Gy MHDc\n• RT 5–15 Gy MHDe + doxorubicinb\n≥100 mg/m2\n• Poorly controlled CVRF\nModerate risk | • Moderate baseline CV toxicity risk\n• Doxorubicinb 100–249 mg/m2\n• RT 5–15 Gy MHDe\n• RT , 5 Gy MHDf + doxorubicinb ≥100 mg/\nm2\nLow risk | • Low baseline CV toxicity risk and normal\nend-of-therapy cardiac assessment\n• Mild CTRCD during therapy but recovered by\nthe end of cancer therapy\n• RT , 5 Gy MHDf\n• Doxorubicinb , 100 mg/m2",
          "rows": 6,
          "cols": 2
        },
        {
          "title": "Table on page 86",
          "page": 86,
          "content": "Recommendations | Classa | Levelb\nAnnual CV risk assessment,c including ECG and\nNP, and CVRF management is recommended in\nCS who were treated with a potentially\ncardiotoxic cancer drug or RT.d,631–633,671,672 | I | B\nCV toxicity risk restratificatione is recommended\n5 years after therapy to organize long-term\nfollow-up. | I | C\nEchocardiography at years 1, 3, and 5 after\ncompletion of cardiotoxic cancer therapy and\nevery 5 years thereafter should be considered in\nasymptomatic very high- and early high-risk adult\nCS.f | IIa | C\nEchocardiography should be considered in\nasymptomatic late high-risk adult CSf starting at 5\nyears after radiation to a volume including the\nheart and then every 5 years. | IIa | C\nEchocardiography may be considered every 5\nyears in asymptomatic moderate-risk adult CS.f | IIb | C\nNon-invasive screening for CADg should be\nconsidered every 5–10 years in asymptomatic\npatients who received .15 Gy MHD,d starting at\n5 years after radiation. | IIa | C\nCarotid ultrasound imaging should be considered\nevery 5 years in asymptomatic patients with a\nhistory of head/neck RT, starting at 5 years after\nradiation and every 5–10 years thereafter. | IIa | C",
          "rows": 8,
          "cols": 3
        },
        {
          "title": "Table on page 88",
          "page": 88,
          "content": "Recommendations | Classa | Levelb\nACE-I/ARB and/or beta-blockers are\nrecommended in adult CS with moderate\nasymptomatic CTRCD.c,208,425,675–678 | I | C\nACE-I/ARB and/or beta-blockers may be\nconsidered in adult CS with mild asymptomatic\nCTRCD.d | IIb | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 88",
          "page": 88,
          "content": "Recommendations |  | Classa | Levelb | \n | Asymptomatic radiation-induced CAD detected during\nsurveillance |  |  | \nNon-invasive stress testingc is recommended in\nasymptomatic CS with new moderate or severe\nradiation-induced CAD detected on CCTA to\nguide ischaemia-directed management.635,688 |  | I | C | \nA MDT discussion is recommended for clinical\ndecision-making in patients with radiation-induced\nCAD and inducible ischaemia or severe left main\nCAD. |  | I | C | \n | Symptomatic CAD |  |  | \nPre-operative assessment of LIMA and RIMA\nviability, venous access, and sternal wound healing\nis recommended in CS with radiation-induced\nCAD where CABG is considered. |  | I | C | ",
          "rows": 6,
          "cols": 5
        },
        {
          "title": "Table on page 89",
          "page": 89,
          "content": "Recommendations | Classa | Levelb\nA MDT approach is recommended to discuss and\ndefine the surgical riskc in CS with severe VHD. | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 90",
          "page": 90,
          "content": "Recommendation | Classa | Levelb\nPatients with acute pericarditis during RT to a\nvolume including the heart are at higher risk of\ndeveloping chronic constrictive pericarditis, hence\nechocardiography surveillance every 5 years may\nbe considered. | IIb | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 91",
          "page": 91,
          "content": "Recommendations | Classa | Levelb\nIn high-risk female CS, pre-pregnancy counselling\nand management during pregnancy and around\ndelivery by a multidisciplinary pregnancy heart\nteam is recommended. | I | C\nA baseline CV evaluation including history,\nphysical examination, ECG, NP, and\nechocardiography is recommended in female CS\nwith a history of CTRCD who are considering\npregnancy. | I | C\nA baseline CV evaluation including history,\nphysical examination, ECG, and echocardiography\nshould be considered in all female CS who\nreceived potentially cardiotoxic cancer therapy\nand are considering pregnancy. | IIa | C\nA CV evaluation including echocardiography is\nrecommended at 12 weeks of pregnancy in female\nCS who are either high-risk or who received\npotentially cardiotoxic cancer therapy and did not\nhave a baseline CV assessment. | I | C\nA second CV evaluation including\nechocardiography should be considered at 20\nweeks of pregnancy in high-risk female CSc who\nreceived potentially cardiotoxic cancer therapy. | IIa | C",
          "rows": 6,
          "cols": 3
        }
      ],
      "keywords": [
        "asymptomatic",
        "complications",
        "term",
        "survivors",
        "long",
        "cardiovascular",
        "follow",
        "chronic",
        "follow-up",
        "diagnosis",
        "echocardiography",
        "cancer",
        "echo",
        "treatment",
        "recommendation",
        "moderate",
        "ct",
        "risk",
        "symptomatic"
      ]
    },
    {
      "number": "11",
      "title": "9. Special populations",
      "start_page": 91,
      "end_page": 102,
      "content": "Management by an expert MDT (the pregnancy heart team) is re-\ncommended for all CS with CTRCD who are considering preg-\nnancy.739,741,742 The risk of HF in CS without CTRCD is low,\nalthough vigilance remains important for potential maternal cardiac\ncomplications.\n8.10. Pulmonary hypertension\nLong-term clinical evaluation may be considered in patients who de-\nvelop PH during therapy (Section 6). In patients with new exertional\ndyspnoea, fatigue, or angina, a TTE is recommended to assess the\nprobability of PH. As TTE alone is not enough to conﬁrm the diagnosis\nof PH, CS diagnosed with high PH probability require a right-heart\ncatheterization to conﬁrm the diagnosis. PH should be treated accord-\ning to general guidelines with referral to a specialist PH service.620\n9. Special populations\n9.1. Cardiac tumours\nCardiac tumours are classiﬁed as either benign or malignant.743 Over\n90% of primary cardiac tumours are benign (myxomas are\npredominant in adults, rhabdomyomas in children).744 Malignant pri-\nmary tumours most commonly consist of sarcomas (approximately\n65%) or lymphomas (approximately 25%).745 Cardiac metastases\n(from melanoma, lymphoma, leukaemia, breast, lung, and oesopha-\ngeal cancers) are much more common than primary cardiac tumours\n(Figure 39).746 Presenting symptoms are paraneoplastic (fever, weak-\nness, fatigue), thromboembolic, haemodynamic (due to compression\nor obstruction from the tumour) or arrhythmic.747,748\nThe diagnostic pathway should be based on knowledge about\ntumour type epidemiology, imaging features, and usually the\nrequirement for a histopathological diagnosis. This topic has been\nextensively reviewed in\nESC CardioMed,749 and here we\nsummarize the main recommendations for differential diagnosis\nand management. Differential diagnosis should exclude cardiac\nthrombi or the presence of chemotherapy catheters. Imaging must\nassess the possibilities of cardiac surgery, and may include: (1) echo-\ncardiography (initial approach using TTE or transoesophageal\nechocardiography)748,750; (2) CMR (for cardiac tumour tissue char-\nacterization)751,752; and (3) CT and PET (to distinguish malignant\nfrom benign lesions and assess for non-cardiac metastatic disease\nor primary cancers) (Figure 40).753,754\nMyxomas are primarily treated with surgery with a good progno-\nsis. Malignant tumours are associated with a poor prognosis and evi-\ndence of the best treatment is lacking. Complete surgical resection is\noften impossible and adjuvant RT, systemic chemotherapy, and/or\ndebulking palliative surgery are needed.755 Cardiac aggressive B-cell\nlymphomas require histopathological diagnosis (often obtained via\nanalysis of pericardial effusion, EMB, or direct surgical biopsy) and\nare\ntreated\nwith\nchemotherapy,\npossibly\nfollowed\nby\nRT\n(Table 13).756\n9.2. Pregnant patients with cancer\nThe diagnosis of cancer during pregnancy is uncommon (1 in every\n1000 pregnant women is diagnosed with cancer), with BC, melan-\noma, and cervical cancer being the most frequent diagnoses.757\nChemotherapy is generally not applied during the ﬁrst trimester\ndue to the high risk of foetal congenital abnormalities (up to 20%)\nand cytotoxic chemotherapies have different risk proﬁles during\nthe second or third trimesters.758,759 Furthermore, chemotherapy\nadministration is usually not given beyond week 34 of gestation to\nprovide a 3-week window between the last cycle and delivery.757\nSupplementary data, Table S19 summarizes the chemotherapies\nfor pregnant patients with cancer.760,761\nCardiac assessment prior to chemotherapy in pregnant women\nwith cancer should consist of clinical history, physical examination,\nECG, cardiac biomarker assessment and TTE (Figure 41).741\nBaseline and follow-up TTE should be interpreted in the context\nof physiological haemodynamic alterations during pregnancy. In nor-\nmal pregnancy, increase in stroke volume, heart rate, and pre-load\nblood volume, and decrease in systemic vascular resistance, lead to\nan increase in cardiac output from the ﬁrst trimester to 80–85%\nabove baseline by the third trimester.762–764 An increase in LV\nmass and LV and RV volumes is observed in the third trimester.\nDuring normal pregnancy, LVEF is usually unchanged and can be\nused for CTRCD monitoring. Although NP and cTn may be slightly\nelevated during normal pregnancy (NT-proBNP , 300 ng/L, BNP ,\n100 pg/mL,14 and hs-cTnT765,766), serial evaluation may be useful for\nRecommendation Table 46 — Recommendations for\ncardiovascular monitoring in cancer survivors during\npregnancy\nRecommendations\nClassa\nLevelb\nIn high-risk female CS, pre-pregnancy counselling\nand management during pregnancy and around\ndelivery by a multidisciplinary pregnancy heart\nteam is recommended.\nI\nC\nA baseline CV evaluation including history,\nphysical examination, ECG, NP, and\nechocardiography is recommended in female CS\nwith a history of CTRCD who are considering\npregnancy.\nI\nC\nA baseline CV evaluation including history,\nphysical examination, ECG, and echocardiography\nshould be considered in all female CS who\nreceived potentially cardiotoxic cancer therapy\nand are considering pregnancy.\nIIa\nC\nA CV evaluation including echocardiography is\nrecommended at 12 weeks of pregnancy in female\nCS who are either high-risk or who received\npotentially cardiotoxic cancer therapy and did not\nhave a baseline CV assessment.\nI\nC\nA second CV evaluation including\nechocardiography should be considered at 20\nweeks of pregnancy in high-risk female CSc who\nreceived potentially cardiotoxic cancer therapy.\nIIa\nC\n© ESC 2022\nCS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV,\ncardiovascular; ECG, electrocardiogram, NP, natriuretic peptides.\naClass of recommendation.\nbLevel of evidence.\ncSee Tables 11 and 12.\nESC Guidelines\n4319\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nclose CTRCD monitoring during cancer treatment with the higher\ncut-off NP levels for pregnancy.\nThe topic of CVD during pregnancy has been extensively re-\nviewed in the 2018 ESC Guidelines for the management of CVD\nduring pregnancy.741 Here we focus on speciﬁc recommendations\nin\npregnant\nwomen\nwith\ncancer\nreceiving\nanthracycline\nchemotherapy.\n9.2.1. Left ventricular dysfunction and heart failure\nMedical history evaluating signs and symptoms of HF should be per-\nformed at every clinical visit of pregnant women with cancer receiv-\ning anthracycline chemotherapy. More frequent CV evaluations with\nTTE during treatments with potential CTRCD risk should be advised\n(e.g. every 4–8 weeks or every two cycles for a 3-weekly anthracycline\nchemotherapy cycle). The management of clinical HF or asymptomatic\nLVD during pregnancy is fully described in the 2018 ESC Guidelines for\nthe management of CVD during pregnancy.741\n9.2.2. Venous thromboembolism and pulmonary\nembolism\nPregnant patients with cancer have an increased risk of\ndeveloping\nVTE,\nespecially\nwhen\nhospitalized.767–769\nIdentiﬁed risks for VTE in pregnant patients include having a\nhistory of BC or previous chemotherapy in the past 6 months.\nLipoma\nMetastasis\nMyxoma\nSarcoma\nLeft atrium\nLung tumours\nSarcoma\nPulmonary veins\nFibroelastoma\nMetastasis\nValves\nLeft ventricle\nFibroma\nLipoma\nLymphoma\nMetastasis\nRhabdomyoma\nSarcoma\nLeiomyoma\nRenal tumour\nInferior cava vein\nRight atrium\nLipoma\nLymphoma\nMetastasis\nMyxoma\nSarcoma\nRight ventricle\nFibroma\nLipoma\nLymphoma\nMetastasis\nRhabdomyoma\nPericardium\nLipo-sarcoma\nLipoma\nLymphoma\nMesothelioma\nMetastasis\nSarcoma\nPulmonary artery\nFigure 39 Location of primary and secondary cardiac tumours.\n4320\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCTb\nEchocardiographya\nPETd\nCMRc\nSecondary tumour\n(metastasis)f\nBenign primary\ntumour\nMalignant primary\ntumour\nDiagnostic algorithm for cardiac masses\nNon-invasive assessment of single or multiple cardiac masses\nTumour\nType\nThrombus, vegetation, structural\nConsider cardiac mass biopsy if malignant primary\ntumour suspected or diagnosis uncertain on imaginge\nLymphoma\nSarcoma\nAngioma, lipoma, papillary\nfibroelastoma\nMyxoma \nLeukaemias \nLymphomas\nMelanomas\nSolid tumours: breast, lung,\nand oesophageal cancers\nFigure 40 Diagnostic algorithm for cardiac masses. CMR, cardiac magnetic resonance; CT, computed tomography; PET, positron emission tomog-\nraphy; TTE, transthoracic echocardiography. aTTE/transoesophageal echocardiography: location, size, and haemodynamic disturbances. Contrast echo-\ncardiography to assess vascularization. bIdentify primary extra-cardiac malignancy. Reveal extra-cardiac changes. Staging of malignant lesions. cTissue\ncharacterization (fat inﬁltration, necrosis, haemorrhage, calciﬁcation, and vascularization). Exclude thrombus. dDistinguish malignant vs. benign lesions.\nStaging of malignant lesions. eMass biopsy of suspected primary malignant cardiac tumours and/or biopsy of extracardiac masses if detected and safer\nto biopsy. f20–30 times more likely than primary tumours.\nTable 13\nManagement strategies and surgery indications for symptomatic and asymptomatic patients with benign\nand malignant cardiac tumours\nClassiﬁcation\nManagement strategies\nSurgery indications\nBenign\ntumours\nAsymptomatic\nMDT discussion is required considering: tumour type,\nlocation, size, growth rate, and likelihood of embolism.\nAnticoagulation should be considered for left-sided\ntumours or right-sided tumours associated with an\nintracardiac shunt, according to the individual’s embolic and\nbleeding risk\nIf left-sided and endocardial: even if small and incidental, a\nMDT is needed to consider the indication for surgical\nremoval due to the embolic risk\nSymptomatic\nNon-surgical management for:\n• Rhabdomyomas (possible spontaneous regression)\n• Intramural haemangioma (possible response to\ncorticosteroids)\n• Unresectable cases: if antiarrhythmic therapy is sufﬁcient\nSurgical resection is indicated in all other cases.\nFor large, benign, unresectable, symptomatic cardiac\ntumours (obstruction, severe HF, or malignant\narrhythmias), heart transplantation may be indicated in\nsome cases\nMalignant\ntumours\nAsymptomatic\nHistopathological diagnosis is required\nIf primary cardiac sarcoma, a complete surgical resection\nmay increase survival\nSymptomatic\nChemotherapy and/or RT are the only therapeutic options\nfor secondary cardiac tumours.\nIf primary cardiac lymphoma: chemotherapy\nSecondary cardiac tumours may also be treated with\npalliative cardiac surgery\n© ESC 2022\nHF, heart failure; MDT, multidisciplinary team; RT, radiotherapy.\nESC Guidelines\n4321\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendations for the diagnosis and treatment of PE during preg-\nnancy are the same as in the general 2018 ESC Guidelines for the man-\nagement of CVD during pregnancy741 and 2019 ESC Guidelines for the\ndiagnosis and management of acute pulmonary embolism.566\nDetermination of VTE risk score and the use of thrombo-\nprophylaxis protocols may be useful to prevent maternal\nmorbidity and/or mortality due to VTE.770 LMWH have be-\ncome the drug of choice for the prophylaxis and treatment\nof VTE in pregnant patients.741 The recommendation for\nthromboprophylaxis should be individualized, weighing the\nrisks of bleeding vs. thromboembolism in pregnant patients\nwith cancer.\n1st trimester\nFollow-up\nAnthracycline chemotherapy\n1st trimester\nAnthracycline chemotherapy\nFollow-up\nECG\nTTE\nPhysical examination\nBaseline\nWeek\n12\nWeek\n20\nEvery visit\nEvery\n4–8 W\nWeek\n34\nDelivery\n12 M\nCardiac monitoring protocol for pregnant women receiving\nanthracycline-based chemotherapy\nECG\ncTn/NP\nClass 1\nClass 1Ia\nClass 1Ib\nFigure 41 Cardiac monitoring protocol for pregnant women receiving anthracycline-based chemotherapy. cTn, cardiac troponin; ECG, electrocardio-\ngram; M, months; NP, natriuretic peptides; TTE, transoesophageal echocardiography; W, week.\n4322\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n9.3. Carcinoid valvular heart disease\nCarcinoid tumours represent rare neuroendocrine malignancies ori-\nginating from the enterochromafﬁn cells (Figure 42).771 Carcinoid\nsyndrome is a rare cause of acquired VHD including mainly right-\nsided valvular lesions, but also left-sided involvement, pericardial ef-\nfusion, and myocardial metastases.772 Coronary artery vasospasm\nand paroxysmal atrial or ventricular tachycardias may rarely occur\ndue to sympathetic stimulation. Cardiac metastases are reported\nwith an incidence of 3.8% on the ventricles, conﬁrmed by PET-CT\nscans.773,774 Data from the SEER (Surveillance, Epidemiology, and\nEnd Results) registry identiﬁed that approximately 20% of patients\nwith neuroendocrine malignancies develop carcinoid syndrome\n(7.6–32.4%), which is associated with shorter survival (4.7 years\ncompared with 7.1 years in patients without carcinoid syndrome)\nand poor quality of life.775 It is estimated that 20–50% of these pa-\ntients present cardiac involvement, especially of the right-sided car-\ndiac valves.771 In the presence of a patent foramen ovale, interatrial\nshunt, primary bronchial neuroendocrine tumour, or extensive liver\nmetastases, humoral substances directly enter the systemic circula-\ntion, causing left-sided valvular involvement in up to one-third of\ncases.776\nNP should be considered for screening and surveillance of patients\nat risk of carcinoid cardiac involvement and TTE is recommended in\npatients with NT-proBNP . 260 pg/mL or clinical signs or symp-\ntoms.777–780 In asymptomatic patients with NT-proBNP , 260 pg/\nmL, repeat clinical and NP assessment should be considered every\n6 months.\nSurvival has improved in carcinoid tumours, with the use of som-\natostatin analogues and surgical techniques in liver metastasis.\nHowever, right HF still represents a major cause of death.781,782\nMany patients with severe tricuspid regurgitation due to carcinoid\nsyndrome require both tricuspid and pulmonary valve surgery.783\nAdministration of i.v. somatostatin analogues (e.g. octreotide) is re-\ncommended to avoid a peri-operative carcinoid crisis. The infusion\nshould be started on the morning of the procedure (up to 12 h pre-\noperatively), continued throughout the procedure (surgery, pre-\noperative coronary angiography, pacemaker implantation), and post-\noperatively for at least 48 h following valve surgery or until stable if a\ncarcinoid crisis is triggered post-operatively.772\nThe optimal choice of valve prosthesis is still a matter of debate\ndue to the balance of risk of both accelerated bioprosthetic valve de-\ngeneration vs. bleeding risks in patients with extensive liver metasta-\nses requiring therapeutic anticoagulation for mechanical valves.784,785\nComplications include AV block, requiring pacemaker implantation\nin 25% of patients.786 Frequently, the reduced RV function does\nnot improve despite tricuspid valve replacement and HF persists.787\nThrombus formation on the tricuspid bioprosthesis can occur, espe-\ncially during the ﬁrst 3 months post-operatively, and oral anticoagu-\nlation with VKA may be considered. Persistent serotonin elevation\ncan cause recurrent bioprosthesis valve ﬁbrosis. Valve-in-valve trans-\ncatheter intervention has been reported in bioprosthetic valve failure\nin metastatic carcinoid heart disease; however, future research is\nneeded to deﬁne its role.783,788,789\nIn patients with left-sided carcinoid valvular involvement, closure\nof interatrial shunts should be considered, although only sparse\ndata exist for this approach.\nRecommendation Table 47 — Recommendations for\ncardiovascular assessment and monitoring of pregnant\nwomen with cancer\nRecommendations\nClassa\nLevelb\nManagement by an expert MDT (the pregnancy\nheart team) in an expert centre is recommended\nfor pregnant women with cancer who require\ncardiotoxic cancer therapy.741\nI\nC\nCardiac assessment prior to cardiotoxic cancer\ntherapy in pregnant women is recommended and\nconsists of clinical history, physical examination,\nECG, and echocardiography.741\nI\nC\nMonthly or bimonthly CV evaluation, including\nTTE, should be considered during cardiotoxic\ncancer therapyc in pregnant women with cancer.\nIIa\nC\ncTn may be considered at baseline and during\nanthracycline chemotherapy in pregnant women\nwith cancer.\nIIb\nC\n© ESC 2022\ncTn,\ncardiac\ntroponin;\nCV,\ncardiovascular;\nECG,\nelectrocardiogram;\nMDT,\nmultidisciplinary team; TTE, transthoracic echocardiography.\naClass of recommendation.\nbLevel of evidence.\ncFor patients receiving anthracycline-based chemotherapy.\nRecommendation Table 48 — Recommendations for\ncarcinoid valvular heart diseases\nRecommendations\nClassa\nLevelb\nEchocardiographyc is recommended for the\ndetection of carcinoid cardiac involvement in all\npatients with carcinoid syndrome and elevated NP\nlevels and/or clinical signs of carcinoid heart\ndisease, and for surveillance every 3 or 6 months\ndepending on the severity of cardiac involvement\nand clinical status.772,790,791\nI\nB\nNP should be considered for screening and\nsurveillance of carcinoid heart disease every 6\nmonths.777–780\nIIa\nB\nA MDT discussion for optimal medial\nmanagement to prevent carcinoid crisis is\nrecommended before any invasive or surgical\ncardiac procedure.\nI\nC\nValve replacement surgery is recommended in\nsymptomatic patients with severe carcinoid\ntricuspid or pulmonary VHD and an expected\nsurvival ≥12 months.d,783,785\nI\nC\nValve replacement surgery should be considered\nin patients with asymptomatic severe carcinoid\ntricuspid or pulmonary VHD, progressive RV\ndysfunction/dilatation, and an expected survival\n≥12 months.d,772\nIIa\nC\nContinued\nESC Guidelines\n4323\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n9.4. Amyloid light-chain cardiac\namyloidosis\nAmyloid light-chain amyloidosis is a plasma cell dyscrasia, which\nis typically treated with therapies very similar to those used in\nMM, including PI-based therapy.792 It can occur in conjunction\nwith myeloma or independently as a light-chain protein-\nproducing disorder. Amyloid light-chain amyloidosis is a systemic\ndisease 793,794 and it is critical to have a high degree of suspicion for\nthe diagnosis of cardiac involvement (amyloid light-chain cardiac\namyloidosis [AL-CA]) because a combination of specialized tests\nis needed to make an accurate diagnosis (Figure 43).290,793,795,796\nValve replacement or repair surgery is\nrecommended in symptomatic patients with\nsevere carcinoid mitral or aortic VHD and an\nexpected survival ≥12 months.783,785\nI\nC\n© ESC 2022\nMDT, multidisciplinary team; NP, natriuretic peptides; RV, right ventricular; VHD,\nvalvular heart disease.\naClass of recommendation.\nbLevel of evidence.\ncIncluding saline contrast infusion at baseline to rule out patent foramen ovale.\ndWith controlled serotonin concentrations.\nFlushing\nBroncho-\nconstriction\nDiarrhoea\nAscites\nPeripheral\noedema\nPleural\neffusion\nCarcinoid heart disease: clinical features\u0002and diagnostic tests\nClinical features\nDiagnostic and pronostic tools\nTTE\nCirculating serotonin\nNP\nUrinary 5HIAA\nCMR\nFigure 42 Carcinoid heart disease: clinical features and diagnostic tests. 5HIAA, 5-hydroxyindoleacetic acid; CMR, cardiac magnetic resonance; NP,\nnatriuretic peptides; TTE, transthoracic echocardiography.\n4324\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nProteinuria\nRenal impairment\nKidney\nCV\nDyspnoea\nPeripheral oedema\nAF/flutter\nHFpEF or unexplained\nright HF\nHypotension or syncope\nNerves\nOrthostatic hypotension\nPeripheral polyneuropathy\nPolyneuropathy\nGI\nConstipation /diarrhoea\nMacroglossia\nMalabsorption/weight\nloss/nausea\nBruising\nSkin\nLaboratorya\nECGb\nTTEc\nCharacteristic echo findingse\nECHO score ≥8d\nCMRf\nNon-invasive diagnosis of AL-CA\nClinical features\nInvestigations\u0002\nFigure 43 Non-invasive diagnosis of amyloid light-chain cardiac amyloidosis. a′, late diastolic velocity of mitral annulus obtained by tissue Doppler im-\naging; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain cardiac amyloidosis; CMR, cardiac magnetic resonance; CV, cardiovascular; E, mitral inﬂow early\ndiastolic velocity obtained by pulsed wave; e′, early diastolic velocity of mitral annulus obtained by tissue doppler imaging; ECG, electrocardiogram; echo,\nechocardiography; ECV, extracellular volume fraction; GI, gastrointestinal; GLS, global longitudinal strain; HF, heart failure; HFpEF, heart failure with pre-\nserved ejection fraction; IVS, interventricular septum; LGE, late gadolinium enhancement; LV, left ventricular; LVEDD, left ventricular end diastolic diam-\neter; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PW, left ventricular posterior wall; s′, systolic velocity of tricuspid annulus obtained by\nDoppler tissue imaging; SPEP, serum protein electrophoresis; TAPSE, tricuspid annular plane systolic excursion; TTE, transthoracic echocardiography;\nUPEP, urine protein electrophoresis. Individually, the clinical manifestations and ﬁndings on cardiac testing for AL-CA are non-speciﬁc. Integration of\nall clinical and diagnostic ﬁndings is necessary when assessing the likelihood of the diagnosis. aDisproportionately high NT-proBNP; persisting elevated\ntroponin levels; abnormal free light-chain levels (AL-CA); positive SPEP and/or UPEP (AL-CA). bDisproportionally low QRS voltage; early conduction\nsystem disease; pseudo-infarct pattern. cUnexplained LV thickness ≥12 mm + 1 or 2 characteristic echo ﬁndings or ECHO score ≥8; idiopathic peri-\ncardial effusion. dECHO score: relative LV wall thickness (IVS + PW/LVEDD) . 0.6 (3 points), Doppler E/e′ . 11 (1 point); TAPSE ≤19 mm (2 points);\nGLS ≥−13% (1 point); systolic longitudinal strain apex to base ratio.2.9 (3 points). eCharacteristic echocardiography ﬁndings: grade ≥2 diastolic dys-\nfunction; reduced s′, e′, and a′ velocities (,5 cm/s); decreased GLS to ≥−15%. fDiffuse subendocardial or transmural LGE; elevated native T1 values;\nabnormal gadolinium kinetics (myocardial nulling preceding or coinciding with the blood pool); ECV ≥0.40% (strongly supportive).\nESC Guidelines\n4325\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCardiac serum biomarkers are an essential step in the diagnostic\nand prognostic assessments for these patients.797–799 AL-CA has\nbeen extensively reviewed in a recent position paper from the\nWorking Group on Myocardial and Pericardial Diseases.290\nThe classical non-invasive deﬁnition of AL-CA is based on clinical\nsuspicion, biomarkers, TTE, CMR, and nuclear scintigraphy criteria\n(Figure 43). Persistent troponin elevation and disproportionately\nhigh NT-proBNP (generally .300 ng/L in the absence of renal fail-\nure or AF) to ventricular function parameters on TTE is a charac-\nteristic red ﬂag for AL-CA.800 A decrease in GLS with a\ndistinctive apical sparing pattern (preserved GLS values in the LV\napical region) is considered speciﬁc for cardiac amyloidosis, al-\nthough it is not helpful to distinguish between amyloid light-chain\nand transthyretin amyloidosis.801 Additionally, GLS ≥−15% may\nserve as an independent prognostic factor of poor overall survival\nin patients with AL-CA.802 CMR with LGE and parametric imaging\nhas emerged as a new non-invasive gold-standard for diagnosis\n(Figure 43).803,804 Nuclear scintigraphy can differentiate transthyre-\ntin amyloidosis from AL-CA supported by the presence of mono-\nclonal protein.290 EMB should be considered in patients with\nsuspected AL-CA involvement if CMR is not diagnostic.290 A rare\ncondition that may coexist with AL-CA is light-chain deposition dis-\nease, which frequently associates extensive renal involvement and\npoor prognosis.799\nRecently, a staging system for AL-CA has demonstrated the prog-\nnostic impact of cTnT and NT-proBNP levels.797 Heart progression\ncriteria are deﬁned by NT-proBNP progression (.30% and\n.300 ng/L increase), cTnT progression (≥33% increase) or ejection\nfraction decrease (≥10% decrease).805–807 However, evaluating a\ncardiac response to treatment using a decrease in NT-proBNP levels\nand New York Heart Association class improvement is still\nchallenging.\nAL-CA frequently results in HF, major cardiac arrhythmias, ortho-\nstatic hypotension, sudden cardiac death, and an increased risk of ar-\nterial and venous thrombosis.808–810 Beta-blockers, ACE-I, ARB, or\nangiotensin receptor-neprilysin inhibitor may not be well tolerated\nbecause of hypotension.290 The management of AF is very complex\nin this population. Amiodarone is the preferred antiarrhythmic treat-\nment and digitalis should be used with caution. Anticoagulation is re-\ncommended in all AL-CA patients with AF independent of the\nCHA2DS2-VASc score due to the high prothrombotic risk unless\nthere is a contraindication.290 Currently, the guidelines for implanted\ndevices, including pacemakers and ICDs, do not provide speciﬁc re-\ncommendations for AL-CA and decisions should be individualized\nafter a MDT discussion.811\nOptimal systemic therapy for AL-CA is rapidly changing, and the\nefﬁcacy\nof\ncertain\ncombination\ntherapies\ncontinues\nto\nim-\nprove.812,813 Autologous HSCT for AL-CA is not universally utilized\nbut is a viable treatment option.814 Therapies for AL-CA are evolv-\ning, and daratumumab and PI show promise for improved out-\ncomes.792,815–817 Clinical observations, but no RCT evidence,\nsuggest the potential role of doxycycline to improve survival in pa-\ntients with AL-CA.818,819\n9.5. Cardiac implantable electronic\ndevices\nRT can cause malfunction of cardiac implantable electronic de-\nvices (CIEDs).443,823 The risk of RT-induced CIED malfunction\ngenerally increases with the radiation dose,824,825 although the\nstrongest\npredictor\nof\nmalfunction\nis\nthe\nmagnitude\nof\nexposure to neutron emission from high-energy photon RT, conven-\ntionally deﬁned as a beam energy .10 megavolts (MV).824,826,827\nNon-neutron-producing treatment is therefore preferable in pa-\ntients with a CIED.826\nRT-induced CIED malfunction can manifest in: (1) transient inter-\nference, with inappropriate triggering during the irradiation only; (2)\na reset, reverting to backup settings, recoverable with device repro-\ngramming; and, rarely (3) permanent damage to the device due to\ndirect CIED irradiation.826,827\nThe clinical consequences of a CIED malfunction include the inhib-\nition of pacing and inappropriate pacing at maximum sensor rate.826\nThe clinical effects of device malfunction are greatest when the pa-\ntient is pacing-dependent. Theoretically, oversensing might lead to\ninappropriate ICD shocks, although this has not been reported in\nthe literature.826\nMore recent registries have reported minimal or no adverse ef-\nfects of RT on CIED malfunction.827,828 Nevertheless, as it is not pos-\nsible to predict the behaviour of a CIED within or close to an RT\ntreatment volume, general recommendations should be followed\nto minimize patient risk (Figures 44–46).188,824,825\nPatients with a CIED should be reviewed by their cardiologist/\nelectrophysiologist to assess the risk of CIED malfunction and\nRecommendation Table 49 — Recommendations for\namyloid light-chain cardiac amyloidosis diagnosis and\nmonitoring\nRecommendations\nClassa\nLevelb\nEchocardiography, NP, and cTn are\nrecommended for the diagnosis of AL-CA in\npatients with plasma cell dyscrasia.290,820–822\nI\nB\nCMR is recommended in patients with suspected\nAL-CA.290,803,804\nI\nA\nEMB should be considered in patients with\nsuspected AL-CA involvement if CMR is not\ndiagnostic.290\nIIa\nC\nAdmission with inpatient ECG monitoring should be\nconsidered for high-risk patients with AL-CA\nrequiring PI during their ﬁrst cycle of therapy.c,808,811\nIIa\nC\n© ESC 2022\nAL-CA, amyloid light-chain cardiac amyloidosis; CMR, cardiac magnetic resonance; cTn,\ncardiac troponin; ECG, electrocardiogram; EMB, endomyocardial biopsy; HFA, Heart\nFailure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic\npeptides; PI, proteasome inhibitors.\naClass of recommendation.\nbLevel of evidence.\ncAccording to baseline evaluation using HFA-ICOS PI risk assessment tools (see\nSection 4).\n4326\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\npatients should be informed of the potential risks of RT.443 For pa-\ntients with rate-adaptive pacemakers, consideration should be given\nto temporary deactivation of the sensor during RT. Although inacti-\nvation of antitachycardia therapies in patients with ICDs is recom-\nmended in several publications, by either reprogramming or\napplication of a magnet to ICDs, it is infrequently performed in clin-\nical practice.826\nCIEDs should not be placed directly in the RT treatment vol-\nume and the cumulative dose should not exceed 2 Gy to a pace-\nmaker or 1 Gy to an ICD.827 If the CIED is situated in the path\nof the planned radiation beam, it could also interfere with\nadequate tumour treatment. The photon beam energy should\nbe kept ,10 MV as the risk of device malfunction/damage in-\ncreases above this threshold. If higher doses are needed or if\nthe CIED cannot be kept out of the beam, consideration should\nbe given to removing and relocating the CIED away from the\nbeam, although this will only very rarely be necessary. The main\nreason for device relocation is to allow adequate RT treatment\nof the tumour, but consideration should also be given to possible\nRT-induced CIED malfunction/damage with consequent need for\nCIED replacement.826 However, CIED explant and resiting carries\nsigniﬁcant risks, including the risk of infection, which may be of\nPacing-\ndependent or\nfrequent ICD\ntherapies \nPacing-\nindependent\n<5 Gy\n≥5 Gy\n<10 Gy or\nneutrons <10 MV\n≥10 Gy or\nneutrons ≥10 MV \nPatient\nAssessing risk of RT to CIED\nDose region\nand risk\ncategory\nLow risk\nHigh risk\nMedium risk\nCIED in the RT\ntreatment\nvolume\nYES\nNO\nRisk areas\nFigure 44 Risk stratiﬁcation in patients with a cardiac implantable electronic device undergoing radiotherapy. CIED, cardiac implantable electronic de-\nvice; Gy, Gray; ICD, implantable cardioverter deﬁbrillator; MV, megavolt; RT, radiotherapy.\nESC Guidelines\n4327\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nparticular importance in patients receiving chemotherapy or\nthose who are immunosuppressed. For most patients in whom\ndeﬁnitive tumour treatment is planned, the risk/beneﬁt ratio will\nusually favour device relocation, whereas for patients receiving\npalliative RT or with signiﬁcant comorbidities, relocation could\nbe avoided.826 These decisions should be made by a MDT in\nconjunction with the patient. Device relocation is not recom-\nmended for CIEDs receiving a maximum cumulative incident\ndose of ,5 Gy, where the risk is considered negligible.826,828\nThere should be continuous visual and voice contact with the pa-\ntient during each treatment fraction. CIEDs should be periodically\nchecked in patients with ICDs, especially those receiving .10 MV\nOR\nConsider moving CIED\nCIED evaluation:\nLeave device in situ\nCIED evaluation:\nfof re RT\nR\nb\nECG and/or pulse oximetry monitoring and external pacing available\na\nduring RT sessions\nR\nWeek\nW\nly during RT\nR\nReduce radiation energ\nr y to minimize exposure to neutrons\nLimit cumulative dose\nBefof re\u0002RT\nR\nb (Class I)\nAudio-visual monitoring\now-risk patients\nHigh-risk patients\nCIED in the RT t\nR\nreatment volume\nMDTa\nConsider RT type and dose\nR\n(Figure 46)\nCIED check-up after completing RT\nR\n(Class I)\nPacing dependent or\nfrequent ICD therapies\nMaximum cumulative\nincident dose of >5 Gy\n(Class I)\nN\nN\nN\nRisk stratification of patients with CIED underg\nr oing thoracic RT\nR\nY\nY\nY\nFigure 45 Management of patients with a cardiac implantable electronic device located in the radiotherapy treatment beam. CIED, cardiac implantable\nelectronic device; ECG, electrocardiogram; Gy, Gray; ICD, implantable cardioverter deﬁbrillator; MDT, multidisciplinary team; N, no; RT, radiotherapy; Y,\nyes. aMultidisciplinary discussion must consider: (1) whether the CIED is interfering with the RT dose delivered to the tumour; (2) whether the\nRT is interfering with CIED function (aim to not exceed 2 Gy to permanent pacemaker and 1 Gy to ICD); (3) risks of moving the CIED: infection (es-\npecially in immunocompromised patients), procedural complications (e.g. bleeding with thrombocytopaenia); for younger patients with good prognosis,\nconsider long-term effects of losing an access site (lead extraction/RT-induced thrombosis). bIf last CIED check .3 months earlier.\n4328\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nphoton beam energy.827,829 For patients receiving electron or kV\nphoton beam RT, CIED evaluation appears largely unnecessary.827\nFor patients treated with proton beam RT, special consideration\nshould be paid to the neutron component of the beam, as the risk\nof CIED reset is potentially signiﬁcant.824,830 The CIED should be re-\nchecked within 2 weeks of completion of RT treatment. Systematic\nremote CIED monitoring may be helpful to optimize the patient’s\nsurveillance.831\nLow-risk patients\nHigh-risk patients\nLow-risk patients\nHigh-risk patients\nHigh-risk patients\nRT type and dose\nR\nPacing-dependent\nCIED evaluation:\nCIED evaluation:\nCIED evaluation:\nCIED evaluation:\nBefof re\u0002RT\nR\na (Class I)\nAudio-visual monitoring\nBefof re\u0002RT\nR\na\nWeek\nW\nly during RT\nR\nECG and/or pulse\noximetry monitoring and\nexternal pacing available\na\nduring RT sessions\nR\nBefof re RT\nR\na\nWeek\nW\nly during RT\nR\nECG and/or pulse\noximetry monitoring and\nexternal pacing available\na\nduring RT sessions\nR\nBefof re RT\nR\na (Class I)\nAudio-visual monitoring\nCIED check-up after completing radiotherapy\np\n(Class I)\n(Class I)\n(Class I)\nPacing-dependent or\nfrequent ICD therapies\nNeutron-generating RT\nR\nor dose ≥2 Gy\n<10 MV photons or\n2–9 Gy\n≥10 MV photons or\n≥10 Gy\nNon-neutron-generating RT\nR\nor dose <2 Gy\nManagement of patients with CIED located outside the RT t\nR\nreatment volume\nN\nN\nY\nY\nFigure 46 Management of patients with a cardiac implantable electronic device located outside the radiotherapy treatment volume. CIED, cardiac\nimplantable electronic device; ECG, electrocardiogram; Gy, Gray; ICD, implantable cardioverter deﬁbrillator; MV, megavolt; N, no; RT, radiotherapy;\nY, yes. aIf last CIED check .3 months earlier.\nESC Guidelines\n4329\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n10. Patient information,\ncommunication, and\nself-management\nCollaboration between different healthcare professionals and pa-\ntients is of paramount importance for the most effective manage-\nment of patients with cancer and CVD. Appropriate language and\ncommunication should be used to allow patients to receive clear\nand accurate information about their condition, and play an active\nrole in managing their treatment.11\nThe ﬁrst goal of this process is to raise the patient’s awareness of\nthe possible presence or development of a CVD, either during can-\ncer or after having some oncological therapy. Patients should under-\nstand that cancer and CVD share many CVRF and reducing risk is\nvital for the prevention of cancer, cancer relapse, and the develop-\nment or worsening of a CVD during or after treatment. Patients\nshould be informed—at the end of chemotherapy—that a persona-\nlized follow-up plan and regular CV controls are needed to detect\npotential reversible stages of CV toxicities. Education, counselling,\nand support to promote healthy lifestyle and to treat modiﬁable\nRecommendation Table 50 — Recommendations for\nriskstratiﬁcationandmonitoringforpatientswithcardiac\nimplantable electronic devices undergoing radiotherapy\nRecommendations\nClassa\nLevelb\nRisk stratiﬁcation including planned radiation type\nand energy, dose to CIED, the patient’s device\ntype, and pacing dependence is recommended\nprior to starting treatment.824,825,827,828\nI\nC\nIn patients undergoing RT, a CIED check is\nrecommended in all patients before and after\ncompleting RT, and during RT according to\nindividual risk.824,826\nI\nC\nIn patients with a CIED undergoing RT at high risk\nof arrhythmia and/or device dysfunction, ECG\nmonitoring and/or pulse oximetry are\nrecommended during every RT session.827,829,831\nI\nC\n© ESC 2022\nCIED, cardiac implantable electronic device; ECG, electrocardiogram; RT, radiotherapy.\naClass of recommendation.\nbLevel of evidence.\nInteraction between healthcare professionals and patients with cancer\nInformation\nRaise awareness\nof possible CVD\nwith cancer\nUnderstand shared\nrisk factors for\ncancer and CVD\nAppropriate lifestyle\nmodification\nActive treatment\nof CVRF\nRecognition and\nreport of early CV\nsymptoms and signs\nRegular CV follow-up \n(also if asymptomatic)\nDon’t stop\ncardioprotective therapy\nwithout medical advice\nTimely EoL and\nDNR discussion\nEducation, counselling, and support\nConsider specific psychologic and social conditions\nAid of digital health tools or information leaflets\nAppropriate language\nand communication\nFigure 47 Patient information, communication, and self-management. CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk fac-\ntors; DNR, do not resuscitate; EoL, end of life.\n4330\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 91",
          "page": 91,
          "content": "Recommendations | Classa | Levelb\nIn high-risk female CS, pre-pregnancy counselling\nand management during pregnancy and around\ndelivery by a multidisciplinary pregnancy heart\nteam is recommended. | I | C\nA baseline CV evaluation including history,\nphysical examination, ECG, NP, and\nechocardiography is recommended in female CS\nwith a history of CTRCD who are considering\npregnancy. | I | C\nA baseline CV evaluation including history,\nphysical examination, ECG, and echocardiography\nshould be considered in all female CS who\nreceived potentially cardiotoxic cancer therapy\nand are considering pregnancy. | IIa | C\nA CV evaluation including echocardiography is\nrecommended at 12 weeks of pregnancy in female\nCS who are either high-risk or who received\npotentially cardiotoxic cancer therapy and did not\nhave a baseline CV assessment. | I | C\nA second CV evaluation including\nechocardiography should be considered at 20\nweeks of pregnancy in high-risk female CSc who\nreceived potentially cardiotoxic cancer therapy. | IIa | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "Classification |  | Management strategies | Surgery indications\nBenign\ntumours | Asymptomatic | MDT discussion is required considering: tumour type,\nlocation, size, growth rate, and likelihood of embolism.\nAnticoagulation should be considered for left-sided\ntumours or right-sided tumours associated with an\nintracardiac shunt, according to the individual’s embolic and\nbleeding risk | If left-sided and endocardial: even if small and incidental, a\nMDT is needed to consider the indication for surgical\nremoval due to the embolic risk\n | Symptomatic | Non-surgical management for:\n• Rhabdomyomas (possible spontaneous regression)\n• Intramural haemangioma (possible response to\ncorticosteroids)\n• Unresectable cases: if antiarrhythmic therapy is sufficient | Surgical resection is indicated in all other cases.\nFor large, benign, unresectable, symptomatic cardiac\ntumours (obstruction, severe HF, or malignant\narrhythmias), heart transplantation may be indicated in\nsome cases\nMalignant\ntumours | Asymptomatic | Histopathological diagnosis is required | If primary cardiac sarcoma, a complete surgical resection\nmay increase survival\n | Symptomatic | Chemotherapy and/or RT are the only therapeutic options\nfor secondary cardiac tumours.\nIf primary cardiac lymphoma: chemotherapy | Secondary cardiac tumours may also be treated with\npalliative cardiac surgery",
          "rows": 5,
          "cols": 4
        },
        {
          "title": "Table on page 95",
          "page": 95,
          "content": "Recommendations | Classa | Levelb\nManagement by an expert MDT (the pregnancy\nheart team) in an expert centre is recommended\nfor pregnant women with cancer who require\ncardiotoxic cancer therapy.741 | I | C\nCardiac assessment prior to cardiotoxic cancer\ntherapy in pregnant women is recommended and\nconsists of clinical history, physical examination,\nECG, and echocardiography.741 | I | C\nMonthly or bimonthly CV evaluation, including\nTTE, should be considered during cardiotoxic\ncancer therapyc in pregnant women with cancer. | IIa | C\ncTn may be considered at baseline and during\nanthracycline chemotherapy in pregnant women\nwith cancer. | IIb | C",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 95",
          "page": 95,
          "content": "Recommendations | Classa | Levelb\nEchocardiographyc is recommended for the\ndetection of carcinoid cardiac involvement in all\npatients with carcinoid syndrome and elevated NP\nlevels and/or clinical signs of carcinoid heart\ndisease, and for surveillance every 3 or 6 months\ndepending on the severity of cardiac involvement\nand clinical status.772,790,791 | I | B\nNP should be considered for screening and\nsurveillance of carcinoid heart disease every 6\nmonths.777–780 | IIa | B\nA MDT discussion for optimal medial\nmanagement to prevent carcinoid crisis is\nrecommended before any invasive or surgical\ncardiac procedure. | I | C\nValve replacement surgery is recommended in\nsymptomatic patients with severe carcinoid\ntricuspid or pulmonary VHD and an expected\nsurvival ≥12 months.d,783,785 | I | C\nValve replacement surgery should be considered\nin patients with asymptomatic severe carcinoid\ntricuspid or pulmonary VHD, progressive RV\ndysfunction/dilatation, and an expected survival\n≥12 months.d,772 | IIa | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 98",
          "page": 98,
          "content": "Recommendations | Classa | Levelb\nEchocardiography, NP, and cTn are\nrecommended for the diagnosis of AL-CA in\npatients with plasma cell dyscrasia.290,820–822 | I | B\nCMR is recommended in patients with suspected\nAL-CA.290,803,804 | I | A\nEMB should be considered in patients with\nsuspected AL-CA involvement if CMR is not\ndiagnostic.290 | IIa | C\nAdmission with inpatient ECG monitoring should be\nconsidered for high-risk patients with AL-CA\nrequiring PI during their first cycle of therapy.c,808,811 | IIa | C",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 102",
          "page": 102,
          "content": "Recommendations | Classa | Levelb\nRisk stratification including planned radiation type\nand energy, dose to CIED, the patient’s device\ntype, and pacing dependence is recommended\nprior to starting treatment.824,825,827,828 | I | C\nIn patients undergoing RT, a CIED check is\nrecommended in all patients before and after\ncompleting RT, and during RT according to\nindividual risk.824,826 | I | C\nIn patients with a CIED undergoing RT at high risk\nof arrhythmia and/or device dysfunction, ECG\nmonitoring and/or pulse oximetry are\nrecommended during every RT session.827,829,831 | I | C",
          "rows": 4,
          "cols": 3
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "prognosis",
        "echo",
        "special",
        "catheterization",
        "surgery",
        "risk",
        "pulmonary hypertension",
        "populations",
        "treatment",
        "imaging",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "12",
      "title": "10. Patient information, communication, and self-management",
      "start_page": 102,
      "end_page": 103,
      "content": "10. Patient information,\ncommunication, and\nself-management\nCollaboration between different healthcare professionals and pa-\ntients is of paramount importance for the most effective manage-\nment of patients with cancer and CVD. Appropriate language and\ncommunication should be used to allow patients to receive clear\nand accurate information about their condition, and play an active\nrole in managing their treatment.11\nThe ﬁrst goal of this process is to raise the patient’s awareness of\nthe possible presence or development of a CVD, either during can-\ncer or after having some oncological therapy. Patients should under-\nstand that cancer and CVD share many CVRF and reducing risk is\nvital for the prevention of cancer, cancer relapse, and the develop-\nment or worsening of a CVD during or after treatment. Patients\nshould be informed—at the end of chemotherapy—that a persona-\nlized follow-up plan and regular CV controls are needed to detect\npotential reversible stages of CV toxicities. Education, counselling,\nand support to promote healthy lifestyle and to treat modiﬁable\nRecommendation Table 50 — Recommendations for\nriskstratiﬁcationandmonitoringforpatientswithcardiac\nimplantable electronic devices undergoing radiotherapy\nRecommendations\nClassa\nLevelb\nRisk stratiﬁcation including planned radiation type\nand energy, dose to CIED, the patient’s device\ntype, and pacing dependence is recommended\nprior to starting treatment.824,825,827,828\nI\nC\nIn patients undergoing RT, a CIED check is\nrecommended in all patients before and after\ncompleting RT, and during RT according to\nindividual risk.824,826\nI\nC\nIn patients with a CIED undergoing RT at high risk\nof arrhythmia and/or device dysfunction, ECG\nmonitoring and/or pulse oximetry are\nrecommended during every RT session.827,829,831\nI\nC\n© ESC 2022\nCIED, cardiac implantable electronic device; ECG, electrocardiogram; RT, radiotherapy.\naClass of recommendation.\nbLevel of evidence.\nInteraction between healthcare professionals and patients with cancer\nInformation\nRaise awareness\nof possible CVD\nwith cancer\nUnderstand shared\nrisk factors for\ncancer and CVD\nAppropriate lifestyle\nmodification\nActive treatment\nof CVRF\nRecognition and\nreport of early CV\nsymptoms and signs\nRegular CV follow-up \n(also if asymptomatic)\nDon’t stop\ncardioprotective therapy\nwithout medical advice\nTimely EoL and\nDNR discussion\nEducation, counselling, and support\nConsider specific psychologic and social conditions\nAid of digital health tools or information leaflets\nAppropriate language\nand communication\nFigure 47 Patient information, communication, and self-management. CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk fac-\ntors; DNR, do not resuscitate; EoL, end of life.\n4330\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCVRF should be offered to patients with cancer, in order to reduce\nthe burden of complications during and after anticancer therapy.\nPatients should receive guidance to recognize and to report signs\nand symptoms of CVD, in order to receive prompt and effective treat-\nment, ideally without interfering with their cancer treatment. Patients\nshould also be advised not to stop cardioprotective therapies without\nmedical guidance, even if they recover their cardiac function. To help\nin this complex task, leaﬂets speciﬁcally designed for this context may\nbe used,832,833 eventually with the aid of digital tools (Figure 47).\n11. The role of scientiﬁc societies\nin the promotion and\ndevelopment of cardio-oncology\nin modern medicine\nCardio-oncology is a subspecialty that has seen huge development and\ngrowth in recent years with the formation—in almost all national and\ninternational\nsocieties—of\ncardio-oncology\nworking\ngroups.\nMoreover, cancer and medical associations have also developed an in-\ncreasing interest in cardio-oncology. Important roles of these scientiﬁc\nsocieties are clinical research, education, and advocacy. The ESC-CCO\nstrategic plan and mission include improvement of prevention, diagno-\nsis, treatment, and management of CTR-CVT and enhancement of the\nstandard of care for patients with cancer (Figure 48).\n12. Key messages\nThis is the ﬁrst ESC cardio-oncology Guideline and contains 272 new\nrecommendations. The key messages from this guideline are:\n• A guiding principle of cardio-oncology is integration, and\ncardio-oncology providers must have knowledge of the broad\nscope of cardiology, oncology, and haematology. Communication\nbetween different healthcare professionals is critical to optimize\nthe care of patients with cancer and CVD.\n• Cardio-oncology programmes facilitate cancer treatment by min-\nimizing unnecessary cancer therapy interruptions and CTR-CVT\nThe role of scientific societies in the promotion and\ndevelopment of cardio-oncology\nCardio-\noncology\nAdvocacy\nResearch\nEducation\nEngagement\nBasic and translational\nresearch\nClinical research\nLong-term survivorship\nprogrammes\nAppropriate\nresources\nCommunication\nKnowledge\nOrganization\nCommunity level\nInternational level\nNational level\nRegional level\nPolitical strategies\nagainst cancer and CVD\nCommunity\nHealthcare authorities\nHealthcare professionals\nPatients\nCommunication\nstrategies\nFigure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.\nESC Guidelines\n4331\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 102",
          "page": 102,
          "content": "Recommendations | Classa | Levelb\nRisk stratification including planned radiation type\nand energy, dose to CIED, the patient’s device\ntype, and pacing dependence is recommended\nprior to starting treatment.824,825,827,828 | I | C\nIn patients undergoing RT, a CIED check is\nrecommended in all patients before and after\ncompleting RT, and during RT according to\nindividual risk.824,826 | I | C\nIn patients with a CIED undergoing RT at high risk\nof arrhythmia and/or device dysfunction, ECG\nmonitoring and/or pulse oximetry are\nrecommended during every RT session.827,829,831 | I | C",
          "rows": 4,
          "cols": 3
        }
      ],
      "keywords": [
        "ct",
        "communication",
        "asymptomatic",
        "follow-up",
        "monitoring",
        "information",
        "management",
        "risk",
        "symptomatic",
        "patient",
        "treatment",
        "self",
        "recommendation"
      ]
    },
    {
      "number": "13",
      "title": "11. The role of scientific societies in the promotion and development of cardio-oncology in modern medicine",
      "start_page": 103,
      "end_page": 103,
      "content": "CVRF should be offered to patients with cancer, in order to reduce\nthe burden of complications during and after anticancer therapy.\nPatients should receive guidance to recognize and to report signs\nand symptoms of CVD, in order to receive prompt and effective treat-\nment, ideally without interfering with their cancer treatment. Patients\nshould also be advised not to stop cardioprotective therapies without\nmedical guidance, even if they recover their cardiac function. To help\nin this complex task, leaﬂets speciﬁcally designed for this context may\nbe used,832,833 eventually with the aid of digital tools (Figure 47).\n11. The role of scientiﬁc societies\nin the promotion and\ndevelopment of cardio-oncology\nin modern medicine\nCardio-oncology is a subspecialty that has seen huge development and\ngrowth in recent years with the formation—in almost all national and\ninternational\nsocieties—of\ncardio-oncology\nworking\ngroups.\nMoreover, cancer and medical associations have also developed an in-\ncreasing interest in cardio-oncology. Important roles of these scientiﬁc\nsocieties are clinical research, education, and advocacy. The ESC-CCO\nstrategic plan and mission include improvement of prevention, diagno-\nsis, treatment, and management of CTR-CVT and enhancement of the\nstandard of care for patients with cancer (Figure 48).\n12. Key messages\nThis is the ﬁrst ESC cardio-oncology Guideline and contains 272 new\nrecommendations. The key messages from this guideline are:\n• A guiding principle of cardio-oncology is integration, and\ncardio-oncology providers must have knowledge of the broad\nscope of cardiology, oncology, and haematology. Communication\nbetween different healthcare professionals is critical to optimize\nthe care of patients with cancer and CVD.\n• Cardio-oncology programmes facilitate cancer treatment by min-\nimizing unnecessary cancer therapy interruptions and CTR-CVT\nThe role of scientific societies in the promotion and\ndevelopment of cardio-oncology\nCardio-\noncology\nAdvocacy\nResearch\nEducation\nEngagement\nBasic and translational\nresearch\nClinical research\nLong-term survivorship\nprogrammes\nAppropriate\nresources\nCommunication\nKnowledge\nOrganization\nCommunity level\nInternational level\nNational level\nRegional level\nPolitical strategies\nagainst cancer and CVD\nCommunity\nHealthcare authorities\nHealthcare professionals\nPatients\nCommunication\nstrategies\nFigure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.\nESC Guidelines\n4331\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "societies",
        "ct",
        "cardio",
        "scientific",
        "role",
        "medicine",
        "oncology",
        "modern",
        "development",
        "treatment",
        "promotion",
        "recommendation"
      ]
    },
    {
      "number": "14",
      "title": "12. Key messages",
      "start_page": 103,
      "end_page": 104,
      "content": "CVRF should be offered to patients with cancer, in order to reduce\nthe burden of complications during and after anticancer therapy.\nPatients should receive guidance to recognize and to report signs\nand symptoms of CVD, in order to receive prompt and effective treat-\nment, ideally without interfering with their cancer treatment. Patients\nshould also be advised not to stop cardioprotective therapies without\nmedical guidance, even if they recover their cardiac function. To help\nin this complex task, leaﬂets speciﬁcally designed for this context may\nbe used,832,833 eventually with the aid of digital tools (Figure 47).\n11. The role of scientiﬁc societies\nin the promotion and\ndevelopment of cardio-oncology\nin modern medicine\nCardio-oncology is a subspecialty that has seen huge development and\ngrowth in recent years with the formation—in almost all national and\ninternational\nsocieties—of\ncardio-oncology\nworking\ngroups.\nMoreover, cancer and medical associations have also developed an in-\ncreasing interest in cardio-oncology. Important roles of these scientiﬁc\nsocieties are clinical research, education, and advocacy. The ESC-CCO\nstrategic plan and mission include improvement of prevention, diagno-\nsis, treatment, and management of CTR-CVT and enhancement of the\nstandard of care for patients with cancer (Figure 48).\n12. Key messages\nThis is the ﬁrst ESC cardio-oncology Guideline and contains 272 new\nrecommendations. The key messages from this guideline are:\n• A guiding principle of cardio-oncology is integration, and\ncardio-oncology providers must have knowledge of the broad\nscope of cardiology, oncology, and haematology. Communication\nbetween different healthcare professionals is critical to optimize\nthe care of patients with cancer and CVD.\n• Cardio-oncology programmes facilitate cancer treatment by min-\nimizing unnecessary cancer therapy interruptions and CTR-CVT\nThe role of scientific societies in the promotion and\ndevelopment of cardio-oncology\nCardio-\noncology\nAdvocacy\nResearch\nEducation\nEngagement\nBasic and translational\nresearch\nClinical research\nLong-term survivorship\nprogrammes\nAppropriate\nresources\nCommunication\nKnowledge\nOrganization\nCommunity level\nInternational level\nNational level\nRegional level\nPolitical strategies\nagainst cancer and CVD\nCommunity\nHealthcare authorities\nHealthcare professionals\nPatients\nCommunication\nstrategies\nFigure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.\nESC Guidelines\n4331\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nacross the entire continuum of cancer care. In patients who de-\nvelop CTR-CVT, a MDT discussion is required to balance the\nrisk/beneﬁt of cancer treatment discontinuation.\n• There is a new international deﬁnition of CTR-CVT (Table 3).\n• CV toxicity risk is a dynamic variable. This guideline is structured to\nprovide a personalized approach to care based upon the baseline\nCV toxicity risk. A baseline CV risk assessment is recommended\nfor all patients with cancer scheduled to receive a potentially car-\ndiotoxic anticancer therapy. This enables the oncology team to\nconsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, and personalizing CV surveillance\nand follow-up strategy.\n• Primary prevention of CV toxicity from cancer therapy aims to\navoid or minimize the development of CTR-CVT in patients with-\nout CVD.\n• Secondary prevention refers to interventions in patients with pre-\nexisting CVD, including prior or new CTR-CVT. A MDT is recom-\nmended when patients with cancer have complex CVD that may\nimpact on their cancer treatment.\n• Deﬁning and delivering an appropriate prevention and surveillance\nplan for potential CV complications is recommended. Optimal\nmanagement of CVRF and pre-existing CVD is mandatory to facili-\ntate cancer therapy and to improve patients’ prognosis.\n• Detailed monitoring pathways during cancer therapy—including\n3D echocardiography, GLS, and cardiac biomarkers—are pro-\nvided to detect CV toxicity based upon speciﬁc cancer therapies\nand baseline CV toxicity risk.\n• Treatment recommendations for CTRCD during and after cancer\ntherapy depend upon CTRCD severity and symptoms. New guid-\nance on continuing trastuzumab in BC patients who develop\nasymptomatic moderate CTRCD (LVEF 40–49%) while starting\ncardioprotective medication is provided.\n• Use of a structured algorithm to guide decisions regarding anticoa-\ngulation management in patients with cancer presenting with AF\nor VTE encompassing the TBIP assessment is encouraged.\n• After\ncancer\ntreatment\nis\ncompleted,\nthe\nfocus\nof\nthe\ncardio-oncology team shifts to coordination of long-term follow-\nup. This starts with an ‘end-of-treatment’ assessment in the ﬁrst\nyear after treatment, reviewing patients with cancer who have re-\nceived cardiotoxic anticancer therapies to reassess their CV tox-\nicity risk and guide long-term surveillance planning.\n• A new algorithm (Figure 37) is provided to guide weaning off of CV\nmedication in CS.\n• Patients with cancer, CS, and the patient’s family/carers should re-\nceive guidance to promote healthy lifestyle and recognize and re-\nport signs and symptoms of CVD, to receive prompt and effective\ntreatment, without interfering with their cancer treatment.\n• Patients must receive psychological support when needed and\nclear and accurate information about their condition to play an ac-\ntive role in managing their treatment and increase adherence to\ncancer and CV treatments.\n13. Future needs\nThere are a low number of dedicated cardio-oncology services and\nmost patients are reviewed in general cardiology clinics in Europe\nand worldwide. Strategic investments in cardio-oncology care\nnetworks and cardio-oncology services provision are needed to\nmeet the projected increased clinical demand in the near fu-\nture,834 and to facilitate research, training, and educational activ-\nities. A dedicated training core curriculum for a minimum of\n1-year medical training is urgently needed. It may include: (1)\nknowledge of the broad scope of cardiology, oncology, and\nhaematology; (2) CV competencies for CTR-CVT prevention,\nsurveillance, and management of patients with cancer in dedicated\noutpatients’ cardio-oncology clinics; (3) inpatient consultative\nservices; and (4) dedicated time to achieve competences in CV im-\naging, HF, and vascular cardiology.\nCollaboration between healthcare providers, clinical and basic in-\nvestigators, healthcare authorities, regulatory bodies, advocacy\ngroups, and patients’ associations is needed to address future needs\n(see Section 11).\nAs this Guideline was developed, it became clear that there is a sig-\nniﬁcant lack of RCT to guide decision-making, with many recommen-\ndations supported by level of evidence C. This is complicated by the\nfast-moving pace of new oncology treatment developments against a\nbackground of dynamic CV toxicity likelihood. Therefore, large num-\nbers of patients and longer follow-up are required to provide sufﬁ-\ncient statistical power and deﬁnitive answers. In the future, the\nfollowing strategies and areas of research are priorities:\n• New trial designs focusing upon the ‘at-risk’ cancer patient\npopulations.\n• Validating current HFA-ICOS risk assessment tools and surveil-\nlance algorithms.\n• Assessment of new technologies for the detection of early\nCTRCD, broadening the biomarker panel and recognizing the spe-\nciﬁc patterns in early myocardial damage.\n• Reﬁning\nCV\nrisk\nscores\n(e.g.\nEuroSCORE\nII,\nSCORE2,\nSCORE2-OP, CHA2DS2-VASc, HAS-BLED, SYNTAX) for appli-\ncation in cancer populations.\n• Optimal treatment of steroid-resistant ICI CV toxicity and long-\nterm CV effects of ICI therapy.\n• Selection criteria for modern percutaneous structural (TAVI,\nMitraclip, LAA occluder devices) and electrophysiological (abla-\ntion) CV therapies in patients with active cancer.\n• Patient-speciﬁc predictive algorithms for QTc prolongation with\ncancer drugs.\n• Assessment of genetic proﬁles in more speciﬁc CTRCD risk\nprediction.\n• Identiﬁcation of the cancer patient populations with mild or mod-\nerate CTRCD during treatment who can safely wean off long-term\nCV medication.\n• Optimal modalities for screening long-term survivor populations\nfor the complications of anthracycline chemotherapy and medias-\ntinal radiation.\n• Creation of large cardio-oncology registries to collect ‘big data’ on\nlarge patient populations.\n• Application of artiﬁcial intelligence and other new data analytics to\nidentify new patients with cancer at risk and new parameters that\ncan predict risk of CTR-CVT, response to speciﬁc cardioprotec-\ntive interventions, and long-term risk and safety to wean off CV\ntherapies initiated during cancer treatment.\n4332\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "messages",
        "risk",
        "treatment",
        "recommendation"
      ]
    },
    {
      "number": "15",
      "title": "13. Future needs",
      "start_page": 104,
      "end_page": 105,
      "content": "across the entire continuum of cancer care. In patients who de-\nvelop CTR-CVT, a MDT discussion is required to balance the\nrisk/beneﬁt of cancer treatment discontinuation.\n• There is a new international deﬁnition of CTR-CVT (Table 3).\n• CV toxicity risk is a dynamic variable. This guideline is structured to\nprovide a personalized approach to care based upon the baseline\nCV toxicity risk. A baseline CV risk assessment is recommended\nfor all patients with cancer scheduled to receive a potentially car-\ndiotoxic anticancer therapy. This enables the oncology team to\nconsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, and personalizing CV surveillance\nand follow-up strategy.\n• Primary prevention of CV toxicity from cancer therapy aims to\navoid or minimize the development of CTR-CVT in patients with-\nout CVD.\n• Secondary prevention refers to interventions in patients with pre-\nexisting CVD, including prior or new CTR-CVT. A MDT is recom-\nmended when patients with cancer have complex CVD that may\nimpact on their cancer treatment.\n• Deﬁning and delivering an appropriate prevention and surveillance\nplan for potential CV complications is recommended. Optimal\nmanagement of CVRF and pre-existing CVD is mandatory to facili-\ntate cancer therapy and to improve patients’ prognosis.\n• Detailed monitoring pathways during cancer therapy—including\n3D echocardiography, GLS, and cardiac biomarkers—are pro-\nvided to detect CV toxicity based upon speciﬁc cancer therapies\nand baseline CV toxicity risk.\n• Treatment recommendations for CTRCD during and after cancer\ntherapy depend upon CTRCD severity and symptoms. New guid-\nance on continuing trastuzumab in BC patients who develop\nasymptomatic moderate CTRCD (LVEF 40–49%) while starting\ncardioprotective medication is provided.\n• Use of a structured algorithm to guide decisions regarding anticoa-\ngulation management in patients with cancer presenting with AF\nor VTE encompassing the TBIP assessment is encouraged.\n• After\ncancer\ntreatment\nis\ncompleted,\nthe\nfocus\nof\nthe\ncardio-oncology team shifts to coordination of long-term follow-\nup. This starts with an ‘end-of-treatment’ assessment in the ﬁrst\nyear after treatment, reviewing patients with cancer who have re-\nceived cardiotoxic anticancer therapies to reassess their CV tox-\nicity risk and guide long-term surveillance planning.\n• A new algorithm (Figure 37) is provided to guide weaning off of CV\nmedication in CS.\n• Patients with cancer, CS, and the patient’s family/carers should re-\nceive guidance to promote healthy lifestyle and recognize and re-\nport signs and symptoms of CVD, to receive prompt and effective\ntreatment, without interfering with their cancer treatment.\n• Patients must receive psychological support when needed and\nclear and accurate information about their condition to play an ac-\ntive role in managing their treatment and increase adherence to\ncancer and CV treatments.\n13. Future needs\nThere are a low number of dedicated cardio-oncology services and\nmost patients are reviewed in general cardiology clinics in Europe\nand worldwide. Strategic investments in cardio-oncology care\nnetworks and cardio-oncology services provision are needed to\nmeet the projected increased clinical demand in the near fu-\nture,834 and to facilitate research, training, and educational activ-\nities. A dedicated training core curriculum for a minimum of\n1-year medical training is urgently needed. It may include: (1)\nknowledge of the broad scope of cardiology, oncology, and\nhaematology; (2) CV competencies for CTR-CVT prevention,\nsurveillance, and management of patients with cancer in dedicated\noutpatients’ cardio-oncology clinics; (3) inpatient consultative\nservices; and (4) dedicated time to achieve competences in CV im-\naging, HF, and vascular cardiology.\nCollaboration between healthcare providers, clinical and basic in-\nvestigators, healthcare authorities, regulatory bodies, advocacy\ngroups, and patients’ associations is needed to address future needs\n(see Section 11).\nAs this Guideline was developed, it became clear that there is a sig-\nniﬁcant lack of RCT to guide decision-making, with many recommen-\ndations supported by level of evidence C. This is complicated by the\nfast-moving pace of new oncology treatment developments against a\nbackground of dynamic CV toxicity likelihood. Therefore, large num-\nbers of patients and longer follow-up are required to provide sufﬁ-\ncient statistical power and deﬁnitive answers. In the future, the\nfollowing strategies and areas of research are priorities:\n• New trial designs focusing upon the ‘at-risk’ cancer patient\npopulations.\n• Validating current HFA-ICOS risk assessment tools and surveil-\nlance algorithms.\n• Assessment of new technologies for the detection of early\nCTRCD, broadening the biomarker panel and recognizing the spe-\nciﬁc patterns in early myocardial damage.\n• Reﬁning\nCV\nrisk\nscores\n(e.g.\nEuroSCORE\nII,\nSCORE2,\nSCORE2-OP, CHA2DS2-VASc, HAS-BLED, SYNTAX) for appli-\ncation in cancer populations.\n• Optimal treatment of steroid-resistant ICI CV toxicity and long-\nterm CV effects of ICI therapy.\n• Selection criteria for modern percutaneous structural (TAVI,\nMitraclip, LAA occluder devices) and electrophysiological (abla-\ntion) CV therapies in patients with active cancer.\n• Patient-speciﬁc predictive algorithms for QTc prolongation with\ncancer drugs.\n• Assessment of genetic proﬁles in more speciﬁc CTRCD risk\nprediction.\n• Identiﬁcation of the cancer patient populations with mild or mod-\nerate CTRCD during treatment who can safely wean off long-term\nCV medication.\n• Optimal modalities for screening long-term survivor populations\nfor the complications of anthracycline chemotherapy and medias-\ntinal radiation.\n• Creation of large cardio-oncology registries to collect ‘big data’ on\nlarge patient populations.\n• Application of artiﬁcial intelligence and other new data analytics to\nidentify new patients with cancer at risk and new parameters that\ncan predict risk of CTR-CVT, response to speciﬁc cardioprotec-\ntive interventions, and long-term risk and safety to wean off CV\ntherapies initiated during cancer treatment.\n4332\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n14. Gaps in evidence\nCancer and CVD are the two major public health problems with great\neconomic and social impact. In addition, CTR-CVT are associated with\nanexcessofbothCVandoncologicalmortality,especiallywhenthey limit\npatients’ ability to complete effective treatments. However, the intersec-\ntion of cancer and CVD has only recently gained wider interest and many\nareas with lack of evidence need to be addressed in future research.\nRole of cardio-oncology services and cardio-oncology\ncare networks\n• Robust evidence on the impact of dedicated cardio-oncology pro-\ngrammes and cardio-oncology rehabilitation on the prognosis of\npatients with cancer and survivors.\n• Speciﬁcation of roles of different healthcare professionals (includ-\ning nurses and pharmacists) in cardio-oncology teams.\n• Cardio-oncology care networks to improve the management of\npatients with cancer and to discuss difﬁcult cases.\n• Cardio-oncology team support and involvement in oncology trials\ndesign (including patients’ representatives).\n• Understand how to engage patients with cancer in their own CV\ncare (inclusion of digital tools).\nResearch, education, and training in cardio-oncology\n• Consensus about CV toxicity deﬁnitions used in oncology trials.\n• Deﬁne standards for CV toxicity monitoring in oncology trials to\navoid unexpected CV toxicities when new drugs are approved for\nclinical use.\n• Relevant model systems to allow high-throughput screening of\nnew cancer treatments for CV toxicity.\n• Improved knowledge on CV toxicity mechanisms of new targeted\ncancer therapies and ICI and optimal treatment of CV toxicities.\n• Improved knowledge on the effects of radiation to speciﬁc cardiac\nsubstructures and the interactions between cardiotoxic systemic\ntherapy and RT.\n• Further research into the underlying mechanisms that connect\nCVD and cancer, such as a genetic predisposition to CV toxicity.\n• Personalized medicine and use of big data and artiﬁcial intelligence\ntools.\nCardiovascular toxicity risk stratiﬁcation\n• Development of CV toxicity risk prediction tools including both\ntreatment- and patient-related risk factors.\n• Validated prospective CV toxicity risk scores based on clinical\noutcomes.\n• Further research on the role of genetics in CV toxicity risk\nstratiﬁcation.\n• Validation of CPET parameters for CV outcomes in patients with\ncancer.\nPrevention, diagnosis, and management of CTR-CVT\n• Raise awareness of the beneﬁts of minimizing CV risk in patients\nwith cancer in order to reduce the risk of CTR-CVT.\n• More data on new technologies (biomarkers, advanced echocardi-\nography, CMR, etc.) and genetic proﬁles for the detection of early\nCV toxicity.\n• Prospective studies showing the impact on outcomes and/or qual-\nity of life (and frailty) of early CTR-CVT diagnosis and treatment.\n• Further evidence from prospective RCTs to deﬁne when cardio-\nprotective medications improve patients’ outcomes.\n• Further research on the potential for aerobic exercise to reduce\nCTR-CVT.\n• RCTs of (new) CV therapies in patients with different types of\nCTR-CVT.\nLong-term cancer survivorship programmes\n• Development of optimal CV follow-up programmes after treat-\nment for cancer (research on risk stratiﬁcation, efﬁcacy, and fre-\nquency of screening protocols).\n• Best screening strategies for RT-induced CAD.\n• Further research on CV preventive strategies for long-term CS.\n15. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendation Table 1 for a general approach to cardiovascular toxicity risk categorization\nCV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer.\nI\nB\nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended.\nI\nC\nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay.\nI\nC\nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.\nI\nC\nDiscussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended.\nI\nC\nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy.\nI\nC\nContinued\nESC Guidelines\n4333\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 105",
          "page": 105,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendation Table 1 for a general approach to cardiovascular toxicity risk categorization |  |  | \nCV toxicity risk stratification before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer. |  | I | B | \nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended. |  | I | C | \nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay. |  | I | C | \nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy. |  | I | C | \nDiscussion of the risk/benefit balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended. |  | I | C | \nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal findings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy. |  | I | C | ",
          "rows": 8,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "intervention",
        "prognosis",
        "echo",
        "ct",
        "moderate",
        "asymptomatic",
        "monitoring",
        "follow-up",
        "future",
        "needs",
        "risk",
        "symptomatic",
        "treatment",
        "recommendation"
      ]
    },
    {
      "number": "16",
      "title": "14. Gaps in evidence",
      "start_page": 105,
      "end_page": 105,
      "content": "14. Gaps in evidence\nCancer and CVD are the two major public health problems with great\neconomic and social impact. In addition, CTR-CVT are associated with\nanexcessofbothCVandoncologicalmortality,especiallywhenthey limit\npatients’ ability to complete effective treatments. However, the intersec-\ntion of cancer and CVD has only recently gained wider interest and many\nareas with lack of evidence need to be addressed in future research.\nRole of cardio-oncology services and cardio-oncology\ncare networks\n• Robust evidence on the impact of dedicated cardio-oncology pro-\ngrammes and cardio-oncology rehabilitation on the prognosis of\npatients with cancer and survivors.\n• Speciﬁcation of roles of different healthcare professionals (includ-\ning nurses and pharmacists) in cardio-oncology teams.\n• Cardio-oncology care networks to improve the management of\npatients with cancer and to discuss difﬁcult cases.\n• Cardio-oncology team support and involvement in oncology trials\ndesign (including patients’ representatives).\n• Understand how to engage patients with cancer in their own CV\ncare (inclusion of digital tools).\nResearch, education, and training in cardio-oncology\n• Consensus about CV toxicity deﬁnitions used in oncology trials.\n• Deﬁne standards for CV toxicity monitoring in oncology trials to\navoid unexpected CV toxicities when new drugs are approved for\nclinical use.\n• Relevant model systems to allow high-throughput screening of\nnew cancer treatments for CV toxicity.\n• Improved knowledge on CV toxicity mechanisms of new targeted\ncancer therapies and ICI and optimal treatment of CV toxicities.\n• Improved knowledge on the effects of radiation to speciﬁc cardiac\nsubstructures and the interactions between cardiotoxic systemic\ntherapy and RT.\n• Further research into the underlying mechanisms that connect\nCVD and cancer, such as a genetic predisposition to CV toxicity.\n• Personalized medicine and use of big data and artiﬁcial intelligence\ntools.\nCardiovascular toxicity risk stratiﬁcation\n• Development of CV toxicity risk prediction tools including both\ntreatment- and patient-related risk factors.\n• Validated prospective CV toxicity risk scores based on clinical\noutcomes.\n• Further research on the role of genetics in CV toxicity risk\nstratiﬁcation.\n• Validation of CPET parameters for CV outcomes in patients with\ncancer.\nPrevention, diagnosis, and management of CTR-CVT\n• Raise awareness of the beneﬁts of minimizing CV risk in patients\nwith cancer in order to reduce the risk of CTR-CVT.\n• More data on new technologies (biomarkers, advanced echocardi-\nography, CMR, etc.) and genetic proﬁles for the detection of early\nCV toxicity.\n• Prospective studies showing the impact on outcomes and/or qual-\nity of life (and frailty) of early CTR-CVT diagnosis and treatment.\n• Further evidence from prospective RCTs to deﬁne when cardio-\nprotective medications improve patients’ outcomes.\n• Further research on the potential for aerobic exercise to reduce\nCTR-CVT.\n• RCTs of (new) CV therapies in patients with different types of\nCTR-CVT.\nLong-term cancer survivorship programmes\n• Development of optimal CV follow-up programmes after treat-\nment for cancer (research on risk stratiﬁcation, efﬁcacy, and fre-\nquency of screening protocols).\n• Best screening strategies for RT-induced CAD.\n• Further research on CV preventive strategies for long-term CS.\n15. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendation Table 1 for a general approach to cardiovascular toxicity risk categorization\nCV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer.\nI\nB\nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended.\nI\nC\nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay.\nI\nC\nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.\nI\nC\nDiscussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended.\nI\nC\nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy.\nI\nC\nContinued\nESC Guidelines\n4333\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 105",
          "page": 105,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendation Table 1 for a general approach to cardiovascular toxicity risk categorization |  |  | \nCV toxicity risk stratification before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer. |  | I | B | \nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended. |  | I | C | \nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay. |  | I | C | \nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy. |  | I | C | \nDiscussion of the risk/benefit balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended. |  | I | C | \nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal findings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy. |  | I | C | ",
          "rows": 8,
          "cols": 5
        }
      ],
      "keywords": [
        "ct",
        "prognosis",
        "echo",
        "monitoring",
        "gaps",
        "risk",
        "evidence",
        "treatment",
        "diagnosis"
      ]
    },
    {
      "number": "17",
      "title": "15. ‘What to do’ and ‘what not to do’ messages from the Guidelines",
      "start_page": 105,
      "end_page": 114,
      "content": "14. Gaps in evidence\nCancer and CVD are the two major public health problems with great\neconomic and social impact. In addition, CTR-CVT are associated with\nanexcessofbothCVandoncologicalmortality,especiallywhenthey limit\npatients’ ability to complete effective treatments. However, the intersec-\ntion of cancer and CVD has only recently gained wider interest and many\nareas with lack of evidence need to be addressed in future research.\nRole of cardio-oncology services and cardio-oncology\ncare networks\n• Robust evidence on the impact of dedicated cardio-oncology pro-\ngrammes and cardio-oncology rehabilitation on the prognosis of\npatients with cancer and survivors.\n• Speciﬁcation of roles of different healthcare professionals (includ-\ning nurses and pharmacists) in cardio-oncology teams.\n• Cardio-oncology care networks to improve the management of\npatients with cancer and to discuss difﬁcult cases.\n• Cardio-oncology team support and involvement in oncology trials\ndesign (including patients’ representatives).\n• Understand how to engage patients with cancer in their own CV\ncare (inclusion of digital tools).\nResearch, education, and training in cardio-oncology\n• Consensus about CV toxicity deﬁnitions used in oncology trials.\n• Deﬁne standards for CV toxicity monitoring in oncology trials to\navoid unexpected CV toxicities when new drugs are approved for\nclinical use.\n• Relevant model systems to allow high-throughput screening of\nnew cancer treatments for CV toxicity.\n• Improved knowledge on CV toxicity mechanisms of new targeted\ncancer therapies and ICI and optimal treatment of CV toxicities.\n• Improved knowledge on the effects of radiation to speciﬁc cardiac\nsubstructures and the interactions between cardiotoxic systemic\ntherapy and RT.\n• Further research into the underlying mechanisms that connect\nCVD and cancer, such as a genetic predisposition to CV toxicity.\n• Personalized medicine and use of big data and artiﬁcial intelligence\ntools.\nCardiovascular toxicity risk stratiﬁcation\n• Development of CV toxicity risk prediction tools including both\ntreatment- and patient-related risk factors.\n• Validated prospective CV toxicity risk scores based on clinical\noutcomes.\n• Further research on the role of genetics in CV toxicity risk\nstratiﬁcation.\n• Validation of CPET parameters for CV outcomes in patients with\ncancer.\nPrevention, diagnosis, and management of CTR-CVT\n• Raise awareness of the beneﬁts of minimizing CV risk in patients\nwith cancer in order to reduce the risk of CTR-CVT.\n• More data on new technologies (biomarkers, advanced echocardi-\nography, CMR, etc.) and genetic proﬁles for the detection of early\nCV toxicity.\n• Prospective studies showing the impact on outcomes and/or qual-\nity of life (and frailty) of early CTR-CVT diagnosis and treatment.\n• Further evidence from prospective RCTs to deﬁne when cardio-\nprotective medications improve patients’ outcomes.\n• Further research on the potential for aerobic exercise to reduce\nCTR-CVT.\n• RCTs of (new) CV therapies in patients with different types of\nCTR-CVT.\nLong-term cancer survivorship programmes\n• Development of optimal CV follow-up programmes after treat-\nment for cancer (research on risk stratiﬁcation, efﬁcacy, and fre-\nquency of screening protocols).\n• Best screening strategies for RT-induced CAD.\n• Further research on CV preventive strategies for long-term CS.\n15. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendation Table 1 for a general approach to cardiovascular toxicity risk categorization\nCV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer.\nI\nB\nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended.\nI\nC\nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay.\nI\nC\nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.\nI\nC\nDiscussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended.\nI\nC\nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy.\nI\nC\nContinued\nESC Guidelines\n4333\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 2 for electrocardiogram baseline assessment\nAn ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment.\nI\nC\nIn patients with an abnormal baseline ECG, referral to a cardiologist is recommended.\nI\nC\nRecommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies\nBaseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to\nbe measured during treatment to detect CTRCD.\nI\nC\nRecommendation Table 4 for cardiac imaging modalities in patients with cancer\nGeneral\nEchocardiography is recommended as the ﬁrst-line modality for the assessment of cardiac function in patients with cancer.\nI\nC\n3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF.\nI\nB\nGLS is recommended in all patients with cancer having echocardiography, if available.\nI\nC\nBaseline cardiac imaging prior to potentially cardiotoxic therapies\nBaseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting\nanticancer therapy.\nI\nC\nRecommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity\nManagement of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and\nafter cancer therapy.\nI\nC\nRecommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity\nManagement of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy.\nI\nC\nRecommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months\nafter therapy\nTTE\nBaseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy.\nI\nB\nIn all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment.\nI\nB\nIn high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing\ntreatment.\nI\nC\nCardiac serum biomarkers\nBaseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy.\nI\nB\ncTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is\nrecommended in high- and very high-risk patients.\nI\nB\nRecommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the ﬁrst 12 months\nafter therapy\nTTE\nBaseline echocardiography is recommended before HER2-targeted therapies in all patients.\nI\nB\nIn patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within\n12 months after completing treatment.\nI\nB\nIn metastatic HER2+ disease, echocardiography is recommended every 3 months during the ﬁrst year; if the patient remains\nasymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment.\nI\nC\nCardiac biomarkers\nBaseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies.\nI\nC\nContinued\n4334\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 9 for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy\nBaseline CV risk assessment and evaluation including BP measurement, ECG, lipid proﬁle, HbA1c measurement, and SCORE2/SCORE2-\nOP or equivalent is recommended before starting ﬂuoropyrimidines.\nI\nC\nA baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting ﬂuoropyrimidines.\nI\nC\nRecommendation Table 10 for baseline risk assessment and monitoring during VEGFi\nBP monitoring\nBP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit.\nI\nC\nDaily home monitoring of BP for patients treated with VEGFi during the ﬁrst cycle, after each increase of VEGFi dose, and every 2–3\nweeks thereafter is recommended.\nI\nC\nECG monitoring\nIn patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the ﬁrst\n3 months and every 3–6 months thereafter.\nI\nC\nEchocardiography\nBaseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab.\nI\nC\nRecommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine\nkinase inhibitors\nBaseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI.\nI\nC\nIn patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the ﬁrst year and every 6–12\nmonths thereafter.\nI\nC\nBaseline echocardiography is recommended in patients scheduled to receive dasatinib.\nI\nC\nRecommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy\nBP monitoring and management\nBP measurement is recommended for patients treated with BTK inhibitors at every clinical visit.\nI\nB\nEchocardiography\nBaseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors.\nI\nC\nTTE is recommended in all patients who develop AF during BTK inhibitor therapy.\nI\nC\nAF\nOpportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy.\nI\nC\nRecommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies\nBP monitoring\nBP measurement is recommended for patients treated with PI at every clinical visit.\nI\nC\nCardiac serum biomarkers\nMeasurement of NP is recommended prior to PI in high- and very high-risk patients.\nI\nC\nNP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA.\nI\nB\nTTE\nBaseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI.\nI\nC\nContinued\nESC Guidelines\n4335\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nVTE prophylaxis\nTherapeutic doses of LMWH are recommended in patients with MM with previous VTE.\nI\nB\nProphylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least\nduring the ﬁrst 6 months of therapy.\nI\nA\nRecommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy\nBP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is\nrecommended.\nI\nC\nIn patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3\nmonths thereafter.\nI\nC\nBaseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK\ninhibitors.\nI\nC\nRecommendation Table 15 for baseline risk assessment and monitoring during immunotherapy\nECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy.\nI\nB\nBaseline echocardiography is recommended in high-risk patients before starting ICI therapy.\nI\nB\nCV assessment is recommended every 6–12 months in high-risk patients who require long-term (.12 months) ICI treatment.\nI\nC\nRecommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer\nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\npatients treated with ADT without pre-existing CVD.\nI\nB\nBaseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy.\nI\nB\nAnnual CV risk assessment is recommended during ADT.\nI\nB\nRecommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer\nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\nBC patients receiving endocrine therapies without pre-existing CVD.\nI\nC\nAnnual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV\nevents according to SCORE2/SCORE2-OP.\nI\nC\nRecommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy\nQTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib.\nI\nA\nQTc monitoring is recommended in patients treated with ribociclib with any dose increase.\nI\nB\nRecommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors\nBaseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors.\nI\nC\nBaseline echocardiography is recommended in all patients with cancer before starting osimertinib.\nI\nB\nRecommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell\nand tumour-inﬁltrating lymphocytes therapies\nBaseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies.\nI\nC\nA baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies.\nI\nC\nMeasurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2.\nI\nC\nContinued\n4336\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 21 for baseline risk assessment of patients before radiotherapy to a volume including the heart\nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended.\nI\nB\nRecommendation Table 22 for baseline risk assessment in haematopoietic stem cell transplantation patients\nBaseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is\nrecommended in HSCT patients.\nI\nC\nEchocardiography is recommended in all patients before HSCT.\nI\nC\nRecommendation Table 23 for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in\npatients receiving anticancer treatment\nA specialist CV assessment is recommended for optimal diagnostic workup and management of patients with cancer who present with\nnew CV toxicity during and after cancer treatment.\nI\nC\nRecommendation Table 24 for the management of cancer treatment-related cardiac dysfunction during anthracycline\nchemotherapy\nAnthracycline chemotherapy-induced symptomatic CTRCD\nHF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy.\nI\nB\nDiscontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD.\nI\nC\nTemporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCD and\na multidisciplinary approach regarding the decision to restart is recommended.\nI\nC\nA multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who\ndevelop mild symptomatic CTRCD.\nI\nC\nAnthracycline chemotherapy-induced asymptomatic CTRCD\nTemporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop\nasymptomatic moderate or severe CTRCD.\nI\nC\nA multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe\nasymptomatic CTRCD.\nI\nC\nContinuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have\ndeveloped a signiﬁcant fall in GLS or a troponin or a NP elevation .ULN.\nI\nC\nRecommendation Table 25 for the management of cancer treatment-related cardiac dysfunction during HER2-targeted therapies\nHER2-targeted therapy-induced symptomatic CTRCD\nHF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF , 50% during HER2-\ntargeted treatment.\nI\nB\nTemporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD\nand the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.\nI\nC\nIn patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs.\ninterrupt HER2-targeted therapy are recommended.\nI\nC\nHER2-targeted therapy-induced asymptomatic CTRCD\nTemporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic\nsevere CTRCD.\nI\nC\nA multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe\nasymptomatic CTRCD.\nI\nC\nContinuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with\nmore frequent cardiac monitoring.\nI\nC\nACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc during\nHER2-targeted treatment.\nI\nC\nRecommendation Table 26 for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis\ncTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis.\nI\nB\nIn patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is\nconﬁrmed or refuted.\nI\nC\nContinued\nESC Guidelines\n4337\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nInterruption of ICI treatment is recommended in patients with conﬁrmed ICI-associated myocarditis.\nI\nC\nContinuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients\nwith symptomatic ICI-associated myocarditis.\nI\nC\nEarly high-dose corticosteroids are recommended in patients with cancer and conﬁrmed ICI-associated myocarditis.\nI\nC\nContinuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of\nsymptoms, LV systolic dysfunction, conduction abnormalities, and signiﬁcant cTn reduction.\nI\nC\nAdmission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when\nindicated) is recommended for patients with ICI-associated fulminant myocarditis.\nI\nC\nA multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICI-\nassociated myocarditis.\nI\nC\nRecommendation Table 27 for the diagnosis and management of Takotsubo syndrome in patients with cancer\nCoronary angiography (invasive or CCTA) is recommended to exclude ACS.\nI\nC\nCMR is recommended to exclude myocarditis and MI.\nI\nB\nQT-prolonging drugs are not recommended during the acute TTS phase.\nIII\nC\nRecommendation Table 28 for the management of acute coronary syndromes in patients receiving anticancer treatment\nAn invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6\nmonths.\nI\nB\nA temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause.\nI\nC\nIn patients with cancer, thrombocytopaenia and ACS, aspirin is not recommended if platelets ,10 000/µL.\nIII\nC\nIn patients with cancer, thrombocytopaenia and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or\nticagrelor are not recommended if platelets ,50 000/µL.\nIII\nC\nRecommendation Table 29 for the management of chronic coronary syndromes in patients receiving anticancer treatment\nIndividualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/\nischaemic and bleeding risk, type and stage of cancer, and current cancer treatment.\nI\nC\nRecommendation Table 30 for the management of valvular heart disease in patients receiving anticancer treatment\nIn patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/EACTS Guidelines for the management\nof VHD is recommended, taking into consideration cancer prognosis and patient preferences.\nI\nC\nIn patients with cancer developing new VHD during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the\nmanagement of VHD is recommended, taking into consideration cancer prognosis and patient comorbidities.\nI\nC\nRecommendation Table 31 for the management of atrial ﬁbrillation in patients receiving anticancer treatment\nLong-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a\nCHA2DS2-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.\nI\nC\nThromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF.\nI\nC\nAntiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with\ncancer.\nIII\nC\nRecommendation Table 32 for the management of long QTc and ventricular arrhythmias in patients receiving anticancer treatment\nHow to manage QTc prolongation in patients with cancer\nDiscontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular\ntachyarrhythmias during treatment.\nI\nC\nTemporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms\nand an ECG should be repeated every 24 h until resolution of the QTcF prolongation.\nI\nC\nImmediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factors is recommended in\npatients with cancer who develop QTcF ≥500 ms.\nI\nC\nWeekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTc-\nprolonging cancer therapy.\nI\nC\nContinued\n4338\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nA 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy.\nI\nC\nRestarting QTc-prolonging cancer therapy\nA multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed signiﬁcant QTcF\nprolongation, to discuss alternative cancer treatments.\nI\nC\nWeekly ECG monitoring during the ﬁrst 4–6 weeks and then monthly thereafter is recommended in patients with cancer after\nrestarting QTc-prolonging cancer therapy.\nI\nC\nRecommendation Table 33 for the management of arterial hypertension in patients receiving anticancer treatment\nGeneral\nEffective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is\nrecommended.\nI\nC\nA BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy.\nI\nC\nThe competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any\ncancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values\n,160 mmHg (systolic) and ,100 mmHg (diastolic).\nI\nC\nCancer therapy-induced arterial hypertension treatment\nACE-I or ARB are the ﬁrst-line antihypertensive drugs recommended for BP management in patients with cancer.\nI\nB\nDihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP.\nI\nC\nCombination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic\nBP ≥160 mmHg and diastolic BP ≥100 mmHg.\nI\nC\nDiltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug\ninteractions.\nIII\nC\nRecommendation Table 34 for the management of venous thromboembolism in patients receiving anticancer treatment\nApixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incidental VTE in patients with cancer\nwithout contraindications.\nI\nA\nLMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL.\nI\nA\nCatheter-associated VTE\nDuration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and\ncontinuing longer if the catheter remains in situ.\nI\nC\nRecommendation Table 35 for venous thromboembolism prophylaxis during anticancer treatment\nExtended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or\nlaparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk.\nI\nB\nProphylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bed\nrest or reduced mobility in the absence of bleeding or other contraindications.\nI\nB\nA discussion with the patient about the relative beneﬁts and harms, cancer prognosis, drug cost, and duration of treatment is\nrecommended prior to prophylactic anticoagulation for the primary prevention of VTE.\nI\nC\nRecommendation Table 36 for management of peripheral artery disease during anticancer treatment\nIn patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt\nculprit cancer therapy is recommended.\nI\nC\nRecommendation Table 37 for the management of pulmonary hypertension during anticancer treatment\nRight-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic\nincrease in peak TRV . 3.4 m/s.\nI\nC\nIn patients with conﬁrmed dasatinib-induced PAH or new asymptomatic peak TRV . 3.4 m/s, an alternative BCR-ABL inhibitor is\nrecommended after peak TRV recovery to ,2.8 m/s.\nI\nC\nRecommendation Table 38 for the management of pericardial diseases in patients receiving anticancer treatment\nGeneral\nDiagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and\nmanagement of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy.\nI\nC\nContinued\nESC Guidelines\n4339\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nDiagnosis and management of ICI-associated pericarditis\nMultimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to\nconﬁrm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis.\nI\nC\nPrednisolone and colchicine are recommended for patients with ICI-associated pericarditis.\nI\nC\nInterruption of ICI treatment in patients with conﬁrmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is\nrecommended.\nI\nC\nA multidisciplinary discussion is recommended before restarting ICI treatment.\nI\nC\nRecommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment\nEducating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended.\nI\nC\nEducation is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD.\nI\nC\nCVRF assessment is recommended during the ﬁrst year after cancer therapy and thereafter according to the 2021 ESC Guidelines on\nCVD prevention in clinical practice.\nI\nB\nIn asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after\ncompletion of cancer therapy.\nI\nB\nCardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in\nechocardiography and/or cardiac serum biomarkers at the end of therapy assessment.\nI\nC\nLong-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy.\nI\nC\nCV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer\ntherapy.\nI\nC\nCV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy.\nI\nC\nECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy.\nI\nC\nRecommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer\nsurvivors\nEducation of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding their increased CV risk is recommended.\nI\nB\nAnnual screening for modiﬁable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including the heart.\nI\nC\nCV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the ﬁrst trimester.\nI\nC\nRecommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors\nAnnual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially\ncardiotoxic cancer drug or RT.\nI\nB\nCV toxicity risk restratiﬁcation is recommended 5 years after therapy to organize long-term follow-up.\nI\nC\nRecommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic\ncancer therapy\nACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD.\nI\nC\nRecommendation Table 43 for adult cancer survivors with coronary artery disease\nAsymptomatic radiation-induced CAD detected during surveillance\nNon-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on\nCCTA to guide ischaemia-directed management.\nI\nC\nA MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or\nsevere left main CAD.\nI\nC\nContinued\n4340\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nSymptomatic CAD\nPre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiation-\ninduced CAD where CABG is considered.\nI\nC\nRecommendation Table 44 for adult cancer survivors with valvular heart disease\nA MDT approach is recommended to discuss and deﬁne the surgical risk in CS with severe VHD.\nI\nC\nRecommendation Table 46 for cardiovascular monitoring in cancer survivors during pregnancy\nIn high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary\npregnancy heart team is recommended.\nI\nC\nA baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a\nhistory of CTRCD who are considering pregnancy.\nI\nC\nA CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who\nreceived potentially cardiotoxic cancer therapy and did not have a baseline CV assessment.\nI\nC\nRecommendation Table 47 for cardiovascular assessment and monitoring of pregnant women with cancer\nManagement by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who\nrequire cardiotoxic cancer therapy.\nI\nC\nCardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical\nexamination, ECG, and echocardiography.\nI\nC\nRecommendation Table 48 for carcinoid valvular heart diseases\nEchocardiography is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and\nelevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of\ncardiac involvement and clinical status.\nI\nB\nA MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac\nprocedure.\nI\nC\nValve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an\nexpected survival ≥12 months.\nI\nC\nValve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an\nexpected survival ≥12 months.\nI\nC\nRecommendation Table 49 for amyloid light-chain cardiac amyloidosis diagnosis and monitoring\nEchocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia.\nI\nB\nCMR is recommended in patients with suspected AL-CA.\nI\nA\nRecommendation Table 50 for risk stratiﬁcation and monitoring for patients with cardiac implantable electronic devices undergoing\nradiotherapy\nRisk stratiﬁcation including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is\nrecommended prior to starting treatment.\nI\nC\nIn patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to\nindividual risk.\nI\nC\nIn patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are\nrecommended during every RT session.\nI\nC\n© ESC 2022\n3D, three-dimensional; ACE-I, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndromes; ADT, androgen deprivation therapy; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain\ncardiac amyloidosis; ALK, anaplastic lymphoma kinase;ARB, angiotensin receptorblocker; ASTCT, AmericanSociety for Transplantation and Cellular;AV, atrioventricular; BC, breast cancer; BCR-\nABL, breakpoint cluster region–Abelson oncogene locus; BP, blood pressure; BTK, Bruton tyrosine kinase; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAR-T, chimeric\nantigen receptor T cell; CCB, calcium channel blockers; CCS, chronic coronary syndromes; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, Congestive heart failure,\nHypertension, Age .75 years (2 points), Diabetes mellitus, Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female); CIED, cardiac implantable electronic device; CMR,\ncardiac magnetic resonance; CRS, cytokine release syndrome; CT, computed tomography; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CS, cancer survivors;\nCV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DAPT, dual antiplatelet therapy; EACTS, European Association for Cardio-Thoracic Surgery; ECG,\nelectrocardiogram; EGFR, epidermal growth factor receptor; ESC, European Society of Cardiology; GLS, global longitudinal strain; HbA1c, glycated haemoglobin; HER2, human epidermal\nreceptor 2; HF, heart failure; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous; LIMA, left internal mammary\nartery; LMWH, low-molecular-weight heparins; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; MEK, mitogen-activated\nextracellular signal-regulated kinase; MI, myocardial infarction; MM, multiple myeloma; NP, natriuretic peptides; NSTE-ACS, non-ST-segment elevation acute coronary syndromes; PAD,\nperipheral artery disease; PAH, pulmonary arterial hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction; RAF, rapidly\naccelerated ﬁbrosarcoma; RIMA, right internal mammary artery; RT, radiotherapy; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—\nOlder Persons; STEMI, ST-segment elevation myocardial infarction; TdP, torsade de pointes; TIL, tumour-inﬁltrating lymphocytes; TKI, tyrosine kinase inhibitors; TTE, transthoracic\nechocardiography; TTS, Takotsubo syndrome; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; VEGFi, vascular endothelial growth factor inhibitors; VHD, valvular heart\ndisease; VTE, venous thromboembolism.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4341\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 105",
          "page": 105,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendation Table 1 for a general approach to cardiovascular toxicity risk categorization |  |  | \nCV toxicity risk stratification before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer. |  | I | B | \nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended. |  | I | C | \nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay. |  | I | C | \nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy. |  | I | C | \nDiscussion of the risk/benefit balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended. |  | I | C | \nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal findings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy. |  | I | C | ",
          "rows": 8,
          "cols": 5
        },
        {
          "title": "Table on page 106",
          "page": 106,
          "content": " | Recommendation Table 2 for electrocardiogram baseline assessment |  |  | \nAn ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment. |  | I | C | \nIn patients with an abnormal baseline ECG, referral to a cardiologist is recommended. |  | I | C | \n | Recommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies |  |  | \nBaseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to\nbe measured during treatment to detect CTRCD. |  | I | C | \n | Recommendation Table 4 for cardiac imaging modalities in patients with cancer |  |  | \n | General |  |  | \nEchocardiography is recommended as the first-line modality for the assessment of cardiac function in patients with cancer. |  | I | C | \n3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF. |  | I | B | \nGLS is recommended in all patients with cancer having echocardiography, if available. |  | I | C | \n | Baseline cardiac imaging prior to potentially cardiotoxic therapies |  |  | \nBaseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting\nanticancer therapy. |  | I | C | \n | Recommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity |  |  | \nManagement of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and\nafter cancer therapy. |  | I | C | \n | Recommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity |  |  | \nManagement of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy. |  | I | C | \n | Recommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the first 12 months\nafter therapy |  |  | \n | TTE |  |  | \nBaseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy. |  | I | B | \nIn all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment. |  | I | B | \nIn high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing\ntreatment. |  | I | C | \n | Cardiac serum biomarkers |  |  | \nBaseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy. |  | I | B | \ncTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is\nrecommended in high- and very high-risk patients. |  | I | B | \n | Recommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the first 12 months\nafter therapy |  |  | \n | TTE |  |  | \nBaseline echocardiography is recommended before HER2-targeted therapies in all patients. |  | I | B | \nIn patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within\n12 months after completing treatment. |  | I | B | \nIn metastatic HER2+ disease, echocardiography is recommended every 3 months during the first year; if the patient remains\nasymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment. |  | I | C | \n | Cardiac biomarkers |  |  | \nBaseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies. |  | I | C | ",
          "rows": 31,
          "cols": 5
        },
        {
          "title": "Table on page 107",
          "page": 107,
          "content": " | Recommendation Table 9 for baseline risk assessment and monitoring during fluoropyrimidine therapy |  |  | \nBaseline CV risk assessment and evaluation including BP measurement, ECG, lipid profile, HbA1c measurement, and SCORE2/SCORE2-\nOP or equivalent is recommended before starting fluoropyrimidines. |  | I | C | \nA baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting fluoropyrimidines. |  | I | C | \n | Recommendation Table 10 for baseline risk assessment and monitoring during VEGFi |  |  | \n | BP monitoring |  |  | \nBP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit. |  | I | C | \nDaily home monitoring of BP for patients treated with VEGFi during the first cycle, after each increase of VEGFi dose, and every 2–3\nweeks thereafter is recommended. |  | I | C | \n | ECG monitoring |  |  | \nIn patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the first\n3 months and every 3–6 months thereafter. |  | I | C | \n | Echocardiography |  |  | \nBaseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab. |  | I | C | \n | Recommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine\nkinase inhibitors |  |  | \nBaseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI. |  | I | C | \nIn patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the first year and every 6–12\nmonths thereafter. |  | I | C | \nBaseline echocardiography is recommended in patients scheduled to receive dasatinib. |  | I | C | \n | Recommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy |  |  | \n | BP monitoring and management |  |  | \nBP measurement is recommended for patients treated with BTK inhibitors at every clinical visit. |  | I | B | \n | Echocardiography |  |  | \nBaseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors. |  | I | C | \nTTE is recommended in all patients who develop AF during BTK inhibitor therapy. |  | I | C | \n | AF |  |  | \nOpportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy. |  | I | C | \n | Recommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies |  |  | \n | BP monitoring |  |  | \nBP measurement is recommended for patients treated with PI at every clinical visit. |  | I | C | \n | Cardiac serum biomarkers |  |  | \nMeasurement of NP is recommended prior to PI in high- and very high-risk patients. |  | I | C | \nNP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA. |  | I | B | \n | TTE |  |  | \nBaseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI. |  | I | C | ",
          "rows": 31,
          "cols": 5
        },
        {
          "title": "Table on page 108",
          "page": 108,
          "content": " | VTE prophylaxis |  |  | \nTherapeutic doses of LMWH are recommended in patients with MM with previous VTE. |  | I | B | \nProphylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least\nduring the first 6 months of therapy. |  | I | A | \n | Recommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy |  |  | \nBP monitoring at each clinical visit and weekly outpatient monitoring during the first 3 months of treatment and monthly thereafter is\nrecommended. |  | I | C | \nIn patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3\nmonths thereafter. |  | I | C | \nBaseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK\ninhibitors. |  | I | C | \n | Recommendation Table 15 for baseline risk assessment and monitoring during immunotherapy |  |  | \nECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy. |  | I | B | \nBaseline echocardiography is recommended in high-risk patients before starting ICI therapy. |  | I | B | \nCV assessment is recommended every 6–12 months in high-risk patients who require long-term (.12 months) ICI treatment. |  | I | C | \n | Recommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer |  |  | \nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\npatients treated with ADT without pre-existing CVD. |  | I | B | \nBaseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy. |  | I | B | \nAnnual CV risk assessment is recommended during ADT. |  | I | B | \n | Recommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer |  |  | \nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\nBC patients receiving endocrine therapies without pre-existing CVD. |  | I | C | \nAnnual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV\nevents according to SCORE2/SCORE2-OP. |  | I | C | \n | Recommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy |  |  | \nQTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib. |  | I | A | \nQTc monitoring is recommended in patients treated with ribociclib with any dose increase. |  | I | B | \n | Recommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors |  |  | \nBaseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors. |  | I | C | \nBaseline echocardiography is recommended in all patients with cancer before starting osimertinib. |  | I | B | \n | Recommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell\nand tumour-infiltrating lymphocytes therapies |  |  | \nBaseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies. |  | I | C | \nA baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies. |  | I | C | \nMeasurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2. |  | I | C | ",
          "rows": 28,
          "cols": 5
        },
        {
          "title": "Table on page 109",
          "page": 109,
          "content": " | Recommendation Table 21 for baseline risk assessment of patients before radiotherapy to a volume including the heart |  |  | \nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended. |  | I | B | \n | Recommendation Table 22 for baseline risk assessment in haematopoietic stem cell transplantation patients |  |  | \nBaseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is\nrecommended in HSCT patients. |  | I | C | \nEchocardiography is recommended in all patients before HSCT. |  | I | C | \n | Recommendation Table 23 for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in\npatients receiving anticancer treatment |  |  | \nA specialist CV assessment is recommended for optimal diagnostic workup and management of patients with cancer who present with\nnew CV toxicity during and after cancer treatment. |  | I | C | \n | Recommendation Table 24 for the management of cancer treatment-related cardiac dysfunction during anthracycline\nchemotherapy |  |  | \n | Anthracycline chemotherapy-induced symptomatic CTRCD |  |  | \nHF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy. |  | I | B | \nDiscontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD. |  | I | C | \nTemporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCD and\na multidisciplinary approach regarding the decision to restart is recommended. |  | I | C | \nA multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who\ndevelop mild symptomatic CTRCD. |  | I | C | \n | Anthracycline chemotherapy-induced asymptomatic CTRCD |  |  | \nTemporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop\nasymptomatic moderate or severe CTRCD. |  | I | C | \nA multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe\nasymptomatic CTRCD. |  | I | C | \nContinuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have\ndeveloped a significant fall in GLS or a troponin or a NP elevation .ULN. |  | I | C | \n | Recommendation Table 25 for the management of cancer treatment-related cardiac dysfunction during HER2-targeted therapies |  |  | \n | HER2-targeted therapy-induced symptomatic CTRCD |  |  | \nHF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF , 50% during HER2-\ntargeted treatment. |  | I | B | \nTemporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD\nand the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved. |  | I | C | \nIn patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs.\ninterrupt HER2-targeted therapy are recommended. |  | I | C | \n | HER2-targeted therapy-induced asymptomatic CTRCD |  |  | \nTemporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic\nsevere CTRCD. |  | I | C | \nA multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe\nasymptomatic CTRCD. |  | I | C | \nContinuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with\nmore frequent cardiac monitoring. |  | I | C | \nACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc during\nHER2-targeted treatment. |  | I | C | \n | Recommendation Table 26 for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis |  |  | \ncTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis. |  | I | B | \nIn patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is\nconfirmed or refuted. |  | I | C | ",
          "rows": 30,
          "cols": 5
        },
        {
          "title": "Table on page 110",
          "page": 110,
          "content": "Interruption of ICI treatment is recommended in patients with confirmed ICI-associated myocarditis. |  | I | C | \nContinuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients\nwith symptomatic ICI-associated myocarditis. |  | I | C | \nEarly high-dose corticosteroids are recommended in patients with cancer and confirmed ICI-associated myocarditis. |  | I | C | \nContinuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of\nsymptoms, LV systolic dysfunction, conduction abnormalities, and significant cTn reduction. |  | I | C | \nAdmission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when\nindicated) is recommended for patients with ICI-associated fulminant myocarditis. |  | I | C | \nA multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICI-\nassociated myocarditis. |  | I | C | \n | Recommendation Table 27 for the diagnosis and management of Takotsubo syndrome in patients with cancer |  |  | \nCoronary angiography (invasive or CCTA) is recommended to exclude ACS. |  | I | C | \nCMR is recommended to exclude myocarditis and MI. |  | I | B | \nQT-prolonging drugs are not recommended during the acute TTS phase. |  | III | C | \n | Recommendation Table 28 for the management of acute coronary syndromes in patients receiving anticancer treatment |  |  | \nAn invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6\nmonths. |  | I | B | \nA temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause. |  | I | C | \nIn patients with cancer, thrombocytopaenia and ACS, aspirin is not recommended if platelets ,10 000/µL. |  | III | C | \nIn patients with cancer, thrombocytopaenia and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or\nticagrelor are not recommended if platelets ,50 000/µL. |  | III | C | \n | Recommendation Table 29 for the management of chronic coronary syndromes in patients receiving anticancer treatment |  |  | \nIndividualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/\nischaemic and bleeding risk, type and stage of cancer, and current cancer treatment. |  | I | C | \n | Recommendation Table 30 for the management of valvular heart disease in patients receiving anticancer treatment |  |  | \nIn patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/EACTS Guidelines for the management\nof VHD is recommended, taking into consideration cancer prognosis and patient preferences. |  | I | C | \nIn patients with cancer developing new VHD during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the\nmanagement of VHD is recommended, taking into consideration cancer prognosis and patient comorbidities. |  | I | C | \n | Recommendation Table 31 for the management of atrial fibrillation in patients receiving anticancer treatment |  |  | \nLong-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a\nCHA DS-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation.\n2 2 |  | I | C | \nThromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF. |  | I | C | \nAntiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with\ncancer. |  | III | C | \n | Recommendation Table 32 for the management of long QTc and ventricular arrhythmias in patients receiving anticancer treatment |  |  | \n | How to manage QTc prolongation in patients with cancer |  |  | \nDiscontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular\ntachyarrhythmias during treatment. |  | I | C | \nTemporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms\nand an ECG should be repeated every 24 h until resolution of the QTcF prolongation. |  | I | C | \nImmediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factors is recommended in\npatients with cancer who develop QTcF ≥500 ms. |  | I | C | \nWeekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTc-\nprolonging cancer therapy. |  | I | C | ",
          "rows": 30,
          "cols": 5
        },
        {
          "title": "Table on page 111",
          "page": 111,
          "content": "A 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy. |  | I | C | \n | Restarting QTc-prolonging cancer therapy |  |  | \nA multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed significant QTcF\nprolongation, to discuss alternative cancer treatments. |  | I | C | \nWeekly ECG monitoring during the first 4–6 weeks and then monthly thereafter is recommended in patients with cancer after\nrestarting QTc-prolonging cancer therapy. |  | I | C | \n | Recommendation Table 33 for the management of arterial hypertension in patients receiving anticancer treatment |  |  | \n | General |  |  | \nEffective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is\nrecommended. |  | I | C | \nA BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy. |  | I | C | \nThe competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any\ncancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values\n,160 mmHg (systolic) and ,100 mmHg (diastolic). |  | I | C | \n | Cancer therapy-induced arterial hypertension treatment |  |  | \nACE-I or ARB are the first-line antihypertensive drugs recommended for BP management in patients with cancer. |  | I | B | \nDihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP. |  | I | C | \nCombination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic\nBP ≥160 mmHg and diastolic BP ≥100 mmHg. |  | I | C | \nDiltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug\ninteractions. |  | III | C | \nRecommendation Table 34 for the management of venous thromboembolism in patients receiving anticancer treatment |  |  |  | \nApixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incidental VTE in patients with cancer\nwithout contraindications. |  | I | A | \nLMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL. |  | I | A | \n | Catheter-associated VTE |  |  | \nDuration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and\ncontinuing longer if the catheter remains in situ. |  | I | C | \n | Recommendation Table 35 for venous thromboembolism prophylaxis during anticancer treatment |  |  | \nExtended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or\nlaparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk. |  | I | B | \nProphylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bed\nrest or reduced mobility in the absence of bleeding or other contraindications. |  | I | B | \nA discussion with the patient about the relative benefits and harms, cancer prognosis, drug cost, and duration of treatment is\nrecommended prior to prophylactic anticoagulation for the primary prevention of VTE. |  | I | C | \n | Recommendation Table 36 for management of peripheral artery disease during anticancer treatment |  |  | \nIn patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt\nculprit cancer therapy is recommended. |  | I | C | \n | Recommendation Table 37 for the management of pulmonary hypertension during anticancer treatment |  |  | \nRight-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic\nincrease in peak TRV . 3.4 m/s. |  | I | C | \nIn patients with confirmed dasatinib-induced PAH or new asymptomatic peak TRV . 3.4 m/s, an alternative BCR-ABL inhibitor is\nrecommended after peak TRV recovery to ,2.8 m/s. |  | I | C | \n | Recommendation Table 38 for the management of pericardial diseases in patients receiving anticancer treatment |  |  | \n | General |  |  | \nDiagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and\nmanagement of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy. |  | I | C | ",
          "rows": 31,
          "cols": 5
        },
        {
          "title": "Table on page 112",
          "page": 112,
          "content": " | Diagnosis and management of ICI-associated pericarditis |  |  | \nMultimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to\nconfirm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis. |  | I | C | \nPrednisolone and colchicine are recommended for patients with ICI-associated pericarditis. |  | I | C | \nInterruption of ICI treatment in patients with confirmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is\nrecommended. |  | I | C | \nA multidisciplinary discussion is recommended before restarting ICI treatment. |  | I | C | \n | Recommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment |  |  | \nEducating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended. |  | I | C | \nEducation is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD. |  | I | C | \nCVRF assessment is recommended during the first year after cancer therapy and thereafter according to the 2021 ESC Guidelines on\nCVD prevention in clinical practice. |  | I | B | \nIn asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after\ncompletion of cancer therapy. |  | I | B | \nCardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in\nechocardiography and/or cardiac serum biomarkers at the end of therapy assessment. |  | I | C | \nLong-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy. |  | I | C | \nCV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer\ntherapy. |  | I | C | \nCV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy. |  | I | C | \nECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy. |  | I | C | \n | Recommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer\nsurvivors |  |  | \nEducation of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding their increased CV risk is recommended. |  | I | B | \nAnnual screening for modifiable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including the heart. |  | I | C | \nCV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the first trimester. |  | I | C | \n | Recommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors |  |  | \nAnnual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially\ncardiotoxic cancer drug or RT. |  | I | B | \nCV toxicity risk restratification is recommended 5 years after therapy to organize long-term follow-up. |  | I | C | \n | Recommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic\ncancer therapy |  |  | \nACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD. |  | I | C | \n | Recommendation Table 43 for adult cancer survivors with coronary artery disease |  |  | \n | Asymptomatic radiation-induced CAD detected during surveillance |  |  | \nNon-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on\nCCTA to guide ischaemia-directed management. |  | I | C | \nA MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or\nsevere left main CAD. |  | I | C | ",
          "rows": 28,
          "cols": 5
        },
        {
          "title": "Table on page 113",
          "page": 113,
          "content": " | Symptomatic CAD |  |  | \nPre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiation-\ninduced CAD where CABG is considered. |  | I | C | \n | Recommendation Table 44 for adult cancer survivors with valvular heart disease |  |  | \nA MDT approach is recommended to discuss and define the surgical risk in CS with severe VHD. |  | I | C | \n | Recommendation Table 46 for cardiovascular monitoring in cancer survivors during pregnancy |  |  | \nIn high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary\npregnancy heart team is recommended. |  | I | C | \nA baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a\nhistory of CTRCD who are considering pregnancy. |  | I | C | \nA CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who\nreceived potentially cardiotoxic cancer therapy and did not have a baseline CV assessment. |  | I | C | \n | Recommendation Table 47 for cardiovascular assessment and monitoring of pregnant women with cancer |  |  | \nManagement by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who\nrequire cardiotoxic cancer therapy. |  | I | C | \nCardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical\nexamination, ECG, and echocardiography. |  | I | C | \n | Recommendation Table 48 for carcinoid valvular heart diseases |  |  | \nEchocardiography is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and\nelevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of\ncardiac involvement and clinical status. |  | I | B | \nA MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac\nprocedure. |  | I | C | \nValve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an\nexpected survival ≥12 months. |  | I | C | \nValve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an\nexpected survival ≥12 months. |  | I | C | \n | Recommendation Table 49 for amyloid light-chain cardiac amyloidosis diagnosis and monitoring |  |  | \nEchocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia. |  | I | B | \nCMR is recommended in patients with suspected AL-CA. |  | I | A | \n | Recommendation Table 50 for risk stratification and monitoring for patients with cardiac implantable electronic devices undergoing\nradiotherapy |  |  | \nRisk stratification including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is\nrecommended prior to starting treatment. |  | I | C | \nIn patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to\nindividual risk. |  | I | C | \nIn patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are\nrecommended during every RT session. |  | I | C | ",
          "rows": 23,
          "cols": 5
        }
      ],
      "keywords": [
        "ct",
        "prognosis",
        "echo",
        "messages",
        "monitoring",
        "risk",
        "guidelines",
        "treatment",
        "diagnosis",
        "what"
      ]
    },
    {
      "number": "18",
      "title": "16. Quality indicators for cardio-oncology",
      "start_page": 114,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "cardio",
        "indicators",
        "quality",
        "oncology",
        "recommendation"
      ]
    },
    {
      "number": "19",
      "title": "17. Supplementary data",
      "start_page": 114,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "data",
        "ct",
        "supplementary",
        "recommendation"
      ]
    },
    {
      "number": "20",
      "title": "18. Data availability statement",
      "start_page": 114,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "statement",
        "data",
        "availability",
        "recommendation"
      ]
    },
    {
      "number": "21",
      "title": "19. Author information",
      "start_page": 114,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "information",
        "ct",
        "author",
        "recommendation"
      ]
    },
    {
      "number": "22",
      "title": "Appendix",
      "start_page": 114,
      "end_page": 115,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRuben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta\nČelutkienė (Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal\n(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy\n(France), Thor Edvardsen (Norway), Laurent Fauchier (France),\nMichael Fradley (United States of America), Julia Grapsa (United\nKingdom), Sigrun Halvorsen (Norway), Michael Heuser (Germany),\nMarc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom),\nBonnie Ky (United States of America), Ulf Landmesser (Germany),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory\nY.\nH.\nLip\n(United\nKingdom),\nMaja-Lisa\nLøchen\n(Norway),\nKatarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra\n(Italy),\nRichard\nMindham\n(United\nKingdom),\nMarie\nMoonen\n(Belgium), Tomas G. Neilan (United States of America), Jens\nCosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva\nPrescott (Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem\n(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien\nten\nBerg\n(Netherlands),\nRhian\nM.\nTouyz\n(Canada/United\nKingdom),\nAgnieszka\nTycinska\n(Poland),\nMatthias\nWilhelm\n(Switzerland), Jose Luis Zamorano (Spain)\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC Guidelines on cardio-oncology: Algeria:\nAlgerian Society of Cardiology, Nadia Laredj; Armenia: Armenian\nCardiologists Association, Parounak Zelveian; Austria: Austrian\nSociety of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan\nSociety of Cardiology, Fuad Samadov; Belarus: Belorussian\nScientiﬁc\nSociety\nof\nCardiologists,\nUladzimir\nAndrushchuk;\nBelgium: Belgian Society of Cardiology, Bernhard L. Gerber;\nBosnia and Herzegovina: Association of Cardiologists of\nBosnia and Herzegovina, Mirsad Selimović; Bulgaria: Bulgarian\nSociety of Cardiology, Elena Kinova; Croatia: Croatian Cardiac\nSociety, Jure Samardzic; Cyprus: Cyprus Society of Cardiology,\nEvagoras Economides; Czechia: Czech Society of Cardiology,\nRadek Pudil; Denmark: Danish Society of Cardiology, Kirsten\nM.\nNielsen;\nEgypt:\nEgyptian\nSociety\nof\nCardiology,\nTarek\nA. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus;\nFinland: Finnish Cardiac Society, Suvi Tuohinen; France: French\nSociety of Cardiology, Stéphane Ederhy; Georgia: Georgian\nSociety of Cardiology, Zurab Pagava; Germany: German Cardiac\nSociety, Tienush Rassaf; Greece: Hellenic Society of Cardiology,\nAlexandros Briasoulis; Hungary: Hungarian Society of Cardiology,\nDániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl\nK. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth;\nIsrael: Israel Heart Society, Zaza Iakobishvili; Italy: Italian\nFederation of Cardiology, Iris Parrini; Kazakhstan: Association of\nCardiologists\nof\nKazakhstan,\nAmina\nRakisheva;\nKosovo\n(Republic of): Kosovo Society of Cardiology, Edita Pllana Pruthi;\nKyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;\nLatvia: Latvian Society of Cardiology, Oskars Kalejs; Lebanon:\nLebanese Society of Cardiology, Hadi Skouri; Libya: Libyan\nCardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society\nof Cardiology, Diana Žaliaduonytė; Luxembourg: Luxembourg\nSociety of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac\nSociety, Alice M. Moore; Moldova (Republic of): Moldavian\nSociety of Cardiology, Daniela Bursacovschi; Morocco: Moroccan\nSociety of Cardiology, Aatif Benyass; Netherlands: Netherlands\nSociety of Cardiology, Olivier Manintveld; North Macedonia:\nNorth\nMacedonian\nSociety\nof Cardiology,\nMarijan Bosevski;\nNorway:\nNorwegian\nSociety\nof\nCardiology,\nGeeta\nGulati;\nPoland: Polish Cardiac Society, Przemysław Leszek; Portugal:\nPortuguese Society of Cardiology, Manuela Fiuza; Romania:\nRomanian Society of Cardiology, Ruxandra Jurcut; Russian\nFederation: Russian Society of Cardiology, Yury Vasyuk; San\nMarino: San Marino Society of Cardiology, Marina Foscoli;\nSerbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:\nSlovak\nSociety\nof\nCardiology,\nMiroslav\nSlanina;\nSlovenia:\nSlovenian Society of Cardiology, Luka Lipar; Spain: Spanish\nSociety of Cardiology, Ana Martin-Garcia; Sweden: Swedish\nSociety of Cardiology, Laila Hübbert; Switzerland: Swiss Society\nof Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Alayed; Tunisia: Tunisian\nSociety of Cardiology and Cardio-Vascular Surgery, Leila Abid;\nTurkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:\nUkrainian Association of Cardiology, Elena Nesukay; United\nKingdom of Great Britain and Northern Ireland: British\nCardiovascular\nSociety,\nCharlotte\nManisty,\nUzbekistan:\nAssociation of Cardiologists of Uzbekistan, Nigora Srojidinova.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),\nAndreas\nBaumbach\n(United\nKingdom),\nMichael\nA.\nBorger\n(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),\nJean-Philippe Collet (France), Volkmar Falk (Germany), Laurent\nFauchier\n(France),\nChris\nP.\nGale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France),\nTiny\nJaarsma\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Richard Mindham (United\nKingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen\n(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (Canada/United\nKingdom).\n21. References\n1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Deﬁning\ncardiovascular toxicities of cancer therapies: an International Cardio-Oncology\nSociety (IC-OS) consensus statement. Eur Heart J 2022;43:280–299.\n2. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation\nand management of patients with heart disease and cancer: Cardio-oncology. Mayo\nClin Proc 2014;89:1287–1306.\n3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global\ncancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-\nwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.\n4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,\nGalderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascu-\nlar toxicity developed under the auspices of the ESC Committee for Practice\nGuidelines. Eur Heart J 2016;37:2768–2801.\n5. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P,\net al. Cardio-oncology services: rationale, organization, and implementation. Eur\nHeart J 2019;40:1756–1763.\n6. Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.\nEvidence-based recommendations for the organization of long-term follow-up\nESC Guidelines\n4343\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "appendix",
        "recommendation"
      ]
    },
    {
      "number": "23",
      "title": "References",
      "start_page": 115,
      "end_page": 115,
      "content": "Ruben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta\nČelutkienė (Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal\n(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy\n(France), Thor Edvardsen (Norway), Laurent Fauchier (France),\nMichael Fradley (United States of America), Julia Grapsa (United\nKingdom), Sigrun Halvorsen (Norway), Michael Heuser (Germany),\nMarc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom),\nBonnie Ky (United States of America), Ulf Landmesser (Germany),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory\nY.\nH.\nLip\n(United\nKingdom),\nMaja-Lisa\nLøchen\n(Norway),\nKatarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra\n(Italy),\nRichard\nMindham\n(United\nKingdom),\nMarie\nMoonen\n(Belgium), Tomas G. Neilan (United States of America), Jens\nCosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva\nPrescott (Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem\n(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien\nten\nBerg\n(Netherlands),\nRhian\nM.\nTouyz\n(Canada/United\nKingdom),\nAgnieszka\nTycinska\n(Poland),\nMatthias\nWilhelm\n(Switzerland), Jose Luis Zamorano (Spain)\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC Guidelines on cardio-oncology: Algeria:\nAlgerian Society of Cardiology, Nadia Laredj; Armenia: Armenian\nCardiologists Association, Parounak Zelveian; Austria: Austrian\nSociety of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan\nSociety of Cardiology, Fuad Samadov; Belarus: Belorussian\nScientiﬁc\nSociety\nof\nCardiologists,\nUladzimir\nAndrushchuk;\nBelgium: Belgian Society of Cardiology, Bernhard L. Gerber;\nBosnia and Herzegovina: Association of Cardiologists of\nBosnia and Herzegovina, Mirsad Selimović; Bulgaria: Bulgarian\nSociety of Cardiology, Elena Kinova; Croatia: Croatian Cardiac\nSociety, Jure Samardzic; Cyprus: Cyprus Society of Cardiology,\nEvagoras Economides; Czechia: Czech Society of Cardiology,\nRadek Pudil; Denmark: Danish Society of Cardiology, Kirsten\nM.\nNielsen;\nEgypt:\nEgyptian\nSociety\nof\nCardiology,\nTarek\nA. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus;\nFinland: Finnish Cardiac Society, Suvi Tuohinen; France: French\nSociety of Cardiology, Stéphane Ederhy; Georgia: Georgian\nSociety of Cardiology, Zurab Pagava; Germany: German Cardiac\nSociety, Tienush Rassaf; Greece: Hellenic Society of Cardiology,\nAlexandros Briasoulis; Hungary: Hungarian Society of Cardiology,\nDániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl\nK. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth;\nIsrael: Israel Heart Society, Zaza Iakobishvili; Italy: Italian\nFederation of Cardiology, Iris Parrini; Kazakhstan: Association of\nCardiologists\nof\nKazakhstan,\nAmina\nRakisheva;\nKosovo\n(Republic of): Kosovo Society of Cardiology, Edita Pllana Pruthi;\nKyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;\nLatvia: Latvian Society of Cardiology, Oskars Kalejs; Lebanon:\nLebanese Society of Cardiology, Hadi Skouri; Libya: Libyan\nCardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society\nof Cardiology, Diana Žaliaduonytė; Luxembourg: Luxembourg\nSociety of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac\nSociety, Alice M. Moore; Moldova (Republic of): Moldavian\nSociety of Cardiology, Daniela Bursacovschi; Morocco: Moroccan\nSociety of Cardiology, Aatif Benyass; Netherlands: Netherlands\nSociety of Cardiology, Olivier Manintveld; North Macedonia:\nNorth\nMacedonian\nSociety\nof Cardiology,\nMarijan Bosevski;\nNorway:\nNorwegian\nSociety\nof\nCardiology,\nGeeta\nGulati;\nPoland: Polish Cardiac Society, Przemysław Leszek; Portugal:\nPortuguese Society of Cardiology, Manuela Fiuza; Romania:\nRomanian Society of Cardiology, Ruxandra Jurcut; Russian\nFederation: Russian Society of Cardiology, Yury Vasyuk; San\nMarino: San Marino Society of Cardiology, Marina Foscoli;\nSerbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:\nSlovak\nSociety\nof\nCardiology,\nMiroslav\nSlanina;\nSlovenia:\nSlovenian Society of Cardiology, Luka Lipar; Spain: Spanish\nSociety of Cardiology, Ana Martin-Garcia; Sweden: Swedish\nSociety of Cardiology, Laila Hübbert; Switzerland: Swiss Society\nof Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Alayed; Tunisia: Tunisian\nSociety of Cardiology and Cardio-Vascular Surgery, Leila Abid;\nTurkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:\nUkrainian Association of Cardiology, Elena Nesukay; United\nKingdom of Great Britain and Northern Ireland: British\nCardiovascular\nSociety,\nCharlotte\nManisty,\nUzbekistan:\nAssociation of Cardiologists of Uzbekistan, Nigora Srojidinova.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),\nAndreas\nBaumbach\n(United\nKingdom),\nMichael\nA.\nBorger\n(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),\nJean-Philippe Collet (France), Volkmar Falk (Germany), Laurent\nFauchier\n(France),\nChris\nP.\nGale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France),\nTiny\nJaarsma\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Richard Mindham (United\nKingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen\n(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (Canada/United\nKingdom).\n21. References\n1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Deﬁning\ncardiovascular toxicities of cancer therapies: an International Cardio-Oncology\nSociety (IC-OS) consensus statement. Eur Heart J 2022;43:280–299.\n2. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation\nand management of patients with heart disease and cancer: Cardio-oncology. Mayo\nClin Proc 2014;89:1287–1306.\n3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global\ncancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-\nwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.\n4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,\nGalderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascu-\nlar toxicity developed under the auspices of the ESC Committee for Practice\nGuidelines. Eur Heart J 2016;37:2768–2801.\n5. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P,\net al. Cardio-oncology services: rationale, organization, and implementation. Eur\nHeart J 2019;40:1756–1763.\n6. Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.\nEvidence-based recommendations for the organization of long-term follow-up\nESC Guidelines\n4343\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "references",
        "ct"
      ]
    },
    {
      "number": "24",
      "title": "References",
      "start_page": 115,
      "end_page": 129,
      "content": "Ruben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta\nČelutkienė (Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal\n(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy\n(France), Thor Edvardsen (Norway), Laurent Fauchier (France),\nMichael Fradley (United States of America), Julia Grapsa (United\nKingdom), Sigrun Halvorsen (Norway), Michael Heuser (Germany),\nMarc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom),\nBonnie Ky (United States of America), Ulf Landmesser (Germany),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory\nY.\nH.\nLip\n(United\nKingdom),\nMaja-Lisa\nLøchen\n(Norway),\nKatarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra\n(Italy),\nRichard\nMindham\n(United\nKingdom),\nMarie\nMoonen\n(Belgium), Tomas G. Neilan (United States of America), Jens\nCosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva\nPrescott (Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem\n(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien\nten\nBerg\n(Netherlands),\nRhian\nM.\nTouyz\n(Canada/United\nKingdom),\nAgnieszka\nTycinska\n(Poland),\nMatthias\nWilhelm\n(Switzerland), Jose Luis Zamorano (Spain)\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC Guidelines on cardio-oncology: Algeria:\nAlgerian Society of Cardiology, Nadia Laredj; Armenia: Armenian\nCardiologists Association, Parounak Zelveian; Austria: Austrian\nSociety of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan\nSociety of Cardiology, Fuad Samadov; Belarus: Belorussian\nScientiﬁc\nSociety\nof\nCardiologists,\nUladzimir\nAndrushchuk;\nBelgium: Belgian Society of Cardiology, Bernhard L. Gerber;\nBosnia and Herzegovina: Association of Cardiologists of\nBosnia and Herzegovina, Mirsad Selimović; Bulgaria: Bulgarian\nSociety of Cardiology, Elena Kinova; Croatia: Croatian Cardiac\nSociety, Jure Samardzic; Cyprus: Cyprus Society of Cardiology,\nEvagoras Economides; Czechia: Czech Society of Cardiology,\nRadek Pudil; Denmark: Danish Society of Cardiology, Kirsten\nM.\nNielsen;\nEgypt:\nEgyptian\nSociety\nof\nCardiology,\nTarek\nA. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus;\nFinland: Finnish Cardiac Society, Suvi Tuohinen; France: French\nSociety of Cardiology, Stéphane Ederhy; Georgia: Georgian\nSociety of Cardiology, Zurab Pagava; Germany: German Cardiac\nSociety, Tienush Rassaf; Greece: Hellenic Society of Cardiology,\nAlexandros Briasoulis; Hungary: Hungarian Society of Cardiology,\nDániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl\nK. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth;\nIsrael: Israel Heart Society, Zaza Iakobishvili; Italy: Italian\nFederation of Cardiology, Iris Parrini; Kazakhstan: Association of\nCardiologists\nof\nKazakhstan,\nAmina\nRakisheva;\nKosovo\n(Republic of): Kosovo Society of Cardiology, Edita Pllana Pruthi;\nKyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;\nLatvia: Latvian Society of Cardiology, Oskars Kalejs; Lebanon:\nLebanese Society of Cardiology, Hadi Skouri; Libya: Libyan\nCardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society\nof Cardiology, Diana Žaliaduonytė; Luxembourg: Luxembourg\nSociety of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac\nSociety, Alice M. Moore; Moldova (Republic of): Moldavian\nSociety of Cardiology, Daniela Bursacovschi; Morocco: Moroccan\nSociety of Cardiology, Aatif Benyass; Netherlands: Netherlands\nSociety of Cardiology, Olivier Manintveld; North Macedonia:\nNorth\nMacedonian\nSociety\nof Cardiology,\nMarijan Bosevski;\nNorway:\nNorwegian\nSociety\nof\nCardiology,\nGeeta\nGulati;\nPoland: Polish Cardiac Society, Przemysław Leszek; Portugal:\nPortuguese Society of Cardiology, Manuela Fiuza; Romania:\nRomanian Society of Cardiology, Ruxandra Jurcut; Russian\nFederation: Russian Society of Cardiology, Yury Vasyuk; San\nMarino: San Marino Society of Cardiology, Marina Foscoli;\nSerbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:\nSlovak\nSociety\nof\nCardiology,\nMiroslav\nSlanina;\nSlovenia:\nSlovenian Society of Cardiology, Luka Lipar; Spain: Spanish\nSociety of Cardiology, Ana Martin-Garcia; Sweden: Swedish\nSociety of Cardiology, Laila Hübbert; Switzerland: Swiss Society\nof Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Alayed; Tunisia: Tunisian\nSociety of Cardiology and Cardio-Vascular Surgery, Leila Abid;\nTurkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:\nUkrainian Association of Cardiology, Elena Nesukay; United\nKingdom of Great Britain and Northern Ireland: British\nCardiovascular\nSociety,\nCharlotte\nManisty,\nUzbekistan:\nAssociation of Cardiologists of Uzbekistan, Nigora Srojidinova.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),\nAndreas\nBaumbach\n(United\nKingdom),\nMichael\nA.\nBorger\n(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),\nJean-Philippe Collet (France), Volkmar Falk (Germany), Laurent\nFauchier\n(France),\nChris\nP.\nGale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France),\nTiny\nJaarsma\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Richard Mindham (United\nKingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen\n(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (Canada/United\nKingdom).\n21. References\n1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Deﬁning\ncardiovascular toxicities of cancer therapies: an International Cardio-Oncology\nSociety (IC-OS) consensus statement. Eur Heart J 2022;43:280–299.\n2. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation\nand management of patients with heart disease and cancer: Cardio-oncology. Mayo\nClin Proc 2014;89:1287–1306.\n3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global\ncancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-\nwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.\n4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,\nGalderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascu-\nlar toxicity developed under the auspices of the ESC Committee for Practice\nGuidelines. Eur Heart J 2016;37:2768–2801.\n5. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P,\net al. Cardio-oncology services: rationale, organization, and implementation. Eur\nHeart J 2019;40:1756–1763.\n6. Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.\nEvidence-based recommendations for the organization of long-term follow-up\nESC Guidelines\n4343\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\ncare for childhood and adolescent cancer survivors: a report from the\nPanCareSurFup Guidelines Working Group. J Cancer Surviv 2019;13:759–772.\n7. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al.\nRecommendations for cardiomyopathy surveillance for survivors of childhood can-\ncer: a report from the International Late Effects of Childhood Cancer Guideline\nHarmonization Group. Lancet Oncol 2015;16:e123–e136.\n8. van Kalsbeek RJ, Mulder RLRL, Skinner R, Kremer LCMCM. The concept of cancer\nsurvivorship and models for long-term follow-up. Front Horm Res 2021;54:1–15.\n9. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and ar-\nrhythmia. Nat Rev Cardiol 2020;17:474–502.\n10. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020;17:\n503–522.\n11. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al.\nCardio-oncology rehabilitation to manage cardiovascular outcomes in cancer pa-\ntients and survivors: a scientiﬁc statement from the American Heart Association.\nCirculation 2019;139:e997–e1012.\n12. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al.\nBaseline cardiovascular risk assessment in cancer patients scheduled to receive car-\ndiotoxic cancer therapies: a position statement and new risk assessment tools from\nthe Cardio-Oncology Study Group of the Heart Failure Association of the\nEuropean Society. Eur J Heart Fail 2020;22:1945–1960.\n13. Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al.\nIncidence of cardiotoxicity and validation of the Heart Failure Association–\nInternational Cardio-Oncology Society risk stratiﬁcation tool in patients treated\nwith trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat\n2021;188:149–163.\n14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.\nEur Heart J 2021;42:3599–3726.\n15. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal\nmuscle: a noncardiac source of increased circulating concentrations of cardiac\ntroponin T. J Am Coll Cardiol 2011;58:1819–1824.\n16. Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger\nB, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll\nCardiol 2018;71:1540–1549.\n17. Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, et al.\nClinical implications of isolated troponinemia following immune checkpoint inhibi-\ntor therapy. ESMO Open 2021;6:100216.\n18. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U,\net al. Cardiovascular magnetic resonance in nonischemic myocardial inﬂammation:\nexpert recommendations. J Am Coll Cardiol 2018;72:3158–3176.\n19. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021\nESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J\n2021;42:3227–3337.\n20. Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V, et al.\nWhich QT correction formulae to use for QT monitoring? J Am Heart Assoc\n2016;5:e003264.\n21. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al.\nPrevention and monitoring of cardiac dysfunction in survivors of adult cancers:\nAmerican Society of Clinical Oncology clinical practice guideline. J Clin Oncol\n2017;35:893–911.\n22. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management\nof cardiac disease in cancer patients throughout oncological treatment: ESMO con-\nsensus recommendations. Ann Oncol 2020;31:171–190.\n23. Rossello X, Dorresteijn JAN, Janssen A, Lambrinou E, Scherrenberg M,\nBonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease preven-\ntion: a report from the ESC Prevention of CVD Programme led by the\nEuropean Association of Preventive Cardiology (EAPC) in collaboration with the\nAcute Cardiovascular Care Association (ACCA) and the Association of\nCardiovascular Nursing and Allied Professions (ACNAP). Eur J Cardiovasc Nurs\n2019;18:534–544.\n24. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year\nfollow-up assessment of cardiac function in NSABP B-31, a randomized trial com-\nparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP\nplus trastuzumab as adjuvant therapy for patients with node-positive, human epi-\ndermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:\n3792–3799.\n25. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and car-\ndiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart\nAssoc 2014;3:e000472.\n26. Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clin-\nical risk score in a real-world cardio-oncology population. Curr Oncol 2017;24:\n176–180.\n27. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The de-\nvelopment of a predictive model to estimate cardiotoxic risk for patients with\nmetastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;\n107:443–450.\n28. Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu J V, et al.\nDevelopment and validation of a multivariable prediction model for major adverse\ncardiovascular events after early stage breast cancer: a population-based cohort\nstudy. Eur Heart J 2019;40:3913–3920.\n29. Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al.\nSymptomatic heart failure in acute leukemia patients treated with anthracyclines.\nJACC CardioOncology 2019;1:208–217.\n30. Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M,\net al. Stratiﬁcation and management of cardiovascular risk in cancer patients. A con-\nsensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC,\nand AECC. Rev Española Cardiol (English Ed) 2021;74:438–448.\n31. Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P,\nRodríguez IR, Gómez Prieto P, et al. Cardiovascular risk factors during cancer treat-\nment. Prevalence and prognostic relevance: insights from the CARDIOTOX regis-\ntry. Eur J Prev Cardiol 2022;29(6):859–868.\n32. Feijen EAM, Leisenring WM, Stratton KL, Ness KK, Van Der Pal HJH, Van Dalen EC,\net al. Derivation of anthracycline and anthraquinone equivalence ratios to doxo-\nrubicin for late-onset cardiotoxicity. JAMA Oncol 2019;5:864–871.\n33. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, et al. Activity and\noutcomes of a cardio-oncology service in the United Kingdom—a ﬁve-year experi-\nence. Eur J Heart Fail 2018;20:1721–1731.\n34. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular\ndisease and cancer. Circulation 2016;133:1104–1114.\n35. Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, et al. Arterial occlu-\nsive events in chronic myeloid leukemia patients treated with ponatinib in the real-\nlife practice are predicted by the Systematic Coronary Risk Evaluation (SCORE)\nchart. Hematol Oncol 2019;37:296–302.\n36. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis:\ncrossroads of aging, cardiovascular disease, and cancer: JACC review topic of the\nweek. J Am Coll Cardiol 2019;74:567–577.\n37. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM,\net al. Genetic variants associated with cancer therapy-induced cardiomyopathy.\nCirculation 2019;140:31–41.\n38. Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC\nCardioOncology 2020;2:539–552.\n39. Katzke VA, Kaaks R, Kühn T. Lifestyle and cancer risk. Cancer J 2015;21:104–110.\n40. Shariﬁ-Rad J, Rodrigues CF, Sharopov F, Docea AO, Karaca AC, Shariﬁ-Rad M, et al.\nDiet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotec-\ntive effects of natural bioactive compounds. Int J Environ Res Public Health 2020;17:\n2326.\n41. Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA, et al.\nOutdoor air pollution and cancer: an overview of the current evidence and public\nhealth recommendations. CA Cancer J Clin 2020;70 :460–479.\n42. Lind PM, Lind L. Are persistent organic pollutants linked to lipid abnormalities, ath-\nerosclerosis and cardiovascular disease? A review. J Lipid Atheroscler 2020;9:\n334–348.\n43. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The\ncancer patient and cardiology. Eur J Heart Fail 2020;22:2290–2309.\n44. Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card\nElectrophysiol Clin 2015;7:341–355.\n45. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al.\nIncidence, diagnosis, and management of QT prolongation induced by cancer ther-\napies: a systematic review. J Am Heart Assoc 2017;6:e007724.\n46. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, et al. Drug-induced\nQTc interval prolongation: a proposal towards an efﬁcient and safe anticancer drug\ndevelopment. Eur J Cancer 2008;44:494–500.\n47. Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in\ncancer patients receiving chemotherapy or radiation. Curr Cardiol Rep 2016;18:52.\n48. Curigliano G, Spitaleri G, De Braud F, Cardinale D, Cipolla C, Civelli M, et al. QTc\nprolongation assessment in anticancer drug development: clinical and methodo-\nlogical issues. Ecancermedicalscience 2009;3:130.\n49. Salem J-E, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, et al.\nAnticancer drug-induced life-threatening ventricular arrhythmias: a World Health\nOrganization pharmacovigilance study. Eur Heart J 2021;42:3915–3928.\n50. Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial ﬁb-\nrillation on ibrutinib treatment. Leuk Lymphoma 2019;60:1447–1453.\n51. Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, et al. Left atrial ab-\nnormality (LAA) as a predictor of ibrutinib-associated atrial ﬁbrillation in patients\nwith chronic lymphocytic leukemia. Cancer Biol Ther 2018;19:1–2.\n52. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of\nsupraventricular arrhythmias during autologous peripheral blood stem cell trans-\nplantation. Biol Blood Marrow Transplant 2013;19:1233–1237.\n4344\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n53. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of\nserum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a pos-\nition statement from the Cardio-Oncology Study Group of the Heart Failure\nAssociation and the Cardio-Oncology Council of the European Society of\nCardiology. Eur J Heart Fail 2020;22:1966–1983.\n54. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P,\nBergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving car-\ndiotoxic therapies: a position statement on behalf of the Heart Failure Association\n(HFA), the European Association of Cardiovascular Imaging (EACVI) and the\nCardio-Oncology Council of the European Society of Cardiology (ESC). Eur J\nHeart Fail 2020;22:1504–1524.\n55. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al.\nTroponins and brain natriuretic peptides for the prediction of cardiotoxicity in can-\ncer patients: a meta-analysis. Eur J Heart Fail 2020;22:350–361.\n56. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in\ncardiac biomarkers during doxorubicin treatment of pediatric patients with high-\nrisk acute lymphoblastic leukemia: associations with long-term echocardiographic\noutcomes. J Clin Oncol 2012;30:1042–1049.\n57. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect\nof dexrazoxane on myocardial injury in doxorubicin-treated children with acute\nlymphoblastic leukemia. N Engl J Med 2004;351:145–153.\n58. Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, et al. Cardiotoxicity as indicated by\nLVEF and troponin T sensitivity following two anthracycline-based regimens in\nlymphoma: results from a randomized prospective clinical trial. Oncotarget 2016;\n7:32519–32531.\n59. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al.\nPrognostic value of troponin I in cardiac risk stratiﬁcation of cancer patients under-\ngoing high-dose chemotherapy. Circulation 2004;109:2749–2754.\n60. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes\nin multiple biomarkers are associated with cardiotoxicity in breast cancer patients\ntreated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015;61:\n1164–1172.\n61. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al.\nTrastuzumab-induced cardiotoxicity: clinical and prognostic implications of tropo-\nnin I evaluation. J Clin Oncol 2010;28:3910–3916.\n62. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of\ntroponins I and T and N-terminal prohormone of brain natriuretic peptide in mon-\nitoring cardiac safety of patients with early-stage human epidermal growth factor\nreceptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study\ncardiac marker substudy. J Clin Oncol 2017;35:878–884.\n63. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.\nHeart Failure Association of the European Society of Cardiology practical guidance\non the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731.\n64. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity\nafter anthracycline chemotherapy in breast carcinoma: effects on left ventricular\nejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:\n194–198.\n65. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, et al.\nChanges in cardiovascular biomarkers with breast cancer therapy and associations\nwith cardiac dysfunction. J Am Heart Assoc 2020;9:e014708.\n66. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of\ncardiac events during proteasome inhibitor therapy for relapsed multiple myeloma.\nJ Clin Oncol 2019;37:1946–1955.\n67. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al.\nCardiovascular biomarkers in patients with cancer and their association with all-\ncause mortality. Heart 2015;101:1874–1880.\n68. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR,\nFarmakis D, et al. Classiﬁcation, prevalence, and outcomes of anticancer\ntherapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020;41:\n1720–1729.\n69. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in mul-\ntiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer\ntreated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:\n809–816.\n70. Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, et al.\nCirculating microRNAs as potential predictors of anthracycline-induced troponin\nelevation in breast cancer patients: diverging effects of doxorubicin and epirubicin.\nJ Clin Med 2020;9:1418.\n71. Beer LA, Kossenkov AV, Liu Q, Luning Prak E, Domchek S, Speicher DW, et al.\nBaseline\nimmunoglobulin\ne\nlevels\nas\na\nmarker\nof\ndoxorubicin-\nand\ntrastuzumab-associated cardiac dysfunction. Circ Res 2016;119:1135–1144.\n72. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality im-\naging in the assessment of cardiovascular toxicity in the cancer patient. JACC\nCardiovasc Imaging 2018;11:1173–1186.\n73. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.\nStandardization of adult transthoracic echocardiography reporting in agreement\nwith recent chamber quantiﬁcation, diastolic function, and heart valve disease re-\ncommendations: an expert consensus document of the European Association of\nCardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–1310.\n74. De Azambuja E, Procter MJ, Van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O,\nSteinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median\nfollow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014;32:\n2159–2165.\n75. Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, et al. 2D and 3D\nstrain for detection of subclinical anthracycline cardiotoxicity in breast cancer pa-\ntients: A balance with feasibility. Eur Heart J Cardiovasc Imaging 2017;18:930–936.\n76. Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, et al.\nAbnormalities in 3-dimensional left ventricular mechanics with anthracycline\nchemotherapy are associated with systolic and diastolic dysfunction. JACC\nCardiovasc Imaging 2018;11:1059–1068.\n77. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L, et al.\nRecommendations for cardiac chamber quantiﬁcation by echocardiography in\nadults: an update from the American Society of Echocardiography and the\nEuropean Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging\n2015;16:233–270.\n78. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH.\nReproducibility of echocardiographic techniques for sequential assessment of left\nventricular ejection fraction and volumes: application to patients undergoing cancer\nchemotherapy. J Am Coll Cardiol 2013;61:77–84.\n79. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of\n3-dimensional echocardiography in measuring left ventricular volumes and ejection\nfraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59:\n1799–1808.\n80. Hoffmann R, Barletta G, Von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C,\net al. Analysis of left ventricular volumes and function: a multicenter comparison of\ncardiac magnetic resonance imaging, cine ventriculography, and unenhanced and\ncontrast-enhanced two-dimensional and three-dimensional echocardiography. J\nAm Soc Echocardiogr 2014;27:292–301.\n81. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume\nmeasurement with echocardiography: a comparison of left ventricular opaciﬁca-\ntion, three-dimensional echocardiography, or both with magnetic resonance im-\naging. Eur Heart J 2009;30:98–106.\n82. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical\napplications of ultrasonic enhancing agents in echocardiography: 2018 American\nSociety of Echocardiography Guidelines Update. J Am Soc Echocardiogr 2018;31:\n241–274.\n83. Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, et al.\nSerial cardiovascular magnetic resonance strain measurements to identify cardio-\ntoxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc\nImaging 2021;14:962–974.\n84. Dobbin SJH, Mangion K, Berry C, Roditi G, Basak S, Sourbron S, et al. Cardiotoxicity\nand myocardial hypoperfusion associated with anti-vascular endothelial growth fac-\ntor therapies: prospective cardiac magnetic resonance imaging in patients with can-\ncer. Eur J Heart Fail 2020;22:1276–1277.\n85. Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M.\nEchocardiographic parameters of left ventricular size and function as predictors\nof symptomatic heart failure in patients with a left ventricular ejection fraction of\n50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015;16:\n977–984.\n86. Čelutkienė J, Plymen CM, Flachskampf FA, de Boer RA, Grapsa J, Manka R, et al.\nInnovative imaging methods in heart failure: a shifting paradigm in cardiac assess-\nment. Position statement on behalf of the Heart Failure Association of the\nEuropean Society of Cardiology. Eur J Heart Fail 2018;20:1615–1633.\n87. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a\nsystematic review and meta-analysis of global longitudinal strain and ejection frac-\ntion. Heart 2014;100:1673–1680.\n88. Baron T, Berglund L, Hedin EM, Flachskampf FA. Test–retest reliability of new and\nconventional echocardiographic parameters of left ventricular systolic function. Clin\nRes Cardiol 2019;108:355–365.\n89. Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, et al.\nVariability in echocardiography and MRI for detection of cancer therapy cardiotoxi-\ncity. Heart 2020;106:817–823.\n90. Thavendiranathan P, Negishi T, Coté MA, Penicka M, Massey R, Cho GY, et al.\nSingle versus standard multiview assessment of global longitudinal strain for the\ndiagnosis of cardiotoxicity during cancer therapy. JACC Cardiovasc Imaging 2018;\n11:1109–1118.\n91. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle\nstrain to assess left ventricular responses to cardiotoxic chemotherapy and cardi-\noprotection. Eur Heart J Cardiovasc Imaging 2014;15:324–331.\nESC Guidelines\n4345\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n92. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myo-\ncardial strain imaging by echocardiography for the early detection of cardiotoxicity\nin patients during and after cancer chemotherapy: a systematic review. J Am Coll\nCardiol 2014;63:2751–2768.\n93. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D,\net al. Assessment of prognostic value of left ventricular global longitudinal strain for\nearly prediction of chemotherapy-induced cardiotoxicity: a systematic review and\nmeta-analysis. JAMA Cardiol 2019;4:1007–1018.\n94. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert\nconsensus for multimodality imaging evaluation of adult patients during and after\ncancer therapy: a report from the American Society of Echocardiography and\nthe European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc\nImaging 2014;15:1063–1093.\n95. Farsalinos KE, Daraban AM, Ünlü S, Thomas JD, Badano LP, Voigt JU. Head-to-head\ncomparison of global longitudinal strain measurements among nine different ven-\ndors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr\n2015;28:1171–1181.e2.\n96. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, et al.\nNoninvasive measures of ventricular–arterial coupling and circumferential strain\npredict cancer therapeutics–related cardiac dysfunction. JACC Cardiovasc Imaging\n2016;9:1131–1141.\n97. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to pre-\ndict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis.\nCardiol Rev 2018;26:29–34.\n98. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al.\nComprehensive assessment of changes in left ventricular diastolic function with\ncontemporary breast cancer therapy. JACC Cardiovasc Imaging 2020;13:198–210.\n99. Phillips WJ, Johnson C, Law A, Turek M, Small AR, Dent S, et al. Comparison of\nFramingham risk score and chest-CT identiﬁed coronary artery calciﬁcation in\nbreast cancer patients to predict cardiovascular events. Int J Cardiol 2019;289:\n138–143.\n100. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.\n2019 ESC Guidelines for the diagnosis and management of chronic coronary syn-\ndromes: The Task Force for the diagnosis and management of chronic coronary\nsyndromes of the European Society of Cardiology (ESC). Eur Heart J 2020;41:\n407–477.\n101. Lopez-Mattei JC, Yang EH, Ferencik M, Baldassarre LA, Dent S, Budoff MJ. Cardiac\ncomputed tomography in cardio-oncology: JACC: CardioOncology primer. Cardio\nOncol 2021;3:635–649.\n102. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al.\nStrain-guided management of potentially cardiotoxic cancer therapy. J Am Coll\nCardiol 2021;77:392–401.\n103. Esmaeilzadeh M, Fresno CMU, Somerset E, Shalmon T, Amir E, Fan CPS, et al. A\ncombined echocardiography approach for the diagnosis of cancer therapy-related\ncardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol 2022;7:\n330–340.\n104. Drafts BC, Twomley KM, D’Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low to\nmoderate dose anthracycline-based chemotherapy is associated with early non-\ninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc\nImaging 2013;6:877–885.\n105. Giusca S, Korosoglou G, Montenbruck M, Geršak B, Schwarz AK, Esch S, et al.\nMultiparametric early detection and prediction of cardiotoxicity using myocardial\nstrain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance\nimaging study during 2 years of follow-up. Circ Cardiovasc Imaging 2021;14:e012459.\n106. Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, et al. Assessment\nof left ventricular function by CMR versus MUGA scans in breast cancer patients\nreceiving trastuzumab: a prospective observational study. Int J Cardiovasc Imaging\n2019;35:2085–2093.\n107. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of three-\ndimensional echocardiography in breast cancer: comparison with two-dimensional\nechocardiography, multiple-gated acquisition scans, and cardiac magnetic reson-\nance imaging. J Clin Oncol 2010;28:3429–3436.\n108. Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, et al. Accuracy\nof left ventricular ejection fraction by contemporary multiple gated acquisition\nscanning in patients with cancer: comparison with cardiovascular magnetic reson-\nance. J Cardiovasc Magn Reson 2017;19:34.\n109. Hoppeler H, Weibel ER. Limits for oxygen and substrate transport in mammals. J\nExp Biol 1998;201:1051–1064.\n110. Kaminsky LA, Imboden MT, Arena R, Myers J. Reference standards for cardio-\nrespiratory ﬁtness measured with cardiopulmonary exercise testing using cycle er-\ngometry: data from the Fitness Registry and the Importance of Exercise National\nDatabase (FRIEND) registry. Mayo Clin Proc 2017;92:228–233.\n111. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL, Kaminsky LA.\nCardiorespiratory ﬁtness and mortality in healthy men and women. J Am Coll\nCardiol 2018;72:2283–2292.\n112. Jetté M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing,\nexercise prescription, and evaluation of functional capacity. Clin Cardiol 1990;13:\n555–565.\n113. Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, et al. Importance of\nassessing cardiorespiratory ﬁtness in clinical practice: a case for ﬁtness as a clinical\nvital sign: a scientiﬁc statement from the American Heart Association. Circulation\n2016;134:e653–e699.\n114. Schmid D, Leitzmann MF. Cardiorespiratory ﬁtness as predictor of cancer mortal-\nity: a systematic review and meta-analysis. Ann Oncol 2015;26:272–278.\n115. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al.\nCardiorespiratory ﬁtness and classiﬁcation of risk of cardiovascular disease mortal-\nity. Circulation 2011;123:1377–1383.\n116. Holtermann A, Marott JL, Gyntelberg F, Søgaard K, Mortensen OS, Prescott E, et al.\nSelf-reported cardiorespiratory ﬁtness: prediction and classiﬁcation of risk of car-\ndiovascular disease mortality and longevity—a prospective investigation in the\nCopenhagen City Heart Study. J Am Heart Assoc 2015;4:e001495.\n117. Stamatakis E, Hamer M, O’Donovan G, Batty GD, Kivimaki M. A non-exercise test-\ning method for estimating cardiorespiratory ﬁtness: associations with all-cause and\ncardiovascular mortality in a pooled analysis of eight population-based cohorts. Eur\nHeart J 2013;34:750–758.\n118. Wickramasinghe CD, Ayers CR, Das S, De Lemos JA, Willis BL, Berry JD.\nPrediction of 30-year risk for cardiovascular mortality by ﬁtness and risk factor le-\nvels: the Cooper Center Longitudinal Study. Circ Cardiovasc Qual Outcomes 2014;7:\n597–602.\n119. Fardman A, Banschick GD, Rabia R, Percik R, Fourey D, Segev S, et al.\nCardiorespiratory ﬁtness and survival following cancer diagnosis. Eur J Prev\nCardiol 2021;28:1242–1249.\n120. Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, et al. Association of\npost-diagnosis cardiorespiratory ﬁtness with cause-speciﬁc mortality in cancer. Eur\nHeart J Qual Care Clin Outcomes 2020;6:315–322.\n121. Jones LM, Stoner L, Brown C, Baldi JC, McLaren B. Cardiorespiratory ﬁtness pre-\ndicts cardiovascular health in breast cancer survivors, independent of body com-\nposition, age and time post-treatment completion. Breast Cancer 2019;26:\n729–737.\n122. Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M. The utility of exercise testing in\npatients with lung cancer. J Thorac Oncol 2016;11:1397–1410.\n123. West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, et al. Cardiopulmonary\nexercise variables are associated with postoperative morbidity after major colonic\nsurgery: a prospective blinded observational study. Br J Anaesth 2014;112:665–671.\n124. West MA, Parry MG, Lythgoe D, Barben CP, Kemp GJ, Grocott MPW, et al.\nCardiopulmonary exercise testing for the prediction of morbidity risk after rectal\ncancer surgery. Br J Surg 2014;101:1166–1172.\n125. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC\nguidelines on cardiovascular assessment and management of patients undergoing non-\ncardiac surgery. Eur Heart J 2022;43:3826–3924.\n126. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding vari-\nant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in child-\nhood cancer. Nat Genet 2015;47:1079–1084.\n127. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al.\nAnthracycline-related cardiomyopathy after childhood cancer: role of polymorph-\nisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J\nClin Oncol 2012;30:1415–1421.\n128. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al.\nNAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are as-\nsociated\nwith\ndoxorubicin-induced\ncardiotoxicity.\nCirculation\n2005;112:\n3754–3762.\n129. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant\nmyocarditis with combination immune checkpoint blockade. N Engl J Med 2016;\n375:1749–1755.\n130. European Society of Cardiology. ESC CardioMed. 3rd ed. Oxford: Oxford\nUniversity Press; 2018.\n131. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med\n2016;375:1457–1467.\n132. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, et al.\nCancer diagnosis in patients with heart failure: epidemiology, clinical implications\nand gaps in knowledge. Eur J Heart Fail 2018;20:879–887.\n133. D’Ascenzi F, Anselmi F, Fiorentini C, Mannucci R, Bonifazi M, Mondillo S. The ben-\neﬁts of exercise in cancer patients and the criteria for exercise prescription in\ncardio-oncology. Eur J Prev Cardiol 2021;28:725–735.\n134. Ogunmoroti O, Allen NB, Cushman M, Michos ED, Rundek T, Rana JS, et al.\nAssociation between life’s simple 7 and noncardiovascular disease: the multi-ethnic\nstudy of atherosclerosis. J Am Heart Assoc 2016;5:e003954.\n135. Michos ED, Marshall CH. Healthy lifestyle beneﬁts both cancer and cardiovascular\ndisease: more bang for the buck. JACC CardioOncology 2021;3:675–677.\n4346\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n136. Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of\ncancer therapy-related cardiac dysfunction in breast cancer patients undergoing\nchemotherapy: systematic review. Eur J Prev Cardiol 2022;29:463–472.\n137. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular tox-\nicity in cancer. Circulation 2018;137:1176–1191.\n138. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/\nESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;\n39:3021–3104.\n139. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC\nGuidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in col-\nlaboration with the EASD. Eur Heart J 2020;41:255–323.\n140. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019\nESC/EAS Guidelines for the management of dyslipidaemias: lipid modiﬁcation to re-\nduce cardiovascular risk. Eur Heart J 2020;41:111–188.\n141. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al.\nCardio-oncology drug interactions: a scientiﬁc statement from the American\nHeart Association. Circulation 2022;145:e811–e838.\n142. Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, et al. Deﬁnition of\nhidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical\nimplications. Eur Heart J 2019;40:1771–1777.\n143. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardio-\ntoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer\n2013;49:2900–2909.\n144. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart\nfailure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.\nJ Am Coll Cardiol 2012;60:2504–2512.\n145. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, De Caralt TM, et al.\nEnalapril and carvedilol for preventing chemotherapy-induced left ventricular sys-\ntolic dysfunction in patients with malignant hemopathies: the OVERCOME trial\n(preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients\nsubmitted\nto\nintensive\nChemOtherapy\nfor\nthe\ntreatment\nof\nMalignant\nhEmopathies). J Am Coll Cardiol 2013;61:2355–2362.\n146. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F,\nGonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of\nchemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018;71:\n2281–2290.\n147. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al.\nAnthracycline-induced cardiotoxicity: a multicenter randomised trial comparing\ntwo\nstrategies\nfor\nguiding\nprevention\nwith\nenalapril:\nThe\nInternational\nCardioOncology Society-one trial. Eur J Cancer 2018;94:126–137.\n148. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of\nspironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail\n2015;17:81–89.\n149. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efﬁciency of ator-\nvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll\nCardiol 2011;58:988–989.\n150. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al.\nPrevention of cardiac dysfunction during adjuvant breast cancer therapy\n(PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical\ntrial of candesartan and metoprolol. Eur Heart J 2016;37:1671–1680.\n151. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, et al. Neurohormonal\nblockade and circulating cardiovascular biomarkers during anthracycline therapy in\nbreast cancer patients: results from the PRADA (Prevention of Cardiac\nDysfunction During Adjuvant Breast Cancer Therapy) study. J Am Heart Assoc\n2017;6:e006513.\n152. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W,\net al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardi-\notoxicity in patients with breast cancer. J Am Coll Cardiol 2019;73:2859–2868.\n153. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al.\nMultidisciplinary approach to novel therapies in cardio-oncology research\n(MANTICORE\n101-Breast):\na\nrandomized\ntrial\nfor\nthe\nprevention\nof\ntrastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870–877.\n154. Boekhout AH, Gietema JA, Kerklaan BM, VanWerkhoven ED, Altena R, Honkoop\nA, et al. Angiotensin II receptor inhibition with candesartan to prevent\ntrastuzumab-related cardiotoxic effects in patients with early breast cancer a ran-\ndomized clinical trial. JAMA Oncol 2016;2:1030–1037.\n155. Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A.\nPrevention of anthracycline-induced cardiotoxicity: a systematic review and\nmeta-analysis. Intern Emerg Med 2021;16:477–486.\n156. Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta-\nblockers in chemotherapy-induced cardiotoxicity—a systematic review and\nmeta-analysis of carvedilol. Heart Fail Rev 2019;24:325–333.\n157. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG, et al. Efﬁcacy of\nneurohormonal therapies in preventing cardiotoxicity in patients with cancer\nundergoing chemotherapy. JACC CardioOncology 2019;1:54–65.\n158. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efﬁcacy of\ndexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC\nCardioOncology 2019;1:68–79.\n159. Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on\nchemotherapy-induced\nheart\nfailure:\na\nsystematic\nreview\nand\nnetwork\nmeta-analysis of randomized controlled trials. Pharmacol Res 2020;151:104577.\n160. Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor/\nangiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a\nmeta-analysis of randomized controlled trials. Heart Fail Rev 2021;26:101–109.\n161. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by\na 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990;65:\n870–873.\n162. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,\net al. American Society of Clinical Oncology 2008 clinical practice guideline update:\nuse of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:\n127–145.\n163. European Medicines Agency. Savene: EPAR—Product Information (Internet) 2008\n(updated 2019).\n164. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: chal-\nlenges and opportunities. J Am Coll Cardiol 2014;64:938–945.\n165. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of\ncardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in\nbreast cancer: a Bayesian network meta-analysis. Eur J Cancer 2015;51:2314–2320.\n166. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed ad-\nministration of dexrazoxane provides cardioprotection for patients with advanced\nbreast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:\n1333–1340.\n167. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective inter-\nventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev\n2011;2011:CD003917.\n168. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal for-\nmulations of doxorubicin with drug administered in free form: changing toxicity\nproﬁles. Drug Saf 2001;24:903–920.\n169. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in\nimage-guided radiotherapy. Nat Rev Cancer 2007;7:949–960.\n170. De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.\nRadiotherapy toxicity. Nat Rev Dis Prim 2019;5:13.\n171. Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, et al.\nAssociation of breast cancer irradiation with cardiac toxic effects: a narrative re-\nview. JAMA Oncol 2021;7:924–932.\n172. Banﬁll K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac tox-\nicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol\n2021;16:216–227.\n173. Mitchell JD, Cehic DA, Morgia M, Bergrom C, Toohey J, Guerrero PA, et al.\nCardiovascular manifestations from therapeutic radiation: a multidisciplinary ex-\npert consensus statement from the International Cardio-Oncology Society. JACC\nCardioOncology 2021;3:360–380.\n174. Kirwan CC, Coles CE, Bliss J, Kirwan C, Kilburn L, Fox L, et al. It’s PRIMETIME.\nPostoperative avoidance of radiotherapy: biomarker selection of women at very\nlow risk of local recurrence. Clin Oncol 2016;28:594–596.\n175. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al.\nPrevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients\nby angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.\n176. Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E,\net al. Statin exposure and risk of heart failure after anthracycline-or trastuzumab-\nbased chemotherapy for early breast cancer: a propensity score⍰matched cohort\nstudy. J Am Heart Assoc 2021;10:e018393.\n177. Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S,\nAmir E, et al. Cardioprotective effect of statins in patients with HER2-positive\nbreast cancer receiving trastuzumab therapy. Can J Cardiol 2019;35:153–159.\n178. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the\nrisk for incident heart failure in patients with breast cancer receiving anthracycline\nchemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012;60:\n2384–2390.\n179. Chotenimitkhun R, D’Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S,\net al. Chronic statin administration may attenuate early anthracycline-associated\ndeclines in left ventricular ejection function. Can J Cardiol 2015;31:302–307.\n180. Obasi M, Abovich A, Vo JB, Gao Y, Papatheodorou SI, Nohria A, et al. Statins to\nmitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastu-\nzumab: a systematic review and meta-analysis. Cancer Causes Control 2021;32:\n1395–1405.\n181. Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin use can attenuate the decline in left\nventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic\nchemotherapy recipients: a systematic review and meta-analysis. J Clin Med 2021;\n10:3731.\nESC Guidelines\n4347\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n182. Sanﬁlippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, et al. Statins are\nassociated with reduced mortality in multiple myeloma. J Clin Oncol 2016;34:\n4008–4014.\n183. Afzal A, Fiala MA, Gage BF, Wildes TM, Sanﬁlippo K. Statins reduce mortality in\nmultiple myeloma: a population-based US study. Clin Lymphoma Myeloma Leuk\n2020;20:e937–e943.\n184. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing\nchemotherapy-induced cardiotoxicity in women with breast cancer: a randomized,\nsingle-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019;24:233–241.\n185. Shahid I, Yamani N, Ali A, Kumar P, Figueredo V, Unzek S, et al. Meta-analysis evalu-\nating the use of statins to attenuate cardiotoxicity in cancer patients receiving an-\nthracyclines and trastuzumab-based chemotherapy. Am J Cardiol 2021;156:\n142–145.\n186. Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective effects of\ncarvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol\n2017;69:279–285.\n187. Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, et al. Electronic\nsystems for patients to report and manage side effects of cancer treatment: system-\natic review. J Med Internet Res 2019;21:e10875.\n188. López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García\nSanz R, Mazón Ramos P, et al. Cardio-onco-hematology in clinical practice. Position\npaper and recommendations. Rev Española Cardiol (English Ed) 2017;70:474–486.\n189. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of\nthe cardiac safety of HER2-targeted therapies in patients with HER2-positive breast\ncancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res\nTreat 2019;175:595–603.\n190. Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al.\nComparison of long-term outcome in anthracycline-related versus idiopathic di-\nlated cardiomyopathy: a single centre experience. Eur J Heart Fail 2018;20:898–906.\n191. Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker GM, et al. Role of bio-\nmarkers for the prevention, assessment, and management of heart failure: a scien-\ntiﬁc statement from the American Heart Association. Circulation 2017;135:\ne1054–e1091. Erratum in: Circulation 2017;136:e345.\n192. De Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in\nheart failure. Eur J Heart Fail 2015;17:559–569.\n193. Piek A, Du W, de Boer RA, Silljé HHW. Novel heart failure biomarkers: why do we\nfail to exploit their potential? Crit Rev Clin Lab Sci 2018;55:246–263.\n194. Du W, Piek A, Marloes Schouten E, van de Kolk CWA, Mueller C, Mebazaa A, et al.\nPlasma levels of heart failure biomarkers are primarily a reﬂection of extracardiac\nproduction. Theranostics 2018;8:4155–4169.\n195. Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, et al. Sex-speciﬁc\nassociations of cardiovascular risk factors and biomarkers with incident heart fail-\nure. J Am Coll Cardiol 2020;76:1455–1465.\n196. Bracun V, Aboumsallem JP, van der Meer P, de Boer RA. Cardiac biomarkers in pa-\ntients with cancer: considerations, clinical implications, and future avenues. Curr\nOncol Rep 2020;22:67.\n197. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc\nTransl Res 2020;13:431–450.\n198. López-Fernández T, Thavendiranathan P. Emerging cardiac imaging modalities for\nthe early detection of cardiotoxicity due to anticancer therapies. Rev Española\nCardiol (English Ed) 2017;70:487–495.\n199. Eschenhagen T, Force T, Ewer MS, De Keulenaer GW, Suter TM, Anker SD, et al.\nCardiovascular side effects of cancer therapies: a position statement from the\nHeart Failure Association of the European Society of Cardiology. Eur J Heart Fail\n2011;13:1–10.\n200. Keramida K, Farmakis D, López Fernández T, Lancellotti P. Focused echocardiog-\nraphy in cardio-oncology. Echocardiography 2020;37:1149–1158.\n201. Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in\ncardio-oncology. JACC CardioOncology 2020;2:677–689.\n202. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and\nincremental value of deformation indices for prediction of trastuzumab-induced\ncardiotoxicity. J Am Soc Echocardiogr 2013;26:493–498.\n203. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Aakhus S, Miyazaki S, et al.\nCardioprotection using strain-guided management of potentially cardiotoxic can-\ncer therapy: 1 year results of the SUCCOUR trial. Eur Heart J 2020;41:\nehaa946.3282.\n204. Vallabhaneni S, Zhang KW, Alvarez JA, Joshua C, Henning DM, Woodard PK, et al.\nRole of cardiovascular magnetic resonance in early detection and treatment of car-\ndiac dysfunction in oncology patients. Int J Cardiovasc Imaging 2021;37:3003–3017.\n205. Lapinskas T, Hireche-Chikaoui H, Zieschang V, Erley J, Stehning C, Gebker R, et al.\nEffect of comprehensive initial training on the variability of left ventricular measures\nusing fast-SENC cardiac magnetic resonance imaging. Sci Rep 2019;9:12223.\n206. Korosoglou G, Giusca S, Montenbruck M, Patel AR, Lapinskas T, Götze C, et al. Fast\nstrain-encoded cardiac magnetic resonance for diagnostic classiﬁcation and risk\nstratiﬁcation of heart failure patients. JACC Cardiovasc Imaging 2021;14:1177–1188.\n207. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/\nAHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management\nof heart failure: a report of the American College of Cardiology/American Heart\nAssociation Task Force on Clinical Practice Guidelines and the Heart Failure\nSociety of America. Circulation 2017;136:e137–e161.\n208. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early\ndetection of anthracycline cardiotoxicity and improvement with heart failure ther-\napy. Circulation 2015;131:1981–1988.\n209. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major cardiac\nevents and the value of echocardiographic evaluation in patients receiving\nanthracycline-based chemotherapy. Am J Cardiol 2015;116:442–446.\n210. Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, et al. Examining the\ncost-effectiveness of baseline left ventricular function assessment among breast\ncancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat\n2019;176:261–270.\n211. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, et al. The utility\nof point-of-care biomarkers to detect cardiotoxicity during anthracycline chemo-\ntherapy: a feasibility study. J Card Fail 2016;22:433–438.\n212. Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, et al.\nCirculating biomarkers and cardiac function over 3 years after chemotherapy\nwith anthracyclines: the ICOS-ONE trial. ESC Heart Fail 2020;7:1452–1466.\n213. Jones M, O’Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-sensitive cardiac\ntroponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac\ninjury. Ann Clin Biochem 2017;54:149–157.\n214. Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, et al.\nCombination therapies for the treatment of HER2-positive breast cancer: current\nand future prospects. Expert Rev Anticancer Ther 2018;18:629–649.\n215. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell\nBiol 2001;2:127–137.\n216. Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al. ErbB2 over-\nexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxy-\ngen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ\nPhysiol 2015;309:H1271–H1280.\n217. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer\ntreatment-induced cardiotoxicity. Expert Opin Drug Saf 2017;16:1021–1038.\n218. de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A\npooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast\nCancer Res Treat 2020;179:161–171.\n219. Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, et al.\nLong-term cardiac outcomes of patients with HER2-positive breast cancer treated\nin the adjuvant lapatinib and/or trastuzumab treatment optimization trial. Br J\nCancer 2020;122:1453–1460.\n220. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment\nof cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophos-\nphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in\nnode-positive, HER2-overexpressing breast cancer. J Clin Oncol 2005;23:\n7811–7819.\n221. Martin M, Press M, Ph D, Mackey J, Glaspy J, Chan A, et al. Adjuvant trastuzumab in\nHER2-positive breast cancer. NEJM 2011;365:1273–1283.\n222. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al.\n2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive\nbreast cancer: a randomised controlled trial. Lancet 2007;369:29–36.\n223. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I,\net al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\nN Engl J Med 2005;353:1659–1672.\n224. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al.\nTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast can-\ncer. N Engl J Med 2005;353:1673–1684.\n225. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de\nAzambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy\nin HER2-positive early breast cancer: ﬁnal analysis of the HERceptin Adjuvant\n(HERA) trial. Lancet 2017;389:1195–1205.\n226. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time trends of\nleft ventricular ejection fraction and myocardial deformation indices in a cohort of\nwomen with breast cancer treated with anthracyclines, taxanes, and trastuzumab. J\nAm Soc Echocardiogr 2015;28:509–514.\n227. Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, et al. A\nprospective study about trastuzumab-induced cardiotoxicity in HER2-positive\nbreast cancer. Am J Clin Oncol Cancer Clin Trials 2020;43:510–516.\n228. Yang ZY, Wang W, Wang X, Qin ZQ. Cardiotoxicity of epidermal growth factor\nreceptor 2-targeted drugs for breast cancer. Front Pharmacol 2021;12:741451.\n229. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden\nC, et al. 2013 ESC guidelines on the management of stable coronary artery disease:\nthe Task Force on the management of stable coronary artery disease of the\nEuropean Society of Cardiology. Eur Heart J 2013;34:2949–3003.\n4348\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n230. Padegimas A, Carver JR. How to\ndiagnose and manage patients with\nﬂuoropyrimidine-induced\nchest\npain:\na\nsingle\ncenter\napproach.\nJACC\nCardioOncology 2020;2:650–654.\n231. Kwakman JJM, Simkens LHJ, Mol L, Kok WEM, Koopman M, Punt CJA. Incidence of\ncapecitabine-related cardiotoxicity in different treatment schedules of metastatic\ncolorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch\nColorectal Cancer Group. Eur J Cancer 2017;76:93–99.\n232. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can\ninduce acute coronary syndrome similar to 5-ﬂuorouracil. Ann Oncol 2002;13:\n797–801.\n233. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the patho-\nphysiology of 5-ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;\n15:47.\n234. Edvardsen T, Asch FM, Davidson B, Delgado V, DeMaria A, Dilsizian V, et al.\nNon-invasive imaging in coronary syndromes: recommendations of the European\nAssociation\nof\nCardiovascular\nImaging\nand\nthe\nAmerican\nSociety\nof\nEchocardiography, in collaboration with the American Society of Nuclear\nCardiology, Society of Cardiovascular Comuted Tomography, and Society for\nCardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging 2022;23:\ne6–e33.\n235. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-ﬂuorouracil\nand cardiotoxicity: a review. Ther Adv Med Oncol 2018;10:1758835918780140.\n236. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with no-\nvel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends\nCardiovasc Med 2013;23:104–113.\n237. Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thrombo-\nembolic events with sunitinib and sorafenib: a systematic review and meta-analysis\nof clinical trials. J Clin Oncol 2010;28:2280–2285.\n238. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibi-\ntors: With a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;\n36:295–316.\n239. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular tox-\nicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and\nmeta-analysis. Cancer Treat Rev 2017;53:120–127.\n240. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients.\nCardio-Oncology 2019;5:7.\n241. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the\ntreatment of cancer on the cardiovascular system: focus on hypertension.\nCirculation 2011;124:1687–1691.\n242. Shah CP, Moreb JS. Cardiotoxicity due to targeted anticancer agents: a growing\nchallenge. Ther Adv Cardiovasc Dis 2019;13:1753944719843435.\n243. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiv-\ning sunitinib. N Engl J Med 2008;358:95–97.\n244. Hamnvik OPR, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical\nrisk factors for the development of hypertension in patients treated with inhibitors\nof the VEGF signaling pathway. Cancer 2015;121:311–319.\n245. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, et al. Congestive\nheart failure with vascular endothelial growth factor receptor tyrosine kinase inhi-\nbitors. Crit Rev Oncol Hematol 2015;94:228–237.\n246. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, et al.\nEchocardiographic assessment for the detection of cardiotoxicity due to vascular\nendothelial growth factor inhibitor therapy in metastatic renal cell and colorectal\ncancers. J Am Soc Echocardiogr 2019;32:267–276.\n247. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib\nand sorafenib. N Engl J Med 2011;365:1649–1650.\n248. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms\nof VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and\nvascular disease. Hypertension 2018;71:E1–E8.\n249. Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and risk of QTc interval\nprolongation among cancer patients treated with vandetanib: a systematic review\nand meta-analysis. PLoS One 2012;7:e30353.\n250. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval pro-\nlongation with vascular endothelial growth factor receptor tyrosine kinase inhibi-\ntors. Br J Cancer 2015;112:296–305.\n251. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identiﬁcation of\nanticancer drugs associated with atrial ﬁbrillation: analysis of the WHO pharmacov-\nigilance database. Eur Heart J Cardiovasc Pharmacother 2021;7:312–320.\n252. EMA. Medicines | European Medicines Agency. Eur Med Agency Sci Med Heal n.d.\n253. FDA. Drugs@FDA: FDA-Approved Drugs. FDA US Food Drug Adm n.d.\n254. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of\ncardiac toxicity in patients receiving vascular endothelial growth factor signaling\npathway inhibitors. Am Heart J 2012;163:156–163.\n255. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial as-\nsessment, surveillance, and management of blood pressure in patients receiving\nvascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst\n2010;102:596–604.\n256. Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic mye-\nloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology 2017;\n2017:110–114.\n257. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity\nin chronic myeloid leukemia. J Clin Oncol 2015;33:4210–4218.\n258. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular\nand metabolic implications of novel targeted cancer therapies: focus on kinase in-\nhibitors. J Am Coll Cardiol 2015;66:1160–1178.\n259. Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on\nchemotherapy and targeted therapies. Circ Arrhythmia Electrophysiol 2017;10:\ne005443.\n260. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al.\nVascular toxicities of cancer therapies: the old and the new—an evolving avenue.\nCirculation 2016;133:1272–1289.\n261. Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine\nkinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse\nevent reporting system database (FAERS). Cancers (Basel) 2020;12:826.\n262. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, et al. Optimising\noutcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy:\nEuropean recommendations for clinical practice. Br J Haematol 2018;180:666–679.\n263. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, et al.\nAtrial ﬁbrillation in patients with chronic lymphocytic leukemia (CLL). Leuk\nLymphoma 2017;58:1630–1639.\n264. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al.\nHypertension and incident cardiovascular events following ibrutinib initiation.\nBlood 2019;134:1919–1928.\n265. Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al.\nCharacterization of atrial ﬁbrillation adverse events reported in ibrutinib rando-\nmized controlled registration trials. Haematologica 2017;102:1796–1805.\n266. López-Fernández, T, Canales M, Farmakis D, García-Sanz R, Bosch F, Loscertales J,\net al. Ibrutinib-associated atrial ﬁbrillation: a practical approach. Ann Hematol Oncol\n2018;5:1203.\n267. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB,\net al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 2019;74:\n1667–1678.\n268. Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular\nrisk associated with ibrutinib use in chronic lymphocytic leukemia: a population-\nbased cohort study. J Clin Oncol 2021;39:3453–3462.\n269. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al.\nAcalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia:\nresults of the ﬁrst randomized phase III trial. J Clin Oncol 2021;39:3441–3452.\n270. Common Terminology Criteria for Adverse Events (CTCAE) v6.0. National Cancer Institute,\n2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.\n271. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al.\nCardiovascular adverse events in patients with chronic lymphocytic leukemia receiv-\ning acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 2022;\n107:1335–1346.\n272. Svennberg E, Tjong F, Goette A, Akoum N, Di Biaise L, Bordachar P, et al. How to use\ndigital devices to detect and manage arrhythmias: an EHRA practical guide. Europace.\n2022;24:979–1005.\n273. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.\n2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation devel-\noped in collaboration with the European Association for Cardio-Thoracic Surgery\n(EACTS). Eur Heart J 2021;42:373–498.\n274. McMullen JR, Boey EJ, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases\nthe risk of atrial ﬁbrillation, potentially through inhibition of cardiac PI3K-Akt signal-\ning. Blood 2014;124:3829–3830.\n275. Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial ﬁbrillation in\npatients with mantle cell lymphoma. Leuk Lymphoma 2016;57:2914–2916.\n276. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratiﬁcation and\nmanagement. Am J Hematol 2020;95:548–567.\n277. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued\nimprovement in survival in multiple myeloma: changes in early mortality and out-\ncomes in older patients. Leukemia 2014;28:1122–1128.\n278. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction—Alzheimer’s dis-\nease of the heart? N Engl J Med 2013;368:455–464.\n279. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al.\nCarﬁlzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N\nEngl J Med 2015;372:142–152.\n280. Chari A, Keith Stewart A, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis\nof carﬁlzomib cardiovascular safety proﬁle across relapsed and/or refractory mul-\ntiple myeloma clinical trials. Blood Adv 2018;2:1633–1644.\nESC Guidelines\n4349\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n281. Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al.\nCarﬁlzomib-associated cardiovascular adverse events: a systematic review and\nmeta-analysis. JAMA Oncol 2018;4:e174519.\n282. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, et al. Causes of late\nmortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016;37:\n378–385.\n283. Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, et al. Irreversible\nproteasome inhibition with carﬁlzomib as ﬁrst line therapy in patients with newly\ndiagnosed multiple myeloma: early in vivo cardiovascular effects. Eur J Pharmacol\n2018;838:85–90.\n284. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety\nproﬁle of single-agent carﬁlzomib: experience from 526 patients enrolled in 4 phase\nII clinical studies. Haematologica 2013;98:1753–1761.\n285. RidolﬁRL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis.\nClinical and pathologic features of 23 patients. Am J Med 1977;62:677–686.\n286. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary compli-\ncations\nof\ncarﬁlzomib\ntreatment\nand\nassociated\nrisk\nfactors\nusing\nthe\nSEER-Medicare database. Cancer 2020;126:808–813.\n287. Feng DL, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al.\nIntracardiac thrombosis and embolism in patients with cardiac amyloidosis.\nCirculation 2007;116:2420–2426.\n288. Mancuso S, Carlisi M, Sarocchi M, Napolitano M, Siragusa S. Cardio-oncology in\nmultiple myeloma: is it time for a speciﬁc focus? Leuk Lymphoma 2018;59:\n1764–1766.\n289. Danhof S, Schreder M, Rasche L, Striﬂer S, Einsele H, Knop S. ‘Real-life’ experience\nof preapproval carﬁlzomib-based therapy in myeloma—analysis of cardiac toxicity\nand predisposing factors. Eur J Haematol 2016;97:25–32.\n290. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and\ntreatment of cardiac amyloidosis. A position statement of the European Society of\nCardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail\n2021;23:512–526.\n291. Feng DL, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac throm-\nbosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:\n2490–2497.\n292. Sonneveld P, Asselbergs E, Zweegman S, Van Der Holt B, Kersten MJ, Vellenga E,\net al. Phase 2 study of carﬁlzomib, thalidomide, and dexamethasone as induction/\nconsolidation therapy for newly diagnosed multiple myeloma. Blood 2015;125:\n449–456.\n293. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, et al. Phase 2\ndose-expansion study (PX-171-006) of carﬁlzomib, lenalidomide, and low-dose\ndexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:\n3122–3128.\n294. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, et al.\nRecurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor\nand immunomodulatory therapy for the treatment of multiple myeloma. Br J\nHaematol 2018;180:271–275.\n295. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular\nand thrombotic complications of novel multiple myeloma therapies: a review. JAMA\nOncol 2017;3:980–988.\n296. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B,\net al. Prevention of thalidomide- and lenalidomide-associated thrombosis in mye-\nloma. Leukemia 2008;22:414–423.\n297. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC,\net al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll\nCardiol 2019;73:1733–1734.\n298. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American\nSociety of Hematology 2021 guidelines for management of venous thromboembol-\nism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927–974.\n299. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous\nthromboembolism prophylaxis and treatment in patients with cancer: ASCO clin-\nical practice guideline update. J Clin Oncol 2020;38:496–520.\n300. Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, et al. Comparison\nof venous thromboembolism incidence in newly diagnosed multiple myeloma pa-\ntients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carﬁlzomib,\nlenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophy-\nlaxis. Br J Haematol 2022;196:105–109.\n301. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, et al.\nPrimary prevention of venous thromboembolism with apixaban for multiple mye-\nloma patients receiving immunomodulatory agents. Br J Haematol 2020;190:\n555–561.\n302. Swan D, Rocci A, Bradbury C, Thachil J. Venous thromboembolism in multiple\nmyeloma—choice of prophylaxis, role of direct oral anticoagulants and special con-\nsiderations. Br J Haematol 2018;183:538–556.\n303. Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, et al.\nPredictive biomarkers and practical considerations in the management of\ncarﬁlzomib-associated cardiotoxicity. Leuk Lymphoma 2018;59:1981–1985.\n304. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin,\nwarfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma\ntreated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol\n2011;29:986–993.\n305. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al.\nAspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed mul-\ntiple myeloma treated with lenalidomide. Blood 2012;119:933–939.\n306. Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness ana-\nlysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in pa-\ntients newly diagnosed with multiple myeloma. Thromb Res 2016;145:119–125.\n307. Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT. Primary\nthromboembolic prevention in multiple myeloma patients: an exploratory\nmeta-analysis on aspirin use. Semin Hematol 2018;55:182–184.\n308. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al.\nCardiovascular adverse events associated with BRAF and MEK inhibitors: a system-\natic review and meta-analysis. JAMA Netw Open 2019;2:e198890.\n309. Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and\nclinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC:\nCardioOncology state-of-the-art review. Cardio Oncol 2022;4:1–18.\n310. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved\nsurvival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;\n367:107–114.\n311. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D,\net al. Improved overall survival in melanoma with combined dabrafenib and trame-\ntinib. N Engl J Med 2015;372:30–39.\n312. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al.\nDabrafenib\nand\ntrametinib\nversus\ndabrafenib\nand\nplacebo\nfor\nVal600\nBRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised con-\ntrolled trial. Lancet 2015;386:444–451.\n313. Bronte E, Bronte G, Novo G, Rinaldi G, Bronte F, Passiglia F, et al. Cardiotoxicity\nmechanisms\nof\nthe\ncombination\nof\nBRAF-inhibitors\nand\nMEK-inhibitors.\nPharmacol Ther 2018;192:65–73.\n314. Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, et al.\nAdverse events associated with encorafenib plus binimetinib in the COLUMBUS\nstudy: incidence, course and management. Eur J Cancer 2019;119:97–106.\n315. Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK in-\nhibitor, trametinib: a case report, literature review, and consideration of mechan-\nism. Cardiovasc Toxicol 2017;17:487–493.\n316. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular\ntoxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:\n854–868.\n317. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated\nwith immune checkpoint blockade. N Engl J Med 2018;378:158–168.\n318. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association\nbetween immune checkpoint inhibitors with cardiovascular events and athero-\nsclerotic plaque. Circulation 2020;142:2299–2311.\n319. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G,\nTorre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor\ntherapy: a meta-analysis. Eur J Heart Fail 2021;23:1739–1747.\n320. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al.\nCardiovascular toxicities associated with immune checkpoint inhibitors: an obser-\nvational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579–1589.\n321. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late car-\ndiac adverse events in patients with cancer treated with immune checkpoint inhi-\nbitors. J Immunother Cancer 2020;8:e000261.\n322. D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The\nrisk of cardiac events in patients receiving immune checkpoint inhibitors: a nation-\nwide Danish study. Eur Heart J 2021;42:1621–1631.\n323. Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, et al.\nCardiovascular immunotoxicities associated with immune checkpoint inhibitors:\na safety meta-analysis. Eur Heart J 2021;42:4964–4977.\n324. Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al.\nFactors associated with immune checkpoint inhibitor–related myocarditis. JAMA\nOncol 2019;5:1635–1637.\n325. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunother-\napy landscape and the epidemiology, diagnosis, and management of cardiotoxicity:\nJACC: CardioOncology primer. JACC CardioOncology 2021;3:35–47.\n326. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors\nand cardiovascular toxicity. Lancet Oncol 2018;19:e447–e458.\n327. Schiffer WB, Deych E, Lenihan DJ, Zhang KW. Coronary and aortic calciﬁcation are\nassociated with cardiovascular events on immune checkpoint inhibitor therapy. Int J\nCardiol 2021;322:177–182.\n4350\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n328. Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al. Anti-PD-1 monoclonal\nantibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J\nImmunother Cancer 2019;7:225.\n329. Allenbach Y, Anquetil\nC, Manouchehri\nA, Benveniste O, Lambotte\nO,\nLebrun-Vignes B, et al. Immune checkpoint inhibitor-induced myositis, the earliest\nand most lethal complication among rheumatic and musculoskeletal toxicities.\nAutoimmun Rev 2020;19:102586.\n330. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al.\nImmune checkpoint inhibitor–associated myositis: expanding the spectrum of car-\ndiac complications of the immunotherapy revolution. Circulation 2018;138:\n743–745.\n331. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al.\nMyocarditis in the setting of cancer therapeutics: proposed case deﬁnitions for\nemerging clinical syndromes in cardio-oncology. Circulation 2019;140:80–91.\n332. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, et al. Clinical\nstrategy for the diagnosis and treatment of immune checkpoint inhibitor-associated\nmyocarditis: a narrative review. JAMA Cardiol 2021;6:1329–1337.\n333. Rini B, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, et al.\nProspective cardiovascular surveillance of immune checkpoint inhibitor-based\ncombination therapy in patients with advanced renal cell cancer: data from the\nphase 3 JAVELIN Renal 101 trial. J Clin Oncol 2022;40:1929–1938.\n334. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al.\nGlobal longitudinal strain and cardiac events in patients with immune checkpoint\ninhibitor-related myocarditis. J Am Coll Cardiol 2020;75:467–478.\n335. Kondapalli L, Bottinor W, Lenneman C. By releasing the brakes with immunother-\napy, are we accelerating atherosclerosis? Circulation 2020;142:2312–2315.\n336. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-\nterm implications of toxicity. Nat Rev Clin Oncol 2022;19:254–267.\n337. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy\nfor prostate cancer is associated with cardiovascular morbidity and mortality: a\nmeta-analysis of population-based observational studies. PLoS One 2014;9:\ne107516.\n338. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al.\nCardiovascular effects of androgen deprivation therapy for the treatment of pros-\ntate cancer: ABCDE Steps to reduce cardiovascular disease in patients with pros-\ntate cancer. Circulation 2016;133:537–541.\n339. Okwuosa TM, Morgans A, Rhee J-W, Reding KW, Maliski S, Plana J-C, et al. Impact\nof hormonal therapies for treatment of hormone-dependent cancers (breast and\nprostate) on the cardiovascular system: effects and modiﬁcations: a scientiﬁc state-\nment from the American Heart Association. Circ Genomic Precis Med 2021;14:\ne000082.\n340. Barber M, Nguyen L, Wassermann J, Spano J, Funck-Brentano C, Salem J. Cardiac\narrhythmia considerations of hormone cancer therapies. Cardiovasc Res 2019;115:\n878–894.\n341. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral\nrelugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J\nMed 2020;382:2187–2196.\n342. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential\nimpact of gonadotropin-releasing hormone antagonist versus agonist on clinical\nsafety and oncologic outcomes on patients with metastatic prostate cancer: a\nmeta-analysis of randomized controlled trials. Eur Urol 2021;79:44–53.\n343. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al.\nCardiovascular safety of degarelix versus leuprolide in patients with prostate can-\ncer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;\n144:1295–1307.\n344. Wilk M, Waśko-Grabowska A, Skoneczna I, Szmit S. Angiotensin system inhibitors\nmay improve outcomes of patients with castration-resistant prostate cancer during\nabiraterone acetate treatment—a cardio-oncology study. Front Oncol 2021;11:\n664741.\n345. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al.\nHypogonadism as a reversible cause of Torsades de Pointes in men. Circulation\n2018;138:110–113.\n346. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Inﬂuence of steroid hor-\nmones on ventricular repolarization. Pharmacol Ther 2016;167:38–47.\n347. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al.\nAndrogenic effects on ventricular repolarization a translational study from the\ninternational pharmacovigilance database to iPSC-cardiomyocytes. Circulation\n2019;140:1070–1080.\n348. Hasegawa K, Ito H, Kaseno K, Miyazaki S, Shiomi Y, Tama N, et al. Impact of medical\ncastration on malignant arrhythmias in patients with prostate cancer. J Am Heart\nAssoc 2021;10:e017267.\n349. Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al.\nRecognition, prevention, and management of arrhythmias and autonomic disorders\nin cardio-oncology: a scientiﬁc statement from the American Heart Association.\nCirculation 2021;144:E41–E55.\n350. Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of degarelix, a\ngonadotropin-releasing hormone receptor antagonist for the treatment of pros-\ntate cancer, on cardiac repolarisation in a randomised, placebo and active compara-\ntor controlled thorough QT/QTc trial in healthy men. Clin Drug Investig 2017;37:\n873–879.\n351. Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM, et al. Anastrozole\nalone or in combination with tamoxifen versus tamoxifen alone for adjuvant treat-\nment of postmenopausal women with early breast cancer: ﬁrst results of the ATAC\nrandomised trial. Lancet 2002;359:2131–2139.\n352. ARIMIDEX® (anastrozole). Highlights of Prescribing Information. Wilmington, DE:\nAstraZeneca Pharmaceuticals LP, 2014.\n353. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B,\nKeshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole\nand tamoxifen in postmenopausal women with early breast cancer. N Engl J Med\n2005;353:2747–2757.\n354. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine\ntherapy in postmenopausal breast cancer patients: a systematic review and\nmeta-analysis. J Natl Cancer Inst 2011;103:1299–1309.\n355. Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocaña A, Ribnikar D, et al.\nToxicity of extended adjuvant therapy with aromatase inhibitors in early breast\ncancer: a systematic review and meta-analysis. J Natl Cancer Inst 2018;110:31–39.\n356. Curigliano G, Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM.\nPrevention, monitoring, and management of cardiac dysfunction in patients with\nmetastatic breast cancer. Oncologist 2019;24:e1034–e1043.\n357. KISQALI (ribociclib). Highlights of Prescribing Information. East Hanover, NJ: Novartis\nPharmaceuticals Corporation, 2018.\n358. IBRANCE (palbociclib). Highlights of Prescribing Information. New York, NY: Pﬁzer,\n2018.\n359. VERZENIO (abemaciclib). Highlights of Prescribing Information. Indianapolis, IN: Eli\nLilly and Company, 2018.\n360. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al.\nDifferent cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expres-\nsion and pharmacological data analyses, biological basis, and therapeutic implica-\ntions. BioDrugs 2019;33:613–620.\n361. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S,\net al. Ribociclib as ﬁrst-line therapy for HR-positive, advanced breast cancer. N\nEngl J Med 2016;375:1738–1748.\n362. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus\nendocrine therapy for premenopausal women with hormone-receptor-positive,\nadvanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet\nOncol 2018;19:904–915.\n363. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letro-\nzole in advanced breast cancer. N Engl J Med 2016;375:1925–1936.\n364. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant\nplus\npalbociclib\nversus\nfulvestrant\nplus\nplacebo\nfor\ntreatment\nof\nhormone-receptor-positive, HER2–negative metastatic breast cancer that pro-\ngressed on previous endocrine therapy (PALOMA-3): ﬁnal analysis of the multicen-\ntre, double-blind, phas. Lancet Oncol 2016;17:425–439.\n365. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III\nrandomized study of ribociclib and fulvestrant in hormone receptor-positive, hu-\nman epidermal growth factor receptor 2-negative advanced breast cancer:\nMONALEESA-3. J Clin Oncol 2018;36:2465–2472.\n366. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al.\nPalbociclib has no clinically relevant effect on the QTc interval in patients with ad-\nvanced breast cancer. Anticancer Drugs 2018;29:271–280.\n367. Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival\nwith ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:\n307–316.\n368. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall\nsurvival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med\n2020;382:514–524.\n369. Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias:\na review. Drug Saf 2015;38:129–152.\n370. Wang L, Wang W. Safety and efﬁcacy of anaplastic lymphoma kinase tyrosine ki-\nnase inhibitors in non-small cell lung cancer (Review). Oncol Rep 2021;45:13–28.\n371. Rao VU, Reeves DJ, Chugh AR, O’Quinn R, Fradley MG, Raghavendra M, et al.\nClinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC\nstate-of-the-art review. J Am Coll Cardiol 2021;77:2693–2716.\n372. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or\ncrizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:\n2018–2029.\n373. Thein KZ, Swarup S, Ball S, Quirch M, Vorakunthada Y, Htwe KK, et al. Incidence of\ncardiac toxicities in patients with advanced non-small cell lung cancer treated with\nosimertinib: a combined analysis of two phase III randomized controlled trials. Ann\nOncol 2018;29:viii500.\nESC Guidelines\n4351\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n374. Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxi-\ncity: a retrospective review of the FDA Adverse Events Reporting System (FAERS).\nJACC CardioOncology 2019;1:172–178.\n375. Kunimasa K, Kamada R, Oka T, Oboshi M, Kimura M, Inoue T, et al. Cardiac adverse\nevents in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC\nCardioOncology 2020;2:1–10.\n376. Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a re-\nview of data. J Clin Oncol 2021;39:328–337.\n377. Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell\ntherapy. Biol Blood Marrow Transplant 2019;25:e123–e127.\n378. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al.\nCardiovascular events among adults treated with chimeric antigen receptor\nT-cells (CAR-T). J Am Coll Cardiol 2019;74:3099–3108.\n379. Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovas-\ncular and pulmonary events associated with chimeric antigen receptor T-cell ther-\napy. J Am Coll Cardiol 2021;78:1800–1813.\n380. Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik\nAA. Cardiovascular toxicity and mortality associated with adoptive cell therapy\nand tumor-inﬁltrating lymphocytes for advanced stage melanoma. J Immunother\n2021;44:86–89.\n381. Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell\ntherapy-related cardiovascular outcomes and management: systemic disease or\ndirect cardiotoxicity? JACC CardioOncology 2020;2:97–109.\n382. Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M.\nCardiovascular effects of CAR T cell therapy: a restrospective study. JACC\nCardioOncology 2020;2:193–203.\n383. Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ. Cardiac events associated with chi-\nmeric antigen receptor T-cells (CAR-T): a VigiBase perspective. J Am Coll Cardiol\n2020;75:2521–2523.\n384. Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen\nreceptor T-cell therapy-associated cardiomyopathy in patients with refractory or\nrelapsed non-Hodgkin lymphoma. Circulation 2020;142:1687–1690.\n385. Lee JB, Vasic D, Kang H, Fang KKL, Zhang L. State-of-art of cellular therapy for acute\nleukemia. Int J Mol Sci 2021;22:4590.\n386. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al.\nSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immune\ncheckpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435.\n387. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, et al.\nDiagnosis, grading and management of toxicities from immunotherapies in children,\nadolescents and young adults with cancer. Nat Rev Clin Oncol 2021;18:435–453.\n388. Maus M V, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society\nfor Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector\ncell-related adverse events. J Immunother Cancer 2020;8:e001511.\n389. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al.\nRisk of ischemic heart disease in women after radiotherapy for breast cancer. N\nEngl J Med 2013;368:987–998.\n390. Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann\nM, et al. Radiation dose-response relationship for risk of coronary heart disease in\nsurvivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–243.\n391. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol ADG,\net al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl\nCancer Inst 2015;107:djv008.\n392. Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, et al. Past,\npresent, and future of radiation-induced cardiotoxicity: reﬁnements in targeting,\nsurveillance, and risk stratiﬁcation. JACC CardioOncology 2021;3:343–359.\n393. Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of\nan underrecognized pathology. J Am Heart Assoc 2021;10:e021686.\n394. Carlson LE, Watt GP, Tonorezos ES, Chow EJ, Yu AF, Woods M, et al. Coronary\nartery disease in young women after radiation therapy for breast cancer. JACC\nCardioOncology 2021;3:381–392.\n395. Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, et al. Is mean\nheart dose a relevant surrogate parameter of left ventricle and coronary arteries\nexposure during breast cancer radiotherapy: a dosimetric evaluation based on\nindividually-determined radiation dose (BACCARAT study). Radiat Oncol 2019;\n14:29.\n396. Hoppe BS, Bates JE, Mendenhall NP, Morris CG, Louis D, Ho MW, et al. The mean-\ningless meaning of mean heart dose in mediastinal lymphoma in the modern radi-\nation therapy era. Pract Radiat Oncol 2020;10:e147–e154.\n397. Maraldo M V, Giusti F, Vogelius IR, Lundemann M, Van der Kaaij MAE, Ramadan S,\net al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of\nnine collaborative EORTC-LYSA trials. Lancet Haematol 2015;2:e492–e502.\n398. Atkins KM, Bitterman DS, Chaunzwa TL, Kozono DE, Baldini EH, Aerts HJWL, et al.\nMean heart dose is an inadequate surrogate for left anterior descending coronary\nartery dose and the risk of major adverse cardiac events in lung cancer radiation\ntherapy. Int J Radiat Oncol 2021;110:1473–1479.\n399. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al.\nCardiac outcomes in a cohort of adult survivors of childhood and adolescent can-\ncer: retrospective analysis of the childhood cancer survivor study cohort. BMJ 2009;\n339:b4606.\n400. Van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers\nJMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment 40-year dis-\nease risk. JAMA Intern Med 2015;175:1007–1017.\n401. Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, et al.\nRadiation dose-response for risk of myocardial infarction in breast cancer survi-\nvors. Int J Radiat Oncol Biol Phys 2019;103:595–604.\n402. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission\ntomography-guided treatment in early-stage favorable Hodgkin lymphoma: ﬁnal re-\nsults of the international, randomized phase III HD16 trial by the German Hodgkin\nStudy Group. J Clin Oncol 2019;37:2835–2845.\n403. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of\na trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med\n2015;372:1598–1607.\n404. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving sur-\ngery with or without irradiation in women aged 65 years or older with early breast\ncancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16:266–273.\n405. Song AJ, Manukian G, Taylor AK, Anne PR, Simone NL. Concerns for active breath-\ning control (ABC) with breast cancer in the era of COVID-19: maximizing infection\ncontrol while minimizing heart dose. Adv Radiat Oncol 2020;5:573–574.\n406. Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al.\nProspective phase II trial of image-guided radiotherapy in Hodgkin lymphoma:\nbeneﬁt of deep inspiration breath-hold. Acta Oncol (Madr) 2015;54:60–66.\n407. Persson GF, Scherman Rydhög J, Josipovic M, Maraldo M V, Nygård L, Costa J, et al.\nDeep inspiration breath-hold volumetric modulated arc radiotherapy decreases\ndose to mediastinal structures in locally advanced lung cancer. Acta Oncol (Madr)\n2016;55:1053–1056.\n408. Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, et al.\nProton therapy for adults with mediastinal lymphomas: the International\nLymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.\nErratum in: Blood 2019;133:1384–1385.\n409. Rotz SJ, Ryan TD, Hayek SS. Cardiovascular disease and its management in children\nand adults undergoing hematopoietic stem cell transplantation. J Thromb\nThrombolysis 2021;51:854–869.\n410. Oliveira GH, Al-Kindi SG, Guha A, Dey AK, Rhea IB, DeLima MJ. Cardiovascular risk\nassessment and management of patients undergoing hematopoietic cell transplant-\nation. Bone Marrow Transplant 2021;56:544–551.\n411. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al.\nHematopoietic cell transplantation (HCT)-speciﬁc comorbidity index: a new tool\nfor risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.\n412. Tichelli A, Bucher C, Rovó A, Stussi G, Stern M, Paulussen M, et al. Premature car-\ndiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood\n2007;110:3463–3471.\n413. Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, et al. Clinical preva-\nlence and outcome of cardiovascular events in the ﬁrst 100 days postallogeneic\nhematopoietic stem cell transplant. Eur J Haematol 2021;106:32–39.\n414. Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac tox-\nicity associated with post-transplant cyclophosphamide in allogeneic stem cell\ntransplantation. JACC CardioOncology 2021;3:250–259.\n415. López-Fernández T, Vadillo IS, de la Guía AL, Barbier KH. Cardiovascular issues in\nhematopoietic stem cell transplantation (HSCT). Curr Treat Options Oncol 2021;22:\n51.\n416. Ohmoto A, Fuji S. Cardiac complications associated with hematopoietic stem-cell\ntransplantation. Bone Marrow Transplant 2021;56:2637–2643.\n417. Takatsuka H, Nakajima T, Nomura K, Okikawa Y, Wakae T, Toda A, et al. Prognosis\nvalue of atrial natriuretic peptide and brain natriuretic peptide for heart failure in\npatients undergoing allogeneic bone marrow transplantation. Hematology 2006;\n11:351–354.\n418. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, et al.\nAssessment of cardiotoxicity during haemopoietic stem cell transplantation with\nplasma brain natriuretic peptide. Bone Marrow Transplant 2000;26:309–313.\n419. Alvarez-Cardona JA, Zhang KW, Mitchell JD, Zaha VG, Fisch MJ, Lenihan DJ.\nCardiac\nbiomarkers\nduring\ncancer\ntherapy:\npractical\napplications\nfor\ncardio-oncology. JACC CardioOncology 2020;2:791–794.\n420. Mohammed J, Smith SR, Burns L, Basak G, Aljurf M, Savani BN, et al. Role of physical\ntherapy before and after hematopoietic stem cell transplantation: white paper re-\nport. Biol Blood Marrow Transplant 2019;25:e191–e198.\n421. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al.\nCardiovascular risk factors and morbidity in long-term survivors of testicular can-\ncer: a 20-year follow-up study. J Clin Oncol 2010;28:4649–4657.\n4352\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n422. Herrmann J. Cardiovascular toxicity with cisplatin in patients with testicular cancer:\nlooking for something heavier than heavy metal. JACC CardioOncology 2020;2:\n456–459.\n423. Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao\nPérez L, Marconi G, et al. Safety of FLT3 inhibitors in patients with acute myeloid\nleukemia. Expert Rev Hematol 2021;14:851–865.\n424. Dong H, Yao L, Wang M, Wang M, Li X, Sun X, et al. Can ACEI/ARB prevent the\ncardiotoxicity caused by chemotherapy in early-stage breast cancer?—A\nmeta-analysis of randomized controlled trials. Transl Cancer Res 2020;11:\n7034–7043.\n425. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al.\nAnthracycline-induced cardiomyopathy: clinical relevance and response to pharma-\ncologic therapy. J Am Coll Cardiol 2010;55:213–220.\n426. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab der-\nuxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:\n610–621.\n427. Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF. Cardiac outcomes of tras-\ntuzumab therapy in patients with HER2-positive breast cancer and reduced left\nventricular ejection fraction. Breast Cancer Res Treat 2019;175:239–246.\n428. Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC,\net al. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.\nJACC CardioOncology 2019;1:1–10.\n429. Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy car-\ndiotoxicity: JACC: CardioOncology state-of-the-art review. Cardio Oncol 2022;4:\n19–37.\n430. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F, et al.\nIndependent adjudication of symptomatic heart failure with the use of doxorubicin\nand cyclophosphamide followed by trastuzumab adjuvant therapy: A combined re-\nview of cardiac data from the National Surgical Adjuvant Breast and Bowel Project\nB-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin\nOncol 2010;28:3416–3421.\n431. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al.\nReversibility of trastuzumab-related cardiotoxicity: new insights based on clinical\ncourse and response to medical treatment. J Clin Oncol 2005;23:7820–7826.\n432. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term\ncardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson\nCancer Center experience. J Clin Oncol 2006;24:4107–4115.\n433. Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, et al. Long-term follow-up\nassessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of\nHER2-targeted therapies in patients with breast cancer and compromised heart\nfunction. Breast Cancer Res Treat 2021;185:863–868.\n434. Mahmood SS, Fradley MG, Cohen J V, Nohria A, Reynolds KL, Heinzerling LM, et al.\nMyocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol\n2018;71:1755–1764.\n435. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al.\nElectrocardiographic manifestations of immune checkpoint inhibitor myocarditis.\nCirculation 2021;144:1521–1523. Erratum in: Circulation 2021;144:e490.\n436. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al.\nMajor adverse cardiovascular events and the timing and dose of corticosteroids\nin immune checkpoint inhibitor-associated myocarditis. Circulation 2020;141:\n2031–2034.\n437. Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Sufﬁotti M, Moslehi JJ, et al.\n68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myo-\ncarditis. J Immunother Cancer 2021;9:e003594.\n438. Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early\ndetection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT.\nFront Cardiovasc Med 2021;8:614997.\n439. Chen Y, Jia Y, Liu Q, Shen Y, Zhu H, Dong X, et al. Myocarditis related to immune\ncheckpoint inhibitors treatment: two case reports and literature review. Ann Palliat\nMed 2021;10:8512–8517.\n440. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al.\nImmune checkpoint inhibitor myocarditis: elucidating the spectrum of disease\nthrough endomyocardial biopsy. Eur J Heart Fail 2021;23:1725–1735.\n441. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al.\n2019 ESC Guidelines for the management of patients with supraventricular tachy-\ncardia. Eur Heart J 2020;41:655–720.\n442. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022\nESC Guidelines for the management of patients with ventricular arrhythmias and\nthe prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126.\n443. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.\n2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur\nHeart J 2021;42:3427–3520.\n444. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015\nESC Guidelines for the diagnosis and management of pericardial diseases: the Task\nForce for the Diagnosis and Management of Pericardial Diseases of the European\nSociety of Cardiology (ESC) Endorsed by: The European Association for\nCardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–2964.\n445. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al.\nManagement of acute myocarditis and chronic inﬂammatory cardiomyopathy: an\nexpert consensus document. Circ Heart Fail 2020;13:e007405.\n446. Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, et al.\nManagement of immune checkpoint inhibitor–induced myocarditis: the French\nWorking Group’s Plea for a pragmatic approach. JACC CardioOncology 2021;3:\n157–161.\n447. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-\nblind, placebo-controlled, pilot trial of inﬂiximab, a chimeric monoclonal antibody\nto tumor necrosis factor-α, in patients with moderate-to-severe heart failure:\nResults of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH)\ntrial. Circulation 2003;107:3133–3140.\n448. Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensiﬁed im-\nmunosuppressive therapy in patients with immune checkpoint inhibitor-induced\nmyocarditis. J Immunother Cancer 2020;8:e001887.\n449. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune\ncheckpoint inhibitor rechallenge after immune-related adverse events in patients\nwith cancer. JAMA Oncol 2020;6:865–871.\n450. Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left ventricular dysfunc-\ntion after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016;23:\ne1925–e1928.\n451. Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, et al. U.S. Food and\nDrug Administration approval summary: atezolizumab for metastatic non–small\ncell lung cancer. Clin Cancer Res 2017;23:4534–4539.\n452. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS,\net al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic\nof the week. J Am Coll Cardiol 2019;74:1714–1727.\n453. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al.\nMyocardial T1 and T2 mapping by magnetic resonance in patients with immune\ncheckpoint inhibitor–associated myocarditis. J Am Coll Cardiol 2021;77:1503–1516.\n454. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al.\nManagement of immune-related adverse events in patients treated with immune\ncheckpoint inhibitor therapy: American Society of Clinical Oncology clinical prac-\ntice guideline. J Clin Oncol 2018;36:1714–1768.\n455. Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular\nevents associated with chimeric antigen receptor T cell therapy: cross-sectional\nFDA adverse events reporting system analysis: cardiovascular events with CAR-T\ntherapy. Biol Blood Marrow Transplant 2020;26:2211–2216.\n456. Kupari M, Volin L, Suokas A, Hekali P, Ruutu T. Cardiac involvement in bone mar-\nrow transplantation: serial changes in left ventricular size, mass and performance. J\nIntern Med 1990;227:259–266.\n457. Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, et al.\nArrhythmias in the setting of hematopoietic cell transplants. Bone Marrow\nTransplant 2015;50:1212–1216.\n458. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020\nESC Guidelines for the management of acute coronary syndromes in patients pre-\nsenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367.\n459. Abo S, Ritchie D, Denehy L, Panek-Hudson Y, Irving L, Granger CL. A hospital and\nhome-based exercise program to address functional decline in people following\nallogeneic stem cell transplantation. Support Care Cancer 2018;26:1727–1736.\n460. Squires RW, Shultz AM, Herrmann J. Exercise training and cardiovascular health in\ncancer patients. Curr Oncol Rep 2018;20:27.\n461. Keen C, Skilbeck J, Ross H, Smith L, Collins K, Dixey J, et al. Is it feasible to conduct a\nrandomised controlled trial of pretransplant exercise (prehabilitation) for patients\nwith multiple myeloma awaiting autologous haematopoietic stem cell transplant-\nation? Protocol for the PREeMPT study. BMJ Open 2018;8:e021333.\n462. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National\nprevalence, trends and outcomes of takotsubo syndrome in hospitalizations with\nprior history of mediastinal/intrathoracic cancer and radiation therapy. Int J\nCardiol 2020;309:14–18.\n463. Sattler K, El-Battrawy I, Lang S, Zhou X, Schramm K, Tülümen E, et al. Prevalence of\ncancer in Takotsubo cardiomyopathy: short and long-term outcome. Int J Cardiol\n2017;238:159–165.\n464. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology\nof Takotsubo syndrome—a joint scientiﬁc statement from the HFA TTS and\nMyocardial Function Working Group of the ESC—Part 2: vascular pathophysi-\nology, gender and sex hormones, genetics, chronic cardiovascular problems and\nclinical implications. Eur J Heart Fail 2022;24:274–286.\n465. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology\nof Takotsubo syndrome—a joint scientiﬁc statement from the HFA TTS Study\nGroup and Myocardial Function Working Group of the ESC—Part 1: overview\nand the central role for catecholamines and sympathetic nervous system. Eur J\nHeart Fail 2022;24:257–273.\nESC Guidelines\n4353\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n466. Couch LS, Fiedler J, Chick G, Clayton R, Dries E, Wienecke LM, et al. Circulating\nmicroRNAs predispose to Takotsubo syndrome following high-dose adrenaline\nexposure. Cardiovasc Res 2022;118:1758–1770.\n467. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International\nexpert consensus document on Takotsubo syndrome (part II): diagnostic workup,\noutcome, and management. Eur Heart J 2018;39:2047–2062.\n468. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International\nexpert consensus document on Takotsubo syndrome (part I): clinical characteris-\ntics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39:2032–2046.\n469. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al.\nCurrent state of knowledge on Takotsubo syndrome: a Position Statement from\nthe Taskforce on Takotsubo Syndrome of the Heart Failure Association of the\nEuropean Society of Cardiology. Eur J Heart Fail 2016;18:8–27.\n470. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al.\nCancers predispose neutrophils to release extracellular DNA traps that contribute\nto cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012;109:13076–13081.\n471. Mrotzek SM, Lena A, Hadzibegovic S, Ludwig R, Al-Rashid F, Mahabadi AA, et al.\nAssessment of coronary artery disease during hospitalization for cancer treatment.\nClin Res Cardiol 2021;110:200–210.\n472. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm\ncausing temporary ST elevation myocardial infarction (inferior STEMI)—systemic\ninﬂammatory response syndrome after use of pembrolizumab. Arch Med Sci\nAtheroscler Dis 2017;2:100–102.\n473. Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al.\nCoronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report\nand review of the literature and international registries. Target Oncol 2018;13:\n509–515.\n474. Iannaccone M, D’Ascenzo F, Vadalà P, Wilton SB, Noussan P, Colombo F, et al.\nPrevalence and outcome of patients with cancer and acute coronary syndrome\nundergoing percutaneous coronary intervention: a BleeMACS substudy. Eur\nHeart Journal Acute Cardiovasc Care 2018;7:631–638.\n475. Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, et al.\nAcute myocardial infarction treatments and outcomes in 6.5 million patients\nwith a current or historical diagnosis of cancer in the USA. Eur Heart J 2020;41:\n2183–2193.\n476. Velders MA, Boden H, Hofma SH, Osanto S, Van Der Hoeven BL, Heestermans\nAACM, et al. Outcome after ST elevation myocardial infarction in patients with\ncancer treated with primary percutaneous coronary intervention. Am J Cardiol\n2013;112:1867–1872.\n477. Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, et al. Ischemia and\nbleeding in cancer patients undergoing percutaneous coronary intervention. JACC\nCardioOncology 2019;1:145–155.\n478. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al.\nPercutaneous coronary intervention in cancer patients: a report of the prevalence\nand outcomes in the United States. Eur Heart J 2019;40:1790–1800.\n479. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary\nintervention in metastatic cancer patients with acute coronary syndrome over a\n10-year period. J Cancer Res Clin Oncol 2016;142:471–479.\n480. Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al.\nTemporal trends and outcomes of acute myocardial infarction in patients with can-\ncer. Ann Transl Med 2017;5:482.\n481. Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and out-\ncomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012;35:\n443–450.\n482. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al.\nEvaluation and management of cancer patients presenting with acute cardiovascu-\nlar disease: a Consensus Document of the Acute CardioVascular Care (ACVC) as-\nsociation and the ESC council of Cardio-Oncology—Part 1: acute coronary\nsyndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;\n10:947–959.\n483. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY,\net al. Effect of primary percutaneous coronary intervention on in-hospital out-\ncomes among active cancer patients presenting with ST-elevation myocardial in-\nfarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care\n2021;10:829–839.\n484. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI\nExpert consensus statement: Evaluation, management, and special considerations\nof cardio-oncology patients in the cardiac catheterization laboratory (endorsed\nby the Cardiological Society of India, and Sociedad Latino Americana de\nCardiologıa Intervencionista). Catheter Cardiovasc Interv 2016;87:E202–E223.\n485. Iliescu CA, Cilingiroglu M, Giza DE, Rosales O, Lebeau J, Guerrero-Mantilla I, et al.\n‘Bringing on the light’ in a complex clinical scenario: optical coherence tomog-\nraphy–guided discontinuation of antiplatelet therapy in cancer patients with coron-\nary artery disease (PROTECT-OCT registry). Am Heart J 2017;194:83–91.\n486. Iliescu C, Balanescu DV, Donisan T, Giza DE, Muñoz Gonzalez ED, Cilingiroglu M,\net al. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients\nwith acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol 2018;\n122:1465–1470.\n487. Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, et al.\nProphylactic options in patients with 5-ﬂuorouracil-associated cardiotoxicity. Br J\nCancer 2003;88:1507–1509.\n488. Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain\nrelieved by diltiazem. Am J Cardiol 2012;110:1623–1626.\n489. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy\nto prevent 5-ﬂuorouracil-related myocardial ischemia: a case report. Cancer\nChemother Pharmacol 1999;43:157–161.\n490. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular com-\nplications of cancer therapy: best practices in diagnosis, prevention, and manage-\nment: part 2. J Am Coll Cardiol 2017;70:2552–2565.\n491. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al.\nCardio-oncology: vascular and metabolic perspectives: a scientiﬁc statement from\nthe American Heart Association. Circulation 2019;139:e579–e602.\n492. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence,\npathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–2247.\n493. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of\ncancer-related treatment. Circ Res 2016;118:1008–1020.\n494. Novo G, Di Lisi D, Bronte E, MacAione F, Accurso V, Badalamenti G, et al.\nCardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors:\na real-world single-center experience. Oncology 2020;98:445–451.\n495. Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary inter-\nventions in cancer patients. Expert Rev Cardiovasc Ther 2020;18:25–32.\n496. Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al.\nPercutaneous coronary intervention in patients with cancer and readmissions with-\nin 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;\n42:1019–1034.\n497. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ,\net al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis\nRegistry. J Am Coll Cardiol 2009;53:1399–1409.\n498. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al.\nDeﬁning high bleeding risk in patients undergoing percutaneous coronary interven-\ntion. Circulation 2019;140:240–261.\n499. Stewart MH, Jahangir E, Polin NM. Valvular heart disease in cancer patients: eti-\nology, diagnosis, and management. Curr Treat Options Cardiovasc Med 2017;19:53.\n500. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid,\nsubclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated\nwith radiation therapy. J Am Med Assoc 2003;290:2831–2837.\n501. Salz T, Zabor EC, de Nully Brown P, Dalton SO, Raghunathan NJ, Matasar MJ, et al.\nPreexisting cardiovascular risk and subsequent heart failure among non-Hodgkin\nlymphoma survivors. J Clin Oncol 2017;35:3837–3843.\n502. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al.\nTrastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk fac-\ntors. Ann Oncol 2012;23:897–902.\n503. Sato A, Yoshihisa A, Miyata-Tatsumi M, Oikawa M, Kobayashi A, Ishida T, et al.\nValvular heart disease as a possible predictor of trastuzumab-induced cardiotoxi-\ncity in patients with breast cancer. Mol Clin Oncol 2019;10:37–42.\n504. Watanabe Y, Kozuma K, Hioki H, Kawashima H, Nara Y, Kataoka A, et al.\nComparison of results of transcatheter aortic valve implantation in patients with\nversus without active cancer. Am J Cardiol 2016;118:572–577.\n505. Nagata H, Kanzaki R, Kanou T, Ose N, Funaki S, Shintani Y, et al. Two cases of lob-\nectomy for lung cancer after transcatheter aortic valve implantation. Surg Case\nReports 2018;4:139.\n506. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al.\nTranscatheter aortic valve replacement in oncology patients with severe aortic\nstenosis. JACC Cardiovasc Interv 2019;12:78–86.\n507. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021\nESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J\n2022;43:561–632.\n508. López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P,\nDíez-Villanueva P, et al. Atrial ﬁbrillation in active cancer patients: expert position\npaper and recommendations. Rev Española Cardiol (English Ed) 2019;72:749–759.\n509. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial ﬁbrillation in\ncancer. J Am Coll Cardiol 2014;63:945–953.\n510. Yun JP, Choi EK, Do Han K, Park SH, Jung JH, Park SH, et al. Risk of atrial ﬁbrillation\naccording\nto\ncancer\ntype:\na\nnationwide\npopulation-based\nstudy.\nJACC\nCardioOncology 2021;3:221–232.\n511. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al.\nIncidence, risk factors, and mortality of atrial ﬁbrillation in breast cancer: a\nSEER-Medicare analysis. Eur Heart J 2021;43:300–312.\n4354\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n512. Hu YF, Liu CJ, Chang PMH, Tsao HM, Lin YJ, Chang SL, et al. Incident thrombo-\nembolism and heart failure associated with new-onset atrial ﬁbrillation in cancer pa-\ntients. Int J Cardiol 2013;165:355–357.\n513. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP.\nAnticoagulation strategies in patients with cancer: JACC review topic of the\nweek. J Am Coll Cardiol 2019;73:1336–1349.\n514. Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, et al. Atrial ﬁb-\nrillation in patients with active malignancy and use of anticoagulants: under-\nprescription but no adverse impact on all-cause mortality. Eur J Intern Med 2019;\n59:27–33.\n515. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in pa-\ntients with different types of cancer the unmet need for onco-cardiology. Mayo\nClin Proc 2016;91:81–83.\n516. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE.\nAnticancer drug-induced cardiac rhythm disorders: current knowledge and basic\nunderlying mechanisms. Pharmacol Ther 2018;189:89–103.\n517. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, et al. Practical man-\nagement of ibrutinib in the real life: focus on atrial ﬁbrillation and bleeding. Hematol\nOncol 2018;36:624–632.\n518. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al.\nManagement of cardiovascular complications of Bruton tyrosine kinase inhibitors.\nBr J Haematol 2022;196:70–78.\n519. Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, et al.\nThromboembolism, mortality, and bleeding in 2,435,541 atrial ﬁbrillation patients\nwith and without cancer: a nationwide cohort study. Cancer 2021;127:2122–2129.\n520. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC,\nHeidbuchel H, et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of\nBurden; Substrate): a novel approach to in-depth characterization (rather than clas-\nsiﬁcation) of atrial ﬁbrillation. Thromb Haemost 2021;121:270–278.\n521. Boriani G, Bonini N, Albini A, Venturelli A, Imberti JF, Vitolo M. Cardioversion of\nrecent-onset atrial ﬁbrillation: current evidence, practical considerations, and con-\ntroversies in a complex clinical scenario. Kardiol Pol 2020;78:1088–1098.\n522. Kanmanthareddy A, Vallakati A, Reddy Yeruva M, Dixit S, Di Biase L, Mansour M,\net al. Pulmonary vein isolation for atrial ﬁbrillation in the postpneumonectomy\npopulation: a feasibility, safety, and outcomes study. J Cardiovasc Electrophysiol\n2015;26:385–389.\n523. Lip GYH, Banerjee A, Boriani G, En Chiang C, Fargo R, Freedman B, et al.\nAntithrombotic therapy for atrial ﬁbrillation: CHEST guideline and expert panel re-\nport. Chest 2018;154:1121–1201.\n524. Proietti M, Lane DA, Boriani G, Lip GYH. Stroke prevention, evaluation of bleeding\nrisk, and anticoagulant treatment management in atrial ﬁbrillation contemporary\ninternational guidelines. Can J Cardiol 2019;35:619–633.\n525. Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, et al.\nAnticoagulation in patients with atrial ﬁbrillation and active cancer: an international\nsurvey on patient management. Eur J Prev Cardiol 2021;28:611–621.\n526. D’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, et al.\nCHA2DS2-VASC score and risk of thromboembolism and bleeding in patients\nwith atrial ﬁbrillation and recent cancer. Eur J Prev Cardiol 2018;25:651–658.\n527. Farmakis D. Anticoagulation for atrial ﬁbrillation in active cancer: what the cardiol-\nogists think. Eur J Prev Cardiol 2021;28:608–610.\n528. Cohen A, Donal E, Delgado V, Pepi M, Tsang T, Gerber B, et al. EACVI recommen-\ndations on cardiovascular imaging for the detection of embolic sources: endorsed\nby the Canadian Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2021;\n22:E24–E57.\n529. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Deﬁnition of\nmajor bleeding in clinical investigations of antihemostatic medicinal products in sur-\ngical patients. J Thromb Haemost 2010;8:202–204.\n530. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European\nHeart Rhythm Association practical guide on the use of non-vitamin K antagonist\noral anticoagulants in patients with atrial ﬁbrillation. Europace 2021;23:1612–1676.\n531. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al.\nEfﬁcacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial ﬁb-\nrillation and a history of cancer: Observations from ROCKET AF. Eur Heart J Qual\nCare Clin Outcomes 2019;5:145–152.\n532. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efﬁcacy\nand safety of apixaban versus warfarin in patients with atrial ﬁbrillation and a history\nof cancer: insights from the ARISTOTLE trial. Am J Med 2017;130:1440–1448.e1.\n533. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efﬁcacy and\nsafety of edoxaban in patients with active malignancy and atrial ﬁbrillation: analysis\nof the engage AF-TIMI 48 trial. J Am Heart Assoc 2018;7:e008987.\n534. Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al. Superior\nsafety of direct oral anticoagulants compared to warfarin in patients with atrial ﬁb-\nrillation and underlying cancer: a national Veterans Affairs database study. J Geriatr\nCardiol 2019;16:706–709.\n535. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative\neffectiveness of direct oral anticoagulants and warfarin in patients with cancer and\natrial ﬁbrillation. Blood Adv 2018;2:200–209.\n536. Mariani MV, Magnocavallo M, Straito M, Piro A, Severino P, Iannucci G, et al. Direct\noral anticoagulants versus vitamin K antagonists in patients with atrial ﬁbrillation\nand cancer a meta-analysis. J Thromb Thrombolysis 2021;51:419–429.\n537. Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al.\nEffectiveness and safety of oral anticoagulants among nonvalvular atrial ﬁbrillation\npatients with active cancer. JACC CardioOncology 2021;3:411–424.\n538. Lin YS, Kuan FC, Chao TF, Wu M, Chen SW, Chen MC, et al. Mortality associated\nwith the use of non-vitamin K antagonist oral anticoagulants in cancer patients: da-\nbigatran versus rivaroxaban. Cancer Med 2021;10:7079–7088.\n539. Isogai T, Saad AM, Abushouk AI, Shekhar S, Kuroda S, Gad MM, et al. Procedural\nand short-term outcomes of percutaneous left atrial appendage closure in patients\nwith cancer. Am J Cardiol 2021;141:154–157.\n540. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A,\net al. European Heart Rhythm Association (EHRA) consensus document on man-\nagement of arrhythmias and cardiac electronic devices in the critically ill and post-\nsurgery patient, endorsed by Heart Rhythm Society (HRS), Asia Paciﬁc Heart\nRhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa\n(CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace 2019;\n21:7–8.\n541. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH,\net al. Risk of thromboembolism associated with atrial ﬁbrillation following noncar-\ndiac surgery. J Am Coll Cardiol 2018;72:2027–2036.\n542. Enriquez A, Biagi J, Redfearn D, Boles U, Kamel D, Ali FS, et al. Increased incidence\nof ventricular arrhythmias in patients with advanced cancer and implantable\ncardioverter-deﬁbrillators. JACC Clin Electrophysiol 2017;3:50–56.\n543. Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J\nPhysiol 2016;594:2459–2468.\n544. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.\n2017 AHA/ACC/HRS guideline for management of patients with ventricular ar-\nrhythmias and the prevention of sudden cardiac death: Executive summary: a re-\nport of the American College of Cardiology/American Heart Association Task\nForce on Clinical Practice Guidelines and the Heart Rhythm Society. Heart\nRhythm 2018;15:e190–e252.\n545. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long\nQT syndrome. An update. Circulation 1993;88:782–784.\n546. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al.\nDrug-induced arrhythmias: a scientiﬁc statement from the American Heart\nAssociation. Circulation 2020;142:E214–E233.\n547. AZCERT. CredibleMeds.org n.d.\n548. Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of\nQT prolongation induced by anti-cancer drugs: target therapy and old agents.\nDifferent algorithms for different drugs. Cancer Treat Rev 2018;63:135–143.\n549. European Medicines Agency. ICH guideline E14/S7B on clinical and nonclinical\nevaluation of QT/QTc interval prolongation and proarrhythmic potential—ques-\ntions & answers. Sci Med Heal 2020:EMA/CHMP/ICH/415588/2020.\n550. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune check-\npoint inhibitor therapy and myocarditis: a systematic review of reported cases. J\nCancer Res Clin Oncol 2019;145:1527–1557.\n551. Cirne F, Zhou S, Kappel C, El-Kadi A, Barron CC, Ellis PM, et al. ALK inhibitor-\ninduced bradycardia: a systematic review and meta-analysis. Lung Cancer 2021;\n161:9–17.\n552. Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the cardio-oncology clinic. Heart\nFail Clin 2019;15:487–495.\n553. Szmit S, Jurczak W, Zaucha JM, Drozd-Sokołowska J, Spychałowicz W, Joks M, et al.\nPre-existing arterial hypertension as a risk factor for early left ventricular systolic\ndysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am\nSoc Hypertens 2014;8:791–799.\n554. Di Lorenzo G, Autorino R, Bruni G, Cartentì G, Ricevuto E, Tudini M, et al.\nCardiovascular toxicity following sunitinib therapy in metastatic renal cell carcin-\noma: a multicenter analysis. Ann Oncol 2009;20:1535–1542.\n555. Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treat-\nment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcin-\noma. Clin Genitourin Cancer 2017;15:384–390.e3.\n556. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angioten-\nsin system inhibitors: impact on outcome in sunitinib-treated patients for metastat-\nic renal cell carcinoma. Ann Oncol 2015;26:1128–1133.\n557. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OPR, Sabbisetti VS,\net al. Angiotensin system inhibitors and survival outcomes in patients with meta-\nstatic renal cell carcinoma. Clin Cancer Res 2015;21:2471–2479.\n558. Khorana\nAA,\nFrancis\nCW,\nCulakova\nE,\nKuderer\nNM,\nLyman\nGH.\nThromboembolism is a leading cause of death in cancer patients receiving out-\npatient chemotherapy. J Thromb Haemost 2007;5:632–634.\nESC Guidelines\n4355\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n559. Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ.\nEpidemiology of venous thromboembolism in the Framingham Heart Study.\nThromb Res 2016;145:27–33.\n560. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thrombo-\nembolism in patients with cancer—a cohort study using linked United Kingdom da-\ntabases. Eur J Cancer 2013;49:1404–1413.\n561. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden\nof disease and beneﬁts of thromboprophylaxis. Cancer 2011;117:1334–1349.\n562. Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A\nmeta-analysis of case fatality rates of recurrent venous thromboembolism and ma-\njor bleeding in patients with cancer. Thromb Haemost 2020;120:702–713.\n563. Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Risk\nscores for occult cancer in patients with unprovoked venous thromboembolism:\nresults from an individual patient data meta-analysis. J Thromb Haemost 2020;18:\n2622–2628.\n564. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the pa-\ntient with cancer. J Clin Oncol 2009;27:4839–4847.\n565. Li X, Hu Y, Lin P, Zhang J, Tang Y, Yi Q, et al. Comparison of different clinical prog-\nnostic scores in patients with pulmonary embolism and active cancer. Thromb\nHaemost 2021;121:834–844.\n566. Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W, et al. 2019\nESC Guidelines for the diagnosis and management of acute pulmonary embolism\ndeveloped in collaboration with the European Respiratory Society (ERS). Eur\nHeart J 2020;41:543–603.\n567. Mazzolai L, Ageno W, Alatri A, Bauersachs R, Becattini C, Brodmann M, et al. Second\nconsensus document on diagnosis and management of acute deep vein thrombosis:\nupdated document elaborated by the ESC Working Group on aorta and peripheral\nvascular diseases and the ESC Working Group on pulmonary circulation and right\nventricular function. Eur J Prev Cardiol 2022;29:1248–1263\n568. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MS V, et al. Risk of arterial\nthromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926–938.\n569. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J\nCardiol 2018;72:89–93.\n570. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al.\nScreening adult survivors of childhood cancer for cardiomyopathy: comparison\nof echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;\n30:2876–2884.\n571. Hooks M, Okasha O, Velangi PS, Nijjar PS, Farzaneh-Far A, Shenoy C. Left ventricu-\nlar thrombus on cardiovascular magnetic resonance imaging in non-ischaemic car-\ndiomyopathy. Eur Heart J Cardiovasc Imaging 2020. doi:10.1093/ehjci/jeaa244.\nOnline ahead of print 7 October 2020.\n572. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al.\nLow-molecular-weight heparin versus a coumarin for the prevention of recurrent\nvenous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–153.\n573. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term\nlow-molecular-weight heparin versus usual care in proximal-vein thrombosis pa-\ntients with cancer. Am J Med 2006;119:1062–1072.\n574. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary preven-\ntion of venous thromboembolic events in patients with active cancer: enoxaparin\nalone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl\nThromb 2006;12:389–396.\n575. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al.\nComparison of low-molecular-weight heparin and warfarin for the secondary pre-\nvention of venous thromboembolism in patients with cancer: a randomized con-\ntrolled study. Arch Intern Med 2002;162:1729–1735.\n576. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al.\nTinzaparin vs warfarin for treatment of acute venous thromboembolism in patients\nwith active cancer: a randomized clinical trial. JAMA J Am Med Assoc 2015;314:\n677–686.\n577. Lee YJ, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Bleeding risk and major ad-\nverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol\n2016;203:372–378.\n578. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al.\nEdoxaban for the treatment of cancer-associated venous thromboembolism. N\nEngl J Med 2018;378:615–624.\n579. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison\nof an oral factor Xa inhibitor with low molecular weight heparin in patients with\ncancer\nwith\nvenous\nthromboembolism:\nresults\nof\na\nrandomized\ntrial\n(SELECT-D). J Clin Oncol 2018;36:2017–2023.\n580. McBane II RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A,\net al. Apixaban and dalteparin in active malignancy-associated venous thrombo-\nembolism: the ADAM VTE trial. J Thromb Haemost 2020;18:411–421.\n581. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman M V, Connors JM, et al.\nApixaban for the treatment of venous thromboembolism associated with cancer.\nN Engl J Med 2020;382:1599–1607.\n582. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous\nthromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019;30:\n897–907.\n583. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al.\nBleeding with apixaban and dalteparin in patients with cancer-associated venous\nthromboembolism: results from the Caravaggio study. Thromb Haemost 2021;\n121:616–624.\n584. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al.\nEffectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin\namong venous thromboembolism patients with active cancer: a US claims data ana-\nlysis. Thromb Haemost 2021;121:383–395.\n585. Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al.\nDirect oral anticoagulants for the treatment of acute venous thromboembolism as-\nsociated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020;\n120:1128–1136.\n586. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, IndolﬁC. Direct oral anticoagulants\nin patients with active cancer: a systematic review and meta-analysis. JACC\nCardioOncology 2020;2:428–440.\n587. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism.\nBlood 2019;133:291–298.\n588. Den Exter PL, Hooijer J, Dekkers OM, Huisman M V. Risk of recurrent venous\nthromboembolism and mortality in patients with cancer incidentally diagnosed\nwith pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol\n2011;29:2405–2409.\n589. Jara-Palomares\nL,\nSolier-Lopez\nA,\nElias-Hernandez\nT,\nAsensio-Cruz\nM,\nBlasco-Esquivias I, Marin-Barrera L, et al. Tinzaparin in cancer associated throm-\nbosis beyond 6 months: TiCAT study. Thromb Res 2017;157:90–96.\n590. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman M V, et al.\nTreatment of venous thromboembolism in cancer patients with dalteparin for up\nto 12 months: the DALTECAN Study. J Thromb Haemost 2015;13:1028–1035.\n591. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020\nACC/AHA guideline for the management of patients with valvular heart disease: a\nreport of the American College of Cardiology/American Heart Association Joint\nCommittee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:e25–e197.\n592. Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous\nthromboembolism in cancer patients on simultaneous and palliative care. Cancers\n(Basel) 2020;12:1167.\n593. Xin Z, Liu F, Du Y, Mao F, Wang X, Xu P, et al. Primary prophylaxis for venous\nthromboembolism in ambulatory cancer patients: a systematic review and network\nmeta-analysis. Ann Cardiothorac Surg 2020;9:2970–2981.\n594. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 internation-\nal clinical practice guidelines for the treatment and prophylaxis of venous thrombo-\nembolism in patients with cancer. Lancet Oncol 2019;20:e566–e581.\n595. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al.\nDuration of prophylaxis against venous thromboembolism with enoxaparin after\nsurgery for cancer. N Engl J Med 2002;346:975–980.\n596. Khorana A, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and\nvalidation of a predictive model for chemotherapy-associated thrombosis. Blood\n2008;111:4902–4907.\n597. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El\nShemmari S, et al. A predictive score for thrombosis associated with breast, colo-\nrectal, lung, or ovarian cancer: the prospective COMPASS–cancer-associated\nthrombosis study. Oncologist 2017;22:1222–1231.\n598. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.\nNadroparin for the prevention of thromboembolic events in ambulatory patients\nwith metastatic or locally advanced solid cancer receiving chemotherapy: a rando-\nmised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943–949.\n599. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al.\nSemuloparin for thromboprophylaxis in patients receiving chemotherapy for can-\ncer. N Engl J Med 2012;366:601–609.\n600. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AWSS. Primary\nprophylaxis for venous thromboembolism in ambulatory cancer patients receiving\nchemotherapy. Cochrane Database Syst Rev 2016;12:CD008500.\n601. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al.\nApixaban to prevent venous thromboembolism in patients with cancer. N Engl J\nMed 2019;380:711–719.\n602. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban\nfor thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med\n2019;380:720–728.\n603. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk\nfactors among cancer patients treated with anticoagulation. Am J Hematol 2019;94:\n780–785.\n604. Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thrombo-\nembolism and bleeding on anticoagulation. Thromb Res 2016;140:S93–S98.\n4356\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n605. Roule V, Verdier L, Blanchart K, Ardouin P, Lemaitre A, Bignon M, et al. Systematic\nreview and meta-analysis of the prognostic impact of cancer among patients with\nacute coronary syndrome and/or percutaneous coronary intervention. BMC\nCardiovasc Disord 2020;20:38.\n606. Freedberg DE, Kim LS, Yang YX. The risks and beneﬁts of long-term use of proton\npump inhibitors: expert review and best practice advice from the American\nGastroenterological Association. Gastroenterology 2017;152:706–715.\n607. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC\nfocused update on dual antiplatelet therapy in coronary artery disease developed\nin collaboration with EACTS. Eur Heart J 2018;39:213–260.\n608. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical\nexpert consensus statement on the classiﬁcation of cardiogenic shock: This docu-\nment was endorsed by the American College of Cardiology (ACC), the American\nHeart Association (AHA), the Society of Critical Care Medicine (SCCM), and the\nSociety of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv\n2019;94:29–37.\n609. Schiffer CA, Bohlke K, Anderson KC. Platelet transfusion for patients with cancer:\nAmerican Society of Clinical Oncology Clinical Practice Guideline Update\nSummary. J Oncol Pract 2018;14:129–133.\n610. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding,\nand anticoagulation in patients with malignancy. Blood Adv 2019;3:3770–3779.\n611. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer\ntherapy-related increases in arterial stiffness: a systematic review and meta-analysis.\nJ Am Heart Assoc 2020;9:e015598.\n612. Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular\nsyndrome in a patient with metastatic melanoma under immune checkpoint block-\nade. BMC Cancer 2017;17:327.\n613. Aichberger\nKJ,\nHerndlhofer\nS,\nSchernthaner\nGH,\nSchillinger\nM,\nMitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlu-\nsive disease and other vascular events during nilotinib therapy in CML. Am J Hematol\n2011;86:533–539.\n614. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al.\nImpact of dose intensity of ponatinib on selected adverse events: multivariate ana-\nlyses from a pooled population of clinical trial patients. Leuk Res 2016;48:84–91.\n615. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, Le Coutre P. Vascular\nsafety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;\n125:901–906.\n616. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary\narterial hypertension in patients treated by dasatinib. Circulation 2012;125:\n2128–2137.\n617. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, et al.\nChemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J\nPathol 2015;185:356–371.\n618. Jevnikar M, Montani D, Savale L, Seferian A, Jutant EM, Boucly A, et al. Chronic\nthromboembolic pulmonary hypertension and totally implantable central venous\naccess systems. Eur Respir J 2021;57:2002208.\n619. Price LC, Seckl MJ, Dorfmüller P, Wort SJ. Tumoral pulmonary hypertension. Eur\nRespir Rev 2019;28:180065.\n620. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022\nESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\nEur Heart J 2022;43:3618–3731.\n621. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib ver-\nsus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J\nMed 2010;362:2260–2270.\n622. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer:\nContemporary prevalence, management and outcomes. Heart 2020;106:569–574.\n623. Kim SR, Kim EK, Cho J, Chang SA, Park SJ, Lee SC, et al. Effect of anti-inﬂammatory\ndrugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll\nCardiol 2020;76:1551–1561.\n624. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, et al. Pericardial\ndisease in patients treated with immune checkpoint inhibitors. J Immunother Cancer\n2021;9:e002771.\n625. Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint\ninhibitors-associated pericardial disease: a systematic review of case reports.\nCancer Immunol Immunother 2021;70:3041–3053.\n626. Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, De Agustín A, Vivas D,\nPalacios-Rubio J, et al. Cause and long-term outcome of cardiac tamponade. Am J\nCardiol 2016;117:664–669.\n627. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of\ncytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419\nspecimens. Cancer Cytopathol 2017;125:128–137.\n628. Patel N, Raﬁque AM, Eshaghian S, Mendoza F, Biner S, Cercek B, et al. Retrospective\ncomparison of outcomes, diagnostic value, and complications of percutaneous pro-\nlonged drainage versus surgical pericardiotomy of pericardial effusion associated\nwith malignancy. Am J Cardiol 2013;112:1235–1239.\n629. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, et al. Targeted cancer\ntherapies with pericardial effusions requiring pericardiocentesis focusing on im-\nmune checkpoint inhibitors. Am J Cardiol 2019;123:1351–1357.\n630. Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of\nnivolumab-induced pericardial effusion: a case report and review of literature.\nExp Hematol Oncol 2018;7:11.\n631. Dixon SB, Howell CR, Lu L, Plana JC, Joshi VM, Luepker R V, et al. Cardiac biomar-\nkers and association with subsequent cardiomyopathy and mortality among adult\nsurvivors of childhood cancer: a report from the St. Jude Lifetime Cohort.\nCancer 2021;127:458–466.\n632. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association\nof cardiovascular risk factors with cardiac events and survival outcomes among pa-\ntients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018;36:\n2710–2717.\n633. Nolan MT, Marwick TH, Plana JC, Li Z, Ness KK, Joshi VM, et al. Effect of traditional\nheart failure risk factors on myocardial dysfunction in adult survivors of childhood\ncancer. JACC Cardiovasc Imaging 2018;11:1202–1203.\n634. Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of\nchemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast\ncancer patients. Breast Cancer Res Treat 2020;182:333–343.\n635. Smarz K, Jaxa-Chamiec T, Chwyczko T, Główczyńska R, Jegier A, Niedoszytko P,\net al. Cardiopulmonary exercise testing in adult cardiology: expert opinion of the\nWorking Group of Cardiac Rehabilitation and Exercise Physiology of the Polish\nCardiac Society. Kardiol Pol 2019;77:730–756.\n636. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efﬁcacy of\nexercise therapy on cardiorespiratory ﬁtness in patients with cancer: a systematic\nreview and meta-analysis. J Clin Oncol 2018;36:2297–2304.\n637. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for\nprescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015;6:\n115–124.\n638. Wallen MP, Hennessy D, Brown S, Evans L, Rawstorn JC, Wong Shee A, et al.\nHigh-intensity interval training improves cardiorespiratory ﬁtness in cancer patients\nand survivors: a meta-analysis. Eur J Cancer Care (Engl) 2020;29:e13267.\n639. Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L,\net al. Effect of aerobic and resistance exercise intervention on cardiovascular dis-\nease risk in women with early-stage breast cancer: a randomized clinical trial.\nJAMA Oncol 2019;5:710–714.\n640. Adams SC, Delorey DS, Davenport MH, Fairey AS, North S, Courneya KS. Effects\nof high-intensity interval training on fatigue and quality of life in testicular cancer\nsurvivors. Br J Cancer 2018;118:1313–1321.\n641. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, et al.\nHigh-intensity exercise during chemotherapy induces beneﬁcial effects 12 months\ninto breast cancer survivorship. J Cancer Surviv 2019;13:244–256.\n642. Marriott CFS, Petrella AFM, Marriott ECS, Boa Sorte Silva NC, Petrella RJ.\nHigh-intensity interval training in older adults: a scoping review. Sport Med - Open\n2021;7:49.\n643. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al.\nCardiovascular health of patients with cancer and cancer survivors: a roadmap\nto the next level. J Am Coll Cardiol 2015;65:2739–2746.\n644. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al.\nCardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;\n370:2011–2019.\n645. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart\nfailure associated with sunitinib malate: a multitargeted receptor tyrosine kinase in-\nhibitor. Cancer 2008;112:2500–2508.\n646. Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to diagnose\nand manage QT prolongation in cancer patients. JACC CardioOncology 2021;3:\n145–149.\n647. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood\ncancer survival in Europe 1999–2007: results of EUROCARE-5—a population-\nbased study. Lancet Oncol 2014;15:35–47.\n648. Geenen MM, Cardous-Ubbink MC, Kremer LCM, Van Den Bos C, Van Der Pal\nHJH, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term\nsurvivors of childhood cancer. J Am Med Assoc 2007;297:2705–2715.\n649. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, et al.\nCardiovascular disease in survivors of childhood cancer: insights into epidemiology,\npathophysiology, and prevention. J Clin Oncol 2018;36:2135–2144.\n650. Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, et al.\nPopulation-based long-term cardiac-speciﬁc mortality among 34 489 ﬁve-year sur-\nvivors of childhood cancer in Great Britain. Circulation 2017;135:951–963.\n651. Kremer LCM, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of\nanthracycline-induced clinical heart failure in children: a systematic review. Ann\nOncol 2002;13:503–512.\nESC Guidelines\n4357\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "references",
        "ct"
      ]
    }
  ]
}